<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00421</drugbank-id>
  <drugbank-id>APRD01234</drugbank-id>
  <name>Spironolactone</name>
  <description>Spironolactone is a potassium sparing diuretic like [eplerenone] that competitively inhibits mineralocorticoid receptors in the distal convoluted tubule to promote sodium and water excretion and potassium retention.[A11837]. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837,A178246] It is indicated to treat a number of conditions including heart failure, deem, hyperaldosteronism, adrenal hyperplasia, hypertension, and nephrotic syndrome.[Label] Off label uses of spironolactone involving its antiandrogenic activity include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135] Spironolactone is also frequently used in medical gender transition.[A178138]&#13;
&#13;
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243,L6187]</description>
  <cas-number>52-01-7</cas-number>
  <unii>27O7W4T232</unii>
  <average-mass>416.573</average-mass>
  <monoisotopic-mass>416.202130202</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A178126</ref-id>
        <pubmed-id>9144743</pubmed-id>
        <citation>Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M: Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm Res. 1997 Apr;14(4):522-6.</citation>
      </article>
      <article>
        <ref-id>A178069</ref-id>
        <pubmed-id>3675606</pubmed-id>
        <citation>LaCagnin LB, Lutsie P, Colby HD: Conversion of spironolactone to 7 alpha-thiomethylspironolactone by hepatic and renal microsomes. Biochem Pharmacol. 1987 Oct 15;36(20):3439-44.</citation>
      </article>
      <article>
        <ref-id>A178072</ref-id>
        <pubmed-id>7895608</pubmed-id>
        <citation>Los LE, Pitzenberger SM, Ramjit HG, Coddington AB, Colby HD: Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites. Drug Metab Dispos. 1994 Nov-Dec;22(6):903-8.</citation>
      </article>
      <article>
        <ref-id>A178135</ref-id>
        <pubmed-id>22468178</pubmed-id>
        <citation>Kim GK, Del Rosso JQ: Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012 Mar;5(3):37-50.</citation>
      </article>
      <article>
        <ref-id>A178138</ref-id>
        <pubmed-id>31065620</pubmed-id>
        <citation>Millington K, Liu E, Chan YM: The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone. J Endocr Soc. 2019 Apr 4;3(5):1031-1038. doi: 10.1210/js.2019-00030. eCollection 2019 May 1.</citation>
      </article>
      <article>
        <ref-id>A178165</ref-id>
        <pubmed-id>363379</pubmed-id>
        <citation>Karim A: Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8(1):151-88. doi: 10.3109/03602537808993782.</citation>
      </article>
      <article>
        <ref-id>A178192</ref-id>
        <pubmed-id>28024992</pubmed-id>
        <citation>Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A: Spironolactone. J Pain Symptom Manage. 2017 Feb;53(2):288-292. doi: 10.1016/j.jpainsymman.2016.12.320. Epub 2016 Dec 23.</citation>
      </article>
      <article>
        <ref-id>A11837</ref-id>
        <pubmed-id>15947888</pubmed-id>
        <citation>Sica DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005 Jan;10(1):23-9. doi: 10.1007/s10741-005-2345-1.</citation>
      </article>
      <article>
        <ref-id>A178207</ref-id>
        <pubmed-id>2723123</pubmed-id>
        <citation>Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A: Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989 Apr;29(4):342-7.</citation>
      </article>
      <article>
        <ref-id>A178243</ref-id>
        <pubmed-id>15134800</pubmed-id>
        <citation>Menard J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. doi: 10.1016/j.mce.2003.10.008.</citation>
      </article>
      <article>
        <ref-id>A178246</ref-id>
        <pubmed-id>13608362</pubmed-id>
        <citation>BOLTE E, VERDY M, MARC-AURELE J, BROUILLET J, BEAUREGARD P, GENEST J: Studies on new diuretic compounds: spirolactone and chlorothiazide. Can Med Assoc J. 1958 Dec 1;79(11):881-8.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L6187</ref-id>
        <title>FDA Approved Drug Products: Spironolactone</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=012151</url>
      </link>
      <link>
        <ref-id>L4449</ref-id>
        <title>Aldactone® (spironolactone) FDA Label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Giuseppe Bernini, "Process for preparing micronized spironolactone." U.S. Patent US4332721, issued July, 1975.</synthesis-reference>
  <indication>Spironolactone is indicated for the treatment of New York Heart Association Class III-IV heart failure, management of edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micro/macronodular adrenal hyperplasia, as an add-on therapy in hypertension, and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequate.[Label]&#13;
&#13;
Spironolactone has antiandrogenic activity which leads to many of its off label uses. Spironolactone is used off label in the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135]&#13;
&#13;
Spironolactone is also frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing male-pattern hair growth.[A178138]</indication>
  <pharmacodynamics>Originally spironolactone was only studied for its potassium sparing diuretic effect.[A11837] Spironolactone competitively inhibits mineralocorticoid receptors in the distal convoluted tubule to promote sodium and water excretion and potassium retention.[A11837]. Inhibition of this receptor leads to increased renin and aldosterone levels.[A11837]&#13;
&#13;
Spironolactone is structurally similar to progesterone and as a result is associated with progestogenic and antiandrogenic effects.[A11837]</pharmacodynamics>
  <mechanism-of-action>Spironolactone competitively inhibits aldosterone dependant sodium potassium exchange channels in the distal convoluted tubule.[Label] This action leads to increased sodium and water excretion, but more potassium retention.[Label] The increased excretion of water leads to diuretic and also antihypertensive effects.[Label]</mechanism-of-action>
  <toxicity>Patients experiencing an overdose may present with drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Vomiting is generally induced or a gastric lavage is performed.[Label] Supportive treatment involves maintining hydration, electrolyte balance, and vital functions[Label].&#13;
&#13;
The oral LD50 in mice, rats, and rabbits is &gt;1g/kg.[Label]&#13;
&#13;
Spironolactone should be avoided in pregnancy due to reports of feminization of male fetuses in animal studies.[Label] Active metabolites of spironolactone are present in breast milk and levels that are likely inconsequential, though the long term effects have not been studied.[Label]&#13;
&#13;
In animal studies, spironolactone slowed follicle development, ovulation, and implantation.[Label] Spironolactone increased the incidence of benign adenomas in the testes of male rats, benign uterine endometrial stromal polyps in female rats, and thyroid follicular cell adenomas in both sexes of rats.[Label] Spironolactone and canrenone are generally not considered to be mutagenic in tests but canrenone occasionally tests positive for mutagenicity with metabolic activation and spironolactone has occasionally tested inconclusive though slightly positive for mutagenicity.[Label]</toxicity>
  <metabolism>Spironolactone is deacetylated to 7α-thiospironolactone.[A178069,A178072] 7α-thiospironolactone is S-methylated to 7α-thiomethylspironolactone or undergoes an elimination reaction to canrenone.[A178069,A178072] 7α-thiomethylspironolactone is reduced to 3α-hydroxythiomethylspironolactone or 3β-hydroxythiomethylspironolactone.[A178069,A178072]&#13;
&#13;
Canrenone was originally thought to be the primary circulating metabolite, however more recent studies have demonstrated that the primary metabolite is actually 7α-thiomethylspironolactone.[A11837,A178207]</metabolism>
  <absorption>Spironolactone reaches a maximum concentration in 2.6 hours and an active metabolite (canrenone) reaches a maximum concentration in 4.3 hours.[Label] When taken with food, the bioavailability of spironolactone increases to 95.4%.[Label]&#13;
&#13;
Giving spironolactone with food increases the maximum concentration from 209ng/mL to 301ng/mL.[A178165] The time to maximum concentration also increases from 2.28 hours to 3.05 hours.[A178165] The area under the curve varies from 2103ng/mL\*hr to 4544ng/mL*hr.[A178165]</absorption>
  <half-life>1.4 hours.[Label,A178192]&#13;
&#13;
Canrenone has a half life of 16.5 hours, 7-α-thiomethylspirolactone has a half life of 13.8 hours, and 6-ß-hydroxy-7-α-thiomethylspirolactone has a half life of 15 hours.[Label,A178192]</half-life>
  <protein-binding>&gt;90%.[Label] Canrenone is as much as 98% protein bound.[A178165]</protein-binding>
  <route-of-elimination>Metabolites of spironolactone are excreted 42-56% in urine, and 14.2-14.6% in the feces.[A178165] No unmetabolized spironolactone is present in the urine.[A178165]</route-of-elimination>
  <volume-of-distribution>Volume of distribution data is not readily available.[Label,A178192]</volume-of-distribution>
  <clearance>Clearance data is not readily available.[Label,A178192]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.</description>
    <direct-parent>Spironolactones and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Steroids and steroid derivatives</class>
    <subclass>Steroid lactones</subclass>
    <alternative-parent>3-oxo delta-4-steroids</alternative-parent>
    <alternative-parent>Carbothioic S-esters</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Cyclohexenones</alternative-parent>
    <alternative-parent>Delta-4-steroids</alternative-parent>
    <alternative-parent>Gamma butyrolactones</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Sulfenyl compounds</alternative-parent>
    <alternative-parent>Tetrahydrofurans</alternative-parent>
    <alternative-parent>Thioesters</alternative-parent>
    <substituent>3-oxo-delta-4-steroid</substituent>
    <substituent>3-oxosteroid</substituent>
    <substituent>Aliphatic heteropolycyclic compound</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carbothioic s-ester</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Cyclic ketone</substituent>
    <substituent>Cyclohexenone</substituent>
    <substituent>Delta-4-steroid</substituent>
    <substituent>Gamma butyrolactone</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Lactone</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Oxosteroid</substituent>
    <substituent>Spironolactone</substituent>
    <substituent>Sulfenyl compound</substituent>
    <substituent>Tetrahydrofuran</substituent>
    <substituent>Thiocarboxylic acid ester</substituent>
    <substituent>Thiocarboxylic acid or derivatives</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="inn">Espironolactona</synonym>
    <synonym language="english/french" coder="inn/ban/jan">Spironolactone</synonym>
    <synonym language="latin" coder="inn">Spironolactonum</synonym>
    <synonym language="english" coder="dcit">Spironolattone</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aldactazide</name>
      <labeller>G.D. Searle LLC Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0025-1011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012616</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aldactazide</name>
      <labeller>G.D. Searle LLC Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0025-1021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012616</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aldactazide 25</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00180408</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aldactazide 50</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00594377</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aldactone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-04-24</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aldactone</name>
      <labeller>G.D. Searle LLC Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0025-1001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aldactone</name>
      <labeller>G.D. Searle LLC Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0025-1041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aldactone</name>
      <labeller>G.D. Searle LLC Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0025-1031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aldactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1396</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aldactone 100 mg</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00285455</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aldactone 25 mg</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00028606</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-spirozide Tab</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00520802</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2% / Tretinoin 0.025%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2% / Tretinoin 0.05%</name>
      <labeller>Sincerus Florida LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CaroSpir</name>
      <labeller>Cmp Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46287-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>25 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA209478</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CaroSpir</name>
      <labeller>Atlantic Biologicals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>25 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA209478</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clindamycin 1% / Niacinamide 4% / Spironolactone 2% / Tretinoin 0.025%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dapsone 6% / Niacinamide 2% / Spironolactone 5%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1061</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dapsone 8.5% / Niacinamide 2% / Spironolactone 5%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1064</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mint-spironolactone</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488140</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-spironolactone</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488159</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niacinamide 2% / Spironolactone 5% / Tretinoin 0.025%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Niacinamide 2% / Spironolactone 5% / Tretinoin 0.05%</name>
      <labeller>Sincerus Florida LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1153</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Niacinamide 4% / Spironolactone 5%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ntp-spironolactone</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347601</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-spironolactone</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347628</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-766</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0592</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0338</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-960</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Med Health Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>51138-322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on>2012-04-20</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on>2012-04-20</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on>2012-04-20</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on>2012-04-20</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66336-916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>63739-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-18</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-1535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-5592</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-6591</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-869</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-895</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-764</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0979</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-2776</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-499</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-523</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-680</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-07</started-marketing-on>
      <ended-marketing-on>2015-03-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-14</started-marketing-on>
      <ended-marketing-on>2013-06-14</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-978</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2013-06-18</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66267-476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-19</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-24</started-marketing-on>
      <ended-marketing-on>2018-06-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-811</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-4477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-717</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4073</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Red Pharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-1403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1992</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-277</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-01-21</started-marketing-on>
      <ended-marketing-on>2017-08-11</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9729</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-24</started-marketing-on>
      <ended-marketing-on>2015-01-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-5015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-9973</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-584</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on>2015-05-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-563</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-12</started-marketing-on>
      <ended-marketing-on>2015-01-06</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9227</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-587</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-969</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on>2017-06-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-246</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-02-03</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>53489-143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>53489-328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>53489-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-15</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on>2018-01-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2018-01-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-822</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-05</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71610-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-5951</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on>2019-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Vintage Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0254-5880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-31</started-marketing-on>
      <ended-marketing-on>2006-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Vintage Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0254-5881</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-31</started-marketing-on>
      <ended-marketing-on>2006-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Vintage Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0254-5882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-31</started-marketing-on>
      <ended-marketing-on>2006-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-5952</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on>2009-12-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-5953</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on>2009-12-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aphena Pharma Solutions - Tennessee, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43353-239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2021-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4094</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-1830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>AvPAK</labeller>
      <ndc-id/>
      <ndc-product-code>50268-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0228-2803</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on>2020-11-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0228-2672</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on>2020-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0228-2673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-03</started-marketing-on>
      <ended-marketing-on>2020-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040353</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>NCS HealthCare of KY, Inc dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8221</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>St Marys Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-981</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-22</started-marketing-on>
      <ended-marketing-on>2018-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0966</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-5341</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-4720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>St. Mary's Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-771</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-2146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-02-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-0243</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-0437</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Greenstone LLC</labeller>
      <ndc-id/>
      <ndc-product-code>59762-5011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-01-21</started-marketing-on>
      <ended-marketing-on>2021-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Greenstone LLC</labeller>
      <ndc-id/>
      <ndc-product-code>59762-5012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-01-21</started-marketing-on>
      <ended-marketing-on>2021-01-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Greenstone LLC</labeller>
      <ndc-id/>
      <ndc-product-code>59762-5013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-01-21</started-marketing-on>
      <ended-marketing-on>2018-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA012151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>McKesson Corporation dba SKY Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>63739-544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>McKesson Corporation dba SKY Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>63739-545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-04</started-marketing-on>
      <ended-marketing-on>2018-11-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferred Pharmaceuticals Inc..</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Direct_Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-772</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2021-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>52125-866</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-11</started-marketing-on>
      <ended-marketing-on>2017-03-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2728</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-216</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-217</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-218</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0455</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1950</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0563</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Quality Care Products, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-1599</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-01-01</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3747</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3375</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7258</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6332</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6895</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6900</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>RedPharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-1100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-515</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-256</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-487</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0665</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aphena Pharma Solutions - Tennessee, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>71610-287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aphena Pharma Solutions - Tennessee, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>71610-288</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Quality Care Products, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-713</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6927</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-367</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0630</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-8132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-8133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>PharmPak, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54348-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-835</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-974</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-979</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-980</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>McKesson Corporation dba SKY Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>63739-416</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>QPharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>42708-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>QPharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>42708-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-225</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-227</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2385</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2384</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2386</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1746</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-832</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5763</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2021-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5764</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2021-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5765</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on>2021-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-861</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203253</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5517</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5055</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-04</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-634</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-661</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-662</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-515</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091426</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205936</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone</name>
      <labeller>Aphena Pharma Solutions - Tennessee, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67544-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-02-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0699</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Med Health Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51138-442</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-28</started-marketing-on>
      <ended-marketing-on>2012-06-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-04-11</started-marketing-on>
      <ended-marketing-on>2018-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-946</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-31</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53489-144</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Greenstone LLC</labeller>
      <ndc-id/>
      <ndc-product-code>59762-5014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-0141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on>2020-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-0403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42292-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Teva-spironolactone</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00613215</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-spironolactone</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00613223</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-spironolactone/hctz</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00613231</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-spironolactone/hctz</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00657182</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Osyrol</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Spiresis</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Spiretic</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Spiroctan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Uractone</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Verospiron</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Xenalon</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>CaroSpir</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>CaroSpir</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Niacinamide 2% / Spironolactone 5% / Tretinoin 0.05%</name>
      <ingredients>Nicotinamide + Spironolactone + Tretinoin</ingredients>
    </mixture>
    <mixture>
      <name>Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2% / Tretinoin 0.05%</name>
      <ingredients>Benzoyl peroxide + Clindamycin + Nicotinamide + Spironolactone + Tretinoin</ingredients>
    </mixture>
    <mixture>
      <name>Clindamycin 1% / Niacinamide 4% / Spironolactone 2% / Tretinoin 0.025%</name>
      <ingredients>Clindamycin + Nicotinamide + Spironolactone + Tretinoin</ingredients>
    </mixture>
    <mixture>
      <name>Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2% / Tretinoin 0.025%</name>
      <ingredients>Benzoyl peroxide + Clindamycin + Nicotinamide + Spironolactone + Tretinoin</ingredients>
    </mixture>
    <mixture>
      <name>Niacinamide 2% / Spironolactone 5% / Tretinoin 0.025%</name>
      <ingredients>Nicotinamide + Spironolactone + Tretinoin</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Niacinamide 4% / Spironolactone 5%</name>
      <ingredients>Nicotinamide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Dapsone 8.5% / Niacinamide 2% / Spironolactone 5%</name>
      <ingredients>Dapsone + Nicotinamide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2%</name>
      <ingredients>Benzoyl peroxide + Clindamycin + Nicotinamide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Dapsone 6% / Niacinamide 2% / Spironolactone 5%</name>
      <ingredients>Dapsone + Nicotinamide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactone 25 mg</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactazide 25</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactone 100 mg</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Aldactazide 50</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-spironolactone/hctz</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-spironolactone/hctz</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-spirozide Tab</name>
      <ingredients>Hydrochlorothiazide + Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-spironolactone</name>
      <ingredients>Spironolactone</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Actavis Group</name>
      <url>http://www.actavis.com</url>
    </packager>
    <packager>
      <name>Advanced Pharmaceutical Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Caremark LLC</name>
      <url>http://www.caremark.com</url>
    </packager>
    <packager>
      <name>Comprehensive Consultant Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Dept Health Central Pharmacy</name>
      <url/>
    </packager>
    <packager>
      <name>DHHS Program Support Center Supply Service Center</name>
      <url/>
    </packager>
    <packager>
      <name>Direct Dispensing Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>GD Searle LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Greenstone LLC</name>
      <url>http://www.greenstonellc.com</url>
    </packager>
    <packager>
      <name>Guna Inc.</name>
      <url>http://www.gunainc.com</url>
    </packager>
    <packager>
      <name>H and H Laboratories</name>
      <url>http://www.hhlabs.com</url>
    </packager>
    <packager>
      <name>Heartland Repack Services LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Innoviant Pharmacy Inc.</name>
      <url>http://www.innoviantpharmacy.com</url>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Liberty Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Mckesson Corp.</name>
      <url>http://www.mckesson.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Mutual Pharmaceutical Co.</name>
      <url/>
    </packager>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
    <packager>
      <name>Neighborcare Repackaging Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Neuman Distributors Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Palmetto Pharmaceuticals Inc.</name>
      <url>http://www.palmettopharm.com</url>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Pharmaceutical Utilization Management Program VA Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Pharmacia Inc.</name>
      <url>http://www.pharmaciaupjohn.com</url>
    </packager>
    <packager>
      <name>Pharmedix</name>
      <url>http://www.pharmedixrx.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Preferred Pharmaceuticals Inc.</name>
      <url>http://www.preferredpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Prepackage Specialists</name>
      <url/>
    </packager>
    <packager>
      <name>Prepak Systems Inc.</name>
      <url>http://www.prepaksys.com</url>
    </packager>
    <packager>
      <name>Professional Co.</name>
      <url/>
    </packager>
    <packager>
      <name>Qualitest</name>
      <url>http://www.worldoftest.com</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Remedy Repack</name>
      <url>http://www.remedyrepack.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Richmond Pharmacy</name>
      <url>http://www.richmondpharmacy.ca</url>
    </packager>
    <packager>
      <name>Sandhills Packaging Inc.</name>
      <url>http://www.sandhillspackaging.com</url>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>UDL Laboratories</name>
      <url>http://www.udllabs.com</url>
    </packager>
    <packager>
      <name>Vangard Labs Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Vintage Pharmaceuticals Inc.</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Gd searle llc</manufacturer>
    <manufacturer generic="true" url="">Actavis elizabeth llc</manufacturer>
    <manufacturer generic="true" url="">Amneal pharmaceuticals</manufacturer>
    <manufacturer generic="true" url="">Ascot hosp pharmaceuticals inc div travenol laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Ivax pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Lederle laboratories div american cyanamid co</manufacturer>
    <manufacturer generic="true" url="">Mutual pharmaceutical co inc</manufacturer>
    <manufacturer generic="true" url="">Mylan pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Purepac pharmaceutical co</manufacturer>
    <manufacturer generic="true" url="">Sandoz inc</manufacturer>
    <manufacturer generic="true" url="">Superpharm corp</manufacturer>
    <manufacturer generic="true" url="">Upsher smith laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Vangard laboratories inc div midway medical co</manufacturer>
    <manufacturer generic="true" url="">Vintage pharmaceuticals llc</manufacturer>
    <manufacturer generic="true" url="">Warner chilcott div warner lambert co</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Aldactazide 25-25 tablet</description>
      <cost currency="USD">1.04</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Aldactazide 25-25 mg tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Spironolactone 100 mg tablet</description>
      <cost currency="USD">1.45</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Aldactone 50 mg tablet</description>
      <cost currency="USD">1.84</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Aldactazide 50-50 tablet</description>
      <cost currency="USD">1.92</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Aldactazide 50-50 mg tablet</description>
      <cost currency="USD">2.02</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Aldactone 100 mg tablet</description>
      <cost currency="USD">2.14</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Spironolactone powder</description>
      <cost currency="USD">12.56</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Novo-Spiroton 25 mg Tablet</description>
      <cost currency="USD">0.11</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Spiroton 100 mg Tablet</description>
      <cost currency="USD">0.25</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Spironolactone 25 mg tablet</description>
      <cost currency="USD">0.5</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Spironolactone-HCTZ 25-25 mg tablet</description>
      <cost currency="USD">0.57</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Aldactone 25 mg tablet</description>
      <cost currency="USD">0.8</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Spironolactone 50 mg tablet</description>
      <cost currency="USD">0.83</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Agents causing hyperkalemia</category>
      <mesh-id/>
    </category>
    <category>
      <category>BSEP/ABCB11 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors</category>
      <mesh-id>D065687</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors (moderate)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Diuretics</category>
      <mesh-id>D004232</mesh-id>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Hormone Antagonists</category>
      <mesh-id>D006727</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hypotensive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lactones</category>
      <mesh-id>D007783</mesh-id>
    </category>
    <category>
      <category>Mineralocorticoid (Aldosterone) Receptor Antagonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Mineralocorticoid Receptor Antagonists</category>
      <mesh-id>D000451</mesh-id>
    </category>
    <category>
      <category>Natriuretic Agents</category>
      <mesh-id>D045283</mesh-id>
    </category>
    <category>
      <category>P-glycoprotein inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>Potassium-Sparing Diuretics</category>
      <mesh-id>D062865</mesh-id>
    </category>
    <category>
      <category>Pregnanes</category>
      <mesh-id>D011278</mesh-id>
    </category>
    <category>
      <category>Pregnenes</category>
      <mesh-id>D011283</mesh-id>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral</route>
      <strength>25 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C03DA01">
      <level code="C03DA">Aldosterone antagonists</level>
      <level code="C03D">POTASSIUM-SPARING AGENTS</level>
      <level code="C03">DIURETICS</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>24:32.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2ab2</pdb-entry>
    <pdb-entry>2oax</pdb-entry>
    <pdb-entry>3vhu</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00421.pdf?1556917394</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00421.pdf?1265922747</msds>
  <patents>
    <patent>
      <number>9757394</number>
      <country>United States</country>
      <approved>2017-09-12</approved>
      <expires>2036-10-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
    <food-interaction>Food increases the bioavailability of spironolactone by almost 100%. </food-interaction>
    <food-interaction>Spironolactone may decrease the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of orthostatic hypotension and syncope can be increased when Spironolactone is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The risk or severity of hypotension and orthostatic hypotension can be increased when Spironolactone is combined with Levodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Spironolactone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>Troglitazone may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>Erythromycin may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>Cimetidine may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>Bosentan may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>Vinblastine may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>Tamoxifen may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>Clofazimine may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>Tipranavir may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>Glyburide may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>Ketoconazole may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>Ursodeoxycholic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>Cholic Acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>Fusidic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>Simeprevir may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Lenvatinib may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>Letermovir may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>Valinomycin may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The therapeutic efficacy of Midodrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>The therapeutic efficacy of Bethanidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00221</drugbank-id>
      <name>Isoetharine</name>
      <description>The therapeutic efficacy of Isoetharine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The therapeutic efficacy of Etomidate can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The therapeutic efficacy of Clonidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The therapeutic efficacy of Metaraminol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The therapeutic efficacy of Guanabenz can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The therapeutic efficacy of Epinephrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The therapeutic efficacy of Tizanidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The therapeutic efficacy of Methoxamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The therapeutic efficacy of Dobutamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The therapeutic efficacy of Benzphetamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The therapeutic efficacy of Ritodrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The therapeutic efficacy of Terbutaline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00901</drugbank-id>
      <name>Bitolterol</name>
      <description>The therapeutic efficacy of Bitolterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The therapeutic efficacy of Salmeterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The therapeutic efficacy of Methyldopa can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The therapeutic efficacy of Formoterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The therapeutic efficacy of Salbutamol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The therapeutic efficacy of Guanfacine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01102</drugbank-id>
      <name>Arbutamine</name>
      <description>The therapeutic efficacy of Arbutamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The therapeutic efficacy of Pergolide can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The therapeutic efficacy of Ergometrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The therapeutic efficacy of Arformoterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Fenoterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01291</drugbank-id>
      <name>Pirbuterol</name>
      <description>The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The therapeutic efficacy of Ephedra sinica root can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The therapeutic efficacy of Ephedrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The therapeutic efficacy of Mephentermine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The therapeutic efficacy of Procaterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>The therapeutic efficacy of Bambuterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01537</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyphenethylamine</name>
      <description>The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01579</drugbank-id>
      <name>Phendimetrazine</name>
      <description>The therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The therapeutic efficacy of Celiprolol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The therapeutic efficacy of Nebivolol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The therapeutic efficacy of Lofexidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The therapeutic efficacy of Indacaterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05395</drugbank-id>
      <name>Amibegron</name>
      <description>The therapeutic efficacy of Amibegron can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The therapeutic efficacy of Nylidrin can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06190</drugbank-id>
      <name>Solabegron</name>
      <description>The therapeutic efficacy of Solabegron can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>The therapeutic efficacy of Droxidopa can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06706</drugbank-id>
      <name>Isometheptene</name>
      <description>The therapeutic efficacy of Isometheptene can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06707</drugbank-id>
      <name>Levonordefrin</name>
      <description>The therapeutic efficacy of Levonordefrin can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06711</drugbank-id>
      <name>Naphazoline</name>
      <description>The therapeutic efficacy of Naphazoline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06814</drugbank-id>
      <name>Protokylol</name>
      <description>The therapeutic efficacy of Protokylol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The therapeutic efficacy of Mirabegron can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08925</drugbank-id>
      <name>Adrafinil</name>
      <description>The therapeutic efficacy of Adrafinil can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08957</drugbank-id>
      <name>Hexoprenaline</name>
      <description>The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The therapeutic efficacy of Etilefrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The therapeutic efficacy of Befunolol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The therapeutic efficacy of Olodaterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The therapeutic efficacy of Vilanterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09202</drugbank-id>
      <name>Cirazoline</name>
      <description>The therapeutic efficacy of Cirazoline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The therapeutic efficacy of Synephrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The therapeutic efficacy of Moxonidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The therapeutic efficacy of Doxofylline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The therapeutic efficacy of Racepinephrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>The therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11373</drugbank-id>
      <name>Amitraz</name>
      <description>The therapeutic efficacy of Amitraz can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The therapeutic efficacy of Medetomidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The therapeutic efficacy of Xylazine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11541</drugbank-id>
      <name>Ractopamine</name>
      <description>The therapeutic efficacy of Ractopamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The therapeutic efficacy of Romifidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The therapeutic efficacy of Detomidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>The therapeutic efficacy of Etafedrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The therapeutic efficacy of Anisodamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11871</drugbank-id>
      <name>PF-00610355</name>
      <description>The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The therapeutic efficacy of Ritobegron can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12100</drugbank-id>
      <name>Abediterol</name>
      <description>The therapeutic efficacy of Abediterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12248</drugbank-id>
      <name>Tulobuterol</name>
      <description>The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12313</drugbank-id>
      <name>Dopexamine</name>
      <description>The therapeutic efficacy of Dopexamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Batefenterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>The therapeutic efficacy of Higenamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12846</drugbank-id>
      <name>Reproterol</name>
      <description>The therapeutic efficacy of Reproterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13251</drugbank-id>
      <name>Octopamine</name>
      <description>The therapeutic efficacy of Octopamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13378</drugbank-id>
      <name>Norfenefrine</name>
      <description>The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13398</drugbank-id>
      <name>Oxyfedrine</name>
      <description>The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13559</drugbank-id>
      <name>Rimiterol</name>
      <description>The therapeutic efficacy of Rimiterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The therapeutic efficacy of Methoxyphenamine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The therapeutic efficacy of Tretoquinol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The therapeutic efficacy of Prenalterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13781</drugbank-id>
      <name>Xamoterol</name>
      <description>The therapeutic efficacy of Xamoterol can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14752</drugbank-id>
      <name>Racephedrine</name>
      <description>The therapeutic efficacy of Racephedrine can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>Spironolactone may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>Spironolactone may increase the excretion rate of Codeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>Spironolactone may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>Spironolactone may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>Spironolactone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>Spironolactone may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Spironolactone may increase the excretion rate of Warfarin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Spironolactone may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00879</drugbank-id>
      <name>Emtricitabine</name>
      <description>Spironolactone may increase the excretion rate of Emtricitabine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>Spironolactone may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Spironolactone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Spironolactone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Spironolactone may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Spironolactone may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Spironolactone may increase the excretion rate of Dimetacrine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>Spironolactone may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14508</drugbank-id>
      <name>Lithium succinate</name>
      <description>Spironolactone may increase the excretion rate of Lithium succinate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The therapeutic efficacy of Mitotane can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Nitrofurantoin may increase the hyperkalemic activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Spironolactone may increase the arrhythmogenic activities of Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>Spironolactone may increase the neuromuscular blocking activities of Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The therapeutic efficacy of Abiraterone can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Aripiprazole lauroxil may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Nicorandil may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Spironolactone may decrease the excretion rate of Acetyldigitoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Spironolactone may decrease the excretion rate of Deslanoside which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Spironolactone may decrease the excretion rate of Ouabain which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Spironolactone may decrease the excretion rate of Oleandrin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>Spironolactone may decrease the excretion rate of Cymarin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>Spironolactone may decrease the excretion rate of Proscillaridin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>Spironolactone may decrease the excretion rate of Lanatoside C which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>Spironolactone may decrease the excretion rate of Gitoformate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>Spironolactone may decrease the excretion rate of Peruvoside which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Spironolactone may decrease the excretion rate of Digitoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meloxicam is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olsalazine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Choline magnesium trisalicylate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antrafenine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Taxifolin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Niflumic acid is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Metamizole is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Cimicoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Felbinac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuproxam is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Loxoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexibuprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic acid is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Firocoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Clonixin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Morniflumate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propacetamol is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Talniflumate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Robenacoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tepoxalin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flunixin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Polmacoxib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nitroaspirin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Betulinic Acid is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indobufen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ebselen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tinoridine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alclofenac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fentiazac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Suxibuzone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bumadizone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flunoxaprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Feprazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Difenpiramide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nifenazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lonazolac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenidap is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bendazac is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pranoprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propyphenazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proglumetacin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Guacetisal is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ethenzamide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carbaspirin calcium is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mofebutazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proquazone is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benorilate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pirprofen is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Imidazole salicylate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when SC-236 is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when NS-398 is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen axetil is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Linezolid may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the orthostatic hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>Butalbital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Pentobarbital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>Methohexital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>Thiopental may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>Primidone may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Methylphenobarbital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>Thiamylal may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>Amobarbital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>Hexobarbital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>Barbital may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>Barbexaclone may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of adverse effects can be increased when Streptokinase is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of adverse effects can be increased when Bortezomib is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The risk or severity of adverse effects can be increased when Ropinirole is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Bupivacaine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of adverse effects can be increased when Olanzapine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Nabilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Amphotericin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Apomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Conivaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide dinitrate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide dinitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Levosimendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01143</drugbank-id>
      <name>Amifostine</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Amifostine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Desflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01282</drugbank-id>
      <name>Carbetocin</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Carbetocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Amyl Nitrite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04899</drugbank-id>
      <name>Nesiritide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Nesiritide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09112</drugbank-id>
      <name>Nitrous acid</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Nitrous acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Valsartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Losartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01342</drugbank-id>
      <name>Forasartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Forasartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Saprisartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01349</drugbank-id>
      <name>Tasosartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of hyperkalemia can be increased when Saralasin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The risk or severity of hyperkalemia can be increased when Candesartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Omapatrilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Rescinnamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Spirapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Temocapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Zofenopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Delapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Benazeprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fosinoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ramiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14209</drugbank-id>
      <name>Trandolaprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Trandolaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14210</drugbank-id>
      <name>Moexiprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Moexiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Perindoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Quinaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Quinoline Yellow WS.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The metabolism of Torasemide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Lovastatin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The metabolism of Dapsone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The metabolism of Diethylstilbestrol can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The metabolism of Morphine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The metabolism of Methadone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The metabolism of Omeprazole can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Diltiazem can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The metabolism of Trimethadione can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The metabolism of Sulfadiazine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Sorafenib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The metabolism of Eszopiclone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Rosiglitazone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The metabolism of Cerivastatin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The metabolism of Lansoprazole can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The metabolism of Quinine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The metabolism of Zidovudine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Erlotinib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The metabolism of Cyclophosphamide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Zafirlukast can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Cisapride can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The metabolism of Chloroquine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The metabolism of Amodiaquine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The metabolism of Paramethadione can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Imatinib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The metabolism of Nicardipine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The metabolism of Simvastatin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The metabolism of Mycophenolate mofetil can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The metabolism of Tretinoin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Estradiol can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00799</drugbank-id>
      <name>Tazarotene</name>
      <description>The metabolism of Tazarotene can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The metabolism of Propofol can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The metabolism of Loperamide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Terbinafine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The metabolism of Repaglinide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The metabolism of Almotriptan can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The metabolism of Buprenorphine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Azelastine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Atorvastatin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The metabolism of Fluvastatin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The metabolism of Tolbutamide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The metabolism of Pioglitazone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The metabolism of Ifosfamide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Domperidone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The metabolism of Zopiclone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The metabolism of Halofantrine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The metabolism of Ketamine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The metabolism of Lapatinib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The metabolism of Sitagliptin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The metabolism of Mestranol can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The metabolism of Licofelone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The metabolism of Beraprost can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06510</drugbank-id>
      <name>Muraglitazar</name>
      <description>The metabolism of Muraglitazar can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Pazopanib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The metabolism of Apixaban can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The metabolism of Odanacatib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The metabolism of Ketobemidone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Seratrodast can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The metabolism of Cabazitaxel can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The metabolism of Pitavastatin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The metabolism of Enzalutamide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The metabolism of Ponatinib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The metabolism of Dabrafenib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The metabolism of Levomilnacipran can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The metabolism of Perospirone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The metabolism of Riociguat can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The metabolism of Dasabuvir can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The metabolism of Lobeglitazone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The metabolism of Netoglitazone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The metabolism of Rivoglitazone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The metabolism of Ciglitazone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The metabolism of Ombitasvir can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The metabolism of Selexipag can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The metabolism of Velpatasvir can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The metabolism of Apalutamide can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The metabolism of Glasdegib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The metabolism of Elagolix can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The metabolism of Voxilaprevir can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The metabolism of Brigatinib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The metabolism of Balaglitazone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Enasidenib can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The metabolism of Testosterone cypionate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The metabolism of Testosterone enanthate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The metabolism of Testosterone undecanoate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Estradiol acetate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Estradiol benzoate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Estradiol cypionate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Estradiol dienanthate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Estradiol valerate can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The metabolism of (S)-Warfarin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The metabolism of Montelukast can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08502</drugbank-id>
      <name>Capravirine</name>
      <description>The metabolism of Capravirine can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The metabolism of Anastrozole can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Esmolol is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Metoprolol is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Isradipine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Atenolol is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Timolol is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of hyperkalemia can be increased when Triamterene is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Nimodipine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Nisoldipine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cinnarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ethosuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Amiloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Levomenthol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dantrolene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02968</drugbank-id>
      <name>Penicillin G Acyl-Serine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Penicillin G Acyl-Serine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclandelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Seletracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tolvaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ammonium chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Agmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Canrenoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Pinaverium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Aranidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Azelnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Darodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Niludipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12097</drugbank-id>
      <name>Mannitol busulfan</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Mannitol busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Canrenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bencyclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lidoflazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Caroverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with WIN 55212-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fish oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09449</drugbank-id>
      <name>Sodium phosphate, monobasic</name>
      <description>Spironolactone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The risk or severity of hypotension and hyperkalemia can be increased when Candesartan cilexetil is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Spironolactone may increase the hypotensive activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium chloride is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium Iodide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09087</drugbank-id>
      <name>Potassium alum</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium alum is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium citrate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>The risk or severity of hyperkalemia can be increased when Monopotassium phosphate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>The risk or severity of hyperkalemia can be increased when Dipotassium phosphate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium perchlorate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09483</drugbank-id>
      <name>Potassium lactate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium lactate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11090</drugbank-id>
      <name>Potassium nitrate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11107</drugbank-id>
      <name>Potassium bitartrate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium bitartrate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11153</drugbank-id>
      <name>Potassium hydroxide</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium hydroxide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13620</drugbank-id>
      <name>Potassium gluconate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13735</drugbank-id>
      <name>Potassium Guaiacolsulfonate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium Guaiacolsulfonate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13831</drugbank-id>
      <name>Potassium permanganate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium permanganate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13977</drugbank-id>
      <name>Potassium carbonate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium carbonate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14492</drugbank-id>
      <name>Potassium triiodide</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium triiodide is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium sulfate is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Lactulose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Lubiprostone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01593</drugbank-id>
      <name>Zinc</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Zinc.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sorbitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04816</drugbank-id>
      <name>Dantron</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Dantron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04823</drugbank-id>
      <name>Oxyphenisatin</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Oxyphenisatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04824</drugbank-id>
      <name>Phenolphthalein</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Phenolphthalein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Prucalopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07715</drugbank-id>
      <name>Emodin</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Emodin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08890</drugbank-id>
      <name>Linaclotide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Linaclotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09020</drugbank-id>
      <name>Bisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Bisacodyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Bisoxatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Picosulfuric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09269</drugbank-id>
      <name>Phenylacetic acid</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Phenylacetic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09311</drugbank-id>
      <name>Polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Polycarbophil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium acetate tetrahydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Glycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09484</drugbank-id>
      <name>Sodium fluorophosphate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium fluorophosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Mineral oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11059</drugbank-id>
      <name>Carboxymethylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Carboxymethylcellulose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11089</drugbank-id>
      <name>Docusate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Docusate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11097</drugbank-id>
      <name>Plantago seed</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Plantago seed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11113</drugbank-id>
      <name>Castor oil</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Castor oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11228</drugbank-id>
      <name>Methylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Methylcellulose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11365</drugbank-id>
      <name>Sennosides</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sennosides.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12942</drugbank-id>
      <name>Lactitol</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Lactitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13170</drugbank-id>
      <name>Plecanatide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Plecanatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13180</drugbank-id>
      <name>Gluconic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Gluconic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13526</drugbank-id>
      <name>Pentaerithrityl</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Pentaerithrityl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13707</drugbank-id>
      <name>Sodium tartrate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium tartrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14232</drugbank-id>
      <name>Deacetylbisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Deacetylbisacodyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14482</drugbank-id>
      <name>Sodium ascorbate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14502</drugbank-id>
      <name>Sodium phosphate, dibasic</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14503</drugbank-id>
      <name>Sodium phosphate, monobasic, unspecified form</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium phosphate, monobasic, unspecified form.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14504</drugbank-id>
      <name>Sodium phosphate, dibasic, unspecified form</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium phosphate, dibasic, unspecified form.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14516</drugbank-id>
      <name>Sodium cation</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14585</drugbank-id>
      <name>Plantago ovata seed</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Plantago ovata seed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14627</drugbank-id>
      <name>Oxyphenisatin acetate</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Oxyphenisatin acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Calcium polycarbophil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14963</drugbank-id>
      <name>Konjac mannan</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Konjac mannan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15477</drugbank-id>
      <name>Alloin</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Alloin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15478</drugbank-id>
      <name>Frangula purshiana bark</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Frangula purshiana bark.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Dehydrocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>Dexamethasone may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>Deoxycholic acid may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>Taurocholic acid may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Spironolactone may decrease the excretion rate of Dipyridamole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Pravastatin may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>Nelfinavir may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>Glimepiride may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>Indinavir may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00301</drugbank-id>
      <name>Flucloxacillin</name>
      <description>Flucloxacillin may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>Terfenadine may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>Spironolactone may decrease the excretion rate of Ritonavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>Spironolactone may decrease the excretion rate of Atropine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>Spironolactone may decrease the excretion rate of Efavirenz which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>Spironolactone may decrease the excretion rate of Astemizole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>Spironolactone may decrease the excretion rate of Fluorescein which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>Spironolactone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>Spironolactone may decrease the excretion rate of Disulfiram which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Spironolactone may decrease the excretion rate of Mifepristone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>Spironolactone may decrease the excretion rate of Ezetimibe which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Spironolactone may decrease the excretion rate of Atazanavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>Spironolactone may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>Spironolactone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Spironolactone may decrease the excretion rate of Ofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>Spironolactone may decrease the excretion rate of Clarithromycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>Spironolactone may decrease the excretion rate of Saquinavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Spironolactone may decrease the excretion rate of Lopinavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>Spironolactone may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09374</drugbank-id>
      <name>Indocyanine green acid form</name>
      <description>Spironolactone may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>Spironolactone may decrease the excretion rate of Benzbromarone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>Spironolactone may decrease the excretion rate of Pilsicainide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>Spironolactone may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13751</drugbank-id>
      <name>Glycyrrhizic acid</name>
      <description>Spironolactone may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>Spironolactone may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>Spironolactone may decrease the excretion rate of Loratadine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>Aldesleukin may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ropivacaine may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>Tolcapone may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Pramipexole may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>Spironolactone may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Spironolactone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Spironolactone may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Spironolactone may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Spironolactone may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Spironolactone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>Spironolactone may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Spironolactone may increase the excretion rate of Empagliflozin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Spironolactone may increase the excretion rate of Sacubitril which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Spironolactone may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Spironolactone may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Spironolactone may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>Spironolactone may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Spironolactone may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Spironolactone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Spironolactone may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>Spironolactone may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Spironolactone may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Spironolactone may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Spironolactone may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Fluvoxamine may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Spironolactone may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Spironolactone may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>Spironolactone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Spironolactone may increase the excretion rate of Glipizide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Spironolactone may increase the excretion rate of Nefazodone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>Spironolactone may increase the excretion rate of Budesonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Spironolactone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Spironolactone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>Spironolactone may increase the excretion rate of Salmon Calcitonin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>Spironolactone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>Spironolactone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>Spironolactone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>Spironolactone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Spironolactone may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00165</drugbank-id>
      <name>Pyridoxine</name>
      <description>Spironolactone may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>Spironolactone may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>Spironolactone may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>Spironolactone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>Spironolactone may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00198</drugbank-id>
      <name>Oseltamivir</name>
      <description>Spironolactone may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00200</drugbank-id>
      <name>Hydroxocobalamin</name>
      <description>Spironolactone may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Spironolactone may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>Spironolactone may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00225</drugbank-id>
      <name>Gadodiamide</name>
      <description>Spironolactone may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Spironolactone may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>Spironolactone may increase the excretion rate of Butabarbital which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>Spironolactone may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>Spironolactone may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Spironolactone may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>Spironolactone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00271</drugbank-id>
      <name>Diatrizoate</name>
      <description>Spironolactone may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>Spironolactone may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Spironolactone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Spironolactone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Spironolactone may increase the excretion rate of Acarbose which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Spironolactone may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Spironolactone may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Spironolactone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>Spironolactone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Spironolactone may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>Spironolactone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00303</drugbank-id>
      <name>Ertapenem</name>
      <description>Spironolactone may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Spironolactone may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Spironolactone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>Spironolactone may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>Spironolactone may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00330</drugbank-id>
      <name>Ethambutol</name>
      <description>Spironolactone may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Spironolactone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00339</drugbank-id>
      <name>Pyrazinamide</name>
      <description>Spironolactone may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>Spironolactone may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>Spironolactone may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Spironolactone may increase the excretion rate of Megestrol acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00355</drugbank-id>
      <name>Aztreonam</name>
      <description>Spironolactone may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>Spironolactone may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Spironolactone may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>Spironolactone may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Spironolactone may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>Spironolactone may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>Spironolactone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>Spironolactone may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>Spironolactone may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>Spironolactone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>Spironolactone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Spironolactone may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>Spironolactone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>Spironolactone may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Spironolactone may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>Spironolactone may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>Spironolactone may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Spironolactone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>Spironolactone may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00548</drugbank-id>
      <name>Azelaic acid</name>
      <description>Spironolactone may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>Spironolactone may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>Spironolactone may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00558</drugbank-id>
      <name>Zanamivir</name>
      <description>Spironolactone may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Spironolactone may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>Spironolactone may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Spironolactone may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>Spironolactone may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>Spironolactone may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>Spironolactone may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00597</drugbank-id>
      <name>Gadoteridol</name>
      <description>Spironolactone may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Spironolactone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>Spironolactone may increase the excretion rate of Clorazepic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>Spironolactone may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>Spironolactone may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>Spironolactone may increase the excretion rate of Metaxalone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>Spironolactone may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Spironolactone may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Spironolactone may increase the excretion rate of Chlorpropamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Spironolactone may increase the excretion rate of Galantamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>Spironolactone may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>Spironolactone may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>Spironolactone may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>Spironolactone may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00716</drugbank-id>
      <name>Nedocromil</name>
      <description>Spironolactone may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>Spironolactone may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Spironolactone may increase the excretion rate of Nateglinide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00733</drugbank-id>
      <name>Pralidoxime</name>
      <description>Spironolactone may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Spironolactone may increase the excretion rate of Gadobenic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>Spironolactone may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00760</drugbank-id>
      <name>Meropenem</name>
      <description>Spironolactone may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Spironolactone may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Spironolactone may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Spironolactone may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>Spironolactone may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00789</drugbank-id>
      <name>Gadopentetic acid</name>
      <description>Spironolactone may increase the excretion rate of Gadopentetic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Spironolactone may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Spironolactone may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>Spironolactone may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00828</drugbank-id>
      <name>Fosfomycin</name>
      <description>Spironolactone may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Spironolactone may increase the excretion rate of Tolazamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>Spironolactone may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>Spironolactone may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>Spironolactone may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>Spironolactone may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>Spironolactone may increase the excretion rate of Testolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>Spironolactone may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Spironolactone may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>Spironolactone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>Spironolactone may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Spironolactone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>Spironolactone may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Spironolactone may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>Spironolactone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>Spironolactone may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Spironolactone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>Spironolactone may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>Spironolactone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>Spironolactone may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00995</drugbank-id>
      <name>Auranofin</name>
      <description>Spironolactone may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>Spironolactone may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>Spironolactone may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>Spironolactone may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01022</drugbank-id>
      <name>Phylloquinone</name>
      <description>Spironolactone may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Spironolactone may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>Spironolactone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>Spironolactone may increase the excretion rate of Probenecid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Spironolactone may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>Spironolactone may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>Spironolactone may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>Spironolactone may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>Spironolactone may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Spironolactone may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>Spironolactone may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>Spironolactone may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>Spironolactone may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Spironolactone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Spironolactone may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>Spironolactone may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Spironolactone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>Spironolactone may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Spironolactone may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>Spironolactone may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Spironolactone may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Spironolactone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01205</drugbank-id>
      <name>Flumazenil</name>
      <description>Spironolactone may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>Spironolactone may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01213</drugbank-id>
      <name>Fomepizole</name>
      <description>Spironolactone may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>Spironolactone may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Spironolactone may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>Spironolactone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>Spironolactone may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01249</drugbank-id>
      <name>Iodixanol</name>
      <description>Spironolactone may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>Spironolactone may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>Spironolactone may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>Spironolactone may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>Spironolactone may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Spironolactone may increase the excretion rate of Tiotropium which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>Spironolactone may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Spironolactone may increase the excretion rate of Testosterone propionate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01427</drugbank-id>
      <name>Amrinone</name>
      <description>Spironolactone may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01428</drugbank-id>
      <name>Oxybenzone</name>
      <description>Spironolactone may increase the excretion rate of Oxybenzone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>Spironolactone may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01550</drugbank-id>
      <name>Fenproporex</name>
      <description>Spironolactone may increase the excretion rate of Fenproporex which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>Spironolactone may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>Spironolactone may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>Spironolactone may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>Spironolactone may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Spironolactone may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Spironolactone may increase the excretion rate of Topiroxostat which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Spironolactone may increase the excretion rate of Estrone sulfate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>Spironolactone may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>Spironolactone may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Spironolactone may increase the excretion rate of Milnacipran which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Spironolactone may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05018</drugbank-id>
      <name>Migalastat</name>
      <description>Spironolactone may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>Spironolactone may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Spironolactone may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06154</drugbank-id>
      <name>Pentaerythritol tetranitrate</name>
      <description>Spironolactone may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>Spironolactone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Spironolactone may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Spironolactone may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Spironolactone may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06211</drugbank-id>
      <name>Doripenem</name>
      <description>Spironolactone may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Spironolactone may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06230</drugbank-id>
      <name>Nalmefene</name>
      <description>Spironolactone may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>Spironolactone may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Spironolactone may increase the excretion rate of Saxagliptin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Spironolactone may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06623</drugbank-id>
      <name>Flupirtine</name>
      <description>Spironolactone may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>Spironolactone may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Spironolactone may increase the excretion rate of Desvenlafaxine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>Spironolactone may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06705</drugbank-id>
      <name>Gadofosveset trisodium</name>
      <description>Spironolactone may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Spironolactone may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06782</drugbank-id>
      <name>Dimercaprol</name>
      <description>Spironolactone may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06796</drugbank-id>
      <name>Mangafodipir</name>
      <description>Spironolactone may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06800</drugbank-id>
      <name>Methylnaltrexone</name>
      <description>Spironolactone may increase the excretion rate of Methylnaltrexone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06809</drugbank-id>
      <name>Plerixafor</name>
      <description>Spironolactone may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>Spironolactone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06823</drugbank-id>
      <name>Tiopronin</name>
      <description>Spironolactone may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>Spironolactone may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08824</drugbank-id>
      <name>Ioflupane I-123</name>
      <description>Spironolactone may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08826</drugbank-id>
      <name>Deferiprone</name>
      <description>Spironolactone may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08840</drugbank-id>
      <name>N-methylnicotinamide</name>
      <description>Spironolactone may increase the excretion rate of N-methylnicotinamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>Spironolactone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>Spironolactone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>Spironolactone may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Spironolactone may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08900</drugbank-id>
      <name>Teduglutide</name>
      <description>Spironolactone may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>Spironolactone may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>Spironolactone may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>Spironolactone may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>Spironolactone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>Spironolactone may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>Spironolactone may increase the excretion rate of Gemeprost which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09050</drugbank-id>
      <name>Ceftolozane</name>
      <description>Spironolactone may increase the excretion rate of Ceftolozane which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin alfa</name>
      <description>Spironolactone may increase the excretion rate of Corifollitropin alfa which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>Spironolactone may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Spironolactone may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09081</drugbank-id>
      <name>Idebenone</name>
      <description>Spironolactone may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Spironolactone may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>Spironolactone may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09106</drugbank-id>
      <name>Hydroxyethyl Starch</name>
      <description>Spironolactone may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09111</drugbank-id>
      <name>Pentastarch</name>
      <description>Spironolactone may increase the excretion rate of Pentastarch which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>Spironolactone may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09121</drugbank-id>
      <name>Aurothioglucose</name>
      <description>Spironolactone may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Spironolactone may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09129</drugbank-id>
      <name>Chromic chloride</name>
      <description>Spironolactone may increase the excretion rate of Chromic chloride which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09132</drugbank-id>
      <name>Gadoteric acid</name>
      <description>Spironolactone may increase the excretion rate of Gadoteric acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09133</drugbank-id>
      <name>Iothalamic acid</name>
      <description>Spironolactone may increase the excretion rate of Iothalamic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09134</drugbank-id>
      <name>Ioversol</name>
      <description>Spironolactone may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09135</drugbank-id>
      <name>Ioxilan</name>
      <description>Spironolactone may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09136</drugbank-id>
      <name>Isosulfan blue</name>
      <description>Spironolactone may increase the excretion rate of Isosulfan blue which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09137</drugbank-id>
      <name>Technetium Tc-99m mebrofenin</name>
      <description>Spironolactone may increase the excretion rate of Technetium Tc-99m mebrofenin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Spironolactone may increase the excretion rate of Technetium Tc-99m oxidronate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09148</drugbank-id>
      <name>Florbetaben (18F)</name>
      <description>Spironolactone may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09149</drugbank-id>
      <name>Florbetapir (18F)</name>
      <description>Spironolactone may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09156</drugbank-id>
      <name>Iopromide</name>
      <description>Spironolactone may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09163</drugbank-id>
      <name>Technetium Tc-99m exametazime</name>
      <description>Spironolactone may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09164</drugbank-id>
      <name>Technetium Tc-99m disofenin</name>
      <description>Spironolactone may increase the excretion rate of Technetium Tc-99m disofenin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09165</drugbank-id>
      <name>Technetium Tc-99m pyrophosphate</name>
      <description>Spironolactone may increase the excretion rate of Technetium Tc-99m pyrophosphate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>Spironolactone may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Spironolactone may increase the excretion rate of Etoperidone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>Spironolactone may increase the excretion rate of Lorpiprazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Spironolactone may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09209</drugbank-id>
      <name>Pholcodine</name>
      <description>Spironolactone may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09210</drugbank-id>
      <name>Piracetam</name>
      <description>Spironolactone may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Spironolactone may increase the excretion rate of Blonanserin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Spironolactone may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Spironolactone may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09257</drugbank-id>
      <name>Gimeracil</name>
      <description>Spironolactone may increase the excretion rate of Gimeracil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Spironolactone may increase the excretion rate of Imidafenacin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>Spironolactone may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Spironolactone may increase the excretion rate of Lixisenatide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09276</drugbank-id>
      <name>Sodium aurothiomalate</name>
      <description>Spironolactone may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>Spironolactone may increase the excretion rate of Choline C 11 which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09301</drugbank-id>
      <name>Chondroitin sulfate</name>
      <description>Spironolactone may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Spironolactone may increase the excretion rate of Synthetic Conjugated Estrogens, A which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Spironolactone may increase the excretion rate of Synthetic Conjugated Estrogens, B which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>Spironolactone may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09324</drugbank-id>
      <name>Sulbactam</name>
      <description>Spironolactone may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09325</drugbank-id>
      <name>Sodium fluoride</name>
      <description>Spironolactone may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>Spironolactone may increase the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>Spironolactone may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09344</drugbank-id>
      <name>Invert sugar</name>
      <description>Spironolactone may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09357</drugbank-id>
      <name>Dexpanthenol</name>
      <description>Spironolactone may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09394</drugbank-id>
      <name>Phosphoric acid</name>
      <description>Spironolactone may increase the excretion rate of Phosphoric acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09395</drugbank-id>
      <name>Sodium acetate</name>
      <description>Spironolactone may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Spironolactone may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>Spironolactone may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09496</drugbank-id>
      <name>Octinoxate</name>
      <description>Spironolactone may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09502</drugbank-id>
      <name>Fludeoxyglucose (18F)</name>
      <description>Spironolactone may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09546</drugbank-id>
      <name>Iobenguane sulfate I-123</name>
      <description>Spironolactone may increase the excretion rate of Iobenguane sulfate I-123 which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>Spironolactone may increase the excretion rate of Polyethylene glycol 400 which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11102</drugbank-id>
      <name>N-acetyltyrosine</name>
      <description>Spironolactone may increase the excretion rate of N-acetyltyrosine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11114</drugbank-id>
      <name>Eucalyptus oil</name>
      <description>Spironolactone may increase the excretion rate of Eucalyptus oil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11127</drugbank-id>
      <name>Selenious acid</name>
      <description>Spironolactone may increase the excretion rate of Selenious acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11135</drugbank-id>
      <name>Selenium</name>
      <description>Spironolactone may increase the excretion rate of Selenium which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11136</drugbank-id>
      <name>Chromium</name>
      <description>Spironolactone may increase the excretion rate of Chromium which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11145</drugbank-id>
      <name>Oxyquinoline</name>
      <description>Spironolactone may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Spironolactone may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11164</drugbank-id>
      <name>Bicisate</name>
      <description>Spironolactone may increase the excretion rate of Bicisate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11251</drugbank-id>
      <name>Tocopherol</name>
      <description>Spironolactone may increase the excretion rate of Tocopherol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11328</drugbank-id>
      <name>Tetradecyl hydrogen sulfate (ester)</name>
      <description>Spironolactone may increase the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11338</drugbank-id>
      <name>Clove oil</name>
      <description>Spironolactone may increase the excretion rate of Clove oil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Spironolactone may increase the excretion rate of Evening primrose oil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11364</drugbank-id>
      <name>Pidotimod</name>
      <description>Spironolactone may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>Spironolactone may increase the excretion rate of Cefroxadine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>Spironolactone may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11577</drugbank-id>
      <name>Indigotindisulfonic acid</name>
      <description>Spironolactone may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Spironolactone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>Spironolactone may increase the excretion rate of Pitolisant which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11691</drugbank-id>
      <name>Naldemedine</name>
      <description>Spironolactone may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>Spironolactone may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>Spironolactone may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>Spironolactone may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Spironolactone may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11989</drugbank-id>
      <name>Benznidazole</name>
      <description>Spironolactone may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12007</drugbank-id>
      <name>Isoflavone</name>
      <description>Spironolactone may increase the excretion rate of Isoflavone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12107</drugbank-id>
      <name>Vaborbactam</name>
      <description>Spironolactone may increase the excretion rate of Vaborbactam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12151</drugbank-id>
      <name>Brincidofovir</name>
      <description>Spironolactone may increase the excretion rate of Brincidofovir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>Spironolactone may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Spironolactone may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12783</drugbank-id>
      <name>Benserazide</name>
      <description>Spironolactone may increase the excretion rate of Benserazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Spironolactone may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>Spironolactone may increase the excretion rate of Nedaplatin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13156</drugbank-id>
      <name>Inosine pranobex</name>
      <description>Spironolactone may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13178</drugbank-id>
      <name>Inositol</name>
      <description>Spironolactone may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13185</drugbank-id>
      <name>Oxabolone cipionate</name>
      <description>Spironolactone may increase the excretion rate of Oxabolone cipionate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13191</drugbank-id>
      <name>Phosphocreatine</name>
      <description>Spironolactone may increase the excretion rate of Phosphocreatine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13269</drugbank-id>
      <name>Dichlorobenzyl alcohol</name>
      <description>Spironolactone may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>Spironolactone may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Spironolactone may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>Spironolactone may increase the excretion rate of Fenofibric acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>Spironolactone may increase the excretion rate of Albutrepenonacog alfa which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Spironolactone may increase the excretion rate of Bismuth subgallate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>Spironolactone may increase the excretion rate of Patent Blue which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>Spironolactone may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14007</drugbank-id>
      <name>Pentetic acid</name>
      <description>Spironolactone may increase the excretion rate of Pentetic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>Spironolactone may increase the excretion rate of Tenofovir which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>Spironolactone may increase the excretion rate of Cinnamaldehyde which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14186</drugbank-id>
      <name>Cinnamyl alcohol</name>
      <description>Spironolactone may increase the excretion rate of Cinnamyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14526</drugbank-id>
      <name>Chromic citrate</name>
      <description>Spironolactone may increase the excretion rate of Chromic citrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14527</drugbank-id>
      <name>Chromic nitrate</name>
      <description>Spironolactone may increase the excretion rate of Chromic nitrate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14528</drugbank-id>
      <name>Chromium gluconate</name>
      <description>Spironolactone may increase the excretion rate of Chromium gluconate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14529</drugbank-id>
      <name>Chromium nicotinate</name>
      <description>Spironolactone may increase the excretion rate of Chromium nicotinate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14530</drugbank-id>
      <name>Chromous sulfate</name>
      <description>Spironolactone may increase the excretion rate of Chromous sulfate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>Spironolactone may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>Spironolactone may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06815</drugbank-id>
      <name>Pyrithione</name>
      <description>Spironolactone may increase the excretion rate of Pyrithione which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11121</drugbank-id>
      <name>Chloroxylenol</name>
      <description>Spironolactone may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>Spironolactone may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Spironolactone may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Spironolactone may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>Spironolactone may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>Spironolactone may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>Spironolactone may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Spironolactone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>Spironolactone may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15593</drugbank-id>
      <name>Golodirsen</name>
      <description>Spironolactone may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The metabolism of Phenprocoumon can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Fosphenytoin can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Ibopamine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13917</drugbank-id>
      <name>Deoxyepinephrine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Deoxyepinephrine is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Tramadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Hydromorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Oxycodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Butorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Naltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Nalbuphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Levorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Hydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Diphenoxylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Oxymorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dezocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Methadyl acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dihydroetorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Diamorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Bezitramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Etorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dextromoramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Desomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Carfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Alphacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dihydromorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Tapentadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with DPDPE.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Lofentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Eluxadoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Opium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Normethadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Piritramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Alphaprodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Nicomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Meptazinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Phenoperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Phenazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Tilidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Carfentanil, C-11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The therapeutic efficacy of Spironolactone can be decreased when used in combination with Benzhydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>The therapeutic efficacy of Remikiren can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>The therapeutic efficacy of Guanadrel can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Chlorthalidone can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>The therapeutic efficacy of Minoxidil can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The therapeutic efficacy of Treprostinil can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The therapeutic efficacy of Bendroflumethiazide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The therapeutic efficacy of Prazosin can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The therapeutic efficacy of Doxazosin can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>The therapeutic efficacy of Candoxatril can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The therapeutic efficacy of Nitroglycerin can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>The therapeutic efficacy of Metyrosine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The therapeutic efficacy of Hydroflumethiazide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>The therapeutic efficacy of Cryptenamine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The therapeutic efficacy of Tolazoline can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The therapeutic efficacy of Chlorothiazide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The therapeutic efficacy of Phenoxybenzamine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>The therapeutic efficacy of Deserpidine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Pentolinium can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Trimethaphan can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The therapeutic efficacy of Diazoxide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The therapeutic efficacy of Bretylium can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The therapeutic efficacy of Terazosin can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The therapeutic efficacy of Polythiazide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Dexpropranolol can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The therapeutic efficacy of Tienilic acid can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The therapeutic efficacy of Debrisoquine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The therapeutic efficacy of Sitaxentan can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The therapeutic efficacy of Ambrisentan can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>The therapeutic efficacy of Diethylnorspermine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>The therapeutic efficacy of Pinacidil can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Ferulic acid can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The therapeutic efficacy of Indoramin can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Hexamethonium can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>The therapeutic efficacy of Trimazosin can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>The therapeutic efficacy of Rauwolfia serpentina root can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>The therapeutic efficacy of Angiotensin 1-7 can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>The therapeutic efficacy of BQ-123 can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The therapeutic efficacy of Ketanserin can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The therapeutic efficacy of Urapidil can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The therapeutic efficacy of Cicletanine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The therapeutic efficacy of Dihydralazine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>The therapeutic efficacy of Guanoxan can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The therapeutic efficacy of Vincamine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The therapeutic efficacy of Linsidomine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>The therapeutic efficacy of Guanoxabenz can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>The therapeutic efficacy of Tolonidine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>The therapeutic efficacy of Endralazine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>The therapeutic efficacy of Cadralazine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>The therapeutic efficacy of Bietaserpine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>The therapeutic efficacy of Guanazodine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>The therapeutic efficacy of Methoserpidine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>The therapeutic efficacy of Guanoclor can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>The therapeutic efficacy of Muzolimine can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The therapeutic efficacy of Xipamide can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Tocopherylquinone can be increased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The serum concentration of Lithium cation can be increased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>The serum concentration of Lithium citrate can be increased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The serum concentration of Lithium carbonate can be increased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>The serum concentration of Lithium hydroxide can be increased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The serum concentration of Metildigoxin can be increased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The serum concentration of Acetyldigoxin can be increased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>The risk or severity of hyperkalemia can be increased when Potassium is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Afatinib can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The serum concentration of Brentuximab vedotin can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Paliperidone can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ledipasvir can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The serum concentration of Vincristine can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Sirolimus can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Quinidine can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Rifampicin can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The serum concentration of Paclitaxel can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Spironolactone may increase the excretion rate of Lefamulin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>The risk or severity of hyperkalemia and metabolic acidosis can be increased when Cholestyramine is combined with Spironolactone.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.98e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan]-6'-ene-5,5'-dione</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>spironolactone</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>416.573</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>416.202130202</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C24H32O4S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LXMSZDCAJNLERA-ZHYRCANASA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>60.44</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>113.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>46.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>18.01</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>134.5 °C</value>
      <source>[MSDS]</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>201</value>
      <source>[MSDS]</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.78</value>
      <source>https://www.ncbi.nlm.nih.gov/pubmed/26642673</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7408</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>9241</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5833</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508525</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07310</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00443</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5628</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50228080</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA451483</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>SNL</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000297</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>2875</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>2875</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Spironolactone</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1393</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/spiron.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ald1010.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/spironolactone.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000134</smpdb-id>
      <name>Spironolactone Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00151</drugbank-id>
          <name>L-Cysteine</name>
        </drug>
        <drug>
          <drugbank-id>DB00421</drugbank-id>
          <name>Spironolactone</name>
        </drug>
        <drug>
          <drugbank-id>DB01345</drugbank-id>
          <name>Potassium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB03904</drugbank-id>
          <name>Urea</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P08235</uniprot-id>
        <uniprot-id>P55017</uniprot-id>
        <uniprot-id>P05023</uniprot-id>
        <uniprot-id>P50993</uniprot-id>
        <uniprot-id>P13637</uniprot-id>
        <uniprot-id>Q13733</uniprot-id>
        <uniprot-id>P05026</uniprot-id>
        <uniprot-id>P14415</uniprot-id>
        <uniprot-id>P54709</uniprot-id>
        <uniprot-id>B7ZKV8</uniprot-id>
        <uniprot-id>P54710</uniprot-id>
        <uniprot-id>P51800</uniprot-id>
        <uniprot-id>P29972</uniprot-id>
        <uniprot-id>Q13621</uniprot-id>
        <uniprot-id>Q4U2R8</uniprot-id>
        <uniprot-id>Q9UHW9</uniprot-id>
        <uniprot-id>O15244</uniprot-id>
        <uniprot-id>P41181</uniprot-id>
        <uniprot-id>Q92482</uniprot-id>
        <uniprot-id>P37088</uniprot-id>
        <uniprot-id>P51168</uniprot-id>
        <uniprot-id>P51172</uniprot-id>
        <uniprot-id>P51170</uniprot-id>
        <uniprot-id>P43005</uniprot-id>
        <uniprot-id>Q9UHI5</uniprot-id>
        <uniprot-id>P08195</uniprot-id>
        <uniprot-id>Q01650</uniprot-id>
        <uniprot-id>Q9NP91</uniprot-id>
        <uniprot-id>Q969I6</uniprot-id>
        <uniprot-id>Q9UM01</uniprot-id>
        <uniprot-id>Q92536</uniprot-id>
        <uniprot-id>Q07837</uniprot-id>
        <uniprot-id>P82251</uniprot-id>
        <uniprot-id>Q15849</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00421</drugbank-id>
        <name>Spironolactone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02481</drugbank-id>
        <name>7alpha-thiospironolactone</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02481</drugbank-id>
        <name>7alpha-thiospironolactone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02482</drugbank-id>
        <name>Canrenone</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02481</drugbank-id>
        <name>7alpha-thiospironolactone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02483</drugbank-id>
        <name>7alpha-thiomethylspironolactone</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET02483</drugbank-id>
        <name>7alpha-thiomethylspironolactone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02484</drugbank-id>
        <name>3alpha-hydroxythiomethylspironolactone</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET02483</drugbank-id>
        <name>7alpha-thiomethylspironolactone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02485</drugbank-id>
        <name>3beta-hydroxythiomethylspironolactone</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000668</id>
      <name>Mineralocorticoid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A11833</ref-id>
            <pubmed-id>11791081</pubmed-id>
            <citation>Sitruk-Ware R: Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause. 2002 Jan-Feb;9(1):6-15.</citation>
          </article>
          <article>
            <ref-id>A11834</ref-id>
            <pubmed-id>14664717</pubmed-id>
            <citation>Rogerson FM, Yao YZ, Smith BJ, Dimopoulos N, Fuller PJ: Determinants of spironolactone binding specificity in the mineralocorticoid receptor. J Mol Endocrinol. 2003 Dec;31(3):573-82.</citation>
          </article>
          <article>
            <ref-id>A11835</ref-id>
            <pubmed-id>14978157</pubmed-id>
            <citation>Gertner RA, Klein JD, Bailey JL, Kim DU, Luo XH, Bagnasco SM, Sands JM: Aldosterone decreases UT-A1 urea transporter expression via the mineralocorticoid receptor. J Am Soc Nephrol. 2004 Mar;15(3):558-65.</citation>
          </article>
          <article>
            <ref-id>A11836</ref-id>
            <pubmed-id>15128471</pubmed-id>
            <citation>Frishman WH, Stier CT Jr: Aldosterone and aldosterone antagonism in systemic hypertension. Curr Hypertens Rep. 2004 Jun;6(3):195-200.</citation>
          </article>
          <article>
            <ref-id>A5444</ref-id>
            <pubmed-id>15554912</pubmed-id>
            <citation>Rogerson FM, Yao Y, Smith BJ, Fuller PJ: Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol. 2004 Oct;31(10):704-9.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A11837</ref-id>
            <pubmed-id>15947888</pubmed-id>
            <citation>Sica DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005 Jan;10(1):23-9. doi: 10.1007/s10741-005-2345-1.</citation>
          </article>
          <article>
            <ref-id>A11838</ref-id>
            <pubmed-id>15808807</pubmed-id>
            <citation>Rossi G, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005 Apr;16(3):104-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08235" source="Swiss-Prot">
        <name>Mineralocorticoid receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.</specific-function>
        <gene-name>NR3C2</gene-name>
        <locus>4q31.1</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.42</theoretical-pi>
        <molecular-weight>107066.575</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7979</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR3C2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M16801</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307166</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>626</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>626</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MCR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>MCR</synonym>
          <synonym>MLR</synonym>
          <synonym>MR</synonym>
          <synonym>Nuclear receptor subfamily 3 group C member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001332|Mineralocorticoid receptor
METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNST
QGSSKEKQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYE
QQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAI
VKSPIMCHEKSPSVCSPLNMTSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPN
AENRGSRSHSPAHASNVGSPLSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSP
ANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPVNNAFSYTASGTSAGSSTLRDVVP
SPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGAFSSSCLGGNSKINSD
SSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGILGPPVPGF
DGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSAR
DQSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPS
KICLVCGDEASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRL
QKCLQAGMNLGARKSKKLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVN
TALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQV
VKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKM
HQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYI
KELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAML
VEIISDQLPKVESGNAKPLYFHRK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020476|Mineralocorticoid receptor (NR3C2)
ATGGAGACCAAAGGCTACCACAGTCTCCCTGAAGGTCTAGATATGGAAAGACGGTGGGGT
CAAGTTTCTCAGGCTGTGGAGCGTTCTTCCCTGGGACCTACAGAGAGGACCGATGAGAAT
AACTACATGGAGATTGTCAACGTAAGCTGTGTTTCCGGTGCTATTCCAAACAACAGTACT
CAAGGAAGCAGCAAAGAAAAACAAGAACTACTCCCTTGCCTTCAGCAAGACAATAATCGG
CCTGGGATTTTAACATCTGATATTAAAACTGAGCTGGAATCTAAGGAACTTTCAGCAACT
GTAGCTGAGTCCATGGGTTTATATATGGATTCTGTAAGAGATGCTGACTATTCCTATGAG
CAGCAGAACCAACAAGGAAGCATGAGTCCAGCTAAGATTTATCAGAATGTTGAACAGCTG
GTGAAATTTTACAAAGGAAATGGCCATCGTCCTTCCACTCTAAGTTGTGTGAACACGCCC
TTGAGATCATTTATGTCTGACTCTGGGAGCTCCGTGAATGGTGGCGTCATGCGCGCCGTT
GTTAAAAGCCCTATCATGTGTCATGAGAAAAGCCCGTCTGTTTGCAGCCCTCTGAACATG
ACATCTTCGGTTTGCAGCCCTGCTGGAATCAACTCTGTGTCCTCCACCACAGCCAGCTTT
GGCAGTTTTCCAGTGCACAGCCCAATCACCCAGGGAACTCCTCTGACATGCTCCCCTAAT
GTTGAAAATCGAGGCTCCAGGTCGCACAGCCCTGCACATGCTAGCAATGTGGGCTCTCCT
CTCTCAAGTCCGTTAAGTAGCATGAAATCCTCAATTTCCAGCCCTCCAAGTCACTGCAGT
GTAAAATCTCCAGTCTCCAGTCCCAATAATGTCACTCTGAGATCCTCTGTGTCTAGCCCT
GCAAATATTAACAACTCAAGGTGCTCTGTTTCCAGCCCTTCGAACACTAATAACAGATCC
ACGCTTTCCAGTCCGGCAGCCAGTACTGTGGGATCTATCTGTAGCCCTGTAAACAATGCC
TTCAGCTACACTGCTTCTGGCACCTCTGCTGGATCCAGTACATTGCGGGATGTGGTTCCC
AGTCCAGACACGCAGGAGAAAGGTGCTCAAGAGGTCCCTTTTCCTAAGACTGAGGAAGTA
GAGAGTGCCATCTCAAATGGTGTGACTGGCCAGCTTAATATTGTCCAGTACATAAAACCA
GAACCAGATGGAGCTTTTAGCAGCTCATGTCTAGGAGGAAATAGCAAAATAAATTCGGAT
TCTTCATTCTCAGTACCAATAAAGCAAGAATCAACCAAGCATTCATGTTCAGGCACCTCT
TTTAAAGGGAATCCAACAGTAAACCCGTTTCCATTTATGGATGGCTCGTATTTTTCCTTT
ATGGATGATAAAGACTATTATTCCCTATCAGGAATTTTAGGACCACCTGTGCCCGGCTTT
GATGGTAACTGTGAAGGCAGCGGATTCCCAGTGGGTATTAAACAAGAACCAGATGATGGG
AGCTATTACCCAGAGGCCAGCATCCCTTCCTCTGCTATTGTTGGGGTGAATTCAGGTGGA
CAGTCCTTCCACTACAGGATTGGTGCTCAAGGTACAATATCTTTATCACGATCGGCTAGA
GACCAATCTTTCCAACACCTGAGTTCCTTTCCTCCTGTCAATACTTTAGTGGAGTCATGG
AAATCACACGGCGACCTGTCGTCTAGAAGAAGTGATGGGTATCCGGTCTTAGAATACATT
CCAGAAAATGTATCAAGCTCTACTTTACGAAGTGTTTCTACTGGATCTTCAAGACCTTCA
AAAATATGTTTGGTGTGTGGGGATGAGGCTTCAGGATGCCATTATGGGGTAGTCACCTGT
GGCAGCTGCAAAGTTTTCTTCAAAAGAGCAGTGGAAGGGCAACACAACTATTTATGTGCT
GGAAGAAATGATTGCATCATTGATAAGATTCGACGAAAGAATTGTCCTGCTTGCAGACTT
CAGAAATGTCTTCAAGCTGGAATGAATTTAGGAGCACGAAAGTCAAAGAAGTTGGGAAAG
TTAAAAGGGATTCACGAGGAGCAGCCACAGCAGCAGCAGCCCCCACCCCCACCCCCACCC
CCGCAAAGCCCAGAGGAAGGGACAACGTACATCGCTCCTGCAAAAGAACCCTCGGTCAAC
ACAGCACTGGTTCCTCAGCTCTCCACAATCTCACGAGCGCTCACACCTTCCCCCGTTATG
GTCCTTGAAAACATTGAACCTGAAATTGTATATGCAGGCTATGACAGCTCAAAACCAGAT
ACAGCCGAAAATCTGCTCTCCACGCTCAACCGCTTAGCAGGCAAACAGATGATCCAAGTC
GTGAAGTGGGCAAAGGTACTTCCAGGATTTAAAAACTTGCCTCTTGAGGACCAAATTACC
CTAATCCAGTATTCTTGGATGTGTCTATCATCATTTGCCTTGAGCTGGAGATCGTACAAA
CATACGAACAGCCAATTTCTCTATTTTGCACCAGACCTAGTCTTTAATGAAGAGAAGATG
CATCAGTCTGCCATGTATGAACTATGCCAGGGGATGCACCAAATCAGCCTTCAGTTCGTT
CGACTGCAGCTCACCTTTGAAGAATACACCATCATGAAAGTTTTGCTGCTACTAAGCACA
ATTCCAAAGGATGGCCTCAAAAGCCAGGCTGCATTTGAAGAAATGAGGACAAATTACATC
AAAGAACTGAGGAAGATGGTAACTAAGTGTCCCAACAATTCTGGGCAGAGCTGGCAGAGG
TTCTACCAACTGACCAAGCTGCTGGACTCCATGCATGACCTGGTGAGCGACCTGCTGGAA
TTCTGCTTCTACACCTTCCGAGAGTCCCATGCGCTGAAGGTAGAGTTCCCCGCAATGCTG
GTGGAGATCATCAGCGACCAGCTGCCCAAGGTGGAGTCGGGGAACGCCAAGCCGCTCTAC
TTCCACCGGAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000132</id>
      <name>Androgen receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17181</ref-id>
            <pubmed-id>18819053</pubmed-id>
            <citation>Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE: Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis. Horm Metab Res. 2009 Jan;41(1):35-9. doi: 10.1055/s-0028-1087188. Epub 2008 Sep 25.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10275" source="Swiss-Prot">
        <name>Androgen receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.</specific-function>
        <gene-name>AR</gene-name>
        <locus>Xq11.2-q12</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.38</theoretical-pi>
        <molecular-weight>98987.9</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:644</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>AR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M20132</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178628</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>628</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>628</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10275</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ANDR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>DHTR</synonym>
          <synonym>Dihydrotestosterone receptor</synonym>
          <synonym>NR3C4</synonym>
          <synonym>Nuclear receptor subfamily 3 group C member 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000263|Androgen receptor
MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQ
QQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSA
LECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLK
DILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKA
VSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKS
TEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSR
DYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGP
GSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPY
GYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLE
TARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRND
CTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLT
VSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAK
ALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRM
YSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDR
IIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIIS
VQVPKILSGKVKPIYFHTQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020451|Androgen receptor (AR)
ATGGAAGTGCAGTTAGGGCTGGGAAGGGTCTACCCTCGGCCGCCGTCCAAGACCTACCGA
GGAGCTTTCCAGAATCTGTTCCAGAGCGTGCGCGAAGTGATCCAGAACCCGGGCCCCAGG
CACCCAGAGGCCGCGAGCGCAGCACCTCCCGGCGCCAGTTTGCTGCTGCTGCAGCAGCAG
CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAA
GAGACTAGCCCCAGGCAGCAGCAGCAGCAGCAGGGTGAGGATGGTTCTCCCCAAGCCCAT
CGTAGAGGCCCCACAGGCTACCTGGTCCTGGATGAGGAACAGCAACCTTCACAGCCGCAG
TCGGCCCTGGAGTGCCACCCCGAGAGAGGTTGCGTCCCAGAGCCTGGAGCCGCCGTGGCC
GCCAGCAAGGGGCTGCCGCAGCAGCTGCCAGCACCTCCGGACGAGGATGACTCAGCTGCC
CCATCCACGTTGTCCCTGCTGGGCCCCACTTTCCCCGGCTTAAGCAGCTGCTCCGCTGAC
CTTAAAGACATCCTGAGCGAGGCCAGCACCATGCAACTCCTTCAGCAACAGCAGCAGGAA
GCAGTATCCGAAGGCAGCAGCAGCGGGAGAGCGAGGGAGGCCTCGGGGGCTCCCACTTCC
TCCAAGGACAATTACTTAGGGGGCACTTCGACCATTTCTGACAACGCCAAGGAGTTGTGT
AAGGCAGTGTCGGTGTCCATGGGCCTGGGTGTGGAGGCGTTGGAGCATCTGAGTCCAGGG
GAACAGCTTCGGGGGGATTGCATGTACGCCCCACTTTTGGGAGTTCCACCCGCTGTGCGT
CCCACTCCTTGTGCCCCATTGGCCGAATGCAAAGGTTCTCTGCTAGACGACAGCGCAGGC
AAGAGCACTGAAGATACTGCTGAGTATTCCCCTTTCAAGGGAGGTTACACCAAAGGGCTA
GAAGGCGAGAGCCTAGGCTGCTCTGGCAGCGCTGCAGCAGGGAGCTCCGGGACACTTGAA
CTGCCGTCTACCCTGTCTCTCTACAAGTCCGGAGCACTGGACGAGGCAGCTGCGTACCAG
AGTCGCGACTACTACAACTTTCCACTGGCTCTGGCCGGACCGCCGCCCCCTCCGCCGCCT
CCCCATCCCCACGCTCGCATCAAGCTGGAGAACCCGCTGGACTACGGCAGCGCCTGGGCG
GCTGCGGCGGCGCAGTGCCGCTATGGGGACCTGGCGAGCCTGCATGGCGCGGGTGCAGCG
GGACCCGGTTCTGGGTCACCCTCAGCCGCCGCTTCCTCATCCTGGCACACTCTCTTCACA
GCCGAAGAAGGCCAGTTGTATGGACCGTGTGGTGGTGGTGGGGGTGGTGGCGGCGGCGGC
GGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGAGGCGGGAGCTGTAGCCCCC
TACGGCTACACTCGGCCCCCTCAGGGGCTGGCGGGCCAGGAAAGCGACTTCACCGCACCT
GATGTGTGGTACCCTGGCGGCATGGTGAGCAGAGTGCCCTATCCCAGTCCCACTTGTGTC
AAAAGCGAAATGGGCCCCTGGATGGATAGCTACTCCGGACCTTACGGGGACATGCGTTTG
GAGACTGCCAGGGACCATGTTTTGCCCATTGACTATTACTTTCCACCCCAGAAGACCTGC
CTGATCTGTGGAGATGAAGCTTCTGGGTGTCACTATGGAGCTCTCACATGTGGAAGCTGC
AAGGTCTTCTTCAAAAGAGCCGCTGAAGGGAAACAGAAGTACCTGTGCGCCAGCAGAAAT
GATTGCACTATTGATAAATTCCGAAGGAAAAATTGTCCATCTTGTCGTCTTCGGAAATGT
TATGAAGCAGGGATGACTCTGGGAGCCCGGAAGCTGAAGAAACTTGGTAATCTGAAACTA
CAGGAGGAAGGAGAGGCTTCCAGCACCACCAGCCCCACTGAGGAGACAACCCAGAAGCTG
ACAGTGTCACACATTGAAGGCTATGAATGTCAGCCCATCTTTCTGAATGTCCTGGAAGCC
ATTGAGCCAGGTGTAGTGTGTGCTGGACACGACAACAACCAGCCCGACTCCTTTGCAGCC
TTGCTCTCTAGCCTCAATGAACTGGGAGAGAGACAGCTTGTACACGTGGTCAAGTGGGCC
AAGGCCTTGCCTGGCTTCCGCAACTTACACGTGGACGACCAGATGGCTGTCATTCAGTAC
TCCTGGATGGGGCTCATGGTGTTTGCCATGGGCTGGCGATCCTTCACCAATGTCAACTCC
AGGATGCTCTACTTCGCCCCTGATCTGGTTTTCAATGAGTACCGCATGCACAAGTCCCGG
ATGTACAGCCAGTGTGTCCGAATGAGGCACCTCTCTCAAGAGTTTGGATGGCTCCAAATC
ACCCCCCAGGAATTCCTGTGCATGAAAGCACTGCTACTCTTCAGCATTATTCCAGTGGAT
GGGCTGAAAAATCAAAAATTCTTTGATGAACTTCGAATGAACTACATCAAGGAACTCGAT
CGTATCATTGCATGCAAAAGAAAAAATCCCACATCCTGCTCAAGACGCTTCTACCAGCTC
ACCAAGCTCCTGGACTCCGTGCAGCCTATTGCGAGAGAGCTGCATCAGTTCACTTTTGAC
CTGCTAATCAAGTCACACATGGTGAGCGTGGACTTTCCGGAAATGATGGCAGAGATCATC
TCTGTGCAAGTGCCCAAGATCCTTTCTGGGAAAGTCAAGCCCATCTATTTCCACACCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF02166</identifier>
            <name>Androgen_recep</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androgen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androgen receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-catenin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein dimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription regulatory region DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of extrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of integrin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of integrin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase III promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostate gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of establishment of protein localization to plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sex differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0000557</id>
      <name>Progesterone receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18226</ref-id>
            <pubmed-id>20650892</pubmed-id>
            <citation>Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P: A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P06401" source="Swiss-Prot">
        <name>Progesterone receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.</specific-function>
        <gene-name>PGR</gene-name>
        <locus>11q22-q23</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.45</theoretical-pi>
        <molecular-weight>98979.96</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8910</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PGR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X51730</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35652</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>627</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>627</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06401</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PRGR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR3C3</synonym>
          <synonym>Nuclear receptor subfamily 3 group C member 3</synonym>
          <synonym>PR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001112|Progesterone receptor
MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLF
PRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLA
PSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAA
AHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGK
PRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTV
MDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPD
CAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLG
PPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPC
KAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPP
YLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHN
YLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPV
GVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQ
LGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAP
DLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQ
FEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRA
LSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010387|Progesterone receptor (PGR)
ATGACTGAGCTGAAGGCAAAGGGTCCCCGGGCTCCCCACGTGGCGGGCGGCCCGCCCTCC
CCCGAGGTCGGATCCCCACTGCTGTGTCGCCCAGCCGCAGGTCCGTTCCCGGGGAGCCAG
ACCTCGGACACCTTGCCTGAAGTTTCGGCCATACCTATCTCCCTGGACGGGCTACTCTTC
CCTCGGCCCTGCCAGGGACAGGACCCCTCCGACGAAAAGACGCAGGACCAGCAGTCGCTG
TCGGACGTGGAGGGCGCATATTCCAGAGCTGAAGCTACAAGGGGTGCTGGAGGCAGCAGT
TCTAGTCCCCCAGAAAAGGACAGCGGACTGCTGGACAGTGTCTTGGACACTCTGTTGGCG
CCCTCAGGTCCCGGGCAGAGCCAACCCAGCCCTCCCGCCTGCGAGGTCACCAGCTCTTGG
TGCCTGTTTGGCCCCGAACTTCCCGAAGATCCACCGGCTGCCCCCGCCACCCAGCGGGTG
TTGTCCCCGCTCATGAGCCGGTCCGGGTGCAAGGTTGGAGACAGCTCCGGGACGGCAGCT
GCCCATAAAGTGCTGCCCCGGGGCCTGTCACCAGCCCGGCAGCTGCTGCTCCCGGCCTCT
GAGAGCCCTCACTGGTCCGGGGCCCCAGTGAAGCCGTCTCCGCAGGCCGCTGCGGTGGAG
GTTGAGGAGGAGGATGGCTCTGAGTCCGAGGAGTCTGCGGGTCCGCTTCTGAAGGGCAAA
CCTCGGGCTCTGGGTGGCGCGGCGGCTGGAGGAGGAGCCGCGGCTGTCCCGCCGGGGGCG
GCAGCAGGAGGCGTCGCCCTGGTCCCCAAGGAAGATTCCCGCTTCTCAGCGCCCAGGGTC
GCCCTGGTGGAGCAGGACGCGCCGATGGCGCCCGGGCGCTCCCCGCTGGCCACCACGGTG
ATGGATTTCATCCACGTGCCTATCCTGCCTCTCAATCACGCCTTATTGGCAGCCCGCACT
CGGCAGCTGCTGGAAGACGAAAGTTACGACGGCGGGGCCGGGGCTGCCAGCGCCTTTGCC
CCGCCGCGGAGTTCACCCTGTGCCTCGTCCACCCCGGTCGCTGTAGGCGACTTCCCCGAC
TGCGCGTACCCGCCCGACGCCGAGCCCAAGGACGACGCGTACCCTCTCTATAGCGACTTC
CAGCCGCCCGCTCTAAAGATAAAGGAGGAGGAGGAAGGCGCGGAGGCCTCCGCGCGCTCC
CCGCGTTCCTACCTTGTGGCCGGTGCCAACCCCGCAGCCTTCCCGGATTTCCCGTTGGGG
CCACCGCCCCCGCTGCCGCCGCGAGCGACCCCATCCAGACCCGGGGAAGCGGCGGTGACG
GCCGCACCCGCCAGTGCCTCAGTCTCGTCTGCGTCCTCCTCGGGGTCGACCCTGGAGTGC
ATCCTGTACAAAGCGGAGGGCGCGCCGCCCCAGCAGGGCCCGTTCGCGCCGCCGCCCTGC
AAGGCGCCGGGCGCGAGCGGCTGCCTGCTCCCGCGGGACGGCCTGCCCTCCACCTCCGCC
TCTGCCGCCGCCGCCGGGGCGGCCCCCGCGCTCTACCCTGCACTCGGCCTCAACGGGCTC
CCGCAGCTCGGCTACCAGGCCGCCGTGCTCAAGGAGGGCCTGCCGCAGGTCTACCCGCCC
TATCTCAACTACCTGAGGCCGGATTCAGAAGCCAGCCAGAGCCCACAATACAGCTTCGAG
TCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCATTATGGT
GTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAGCACAAC
TACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCGCAGAAAAAACTGCCCA
GCATGTCGCCTTAGAAAGTGCTGTCAGGCTGGCATGGTCCTTGGAGGTCGAAAATTTAAA
AAGTTCAATAAAGTCAGAGTTGTGAGAGCACTGGATGCTGTTGCTCTCCCACAGCCAGTG
GGCGTTCCAAATGAAAGCCAAGCCCTAAGCCAGAGATTCACTTTTTCACCAGGTCAAGAC
ATACAGTTGATTCCACCACTGATCAACCTGTTAATGAGCATTGAACCAGATGTGATCTAT
GCAGGACATGACAACACAAAACCTGACACCTCCAGTTCTTTGCTGACAAGTCTTAATCAA
CTAGGCGAGAGGCAACTTCTTTCAGTAGTCAAGTGGTCTAAATCATTGCCAGGTTTTCGA
AACTTACATATTGATGACCAGATAACTCTCATTCAGTATTCTTGGATGAGCTTAATGGTG
TTTGGTCTAGGATGGAGATCCTACAAACACGTCAGTGGGCAGATGCTGTATTTTGCACCT
GATCTAATACTAAATGAACAGCGGATGAAAGAATCATCATTCTATTCATTATGCCTTACC
ATGTGGCAGATCCCACAGGAGTTTGTCAAGCTTCAAGTTAGCCAAGAAGAGTTCCTCTGT
ATGAAAGTATTGTTACTTCTTAATACAATTCCTTTGGAAGGGCTACGAAGTCAAACCCAG
TTTGAGGAGATGAGGTCAAGCTACATTAGAGAGCTCATCAAGGCAATTGGTTTGAGGCAA
AAAGGAGTTGTGTCGAGCTCACAGCGTTTCTATCAACTTACAAAACTTCTTGATAACTTG
CATGATCTTGTCAAACAACTTCATCTGTACTGCTTGAATACATTTATCCAGTCCCGGGCA
CTGAGTGTTGAATTTCCAGAAATGATGTCTGAAGTTATTGCTGCACAATTACCCAAGATA
TTGGCAGGGATGGTGAAACCCCTTCTCTTTCATAAAAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF02161</identifier>
            <name>Prog_receptor</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial outer membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung alveolus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ovulation from ovarian follicle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>paracrine signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>progesterone receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tertiary branching involved in mammary gland duct morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000794</id>
      <name>Glucocorticoid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18226</ref-id>
            <pubmed-id>20650892</pubmed-id>
            <citation>Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P: A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04150" source="Swiss-Prot">
        <name>Glucocorticoid receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic genes expression.</specific-function>
        <gene-name>NR3C1</gene-name>
        <locus>5q31.3</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.31</theoretical-pi>
        <molecular-weight>85658.57</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7978</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR3C1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X03225</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31680</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04150</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GCR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GR</synonym>
          <synonym>GRL</synonym>
          <synonym>Nuclear receptor subfamily 3 group C member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001584|Glucocorticoid receptor
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK
LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN
VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN
SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV
YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG
SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL
CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK
CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE
PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW
MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY
EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK
LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020486|Glucocorticoid receptor (NR3C1)
ATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCAGCAGTGTGCTTGCT
CAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAG
GTTTCTGCGTCTTCACCCTCACTGGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGA
CTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAA
GCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAAT
GACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG
CTTTTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAAG
AGTTCAGCATCCACTGCTGTGTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCAC
TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAAT
GTGAAATTGTATACCACAGACCAAAGCACCTTTGACATTTTGCAGGATTTGGAGTTTTCT
TCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTGGAGATCAGACCTGTTGATAGAT
GAAAACTGTTTGCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAAC
TCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATAAT
GGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTGAAAACAGAAAAA
GAAGATTTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCACAGTT
TACTGTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTCT
GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCC
CTTTCTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCGTTGGT
TCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCTCTGGGGACT
CTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCA
GATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTC
TGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGC
TGTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTACCTATGTGCTGGAAGG
AATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATCGAAAA
TGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAAATAAAAGGAATT
CAGCAGGCCACTACAGGAGTCTCACAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA
GTTCCTGCAACGTTACCACAACTCACCCCTACCCTGGTGTCACTGTTGGAGGTTATTGAA
CCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATG
ACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGAAATGGGCAAAGGCA
ATACCAGGTTTCAGGAACTTACACCTGGATGACCAAATGACCCTACTGCAGTACTCCTGG
ATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCAAGTGCAAACCTG
CTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGCATGTAC
GACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTAT
GAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCTAAGGACGGTCTG
AAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCC
ATTGTCAAGAGGGAAGGAAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAA
CTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACTATTGCTTCCAAACATTT
TTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAG
ATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAAAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF02155</identifier>
            <name>GCR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid-activated RNA polymerase II transcription factor binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to steroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0003542</id>
      <name>Cytochrome P450 11B2, mitochondrial</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16886</ref-id>
            <pubmed-id>976190</pubmed-id>
            <citation>Cheng SC, Suzuki K, Sadee W, Harding BW: Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrinology. 1976 Oct;99(4):1097-106.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P19099" source="Swiss-Prot">
        <name>Cytochrome P450 11B2, mitochondrial</name>
        <general-function>Steroid 11-beta-monooxygenase activity</general-function>
        <specific-function>Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.</specific-function>
        <gene-name>CYP11B2</gene-name>
        <locus>8q21-q22</locus>
        <cellular-location>Mitochondrion membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.78</theoretical-pi>
        <molecular-weight>57559.62</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2592</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X54741</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35200</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1360</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P19099</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>C11B2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ALDOS</synonym>
          <synonym>Aldosterone synthase</synonym>
          <synonym>Aldosterone-synthesizing enzyme</synonym>
          <synonym>CYPXIB2</synonym>
          <synonym>Cytochrome P-450Aldo</synonym>
          <synonym>Cytochrome P-450C18</synonym>
          <synonym>Steroid 18-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017134|Cytochrome P450 11B2, mitochondrial
MALRAKAEVCVAAPWLSLQRARALGTRAARAPRTVLPFEAMPQHPGNRWLRLLQIWREQG
YEHLHLEMHQTFQELGPIFRYNLGGPRMVCVMLPEDVEKLQQVDSLHPCRMILEPWVAYR
QHRGHKCGVFLLNGPEWRFNRLRLNPDVLSPKAVQRFLPMVDAVARDFSQALKKKVLQNA
RGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFM
PRSLSRWISPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFNRPQHYTGIVAELLLKAELS
LEAIKANSMELTAGSVDTTAFPLLMTLFELARNPDVQQILRQESLAAAASISEHPQKATT
ELPLLRAALKETLRLYPVGLFLERVVSSDLVLQNYHIPAGTLVQVFLYSLGRNAALFPRP
ERYNPQRWLDIRGSGRNFHHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHFLVETLTQED
IKMVYSFILRPGTSPLLTFRAIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017135|Cytochrome P450 11B2, mitochondrial (CYP11B2)
ATGGCACTCAGGGCAAAGGCAGAGGTGTGCGTGGCAGCGCCCTGGCTGTCCCTGCAAAGG
GCACGGGCACTGGGCACTAGAGCCGCTCGGGCCCCTAGGACGGTGCTGCCGTTTGAAGCC
ATGCCCCAGCATCCAGGCAACAGGTGGCTGAGGCTGCTGCAGATCTGGAGGGAGCAGGGT
TATGAGCACCTGCACCTGGAGATGCACCAGACCTTCCAGGAGCTGGGGCCCATTTTCAGG
TACAACTTGGGAGGACCACGCATGGTGTGTGTGATGCTGCCGGAGGATGTGGAGAAGCTG
CAACAGGTGGACAGCCTGCATCCCTGCAGGATGATCCTGGAGCCCTGGGTGGCCTACAGA
CAACATCGTGGGCACAAATGTGGCGTGTTCTTGTTGAATGGGCCTGAATGGCGCTTCAAC
CGATTGCGGCTGAACCCAGATGTGCTGTCGCCCAAGGCCGTGCAGAGGTTCCTCCCGATG
GTGGATGCAGTGGCCAGGGACTTCTCCCAGGCCCTGAAGAAGAAGGTGCTGCAGAACGCC
CGGGGGAGCCTGACCCTGGACGTCCAGCCCAGCATCTTCCACTACACCATAGAAGCCAGC
AACTTAGCTCTTTTTGGAGAGCGGCTGGGCCTGGTTGGCCACAGCCCCAGTTCTGCCAGC
CTGAACTTCCTCCATGCCCTGGAGGTCATGTTCAAATCCACCGTCCAGCTCATGTTCATG
CCCAGGAGCCTGTCTCGCTGGATCAGCCCCAAGGTGTGGAAGGAGCACTTTGAGGCCTGG
GACTGCATCTTCCAGTACGGTGACAACTGTATCCAGAAAATCTACCAGGAACTGGCCTTC
AACCGCCCTCAACACTACACAGGCATCGTGGCGGAGCTCCTGTTGAAGGCGGAACTGTCA
CTAGAAGCCATCAAGGCCAACTCTATGGAACTCACTGCAGGGAGCGTGGACACGACAGCG
TTTCCCTTGCTGATGACGCTCTTTGAGCTGGCTCGGAACCCCGACGTGCAGCAGATCCTG
CGCCAGGAGAGCCTGGCCGCCGCAGCCAGCATCAGTGAACATCCCCAGAAGGCAACCACC
GAGCTGCCCTTGCTGCGGGCGGCCCTCAAGGAGACCTTGCGGCTCTACCCTGTGGGTCTG
TTTTTGGAGCGAGTGGTGAGCTCAGACTTGGTGCTTCAGAACTACCACATCCCAGCTGGG
ACATTGGTACAGGTTTTCCTCTACTCGCTGGGTCGCAATGCCGCCTTGTTCCCGAGGCCT
GAGCGGTATAATCCCCAGCGCTGGCTAGACATCAGGGGCTCCGGCAGGAACTTCCACCAC
GTGCCCTTTGGCTTTGGCATGCGCCAGTGCCTCGGGCGGCGCCTGGCAGAGGCAGAGATG
CTGCTGCTGCTGCACCACGTGCTGAAGCACTTCCTGGTGGAGACACTAACTCAAGAGGAC
ATAAAGATGGTCTACAGCTTCATATTGAGGCCTGGCACGTCCCCCCTCCTCACTTTCAGA
GCGATTAACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>corticosterone 18-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid 11-beta-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aldosterone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>C21-steroid hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to peptide hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to potassium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cortisol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mineralocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood volume by renal aldosterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal water homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>secondary metabolite biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="9">
      <id>BE0000344</id>
      <name>Steroid 17-alpha-hydroxylase/17,20 lyase</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18227</ref-id>
            <pubmed-id>984618</pubmed-id>
            <citation>Authors unspecified: Spironolactone and endocrine dysfunction. Ann Intern Med. 1976 Nov;85(5):630-6.</citation>
          </article>
          <article>
            <ref-id>A178138</ref-id>
            <pubmed-id>31065620</pubmed-id>
            <citation>Millington K, Liu E, Chan YM: The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone. J Endocr Soc. 2019 Apr 4;3(5):1031-1038. doi: 10.1210/js.2019-00030. eCollection 2019 May 1.</citation>
          </article>
        </articles>
        <textbooks>
          <textbook>
            <ref-id>T17</ref-id>
            <isbn>978-81-250-2025-7</isbn>
            <citation>Desai; Meena P.; Vijayalakshmi Bhatia &amp; P.S.N. Menon (2001). Pediatric Endocrine Disorders. Orient Blackswan.</citation>
          </textbook>
        </textbooks>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05093" source="Swiss-Prot">
        <name>Steroid 17-alpha-hydroxylase/17,20 lyase</name>
        <general-function>Steroid 17-alpha-monooxygenase activity</general-function>
        <specific-function>Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.</specific-function>
        <gene-name>CYP17A1</gene-name>
        <locus>10q24.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.87</theoretical-pi>
        <molecular-weight>57369.995</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP17A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14564</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1361</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05093</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP17A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.19</synonym>
          <synonym>17-alpha-hydroxyprogesterone aldolase</synonym>
          <synonym>CYP17</synonym>
          <synonym>CYPXVII</synonym>
          <synonym>Cytochrome P450 17A1</synonym>
          <synonym>Cytochrome P450-C17</synonym>
          <synonym>Cytochrome P450c17</synonym>
          <synonym>S17AH</synonym>
          <synonym>Steroid 17-alpha-monooxygenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018942|Steroid 17-alpha-hydroxylase/17,20 lyase
MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKY
GPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAH
WQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVIS
LICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRN
DLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIF
GAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREV
LRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNP
AGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIP
KVVFLIDSFKVKIKVRQAWREAQAEGST</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018943|Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)
ATGTGGGAGCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTGTTTTGGCCCAAGAGA
AGGTGCCCTGGTGCCAAGTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTG
CCATTCCTCCCCAGACACGGCCATATGCATAACAACTTCTTCAAGCTGCAGAAAAAATAT
GGCCCCATCTATTCGGTTCGTATGGGCACCAAGACTACAGTGATTGTCGGCCACCACCAG
CTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAGGACTTCTCTGGGCGGCCTCAAATGGCA
ACTCTAGACATCGCGTCCAACAACCGTAAGGGTATCGCCTTCGCTGACTCTGGCGCACAC
TGGCAGCTGCATCGAAGGCTGGCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAG
AAGCTGGAGAAGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACCCAC
AACGGACAGTCCATAGACATCTCCTTTCCTGTCTTCGTGGCGGTAACCAATGTCATCTCC
TTGATCTGCTTCAATACCTCCTACAAGAATGGGGACCCTGAGTTGAATGTCATACAGAAT
TACAATGAAGGCATCATAGACAACCTGAGCAAAGACAGCCTGGTGGACCTAGTCCCCTGG
TTGAAGATTTTCCCCAACAAAACCCTGGAAAAATTAAAGAGCCATGTTAAAATACGAAAT
GATCTGCTGAATAAAATACTTGAAAATTACAAGGAGAAATTCCGGAGTGACTCTATCACC
AACATGCTGGACACACTGATGCAAGCCAAGATGAACTCAGATAATGGCAATGCTGGCCCA
GATCAAGACTCAGAGCTGCTTTCAGATAACCACATTCTCACCACCATAGGGGACATCTTT
GGGGCTGGCGTGGAGACCACCACCTCTGTGGTTAAATGGACCCTGGCCTTCCTGCTGCAC
AATCCTCAGGTGAAGAAGAAGCTCTACGAGGAGATTGACCAGAATGTGGGTTTCAGCCGC
ACACCAACTATCAGTGACCGTAACCGTCTCCTCCTGCTGGAGGCCACCATCCGAGAGGTG
CTTCGCCTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAAGGCCAACGTTGACTCCAGC
ATCGGTGAGTTTGCTGTGGACAAGGGCACAGAAGTTATCATCAATCTGTGGGCGCTGCAT
CACAATGAGAAGGAGTGGCACCAGCCGGATCAGTTCATGCCTGAGCGTTTCTTGAATCCA
GCGGGGACCCAGCTCATCTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGC
TCCTGTATAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCCTCATCATGGCCTGGCTGCTG
CAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCTCCCTGGAAGGCATCCCC
AAGGTGGTCTTTCTGATCGACTCTTTCAAAGTGAAGATCAAGGTGCGCCAGGCCTGGAGG
GAAGCCCAGGCTGAGGGTAGCACCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>17-alpha-hydroxyprogesterone aldolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid 17-alpha-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>progesterone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sex differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0004887</id>
      <name>3-oxo-5-alpha-steroid 4-dehydrogenase</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18228</ref-id>
            <pubmed-id>166833</pubmed-id>
            <citation>Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J: Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 1975 Jul;97(1):52-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P18405" source="Swiss-Prot">
        <name>3-oxo-5-alpha-steroid 4-dehydrogenase 1</name>
        <general-function>Electron carrier activity</general-function>
        <specific-function>Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.</specific-function>
        <gene-name>SRD5A1</gene-name>
        <locus>5p15</locus>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions>12-29
86-106
111-131
151-171
209-229</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.07</theoretical-pi>
        <molecular-weight>29458.18</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11284</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SRD5A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M32313</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177767</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S5A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.3.1.22</synonym>
          <synonym>S5AR 1</synonym>
          <synonym>SR type 1</synonym>
          <synonym>Steroid 5-alpha-reductase 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010375|3-oxo-5-alpha-steroid 4-dehydrogenase 1
MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRVPARAAWVVQE
LPSLALPLYQYASESAPRLRSAPNCILLAMFLVHYGHRCLIYPFLMRGGKPMPLLACTMA
IMFCTCNGYLQSRYLSHCAVYADDWVTDPRFLIGFGLWLTGMLINIHSDHILRNLRKPGD
TGYKIPRGGLFEYVTAANYFGEIMEWCGYALASWSVQGAAFAFFTFCFLSGRAKEHHEWY
LRKFEEYPKFRKIIIPFLF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010376|3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1)
ATGGCAACGGCGACGGGGGTGGCGGAGGAGCGCCTGCTGGCCGCGCTCGCCTACCTGCAG
TGCGCCGTGGGCTGCGCGGTCTTCGCGCGCAATCGTCAGACGAACTCAGTGTACGGCCGC
CACGCGCTGCCCAGCCACAGGCTCCGAGTGCCGGCGCGGGCCGCCTGGGTGGTGCAGGAG
CTGCCCTCGCTGGCCCTGCCGCTCTACCAGTACGCCAGCGAGTCCGCCCCGCGTCTCCGC
AGCGCGCCCAACTGCATCCTCCTGGCCATGTTCCTCGTCCACTACGGGCATCGGTGCTTA
ATTTACCCATTTCTGATGCGAGGAGGAAAGCCTATGCCACTGTTGGCGTGTACAATGGCG
ATTATGTTCTGTACCTGTAACGGCTATTTGCAAAGCAGATACTTGAGCCATTGTGCAGTG
TATGCTGATGACTGGGTAACAGATCCCCGTTTTCTAATAGGTTTTGGCTTGTGGTTAACG
GGCATGTTGATAAACATCCATTCAGATCATATCCTAAGGAATCTCAGAAAACCAGGAGAT
ACTGGATACAAAATACCAAGGGGAGGCTTATTTGAATACGTAACTGCAGCCAACTATTTT
GGAGAAATCATGGAGTGGTGTGGCTATGCCCTGGCCAGCTGGTCTGTCCAAGGCGCGGCT
TTTGCTTTCTTCACGTTTTGTTTTTTATCTGGTAGAGCAAAAGAGCATCATGAGTGGTAC
CTCCGGAAATTTGAAGAGTATCCAAAGTTCAGAAAAATTATAATTCCATTTTTGTTTTAA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02544</identifier>
            <name>Steroid_dh</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3-oxo-5-alpha-steroid 4-dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholestenone 5-alpha-reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sex determination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sex differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P31213" source="Swiss-Prot">
        <name>3-oxo-5-alpha-steroid 4-dehydrogenase 2</name>
        <general-function>Sterol 5-alpha reductase activity</general-function>
        <specific-function>Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.</specific-function>
        <gene-name>SRD5A2</gene-name>
        <locus>2p23</locus>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions>8-28
72-92
146-166
206-226</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.62</theoretical-pi>
        <molecular-weight>28393.015</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11285</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SRD5A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M74047</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>338469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2633</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31213</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S5A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.3.1.22</synonym>
          <synonym>5 alpha-SR2</synonym>
          <synonym>S5AR 2</synonym>
          <synonym>SR type 2</synonym>
          <synonym>Steroid 5-alpha-reductase 2</synonym>
          <synonym>Type II 5-alpha reductase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016143|3-oxo-5-alpha-steroid 4-dehydrogenase 2
MQVQCQQSPVLAGSATLVALGALALYVAKPSGYGKHTESLKPAATRLPARAAWFLQELPS
FAVPAGILARQPLSLFGPPGTVLLGLFCVHYFHRTFVYSLLNRGRPYPAILILRGTAFCT
GNGVLQGYYLIYCAEYPDGWYTDIRFSLGVFLFILGMGINIHSDYILRQLRKPGEISYRI
PQGGLFTYVSGANFLGEIIEWIGYALATWSLPALAFAFFSLCFLGLRAFHHHRFYLKMFE
DYPKSRKALIPFIF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016144|3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2)
ATGCAGGTTCAGTGCCAGCAGAGCCCAGTGCTGGCAGGCAGCGCCACTTTGGTCGCCCTT
GGGGCACTGGCCTTGTACGTCGCGAAGCCCTCCGGCTACGGGAAGCACACGGAGAGCCTG
AAGCCGGCGGCTACCCGCCTGCCAGCCCGCGCCGCCTGGTTCCTGCAGGAGCTGCCTTCC
TTCGCGGTGCCCGCGGGGATCCTCGCCCGGCAGCCCCTCTCCCTCTTCGGGCCACCTGGG
ACGGTACTTCTGGGCCTCTTCTGCCTACATTACTTCCACAGGACATTTGTGTACTCACTG
CTCAATCGAGGGAGGCCTTATCCAGCTATACTCATTCTCAGAGGCACTGCCTTCTGCACT
GGAAATGGAGTCCTTCAAGGCTACTATCTGATTTACTGTGCTGAATACCCTGATGGGTGG
TACACAGACATACGGTTTAGCTTGGGTGTCTTCTTATTTATTTTGGGAATGGGAATAAAC
ATTCATAGTGACTATATATTGCGCCAGCTCAGGAAGCCTGGAGAAATCAGCTACAGGATT
CCACAAGGTGGCTTGTTTACGTATGTTTCTGGAGCCAATTTCCTCGGTGAGATCATTGAA
TGGATCGGCTATGCCCTGGCCACTTGGTCCCTCCCAGCACTTGCATTTGCATTTTTCTCA
CTTTGTTTCCTTGGGCTGCGAGCTTTTCACCACCATAGGTTCTACCTCAAGATGTTTGAG
GACTACCCCAAATCTCGGAAAGCCCTTATTCCATTCATCTTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02544</identifier>
            <name>Steroid_dh</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell body fiber</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3-oxo-5-alpha-steroid 4-dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>amide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholestenone 5-alpha-reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sterol 5-alpha reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>biphenyl metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female genitalia development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hippocampus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hypothalamus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male genitalia development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phthalate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to follicle-stimulating hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to peptide hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to testosterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9H8P0" source="Swiss-Prot">
        <name>Polyprenol reductase</name>
        <general-function>Plays a key role in early steps of protein N-linked glycosylation by being required for the conversion of polyprenol into dolichol. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Acts as a polyprenol reductase that promotes the reduction of the alpha-isoprene unit of polyprenols into dolichols in a NADP-dependent mechanism. Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT).</general-function>
        <specific-function>3-oxo-5-alpha-steroid 4-dehydrogenase activity</specific-function>
        <gene-name>SRD5A3</gene-name>
        <locus>4q12</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>12-34
81-101
118-138
158-178
195-215
261-281</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>36521.005</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:25812</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9H8P0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PORED_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.3.1.94</synonym>
          <synonym>3-oxo-5-alpha-steroid 4-dehydrogenase 3</synonym>
          <synonym>S5AR 3</synonym>
          <synonym>SR type 3</synonym>
          <synonym>SRD5A2L</synonym>
          <synonym>Steroid 5-alpha-reductase 2-like</synonym>
          <synonym>Steroid 5-alpha-reductase 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013344|Polyprenol reductase
MAPWAEAEHSALNPLRAVWLTLTAAFLLTLLLQLLPPGLLPGCAIFQDLIRYGKTKCGEP
SRPAACRAFDVPKRYFSHFYIISVLWNGFLLWCLTQSLFLGAPFPSWLHGLLRILGAAQF
QGGELALSAFLVLVFLWLHSLRRLFECLYVSVFSNVMIHVVQYCFGLVYYVLVGLTVLSQ
VPMDGRNAYITGKNLLMQARWFHILGMMMFIWSSAHQYKCHVILGNLRKNKAGVVIHCNH
RIPFGDWFEYVSSPNYLAELMIYVSMAVTFGFHNLTWWLVVTNVFFNQALSAFLSHQFYK
SKFVSYPKHRKAFLPFLF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013345|Polyprenol reductase (SRD5A3)
ATGGCTCCCTGGGCGGAGGCCGAGCACTCGGCGCTGAACCCGCTGCGCGCGGTGTGGCTC
ACGCTGACCGCCGCCTTCCTGCTGACCCTACTGCTGCAGCTCCTGCCGCCCGGCCTGCTC
CCGGGCTGCGCGATCTTCCAGGACCTGATCCGCTATGGGAAAACCAAGTGTGGGGAGCCG
TCGCGCCCCGCCGCCTGCCGAGCCTTTGATGTCCCCAAGAGATATTTTTCCCACTTTTAT
ATCATCTCAGTGCTGTGGAATGGCTTCCTGCTTTGGTGCCTTACTCAATCTCTGTTCCTG
GGAGCACCTTTTCCAAGCTGGCTTCATGGTTTGCTCAGAATTCTCGGGGCGGCACAGTTC
CAGGGAGGGGAGCTGGCACTGTCTGCATTCTTAGTGCTAGTATTTCTGTGGCTGCACAGC
TTACGAAGACTCTTCGAGTGCCTCTACGTCAGTGTCTTCTCCAATGTCATGATTCACGTC
GTGCAGTACTGTTTTGGACTTGTCTATTATGTCCTTGTTGGCCTAACTGTGCTGAGCCAA
GTGCCAATGGATGGCAGGAATGCCTACATAACAGGGAAAAATCTATTGATGCAAGCACGG
TGGTTCCATATTCTTGGGATGATGATGTTCATCTGGTCATCTGCCCATCAGTATAAGTGC
CATGTTATTCTCGGCAATCTCAGGAAAAATAAAGCAGGAGTGGTCATTCACTGTAACCAC
AGGATCCCATTTGGAGACTGGTTTGAATATGTTTCTTCCCCTAACTACTTAGCAGAGCTG
ATGATCTACGTTTCCATGGCCGTCACCTTTGGGTTCCACAACTTAACTTGGTGGCTAGTG
GTGACAAATGTCTTCTTTAATCAGGCCCTGTCTGCCTTTCTCAGCCACCAATTCTACAAA
AGCAAATTTGTCTCTTACCCGAAGCATAGGAAAGCTTTCCTACCATTTTTGTTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02544</identifier>
            <name>Steroid_dh</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3-oxo-5-alpha-steroid 4-dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholestenone 5-alpha-reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>polyprenol reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dolichol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dolichol-linked oligosaccharide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dolichyl diphosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>polyprenol catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein glycosylation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="11">
      <id>BE0000685</id>
      <name>Sex hormone-binding globulin</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18229</ref-id>
            <pubmed-id>17881754</pubmed-id>
            <citation>Braunstein GD: Clinical practice. Gynecomastia. N Engl J Med. 2007 Sep 20;357(12):1229-37.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04278" source="Swiss-Prot">
        <name>Sex hormone-binding globulin</name>
        <general-function>Androgen binding</general-function>
        <specific-function>Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.</specific-function>
        <gene-name>SHBG</gene-name>
        <locus>17p13-p12</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-29</signal-regions>
        <theoretical-pi>6.7</theoretical-pi>
        <molecular-weight>43778.755</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10839</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SHBG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X16349</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>296673</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04278</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SHBG_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABP</synonym>
          <synonym>SBP</synonym>
          <synonym>Sex steroid-binding protein</synonym>
          <synonym>SHBG</synonym>
          <synonym>TeBG</synonym>
          <synonym>Testis-specific androgen-binding protein</synonym>
          <synonym>Testosterone-estradiol-binding globulin</synonym>
          <synonym>Testosterone-estrogen-binding globulin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001366|Sex hormone-binding globulin
MESRGPLATSRLLLLLLLLLLRHTRQGWALRPVLPTQSAHDPPAVHLSNGPGQEPIAVMT
FDLTKITKTSSSFEVRTWDPEGVIFYGDTNPKDDWFMLGLRDGRPEIQLHNHWAQLTVGA
GPRLDDGRWHQVEVKMEGDSVLLEVDGEEVLRLRQVSGPLTSKRHPIMRIALGGLLFPAS
NLRLPLVPALDGCLRRDSWLDKQAEISASAPTSLRSCDVESNPGIFLPPGTQAEFNLRDI
PQPHAEPWAFSLDLGLKQAAGSGHLLALGTPENPSWLSLHLQDQKVVLSSGSGPGLDLPL
VLGLPLQLKLSMSRVVLSQGSKMKALALPPLGLAPLLNLWAKPQGRLFLGALPGEDSSTS
FCLNGLWAQGQRLDVDQALNRSHEIWTHSCPQSPGNGTDASH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010477|Sex hormone-binding globulin (SHBG)
ATGGAGAGCAGAGGCCCACTGGCTACCTCGCGCCTGCTGCTGTTGCTGCTGTTGCTACTA
CTGCGTCACACCCGCCAGGGATGGGCCCTGAGACCTGTTCTCCCCACCCAGAGTGCCCAC
GACCCTCCGGCTGTCCACCTCAGCAATGGCCCAGGACAAGAGCCTATCGCTGTCATGACC
TTTGACCTCACCAAGATCACAAAAACCTCCTCCTCCTTTGAGGTTCGAACCTGGGACCCA
GAGGGAGTGATTTTTTATGGGGATACCAACCCTAAGGATGACTGGTTTATGCTGGGACTT
CGAGACGGCAGGCCTGAGATCCAACTGCACAATCACTGGGCCCAGCTTACGGTGGGTGCT
GGACCACGGCTGGATGATGGGAGATGGCACCAGGTGGAAGTCAAGATGGAGGGGGACTCT
GTGCTGCTGGAGGTGGATGGGGAGGAGGTGCTGCGCCTGAGACAGGTCTCTGGGCCCCTG
ACCAGCAAACGCCATCCCATCATGAGGATTGCGCTTGGGGGGCTGCTCTTCCCCGCTTCC
AACCTTCGGTTGCCGCTGGTTCCTGCCCTGGATGGCTGCCTGCGCCGGGATTCCTGGCTG
GACAAACAGGCCGAGATCTCAGCATCTGCCCCCACTAGCCTCAGAAGCTGTGATGTAGAA
TCAAATCCCGGGATATTTCTCCCTCCAGGGACTCAGGCAGAATTCAATCTCCGAGACATT
CCCCAGCCTCATGCAGAGCCCTGGGCCTTCTCTTTGGACCTGGGACTCAAGCAGGCAGCA
GGCTCAGGCCACCTCCTTGCTCTTGGGACACCAGAGAACCCATCTTGGCTCAGTCTCCAC
CTCCAAGATCAAAAGGTGGTGTTGTCTTCTGGGTCGGGGCCAGGGCTGGATCTGCCCCTG
GTCTTGGGACTCCCTCTTCAGCTGAAGCTGAGTATGTCCAGGGTGGTCTTGAGCCAAGGG
TCGAAGATGAAGGCCCTTGCCCTGCCTCCCTTAGGCCTGGCTCCCCTCCTTAACCTCTGG
GCCAAGCCTCAAGGGCGTCTCTTCCTGGGGGCTTTACCAGGAGAAGACTCTTCCACCTCT
TTTTGCCTGAATGGCCTTTGGGCACAAGGTCAGAGGCTGGATGTGGACCAGGCCCTGAAC
AGAAGCCATGAGATCTGGACTCACAGCTGCCCCCAGAGCCCAGGCAATGGCACTGACGCT
TCCCATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00054</identifier>
            <name>Laminin_G_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androgen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>primary spermatocyte growth</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="12">
      <id>BE0004902</id>
      <name>Voltage-dependent calcium channel</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18230</ref-id>
            <pubmed-id>10942165</pubmed-id>
            <citation>Sorrentino R, Autore G, Cirino G, d'Emmanuele de Villa Bianca R, Calignano A, Vanasia M, Alfieri C, Sorrentino L, Pinto A: Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings. J Cardiovasc Pharmacol. 2000 Aug;36(2):230-5.</citation>
          </article>
          <article>
            <ref-id>A18231</ref-id>
            <pubmed-id>872489</pubmed-id>
            <citation>Melander A, Danielson K, Schersten B, Thulin T, Wahlin E: Enhancement by food of canrenone bioavailability from spironolactone. Clin Pharmacol Ther. 1977 Jul;22(1):100-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q06432" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-1 subunit</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.</specific-function>
        <gene-name>CACNG1</gene-name>
        <locus>17q24</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>11-29
105-129
140-155
180-204</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.1</theoretical-pi>
        <molecular-weight>25028.105</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNG1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L07738</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>306473</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q06432</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CACNLG</synonym>
          <synonym>Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016174|Voltage-dependent calcium channel gamma-1 subunit
MSQTKMLKVRVTLFCILAGIVLAMTAVVTDHWAVLSPHMEHHNTTCEAAHFGLWRICTKR
IPMDDSKTCGPITLPGEKNCSYFRHFNPGESSEIFEFTTQKEYSISAAAIAIFSLGFIIL
GSLCVLLSLGKKRDYLLRPASMFYAFAGLCILVSVEVMRQSVKRMIDSEDTVWIEYYYSW
SFACACAAFILLFLGGLALLLFSLPRMPRNPWESCMDAEPEH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016175|Voltage-dependent calcium channel gamma-1 subunit (CACNG1)
ATGTCCCAGACCAAAATGCTGAAGGTCCGCGTGACCCTCTTCTGCATCCTGGCAGGCATC
GTGCTGGCCATGACAGCCGTGGTAACCGACCACTGGGCTGTGCTGAGCCCCCACATGGAG
CACCACAACACTACCTGCGAGGCGGCCCACTTCGGCCTCTGGCGGATTTGTACCAAGCGC
ATCCCCATGGACGACAGCAAGACCTGCGGGCCCATCACCCTGCCCGGGGAGAAGAACTGT
TCCTACTTCAGGCATTTTAACCCCGGCGAGAGCTCGGAGATCTTCGAATTCACCACTCAG
AAGGAGTACAGCATCTCGGCAGCCGCCATCGCCATCTTCAGCCTTGGCTTCATCATCCTG
GGCAGCCTCTGTGTCCTCCTGTCCCTCGGGAAGAAGAGGGACTATCTGCTGCGACCCGCG
TCCATGTTCTATGCCTTTGCAGGTCTCTGCATCCTCGTCTCGGTGGAGGTCATGCGGCAG
TCGGTGAAGCGCATGATTGACAGTGAGGACACCGTCTGGATCGAGTACTATTACTCCTGG
TCCTTTGCCTGCGCCTGTGCCGCCTTCATCCTCCTCTTTCTCGGCGGTCTCGCCCTCCTG
CTGTTCTCCCTGCCTCGAATGCCCCGGAACCCATGGGAGTCCTGCATGGATGCTGAGCCC
GAGCACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13903</identifier>
            <name>Claudin_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sarcoplasmic reticulum calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9Y698" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-2 subunit</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization. Does not show subunit-specific AMPA receptor regulation and regulates all AMPAR subunits. Thought to stabilize the calcium channel in an inactivated (closed) state.</specific-function>
        <gene-name>CACNG2</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>10-30
104-124
134-154
182-202</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>35965.44</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1406</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y698</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neuronal voltage-gated calcium channel gamma-2 subunit</synonym>
          <synonym>TARP gamma-2</synonym>
          <synonym>Transmembrane AMPAR regulatory protein gamma-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013466|Voltage-dependent calcium channel gamma-2 subunit
MGLFDRGVQMLLTTVGAFAAFSLMTIAVGTDYWLYSRGVCKTKSVSENETSKKNEEVMTH
SGLWRTCCLEGNFKGLCKQIDHFPEDADYEADTAEYFLRAVRASSIFPILSVILLFMGGL
CIAASEFYKTRHNIILSAGIFFVSAGLSNIIGIIVYISANAGDPSKSDSKKNSYSYGWSF
YFGALSFIIAEMVGVLAVHMFIDRHKQLRATARATDYLQASAITRIPSYRYRYQRRSRSS
SRSTEPSHSRDASPVGIKGFNTLPSTEISMYTLSRDPLKAATTPTATYNSDRDNSFLQVH
NCIQKENKDSLHSNTANRRTTPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013467|Voltage-dependent calcium channel gamma-2 subunit (CACNG2)
ATGGGGCTGTTTGATCGAGGTGTTCAAATGCTTTTAACCACCGTTGGTGCTTTCGCTGCC
TTCAGCCTGATGACCATAGCTGTGGGAACCGACTATTGGCTCTACTCCAGAGGGGTTTGC
AAGACCAAAAGTGTCAGTGAGAATGAAACCAGCAAAAAGAACGAGGAAGTTATGACCCAT
TCCGGATTATGGAGAACCTGCTGCCTAGAAGGGAATTTCAAAGGTCTGTGCAAGCAAATT
GATCACTTCCCAGAGGATGCAGATTACGAAGCTGACACAGCAGAATATTTCCTCCGGGCC
GTGAGGGCCTCCAGCATTTTCCCAATCCTGAGTGTGATTCTGCTTTTCATGGGTGGCCTC
TGCATCGCAGCCAGCGAGTTCTACAAAACTCGACACAACATCATCCTGAGTGCCGGCATC
TTCTTCGTGTCTGCAGGTCTGAGTAACATCATTGGCATCATAGTGTACATATCTGCCAAT
GCCGGAGACCCCTCCAAGAGCGACTCCAAAAAGAATAGTTACTCATACGGCTGGTCCTTC
TACTTCGGGGCCCTGTCCTTCATCATCGCCGAGATGGTCGGGGTGCTGGCGGTGCACATG
TTTATCGACCGGCACAAACAGCTGCGGGCCACGGCCCGCGCCACGGACTACCTCCAGGCC
TCTGCCATCACCCGCATCCCCAGCTACCGCTACCGCTACCAGCGCCGCAGCCGCTCCAGC
TCGCGCTCCACGGAGCCCTCACACTCCAGGGACGCCTCCCCCGTGGGCATCAAGGGCTTC
AACACCCTGCCGTCCACGGAGATCTCCATGTACACGCTCAGCAGGGACCCCCTGAAGGCC
GCCACCACGCCCACCGCCACCTACAACTCCGACAGGGATAACAGCTTCCTCCAGGTTCAC
AACTGTATCCAGAAGGAGAACAAGGACTCTCTCCACTCCAACACAGCCAACCGCCGGACC
ACCCCCGTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00822</identifier>
            <name>PMP22_Claudin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>AMPA glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane hyperpolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O60359" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-3 subunit</name>
        <general-function>Regulates the trafficking to the somatodendritic compartment and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization. Does not show subunit-specific AMPA receptor regulation and regulates all AMPAR subunits. Thought to stabilize the calcium channel in an inactivated (closed) state.</general-function>
        <specific-function>Channel regulator activity</specific-function>
        <gene-name>CACNG3</gene-name>
        <locus>16p12.1</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>8-28
104-124
135-155
181-201</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>35548.14</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1407</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60359</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neuronal voltage-gated calcium channel gamma-3 subunit</synonym>
          <synonym>TARP gamma-3</synonym>
          <synonym>Transmembrane AMPAR regulatory protein gamma-3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051568|Voltage-dependent calcium channel gamma-3 subunit
MRMCDRGIQMLITTVGAFAAFSLMTIAVGTDYWLYSRGVCRTKSTSDNETSRKNEEVMTH
SGLWRTCCLEGAFRGVCKKIDHFPEDADYEQDTAEYLLRAVRASSVFPILSVTLLFFGGL
CVAASEFHRSRHNVILSAGIFFVSAGLSNIIGIIVYISANAGDPGQRDSKKSYSYGWSFY
FGAFSFIIAEIVGVVAVHIYIEKHQQLRAKSHSEFLKKSTFARLPPYRYRFRRRSSSRST
EPRSRDLSPISKGFHTIPSTDISMFTLSRDPSKITMGTLLNSDRDHAFLQFHNSTPKEFK
ESLHNNPANRRTTPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051569|Voltage-dependent calcium channel gamma-3 subunit (CACNG3)
ATGAGGATGTGTGACAGAGGTATCCAGATGTTGATCACCACTGTAGGAGCCTTTGCCGCT
TTTAGTTTAATGACCATTGCAGTGGGCACGGACTACTGGTTATATTCCAGAGGTGTGTGC
AGGACTAAATCTACAAGTGATAATGAAACCAGCAGGAAGAATGAAGAAGTAATGACCCAT
TCGGGGCTGTGGAGGACCTGCTGCCTAGAAGGGGCTTTCCGAGGCGTGTGCAAGAAAATC
GATCACTTCCCTGAAGATGCTGACTACGAACAGGACACAGCCGAATATCTCCTGCGAGCT
GTGAGGGCCTCCAGTGTCTTCCCCATCCTCAGTGTCACGCTGCTGTTCTTCGGCGGGCTC
TGCGTGGCAGCCAGTGAGTTCCACCGCAGCAGACACAACGTCATTCTCAGCGCGGGCATC
TTTTTTGTCTCTGCAGGGTTAAGCAACATCATTGGCATCATAGTTTATATATCAGCCAAC
GCCGGAGACCCCGGGCAGCGTGACTCCAAAAAAAGTTACTCCTATGGTTGGTCCTTTTAT
TTCGGAGCCTTCTCTTTCATCATCGCAGAAATTGTAGGAGTGGTTGCCGTGCACATCTAT
ATTGAAAAACATCAGCAGTTACGAGCCAAATCCCACTCGGAGTTCCTGAAGAAATCTACT
TTTGCCCGCCTCCCACCCTACAGGTATCGATTCCGGAGGCGGTCAAGTTCTCGCTCCACC
GAGCCCAGATCCCGAGACCTGTCCCCCATCAGCAAAGGCTTCCACACCATCCCTTCCACT
GACATCTCGATGTTCACCCTCTCCCGGGACCCCTCAAAGATCACCATGGGGACCCTCCTC
AACTCCGACCGGGACCACGCTTTTCTACAGTTCCACAATTCCACACCCAAAGAGTTCAAA
GAGTCACTGCATAATAATCCGGCCAACAGGCGCACCACGCCCGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00822</identifier>
            <name>PMP22_Claudin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>AMPA glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>somatodendritic compartment</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein targeting</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of AMPA receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9UBN1" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-4 subunit</name>
        <general-function>Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization and by mediating their resensitization. Does not show subunit-specific AMPA receptor regulation and regulates all AMPAR subunits. Thought to stabilize the calcium channel in an inactivated (closed) state.</general-function>
        <specific-function>Calcium channel activity</specific-function>
        <gene-name>CACNG4</gene-name>
        <locus>17q24.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>10-30
108-128
137-157
187-207</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>36578.39</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1408</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UBN1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neuronal voltage-gated calcium channel gamma-4 subunit</synonym>
          <synonym>TARP gamma-4</synonym>
          <synonym>Transmembrane AMPAR regulatory protein gamma-4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051564|Voltage-dependent calcium channel gamma-4 subunit
MVRCDRGLQMLLTTAGAFAAFSLMAIAIGTDYWLYSSAHICNGTNLTMDDGPPPRRARGD
LTHSGLWRVCCIEGIYKGHCFRINHFPEDNDYDHDSSEYLLRIVRASSVFPILSTILLLL
GGLCIGAGRIYSRKNNIVLSAGILFVAAGLSNIIGIIVYISSNTGDPSDKRDEDKKNHYN
YGWSFYFGALSFIVAETVGVLAVNIYIEKNKELRFKTKREFLKASSSSPYARMPSYRYRR
RRSRSSSRSTEASPSRDVSPMGLKITGAIPMGELSMYTLSREPLKVTTAASYSPDQEASF
LQVHDFFQQDLKEGFHVSMLNRRTTPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051565|Voltage-dependent calcium channel gamma-4 subunit (CACNG4)
ATGGTGCGATGCGACCGCGGGCTGCAGATGCTGCTGACCACGGCCGGAGCCTTCGCCGCC
TTCTCGCTCATGGCCATCGCCATCGGCACCGACTACTGGCTGTACTCCAGCGCGCACATC
TGCAACGGCACCAACCTGACCATGGACGACGGGCCCCCGCCCCGCCGCGCCCGCGGCGAC
CTCACCCACTCTGGTCTGTGGCGGGTGTGCTGCATCGAAGGGATCTATAAAGGGCACTGC
TTCCGGATCAATCACTTCCCAGAGGACAATGACTACGACCACGACAGCTCGGAGTACCTC
CTCCGCATCGTGCGAGCCTCCAGCGTCTTCCCCATCCTCAGCACCATCCTGCTCCTGCTG
GGTGGCCTGTGCATCGGTGCTGGCAGGATCTACAGCCGCAAGAACAACATCGTCCTCAGT
GCCGGCATCCTCTTCGTGGCTGCAGGCCTCAGTAACATCATCGGTATCATCGTCTACATT
TCCAGCAACACAGGTGACCCGAGTGACAAGCGGGACGAAGACAAAAAGAACCATTACAAC
TACGGCTGGTCTTTTTACTTTGGAGCTCTGTCTTTCATTGTGGCTGAGACCGTGGGCGTC
CTGGCTGTAAACATTTACATTGAGAAAAATAAAGAGTTGAGGTTTAAGACCAAACGGGAA
TTCCTTAAGGCGTCTTCCTCTTCTCCTTATGCCAGGATGCCGAGCTACAGGTACCGGCGA
CGGCGCTCGAGGTCCAGCTCAAGGTCCACCGAGGCCTCGCCCTCCAGGGACGTGTCGCCC
ATGGGCCTGAAGATCACAGGGGCCATCCCCATGGGGGAGCTGTCCATGTACACGCTGTCC
AGGGAGCCCCTCAAGGTGACCACCGCAGCCAGCTACAGCCCCGACCAGGAGGCCAGCTTC
CTGCAGGTGCATGACTTTTTCCAGCAGGACCTGAAGGAAGGTTTCCACGTCAGCATGCTG
AACCGACGGACGACCCCTGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00822</identifier>
            <name>PMP22_Claudin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>AMPA glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>somatodendritic compartment</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of AMPA receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9UF02" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-5 subunit</name>
        <general-function>Regulates the gating properties of AMPA-selective glutamate receptors (AMPARs). Modulates their gating properties by accelerating their rates of activation, deactivation and desensitization. Displays subunit-specific AMPA receptor regulation. Shows specificity for GRIA1, GRIA4 and the long isoform of GRIA2. Thought to stabilize the calcium channel in an inactivated (closed) state (By similarity).</general-function>
        <specific-function>Channel regulator activity</specific-function>
        <gene-name>CACNG5</gene-name>
        <locus>17q24.2</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>8-28
103-123
129-149
176-196</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>30902.44</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1409</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UF02</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neuronal voltage-gated calcium channel gamma-5 subunit</synonym>
          <synonym>TARP gamma-5</synonym>
          <synonym>Transmembrane AMPAR regulatory protein gamma-5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051562|Voltage-dependent calcium channel gamma-5 subunit
MSACGRKALTLLSSVFAVCGLGLLGIAVSTDYWLYLEEGVIVPQNQSTEIKMSLHSGLWR
VCFLAGEERGRCFTIEYVMPMNTQLTSESTVNVLKMIRSATPFPLVSLFFMFIGFILNNI
GHIRPHRTILAFVSGIFFILSGLSLVVGLVLYISSINDEMLNRTKDAETYFNYKYGWSFA
FAAISFLLTESAGVMSVYLFMKRYTAEDMYRPHPGFYRPRLSNCSDYSGQFLHPDAWVRG
RSPSDISSEASLQMNSNYPALLKCPDYDQMSSSPC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051563|Voltage-dependent calcium channel gamma-5 subunit (CACNG5)
ATGAGTGCCTGCGGGAGGAAGGCCCTGACCCTGCTGAGCAGTGTCTTTGCTGTCTGTGGC
TTGGGCCTCCTGGGTATCGCGGTCAGCACCGACTACTGGCTGTACCTGGAGGAGGGTGTG
ATTGTGCCCCAGAACCAGAGCACCGAGATCAAGATGTCCCTGCACTCAGGCCTCTGGCGG
GTCTGCTTCCTTGCAGGTGAGGAGCGGGGGCGTTGCTTCACCATAGAATATGTGATGCCC
ATGAACACCCAGCTGACATCCGAGTCCACGGTCAATGTTCTAAAGATGATCCGCTCAGCC
ACACCATTCCCTCTGGTCAGCCTCTTCTTCATGTTCATTGGGTTTATCCTGAACAACATC
GGACACATCCGTCCCCACCGGACGATACTGGCCTTTGTCTCTGGCATCTTCTTTATCCTC
TCAGGCCTCTCTCTCGTGGTGGGCCTGGTGCTCTACATCTCCAGCATCAACGATGAGATG
CTCAACAGGACCAAGGATGCAGAGACCTACTTCAACTACAAGTATGGGTGGTCGTTTGCC
TTCGCCGCCATCTCCTTCCTTTTAACGGAGAGTGCCGGGGTGATGTCTGTGTACCTGTTT
ATGAAGCGGTACACCGCGGAGGACATGTACAGGCCCCACCCTGGCTTCTACCGCCCTCGG
CTGAGCAACTGCTCCGATTACTCAGGCCAGTTCCTACACCCAGACGCCTGGGTCAGGGGC
CGCAGCCCCTCCGACATCTCCAGCGAGGCCTCCCTGCAGATGAACAGCAACTACCCCGCC
TTGCTCAAGTGCCCCGACTATGATCAGATGTCCTCTTCACCCTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00822</identifier>
            <name>PMP22_Claudin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>AMPA glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of AMPA receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9BXT2" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-6 subunit</name>
        <general-function>Thought to stabilize the calcium channel in an inactivated (closed) state.</general-function>
        <specific-function>Voltage-gated calcium channel activity</specific-function>
        <gene-name>CACNG6</gene-name>
        <locus>19q13.42</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>43-63
143-163
169-189
221-241</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>28128.745</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:13625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9BXT2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neuronal voltage-gated calcium channel gamma-6 subunit</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051570|Voltage-dependent calcium channel gamma-6 subunit
MMWSNFFLQEENRRRGAAGRRRAHGQGRSGLTPEREGKVKLALLLAAVGATLAVLSVGTE
FWVELNTYKANGSAVCEAAHLGLWKACTKRLWQADVPVDRDTCGPAELPGEANCTYFKFF
TTGENARIFQRTTKKEVNLAAAVIAVLGLAVMALGCLCIIMVLSKGAEFLLRVGAVCFGL
SGLLLLVSLEVFRHSVRALLQRVSPEPPPAPRLTYEYSWSLGCGVGAGLILLLGAGCFLL
LTLPSWPWGSLCPKRGHRAT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051571|Voltage-dependent calcium channel gamma-6 subunit (CACNG6)
ATGATGTGGTCCAACTTCTTCCTGCAAGAGGAGAACCGGCGGCGGGGGGCCGCGGGCCGG
CGGCGGGCGCACGGGCAGGGCAGGTCGGGGCTGACGCCCGAGCGCGAGGGGAAGGTGAAG
CTGGCGCTGCTGCTGGCCGCCGTGGGCGCCACGCTGGCGGTGCTGTCCGTGGGCACCGAG
TTCTGGGTGGAGCTCAACACCTACAAGGCCAACGGCAGCGCCGTGTGCGAAGCGGCCCAC
CTGGGGCTGTGGAAGGCGTGCACCAAGCGGCTGTGGCAGGCGGACGTGCCCGTGGACAGG
GACACCTGCGGCCCCGCGGAGCTGCCCGGAGAAGCAAACTGCACCTATTTTAAATTCTTC
ACCACGGGGGAGAATGCACGCATCTTTCAGAGAACCACAAAGAAAGAGGTGAATCTGGCA
GCTGCGGTGATAGCAGTGCTGGGCCTGGCAGTCATGGCCTTGGGGTGCCTCTGTATCATC
ATGGTGCTCAGTAAAGGTGCAGAGTTCCTGCTCCGAGTTGGAGCCGTCTGCTTTGGCCTC
TCAGGCCTGCTGCTCTTGGTGAGCCTGGAGGTGTTCCGGCATTCCGTGAGGGCCCTGCTG
CAGAGAGTCAGCCCGGAGCCTCCCCCGGCCCCACGCCTCACCTACGAGTACTCCTGGTCC
CTGGGCTGCGGCGTGGGGGCCGGCCTGATCCTGCTGTTGGGGGCCGGCTGCTTTCTGCTG
CTCACACTGCCTTCCTGGCCCTGGGGGTCCCTCTGTCCCAAGCGGGGGCACCGGGCCACC
TAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13903</identifier>
            <name>Claudin_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ion transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P62955" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-7 subunit</name>
        <general-function>Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization and by mediating their resensitization. Displays subunit-specific AMPA receptor regulation. Shows specificity only for GRIA1 and GRIA2. Thought to stabilize the calcium channel in an inactivated (closed) state.</general-function>
        <specific-function>Channel regulator activity</specific-function>
        <gene-name>CACNG7</gene-name>
        <locus>19q13.42</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>8-28
103-123
129-149
179-199</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>31002.29</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:13626</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P62955</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neuronal voltage-gated calcium channel gamma-7 subunit</synonym>
          <synonym>TARP gamma-7</synonym>
          <synonym>Transmembrane AMPAR regulatory protein gamma-7</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051560|Voltage-dependent calcium channel gamma-7 subunit
MSHCSSRALTLLSSVFGACGLLLVGIAVSTDYWLYMEEGTVLPQNQTTEVKMALHAGLWR
VCFFAGREKGRCVASEYFLEPEINLVTENTENILKTVRTATPFPMVSLFLVFTAFVISNI
GHIRPQRTILAFVSGIFFILSGLSLVVGLVLYISSINDEVMNRPSSSEQYFHYRYGWSFA
FAASSFLLKEGAGVMSVYLFTKRYAEEEMYRPHPAFYRPRLSDCSDYSGQFLQPEAWRRG
RSPSDISSDVSIQMTQNYPPAIKYPDHLHISTSPC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051561|Voltage-dependent calcium channel gamma-7 subunit (CACNG7)
ATGAGTCACTGCAGCAGCCGCGCCCTGACCCTGCTGAGCAGCGTGTTTGGTGCGTGTGGC
CTGCTCCTGGTAGGCATCGCGGTCAGCACTGACTACTGGCTGTACATGGAAGAAGGCACA
GTGCTACCGCAGAACCAGACCACCGAGGTCAAGATGGCCCTGCACGCCGGCCTCTGGCGA
GTCTGCTTCTTTGCAGGTCGGGAGAAAGGTCGCTGTGTGGCCTCAGAATATTTTCTTGAA
CCGGAGATCAATTTGGTGACGGAAAACACGGAGAATATTCTGAAGACAGTGCGCACGGCC
ACCCCCTTCCCCATGGTCAGCCTCTTCCTCGTGTTCACGGCCTTCGTCATCAGCAACATC
GGCCACATCCGCCCGCAGAGGACCATTCTGGCTTTTGTCTCTGGCATCTTCTTCATACTA
TCGGGCCTCTCCTTGGTGGTGGGCTTGGTTCTTTACATCTCCAGCATCAACGACGAGGTC
ATGAACAGGCCCAGCAGCTCTGAGCAGTATTTTCATTATCGCTACGGGTGGTCTTTTGCC
TTCGCCGCTTCCTCCTTCCTACTCAAAGAGGGGGCCGGCGTGATGTCCGTGTACCTGTTC
ACCAAGCGCTACGCGGAGGAGGAGATGTACCGTCCACACCCGGCCTTCTACCGCCCGCGT
CTCAGCGACTGCTCCGACTACTCGGGCCAGTTCCTGCAGCCCGAGGCGTGGCGCCGCGGC
CGGAGCCCCTCCGACATCTCCAGCGACGTGTCCATCCAAATGACGCAGAACTACCCTCCC
GCCATCAAGTACCCGGACCACCTGCACATCTCCACCTCGCCCTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13903</identifier>
            <name>Claudin_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>AMPA glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of AMPA receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q8WXS5" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel gamma-8 subunit</name>
        <general-function>Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization and by mediating their resensitization. Does not show subunit-specific AMPA receptor regulation and regulates all AMPAR subunits. Thought to stabilize the calcium channel in an inactivated (closed) state.</general-function>
        <specific-function>Channel regulator activity</specific-function>
        <gene-name>CACNG8</gene-name>
        <locus>19q13.42</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>19-39
129-149
158-178
208-228
318-338</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>43312.44</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:13628</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8WXS5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCG8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CACNG6</synonym>
          <synonym>Neuronal voltage-gated calcium channel gamma-8 subunit</synonym>
          <synonym>TARP gamma-8</synonym>
          <synonym>Transmembrane AMPAR regulatory protein gamma-8</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051566|Voltage-dependent calcium channel gamma-8 subunit
MESLKRWNEERGLWCEKGVQVLLTTVGAFAAFGLMTIAISTDYWLYTRALICNTTNLTAG
GDDGTPHRGGGGASEKKDPGGLTHSGLWRICCLEGLKRGVCVKINHFPEDTDYDHDSAEY
LLRVVRASSIFPILSAILLLLGGVCVAASRVYKSKRNIILGAGILFVAAGLSNIIGVIVY
ISANAGEPGPKRDEEKKNHYSYGWSFYFGGLSFILAEVIGVLAVNIYIERSREAHCQSRS
DLLKAGGGAGGSGGSGPSAILRLPSYRFRYRRRSRSSSRSSEPSPSRDASPGGPGGPGFA
STDISMYTLSRDPSKGSVAAGLAGAGGGGGGAVGAFGGAAGGAGGGGGGGGGAGAERDRG
GASGFLTLHNAFPKEAGGGVTVTVTGPPAPPAPAPPAPSAPAPGTLAKEAAASNTNTLNR
KTTPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051567|Voltage-dependent calcium channel gamma-8 subunit (CACNG8)
CTGGAGTCGCTGAAGCGCTGGAACGAAGAGCGGGGCCTCTGGTGCGAGAAGGGGGTGCAG
GTGCTGCTGACGACGGTGGGCGCCTTCGCCGCCTTCGGCCTCATGACCATCGCCATCAGC
ACTGACTACTGGCTCTACACGCGCGCCCTCATCTGCAACACCACCAACCTCACGGCCGGC
GGCGACGACGGGACCCCCCACCGCGGGGGCGGCGGCGCCTCGGAGAAGAAGGACCCCGGC
GGCCTCACGCACTCGGGCCTCTGGAGGATCTGCTGCCTGGAAGGGTTGAAAAGAGGCGTC
TGCGTGAAGATCAATCATTTCCCGGAGGACACGGACTACGACCACGACAGCGCGGAGTAT
CTACTCCGAGTTGTCCGGGCCTCCAGCATCTTCCCCATCCTTAGCGCCATCCTGCTGCTG
CTCGGGGGTGTGTGCGTGGCGGCCTCCCGCGTCTACAAGTCCAAGAGGAACATCATTCTG
GGCGCAGGGATCCTGTTCGTGGCAGCAGGCCTGAGCAACATCATCGGCGTGATCGTGTAC
ATCTCCGCCAACGCGGGCGAGCCGGGCCCGAAGCGGGACGAGGAGAAGAAAAACCACTAC
TCGTACGGCTGGTCCTTCTACTTCGGCGGGCTGTCGTTCATCCTGGCCGAGGTGATAGGC
GTGCTGGCCGTCAACATCTACATCGAGCGCAGCCGCGAGGCGCACTGCCAGTCTCGCTCG
GACCTGCTCAAGGCCGGCGGGGGCGCGGGCGGCAGTGGCGGGAGCGGCCCCTCGGCCATC
CTCCGTCTGCCCAGTTACCGCTTCCGCTACCGCCGCCGCTCCCGCTCTAGCTCCCGCTCC
AGCGAGCCGTCGCCGTCGCGGGACGCGTCTCCCGGCGGCCCCGGGGGCCCGGGCTTTGCC
TCCACGGACATCTCCATGTACACGCTCAGCCGCGACCCCTCCAAGGGCAGCGTGGCCGCG
GGGCTGGCGGGGGCCGGCGGCGGCGGCGGCGGCGCCGTGGGGGCGTTCGGCGGCGCGGCC
GGGGGCGCCGGGGGCGGCGGCGGAGGCGGCGGCGGGGCGGGTGCCGAGCGGGACCGCGGG
GGGGCGTCCGGCTTCCTCACGCTGCACAACGCCTTCCCCAAGGAGGCGGGCGGCGGCGTC
ACGGTCACGGTCACCGGGCCGCCCGCCCCGCCCGCGCCCGCGCCACCCGCGCCCTCTGCG
CCCGCCCCCGGGACCCTGGCCAAGGAGGCCGCCGCCTCCAACACCAACACGCTCAACAGG
AAAACCACGCCTGTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00822</identifier>
            <name>PMP22_Claudin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>AMPA glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of AMPA receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P54289" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel subunit alpha-2/delta-1</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).</specific-function>
        <gene-name>CACNA2D1</gene-name>
        <locus>7q21-q22</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1074-1094</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>4.86</theoretical-pi>
        <molecular-weight>124566.93</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA2D1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M76559</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>179762</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P54289</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CA2D1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CACNL2A</synonym>
          <synonym>CCHL2A</synonym>
          <synonym>MHS3</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha-2/delta-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037060|Voltage-dependent calcium channel subunit alpha-2/delta-1
MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDI
YEKYQDLYTVEPNNARQLVEIAARDIEKLLSNRSKALVRLALEAEKVQAAHQWREDFASN
EVVYYNAKDDLDPEKNDSEPGSQRIKPVFIEDANFGRQISYQHAAVHIPTDIYEGSTIVL
NELNWTSALDEVFKKNREEDPSLLWQVFGSATGLARYYPASPWVDNSRTPNKIDLYDVRR
RPWYIQGAASPKDMLILVDVSGSVSGLTLKLIRTSVSEMLETLSDDDFVNVASFNSNAQD
VSCFQHLVQANVRNKKVLKDAVNNITAKGITDYKKGFSFAFEQLLNYNVSRANCNKIIML
FTDGGEERAQEIFNKYNKDKKVRVFTFSVGQHNYDRGPIQWMACENKGYYYEIPSIGAIR
INTQEYLDVLGRPMVLAGDKAKQVQWTNVYLDALELGLVITGTLPVFNITGQFENKTNLK
NQLILGVMGVDVSLEDIKRLTPRFTLCPNGYYFAIDPNGYVLLHPNLQPKPIGVGIPTIN
LRKRRPNIQNPKSQEPVTLDFLDAELENDIKVEIRNKMIDGESGEKTFRTLVKSQDERYI
DKGNRTYTWTPVNGTDYSLALVLPTYSFYYIKAKLEETITQARYSETLKPDNFEESGYTF
IAPRDYCNDLKISDNNTEFLLNFNEFIDRKTPNNPSCNADLINRVLLDAGFTNELVQNYW
SKQKNIKGVKARFVVTDGGITRVYPKEAGENWQENPETYEDSFYKRSLDNDNYVFTAPYF
NKSGPGAYESGIMVSKAVEIYIQGKLLKPAVVGIKIDVNSWIENFTKTSIRDPCAGPVCD
CKRNSDVMDCVILDDGGFLLMANHDDYTNQIGRFFGEIDPSLMRHLVNISVYAFNKSYDY
QSVCEPGAAPKQGAGHRSAYVPSVADILQIGWWATAAAWSILQQFLLSLTFPRLLEAVEM
EDDDFTASLSKQSCITEQTQYFFDNDSKSFSGVLDCGNCSRIFHGEKLMNTNLIFIMVES
KGTCPCDTRLLIQAEQTSDGPNPCDMVKQPRYRKGPDVCFDNNVLEDYTDCGGVSGLNPS
LWYIIGIQFLLLWLVSGSTHRLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016179|Voltage-dependent calcium channel subunit alpha-2/delta-1 (CACNA2D1)
ATGGCTGCTGGCTGCCTGCTGGCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGC
CCCTCGTCGGAGGAGCCGTTCCCTTCGGCCGTCACTATCAAATCATGGGTGGATAAGATG
CAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATT
TATGAGAAATATCAAGATTTGTATACTGTGGAACCAAATAATGCACGCCAGCTGGTAGAA
ATTGCAGCCAGGGATATTGAGAAACTTCTGAGCAACAGATCTAAAGCCCTGGTGCGCCTG
GCATTGGAAGCGGAGAAAGTTCAAGCAGCTCACCAGTGGAGAGAAGATTTTGCAAGCAAT
GAAGTTGTCTACTACAATGCAAAGGATGATCTCGATCCTGAGAAAAATGACAGTGAGCCA
GGCAGCCAGAGGATAAAACCTGTTTTCATTGAAGATGCTAATTTTGGACGACAAATATCT
TATCAGCACGCAGCAGTCCATATTCCTACTGACATCTATGAGGGCTCAACAATTGTGTTA
AATGAACTCAACTGGACAAGTGCCTTAGATGAAGTTTTCAAAAAGAATCGCGAGGAAGAC
CCTTCATTATTGTGGCAGGTTTTTGGCAGTGCCACTGGCCTAGCTCGATATTATCCAGCT
TCACCATGGGTTGATAATAGTAGAACTCCAAATAAGATTGACCTTTATGATGTACGCAGA
AGACCATGGTACATCCAAGGAGCTGCATCTCCTAAAGACATGCTTATTCTGGTGGATGTG
AGTGGAAGTGTTAGTGGATTGACACTTAAACTGATCCGAACATCTGTCTCCGAAATGTTA
GAAACCCTCTCAGATGATGATTTCGTGAATGTAGCTTCATTTAACAGCAATGCTCAGGAT
GTAAGCTGTTTTCAGCACCTTGTCCAAGCAAATGTAAGAAATAAAAAAGTGTTGAAAGAC
GCGGTGAATAATATCACAGCCAAAGGAATTACAGATTATAAGAAGGGCTTTAGTTTTGCT
TTTGAACAGCTGCTTAATTATAATGTTTCCAGAGCAAACTGCAATAAGATTATTATGCTA
TTCACGGATGGAGGAGAAGAGAGAGCCCAGGAGATATTTAACAAATACAATAAAGATAAA
AAAGTACGTGTATTCACGTTTTCAGTTGGTCAACACAATTATGACAGAGGACCTATTCAG
TGGATGGCCTGTGAAAACAAAGGTTATTATTATGAAATTCCTTCCATTGGTGCAATAAGA
ATCAATACTCAGGAATATTTGGATGTTTTGGGAAGACCAATGGTTTTAGCAGGAGACAAA
GCTAAGCAAGTCCAATGGACAAATGTGTACCTGGATGCATTGGAACTGGGACTTGTCATT
ACTGGAACTCTTCCGGTCTTCAACATAACCGGCCAATTTGAAAATAAGACAAACTTAAAG
AACCAGCTGATTCTTGGTGTGATGGGAGTAGATGTGTCTTTGGAAGATATTAAAAGACTG
ACACCACGTTTTACACTGTGCCCCAATGGGTATTACTTTGCAATCGATCCTAATGGTTAT
GTTTTATTACATCCAAATCTTCAGCCAAAGAACCCCAAATCTCAGGAGCCAGTAACATTG
GATTTCCTTGATGCAGAGTTAGAGAATGATATTAAAGTGGAGATTCGAAATAAGATGATT
GATGGGGAAAGTGGAGAAAAAACATTCAGAACTCTGGTTAAATCTCAAGATGAGAGATAT
ATTGACAAAGGAAACAGGACATACACATGGACACCTGTCAATGGCACAGATTACAGTTTG
GCCTTGGTATTACCAACCTACAGTTTTTACTATATAAAAGCCAAACTAGAAGAGACAATA
ACTCAGGCCAGATCAAAAAAGGGCAAAATGAAGGATTCGGAAACCCTGAAGCCAGATAAT
TTTGAAGAATCTGGCTATACATTCATAGCACCAAGAGATTACTGCAATGACCTGAAAATA
TCGGATAATAACACTGAATTTCTTTTAAATTTCAACGAGTTTATTGATAGAAAAACTCCA
AACAACCCATCATGTAACGCGGATTTGATTAATAGAGTCTTGCTTGATGCAGGCTTTACA
AATGAACTTGTCCAAAATTACTGGAGTAAGCAGAAAAATATCAAGGGAGTGAAAGCACGA
TTTGTTGTGACTGATGGTGGGATTACCAGAGTTTATCCCAAAGAGGCTGGAGAAAATTGG
CAAGAAAACCCAGAGACATATGAGGACAGCTTCTATAAAAGGAGCCTAGATAATGATAAC
TATGTTTTCACTGCTCCCTACTTTAACAAAAGTGGACCTGGTGCCTATGAATCGGGCATT
ATGGTAAGCAAAGCTGTAGAAATATATATTCAAGGGAAACTTCTTAAACCTGCAGTTGTT
GGAATTAAAATTGATGTAAATTCCTGGATAGAGAATTTCACCAAAACCTCAATCAGAGAT
CCGTGTGCTGGTCCAGTTTGTGACTGCAAAAGAAACAGTGACGTAATGGATTGTGTGATT
CTGGATGATGGTGGGTTTCTTCTGATGGCAAATCATGATGATTATACTAATCAGATTGGA
AGATTTTTTGGAGAGATTGATCCCAGCTTGATGAGACACCTGGTTAATATATCAGTTTAT
GCTTTTAACAAATCTTATGATTATCAGTCAGTATGTGAGCCCGGTGCTGCACCAAAACAA
GGAGCAGGACATCGCTCAGCATATGTGCCATCAGTAGCAGACATATTACAAATTGGCTGG
TGGGCCACTGCTGCTGCCTGGTCTATTCTACAGCAGTTTCTCTTGAGTTTGACCTTTCCA
CGACTCCTTGAGGCAGTTGAGATGGAGGATGATGACTTCACGGCCTCCCTGTCCAAGCAG
AGCTGCATTACTGAACAAACCCAGTATTTCTTCGATAACGACAGTAAATCATTCAGTGGT
GTATTAGACTGTGGAAACTGTTCCAGAATCTTTCATGGAGAAAAGCTTATGAACACCAAC
TTAATATTCATAATGGTTGAGAGCAAAGGGACATGTCCATGTGACACACGACTGCTCATA
CAAGCGGAGCAGACTTCTGACGGTCCAAATCCTTGTGACATGGTTAAGCAACCCAGATAC
CGAAAAGGGCCTGATGTCTGCTTTGATAACAATGTCTTGGAGGATTATACTGACTGTGGT
GGTGTTTCTGGATTAAATCCCTCCCTGTGGTATATCATTGGAATCCAGTTTCTACTACTT
TGGCTGGTATCTGGCAGCACACACCGCCTGTTATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00092</identifier>
            <name>VWA</name>
          </pfam>
          <pfam>
            <identifier>PF02743</identifier>
            <name>Cache_1</name>
          </pfam>
          <pfam>
            <identifier>PF08473</identifier>
            <name>VGCC_alpha2</name>
          </pfam>
          <pfam>
            <identifier>PF08399</identifier>
            <name>VWA_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>L-type voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9NY47" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel subunit alpha-2/delta-2</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.</specific-function>
        <gene-name>CACNA2D2</gene-name>
        <locus>3p21.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1114-1134</transmembrane-regions>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>5.62</theoretical-pi>
        <molecular-weight>129816.095</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1400</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA2D2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ251368</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NY47</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CA2D2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>KIAA0558</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha-2/delta-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037201|Voltage-dependent calcium channel subunit alpha-2/delta-2
MAVPARTCGASRPGPARTARPWPGCGPHPGPGTRRPTSGPPRPLWLLLPLLPLLAAPGAS
AYSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRNLFEVQENEPQKLVEKVA
GDIESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVER
GSKASTLRLDFIEDPNFKNKVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRR
QDPTLLWQVFGSATGVTRYYPATPWRAPKKIDLYDVRRRPWYIQGASSPKDMVIIVDVSG
SVSGLTLKLMKTSVCEMLDTLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAV
QGMVAKGTTGYKAGFEYAFDQLQNSNITRANCNKMIMMFTDGGEDRVQDVFEKYNWPNRT
VRVFTFSVGQHNYDVTPLQWMACANKGYYFEIPSIGAIRINTQEYLDVLGRPMVLAGKEA
KQVQWTNVYEDALGLGLVVTGTLPVFNLTQDGPGEKKNQLILGVMGIDVALNDIKRLTPN
YTLGANGYVFAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEDENKEEIRRSMIDGN
KGHKQIRTLVKSLDERYIDEVTRNYTWVPIRSTNYSLGLVLPPYSTFYLQANLSDQILQV
KLPISKLKDFEFLLPSSFESEGHVFIAPREYCKDLNASDNNTEFLKNFIELMEKVTPDSK
QCNNFLLHNLILDTGITQQLVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAAEDWTE
NPEPFNASFYRRSLDNHGYVFKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLRPA
VVGVKLDLEAWAEKFKVLASNRTHQDQPQKCGPNSHCEMDCEVNNEDLLCVLIDDGGFLV
LSNQNHQWDQVGRFFSEVDANLMLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVF
VPTVADFLNLAWWTSAAAWSLFQQLLYGLIYHSWFQADPAEAEGSPETRESSCVMKQTQY
YFGSVNASYNAIIDCGNCSRLFHAQRLTNTNLLFVVAEKPLCSQCEAGRLLQKETHSDGP
EQCELVQRPRYRRGPHICFDYNATEDTSDCGRGASFPPSLGVLVSLQLLLLLGLPPRPQP
QVLVHASRRL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011717|Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2)
ATGGCGGTGCCGGCTCGGACCTGCGGCGCCTCTCGGCCCGGCCCAGCGCGGACTGCGCGC
CCCTGGCCCGGCTGCGGCCCCCACCCTGGCCCCGGCACCCGGCGCCCGACGTCCGGGCCC
CCGCGCCCGCTGTGGCTGCTGCTGCCGCTTCTACCGCTGCTCGCCGCCCCCGGCGCCTCT
GCCTACAGCTTCCCCCAGCAGCACACGATGCAGCACTGGGCCCGGCGTCTGGAGCAGGAG
GTCGACGGCGTGATGCGGATTTTTGGAGGCGTCCAGCAGCTCCGTGAGATTTACAAGGAC
AACCGGAACCTGTTCGAGGTACAGGAGAATGAGCCTCAGAAGTTGGTGGAGAAGGTGGCA
GGGGACATTGAGAGCCTTCTGGACAGGAAGGTGCAGGCCCTGAAGAGACTGGCTGATGCT
GCAGAGAACTTCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGTG
TACTATGACGCCAAGGCTGACGCTGAGCTGGACGACCCTGAGAGTGAGGATGTGGAAAGG
GGGTCTAAGGCCAGCACCCTAAGGCTGGACTTCATCGAGGACCCAAACTTCAAGAACAAG
GTCAACTATTCATACGCGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTC
ATCCTCAATGAGCTCAACTGGACAGAGGCCCTGGAGAATGTGTTCATGGAAAACCGCAGA
CAAGACCCCACACTGCTGTGGCAGGTCTTCGGCAGCGCCACAGGAGTCACTCGCTACTAC
CCGGCCACCCCGTGGCGAGCCCCCAAGAAGATCGACCTGTACGATGTCCGAAGGAGACCC
TGGTATATCCAGGGGGCCTCGTCACCCAAAGACATGGTCATCATCGTGGATGTGAGTGGC
AGTGTGAGCGGCCTGACCCTGAAGCTGATGAAGACATCTGTCTGCGAGATGCTGGACACG
CTGTCTGATGATGACTATGTGAATGTGGCCTCGTTCAACGAGAAGGCACAGCCTGTGTCA
TGCTTCACACACCTGGTGCAGGCCAATGTGCGCAACAAGAAGGTGTTCAAGGAAGCTGTG
CAGGGCATGGTGGCCAAGGGCACCACAGGCTACAAGGCCGGCTTTGAGTATGCCTTTGAC
CAGCTGCAGAACTCCAACATCACTCGGGCCAACTGCAACAAGATGATCATGATGTTCACG
GATGGTGGTGAGGACCGCGTGCAGGACGTCTTTGAGAAGTACAATTGGCCAAACCGGACG
GTGCGCGTGTTTACTTTCTCCGTGGGGCAGCATAACTATGACGTCACACCGCTGCAGTGG
ATGGCCTGTGCCAACAAAGGCTACTATTTTGAGATCCCTTCCATCGGAGCCATCCGCATC
AACACACAGGAATATCTAGATGTGTTGGGCAGGCCCATGGTGCTGGCAGGCAAGGAGGCC
AAGCAGGTGCAGTGGACCAACGTGTATGAGGATGCACTGGGACTGGGGTTGGTGGTAACA
GGGACCCTCCCTGTTTTCAACCTGACACAGGATGGCCCTGGGGAAAAGAAGAACCAGCTG
ATCCTGGGCGTGATGGGCATTGACGTGGCTCTGAATGACATCAAGAGGCTGACCCCCAAC
TACACGCTTGGAGCCAACGGCTATGTGTTTGCCATTGACCTGAACGGCTACGTGTTGCTG
CACCCCAATCTCAAGCCCCAGACCACCAACTTCCGGGAGCCTGTGACTCTGGACTTCCTG
GATGCGGAGCTAGAGGATGAGAACAAGGAAGAGATCCGTCGGAGCATGATTGATGGCAAC
AAGGGCCACAAGCAGATCAGAACGTTGGTCAAGTCCCTGGATGAGAGGTACATAGATGAG
GTGACACGGAACTACACCTGGGTGCCTATAAGGAGCACTAACTACAGCCTGGGGCTGGTG
CTCCCACCCTACAGCACCTTCTACCTCCAAGCCAATCTCAGTGACCAGATCCTGCAGGTC
AAGTATTTTGAGTTCCTGCTCCCCAGCAGCTTTGAGTCTGAAGGACACGTTTTCATTGCT
CCCAGAGAGTACTGCAAGGACCTGAATGCCTCAGACAACAACACCGAGTTCCTGAAAAAC
TTTATTGAGCTCATGGAGAAAGTGACTCCAGACTCCAAGCAGTGCAACAACTTCCTTCTG
CACAACCTGATCTTGGACACGGGCATCACGCAGCAGCTGGTAGAGCGTGTGTGGAGGGAC
CAGGATCTCAACACGTACAGCCTACTGGCCGTGTTCGCTGCCACAGACGGTGGCATCACC
CGAGTCTTCCCCAACAAGGCAGCTGAGGACTGGACAGAGAACCCTGAGCCCTTCAATGCC
AGCTTCTACCGCCGCAGCCTGGATAACCACGGTTATGTCTTCAAGCCCCCACACCAGGAT
GCCCTGTTAAGGCCGCTGGAGCTGGAGAATGACACTGTGGGCATCCTCGTCAGCACAGCT
GTGGAGCTCAGCCTAGGCAGGCGCACACTGAGGCCAGCAGTGGTGGGCGTCAAGCTGGAC
CTAGAGGCTTGGGCTGAGAAGTTCAAGGTGCTAGCCAGCAACCGTACCCACCAAGACCAG
CCTCAGAAGTGCGGCCCCAACAGCCACTGTGAGATGGACTGCGAGGTTAACAATGAGGAC
TTACTCTGTGTCCTCATTGATGATGGAGGATTCCTGGTGCTGTCAAACCAGAACCATCAG
TGGGACCAGGTGGGCAGGTTCTTCAGTGAGGTGGATGCCAACCTGATGCTGGCACTCTAC
AATAACTCCTTCTACACCCGCAAGGAGTCCTATGACTATCAGGCAGCCTGTGCCCCTCAG
CCCCCTGGCAACCTGGGTGCTGCACCCCGGGGTGTCTTTGTGCCCACCGTTGCAGATTTC
CTTAACCTGGCCTGGTGGACCTCTGCTGCCGCCTGGTCCCTGTTCCAGCAGCTTCTCTAC
GGCCTCATCTACCACAGCTGGTTCCAAGCAGACCCCGCGGAGGCCGAGGGGAGCCCCGAG
ACGCGCGAGAGCAGCTGCGTCATGAAACAGACCCAGTACTACTTCGGCTCGGTAAACGCC
TCCTACAACGCCATCATCGACTGCGGAAACTGCTCCAGGCTGTTCCACGCGCAGAGACTG
ACCAACACCAATCTTCTCTTTGTGGTGGCCGAGAAGCCGCTGTGCAGCCAGTGCGAGGCT
GGCCGGCTGCTGCAGAAGGAGACGCACTGCCCAGCGGACGGCCCGGAGCAGTGTGAGCTA
GTGCAGAGACCGCGATACCGGAGAGGCCCGCACATCTGCTTCGACTACAACGCGACAGAA
GATACCTCAGACTGTGGCCGCGGGGCCTCCTTCCCGCCGTCGCTGGGCGTCCTGGTCTCC
CTGCAACTGCTGCTCCTCCTGGGCCTGCCGCCCCGGCCGCAGCCTCAAGTCCTCGTCCAC
GCCTCTCGCCGCCTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00092</identifier>
            <name>VWA</name>
          </pfam>
          <pfam>
            <identifier>PF02743</identifier>
            <name>Cache_1</name>
          </pfam>
          <pfam>
            <identifier>PF08473</identifier>
            <name>VGCC_alpha2</name>
          </pfam>
          <pfam>
            <identifier>PF08399</identifier>
            <name>VWA_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle fiber development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhythmic synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q8IZS8" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel subunit alpha-2/delta-3</name>
        <general-function>Voltage-gated ion channel activity</general-function>
        <specific-function>The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity).</specific-function>
        <gene-name>CACNA2D3</gene-name>
        <locus>3p21.1</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1069-1089</transmembrane-regions>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>5.54</theoretical-pi>
        <molecular-weight>123010.22</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:15460</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ272268</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7105926</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8IZS8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CA2D3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Voltage-gated calcium channel subunit alpha-2/delta-3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006864|Voltage-dependent calcium channel subunit alpha-2/delta-3
MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKY
SGSQLLQKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKSEAVRRLVEAAEEAHLKH
EFDADLQYEYFNAVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYN
KDPAIVNGVYWSESLNKVFVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPDENGVIAFD
CRNRKWYIQAATSPKDVVILVDVSGSMKGLRLTIAKQTVSSILDTLGDDDFFNIIAYNEE
LHYVEPCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILSDFNHTGQGSI
CSQAIMLITDGAVDTYDTIFAKYNWPDRKVRIFTYLIGREAAFADNLKWMACANKGFFTQ
ISTLADVQENVMEYLHVLSRPKVIDQEHDVVWTEAYIDSTLPQAQKLTDDQGPVLMTTVA
MPVFSKQNETRSKGILLGVVGTDVPVKELLKTIPKYKLGIHGYAFAITNNGYILTHPELR
LLYEEGKKRRKPNYSSVDLSEVEWEDRDDVLRNAMVNRKTGKFSMEVKKTVDKGKRVLVM
TNDYYYTDIKGTPFSLGVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCNTDL
HPEHRHLSQLEAIKLYLKGKEPLLQCDKELIQEVLFDAVVSAPIEAYWTSLALNKSENSD
KGVEVAFLGTRTGLSRINLFVGAEQLTNQDFLKAGDKENIFNADHFPLWYRRAAEQIPGS
FVYSIPFSTGPVNKSNVVTASTSIQLLDERKSPVVAAVGIQMKLEFFQRKFWTASRQCAS
LDGKCSISCDDETVNCYLIDNNGFILVSEDYTQTGDFFGEIEGAVMNKLLTMGSFKRITL
YDYQAMCRANKESSDGAHGLLDPYNAFLSAVKWIMTELVLFLVEFNLCSWWHSDMTAKAQ
KLKQTLEPCDTEYPAFVSERTIKETTGNIACEDCSKSFVIQQIPSSNLFMVVVDSSCLCE
SVAPITMAPIEIRYNESLKCERLKAQKIRRRPESCHGFHPEENARECGGAPSLQAQTVLL
LLPLLLMLFSR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012478|Voltage-dependent calcium channel subunit alpha-2/delta-3 (CACNA2D3)
ATGGCCGGGCCGGGCTCGCCGCGCCGCGCGTCCCGGGGGGCCTCGGCGCTTCTCGCTGCC
GCGCTTCTCTACGCCGCGCTGGGGGACGTGGTGCGCTCGGAGCAGCAGATACCGCTCTCC
GTGGTGAAGCTCTGGGCCTCGGCTTTTGGTGGGGAGATAAAATCCATTGCTGCTAAGTAC
TCCGGTTCCCAGCTTCTGCAAAAGAAATACAAAGAGTATGAGAAAGACGTTGCCATAGAA
GAAATCGATGGCCTCCAACTGGTAAAGAAGCTGGCAAAGAACATGGAAGAGATGTTTCAC
AAGAAGTCTGAGGCCGTCAGGCGTCTGGTGGAGGCTGCAGAAGAAGCACACCTGAAACAT
GAATTTGATGCAGACTTACAGTATGAATACTTCAATGCTGTGCTGATAAATGAAAGGGAC
AAAGACGGGAATTTTTTGGAGCTGGGAAAGGAATTCATCTTAGCCCCAAATGACCATTTT
AATAATTTGCCTGTGAACATCAGTCTAAGTGACGTCCAAGTACCAACGAACATGTACAAC
AAAGACCCTGCAATTGTCAATGGGGTTTATTGGTCTGAATCTCTAAACAAAGTTTTTGTA
GATAACTTTGACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTGCAAAGGGCTTT
TTTAGGCAGTATCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATTGCCTTCGAC
TGCAGGAACCGAAAATGGTACATCCAGGCAGCAACTTCTCCGAAAGACGTGGTCATTTTA
GTTGACGTCAGTGGCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCA
TCCATTTTGGATACACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAATGAGGAG
CTTCACTATGTGGAACCTTGCCTGAATGGAACTTTGGTGCAAGCCGACAGGACAAACAAA
GAGCACTTCAGGGAGCATCTGGACAAACTTTTCGCCAAAGGAATTGGAATGTTGGATATA
GCTCTGAATGAGGCCTTCAACATTCTGAGTGATTTCAACCACACGGGACAAGGAAGTATC
TGCAGTCAGGCCATCATGCTCATAACTGATGGGGCGGTGGACACCTATGATACAATCTTT
GCAAAATACAATTGGCCAGATCGAAAGGTTCGCATCTTCACATACCTCATTGGACGAGAG
GCTGCGTTTGCAGACAATCTAAAGTGGATGGCCTGTGCCAACAAAGGATTTTTTACCCAG
ATCTCCACCTTGGCTGATGTGCAGGAGAATGTCATGGAATACCTTCACGTGCTTAGCCGG
CCCAAAGTCATCGACCAGGAGCATGATGTGGTGTGGACCGAAGCTTACATTGACAGCACT
CTCCCTCAGGCACAAAAGCTGACTGATGATCAGGGCCCCGTCCTGATGACCACTGTAGCC
ATGCCTGTGTTTAGTAAGCAGAACGAAACCAGATCGAAGGGCATTCTTCTGGGAGTGGTT
GGCACAGATGTCCCAGTGAAAGAACTTCTGAAGACCATCCCCAAATACAAGTTAGGGATT
CACGGTTATGCCTTTGCAATCACAAATAATGGATATATCCTGACGCATCCGGAACTCAGG
CTGCTGTACGAAGAAGGAAAAAAGCGAAGGAAACCTAACTATAGTAGCGTTGACCTCTCT
GAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTATGGTGAATCGAAAGACG
GGGAAGTTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGAAACGGGTTTTGGTGATG
ACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTTCAGTTTAGGTGTGGCGCTT
TCCAGAGGTCATGGGAAATATTTCTTCCGAGGGAATGTAACCATCGAAGAAGGCCTGCAT
GACTTAGAACATCCCGATGTGTCCTTGGCAGATGAATGGTCCTACTGCAACACTGACCTA
CACCCTGAGCACCGCCATCTGTCTCAGTTAGAAGCGATTAAGCTCTACCTAAAAGGCAAA
GAACCTCTGCTCCAGTGTGATAAAGAATTGATCCAAGAAGTCCTTTTTGACGCGGTGGTG
AGTGCCCCCATTGAAGCGTATTGGACCAGCCTGGCCCTCAACAAATCTGAAAATTCTGAC
AAGGGCGTGGAGGTTGCCTTCCTCGGCACTCGCACGGGCCTCTCCAGAATCAACCTGTTT
GTCGGGGCTGAGCAGCTCACCAATCAGGACTTCCTGAAAGCTGGCGACAAGGAGAACATT
TTTAACGCAGACCATTTCCCTCTCTGGTACCGAAGAGCCGCTGAGCAGATTCCAGGGAGC
TTCGTCTACTCGATCCCATTCAGCACTGGACCAGTCAATAAAAGCAATGTGGTGACAGCA
AGTACATCCATCCAGCTCCTGGATGAACGGAAATCTCCTGTGGTGGCAGCTGTAGGCATT
CAGATGAAACTTGAATTTTTCCAAAGGAAGTTCTGGACTGCCAGCAGACAGTGTGCTTCC
CTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACTGTGAATTGTTACCTCATAGAC
AATAATGGATTTATTTTGGTGTCTGAAGACTACACACAGACTGGAGACTTTTTTGGTGAG
ATCGAGGGAGCTGTGATGAACAAATTGCTAACAATGGGCTCCTTTAAAAGAATTACCCTT
TATGACTACCAAGCCATGTGTAGAGCCAACAAGGAAAGCAGCGATGGCGCCCATGGCCTC
CTGGATCCTTATAATGCCTTCCTCTCTGCAGTAAAATGGATCATGACAGAACTTGTCTTG
TTCCTGGTGGAATTTAACCTCTGCAGTTGGTGGCACTCCGATATGACAGCTAAAGCCCAG
AAATTGAAACAGACCCTGGAGCCTTGTGATACTGAATATCCAGCATTCGTCTCTGAGCGC
ACCATCAAGGAGACTACAGGGAATATTGCTTGTGAAGACTGCTCCAAGTCCTTTGTCATC
CAGCAAATCCCAAGCAGCAACCTGTTCATGGTGGTGGTGGACAGCAGCTGCCTCTGTGAA
TCTGTGGCCCCCATCACCATGGCACCCATTGAAATCAGGTATAATGAATCCCTTAAGTGT
GAACGTCTAAAGGCCCAGAAGATCAGAAGGCGCCCAGAATCTTGTCATGGCTTCCATCCT
GAGGAGAATGCAAGGGAGTGTGGGGGTGCGCCGAGTCTCCAAGCCCAGACAGTCCTCCTT
CTGCTCCCTCTGCTTTTGATGCTCTTCTCAAGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02743</identifier>
            <name>Cache_1</name>
          </pfam>
          <pfam>
            <identifier>PF08399</identifier>
            <name>VWA_N</name>
          </pfam>
          <pfam>
            <identifier>PF13768</identifier>
            <name>VWA_3</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q7Z3S7" source="Swiss-Prot">
        <name>Voltage-dependent calcium channel subunit alpha-2/delta-4</name>
        <general-function>The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel.</general-function>
        <specific-function>Metal ion binding</specific-function>
        <gene-name>CACNA2D4</gene-name>
        <locus>12p13.33</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1116-1136</transmembrane-regions>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi/>
        <molecular-weight>127936.93</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:20202</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q7Z3S7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CA2D4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Voltage-gated calcium channel subunit alpha-2/delta-4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051558|Voltage-dependent calcium channel subunit alpha-2/delta-4
MVCGCSALLPLPNPRPTMPATPNFLANPSSSSRWIPLQPMPVAWAFVQKTSALLWLLLLG
TSLSPAWGQAKIPLETVKLWADTFGGDLYNTVTKYSGSLLLQKKYKDVESSLKIEEVDGL
ELVRKFSEDMENMLRRKVEAVQNLVEAAEEADLNHEFNESLVFDYYNSVLINERDEKGNF
VELGAEFLLESNAHFSNLPVNTSISSVQLPTNVYNKDPDILNGVYMSEALNAVFVENFQR
DPTLTWQYFGSATGFFRIYPGIKWTPDENGVITFDCRNRGWYIQAATSPKDIVILVDVSG
SMKGLRMTIAKHTITTILDTLGENDFINIIAYNDYVHYIEPCFKGILVQADRDNREHFKL
LVEELMVKGVGVVDQALREAFQILKQFQEAKQGSLCNQAIMLISDGAVEDYEPVFEKYNW
PDCKVRVFTYLIGREVSFADRMKWIACNNKGYYTQISTLADTQENVMEYLHVLSRPMVIN
HDHDIIWTEAYMDSKLLSSQAQSLTLLTTVAMPVFSKKNETRSHGILLGVVGSDVALREL
MKLAPRYKLGVHGYAFLNTNNGYILSHPDLRPLYREGKKLKPKPNYNSVDLSEVEWEDQA
ESLRTAMINRETGTLSMDVKVPMDKGKRVLFLTNDYFFTDISDTPFSLGVVLSRGHGEYI
LLGNTSVEEGLHDLLHPDLALAGDWIYCITDIDPDHRKLSQLEAMIRFLTRKDPDLECDE
ELVREVLFDAVVTAPMEAYWTALALNMSEESEHVVDMAFLGTRAGLLRSSLFVGSEKVSD
RKFLTPEDEASVFTLDRFPLWYRQASEHPAGSFVFNLRWAEGPESAGEPMVVTASTAVAV
TVDKRTAIAAAAGVQMKLEFLQRKFWAATRQCSTVDGPCTQSCEDSDLDCFVIDNNGFIL
ISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYDYQAMCKPSSHHHSAAQPLVSPISA
FLTATRWLLQELVLFLLEWSVWGSWYDRGAEAKSVFHHSHKHKKQDPLQPCDTEYPVFVY
QPAIREANGIVECGPCQKVFVVQQIPNSNLLLLVTDPTCDCSIFPPVLQEATEVKYNASV
KCDRMRSQKLRRRPDSCHAFHPEENAQDCGGASDTSASPPLLLLPVCAWGLLPQLLR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051559|Voltage-dependent calcium channel subunit alpha-2/delta-4 (CACNA2D4)
ATGGTCTGTGGCTGCTCTGCCCTCCTTCCCCTCCCCAACCCCAGGCCCACCATGCCTGCA
ACTCCCAACTTCCTCGCAAACCCCAGCTCCAGCAGCCGCTGGATTCCCCTCCAGCCAATG
CCCGTGGCCTGGGCCTTTGTGCAGAAGACCTCGGCCCTCCTGTGGCTGCTGCTTCTAGGC
ACCTCCCTGTCCCCTGCGTGGGGACAGGCCAAGATTCCTCTGGAAACAGTGAAGCTATGG
GCTGACACCTTCGGCGGGGACCTGTATAACACTGTGACCAAATACTCAGGCTCTCTCTTG
CTGCAGAAGAAGTACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGAGGTGGATGGCTTG
GAGCTGGTGAGGAAGTTCTCAGAGGACATGGAGAACATGCTGCGGAGGAAAGTCGAGGCG
GTCCAGAATCTGGTGGAAGCTGCCGAGGAGGCCGACCTGAACCACGAATTCAATGAATCC
CTGGTGTTCGACTATTACAACTCGGTCCTGATCAACGAGAGGGACGAGAAGGGCAACTTC
GTGGAGCTGGGCGCCGAGTTCCTCCTGGAGTCCAATGCTCACTTCAGCAACCTGCCGGTG
AACACCTCCATCAGCAGCGTGCAGCTGCCCACCAACGTGTACAACAAAGACCCAGATATT
TTAAATGGAGTCTACATGTCTGAAGCCTTGAATGCTGTCTTCGTGGAGAACTTCCAGAGA
GACCCAACGTTGACCTGGCAATATTTTGGCAGTGCAACTGGATTCTTCAGGATCTATCCA
GGTATAAAATGGACACCTGATGAGAATGGAGTCATTACTTTTGACTGCCGAAACCGCGGC
TGGTACATTCAAGCTGCTACTTCTCCCAAGGACATAGTGATTTTGGTGGACGTGAGCGGC
AGTATGAAGGGGCTGAGGATGACTATTGCCAAGCACACCATCACCACCATCTTGGACACC
CTGGGGGAGAATGACTTCATTAATATCATAGCGTACAATGACTACGTCCATTACATCGAG
CCTTGTTTTAAAGGGATCCTCGTCCAGGCGGACCGAGACAATCGAGAGCATTTCAAACTG
CTGGTGGAGGAGTTGATGGTCAAAGGTGTGGGGGTCGTGGACCAAGCCCTGAGAGAAGCC
TTCCAGATCCTGAAGCAGTTCCAAGAGGCCAAGCAAGGAAGCCTCTGCAACCAGGCCATC
ATGCTCATCAGCGACGGCGCCGTGGAGGACTACGAGCCGGTGTTTGAGAAGTATAACTGG
CCAGACTGTAAGGTCCGAGTTTTCACTTACCTCATTGGGAGAGAAGTGTCTTTTGCTGAC
CGCATGAAGTGGATTGCATGCAACAACAAAGGCTACTACACGCAGATCTCAACGCTGGCG
GACACCCAGGAGAACGTGATGGAATACCTGCACGTGCTCAGCCGCCCCATGGTCATCAAC
CACGACCACGACATCATCTGGACAGAGGCCTACATGGACAGCAAGCTCCTCAGCTCGCAG
GCTCAGAGCCTGACACTGCTCACCACTGTGGCCATGCCAGTCTTCAGCAAGAAGAACGAA
ACGCGATCCCATGGCATTCTCCTGGGTGTGGTGGGCTCAGATGTGGCCCTGAGAGAGCTG
ATGAAGCTGGCGCCCCGGTACAAGCTTGGAGTGCACGGATACGCCTTTCTGAACACCAAC
AATGGCTACATCCTCTCCCATCCCGACCTCCGGCCCCTGTACAGAGAGGGGAAGAAACTA
AAACCCAAACCTAACTACAACAGTGTGGATCTCTCCGAAGTGGAGTGGGAAGACCAGGCT
GAATCTCTGAGAACAGCCATGATCAATAGGGAAACAGGTACTCTCTCGATGGATGTGAAG
GTTCCGATGGATAAAGGGAAGCGAGTTCTTTTCCTGACCAATGACTACTTCTTCACGGAC
ATCAGCGACACCCCTTTCAGTTTGGGGGTGGTGCTGTCCCGGGGCCACGGAGAATACATC
CTTCTGGGGAACACGTCTGTGGAAGAAGGCCTGCATGACTTGCTTCACCCAGACCTGGCC
CTGGCCGGTGACTGGATCTACTGCATCACAGATATTGACCCAGACCACCGGAAGCTCAGC
CAGCTAGAGGCCATGATCCGCTTCCTCACCAGGAAGGACCCAGACCTGGAGTGTGACGAG
GAGCTGGTCCGGGAGGTGCTGTTTGACGCGGTGGTGACAGCCCCCATGGAAGCCTACTGG
ACAGCGCTGGCCCTCAACATGTCCGAGGAGTCTGAACACGTGGTGGACATGGCCTTCCTG
GGCACCCGGGCTGGCCTCCTGAGAAGCAGCTTGTTCGTGGGCTCCGAGAAGGTCTCCGAC
AGGAAGTTCCTGACACCTGAGGACGAGGCCAGCGTGTTCACCCTGGACCGCTTCCCGCTG
TGGTACCGCCAGGCCTCAGAGCATCCTGCTGGCAGCTTCGTCTTCAACCTCCGCTGGGCA
GAAGGACCAGAAAGTGCGGGTGAACCCATGGTGGTGACGGCAAGCACAGCTGTGGCGGTG
ACCGTGGACAAGAGGACAGCCATTGCTGCAGCCGCGGGCGTCCAAATGAAGCTGGAATTC
CTCCAGCGCAAATTCTGGGCGGCAACGCGGCAGTGCAGCACTGTGGATGGGCCGTGCACA
CAGAGCTGCGAGGACAGTGATCTGGACTGCTTCGTCATCGACAACAACGGGTTCATTCTG
ATCTCCAAGAGGTCCCGAGAGACGGGAAGATTTCTGGGGGAGGTGGATGGTGCTGTCCTG
ACCCAGCTGCTCAGCATGGGGGTGTTCAGCCAAGTGACTATGTATGACTATCAGGCCATG
TGCAAACCCTCGAGTCACCACCACAGTGCAGCCCAGCCCCTGGTCAGCCCAATTTCTGCC
TTCTTGACGGCGACCAGGTGGCTGCTGCAGGAGCTGGTGCTGTTCCTGCTGGAGTGGAGT
GTCTGGGGCTCCTGGTACGACAGAGGGGCCGAGGCCAAAAGTGTCTTCCATCACTCCCAC
AAACACAAGAAGCAGGACCCGCTGCAGCCCTGCGACACGGAGTACCCCGTGTTCGTGTAC
CAGCCGGCCATCCGGGAGGCCAACGGGATCGTGGAGTGCGGGCCCTGCCAGAAGGTATTT
GTGGTGCAGCAGATTCCCAACAGTAACCTCCTCCTCCTGGTGACAGACCCCACCTGTGAC
TGCAGCATCTTCCCACCAGTGCTGCAGGAGGCGACAGAAGTCAAATATAATGCCTCTGTC
AAATGTGACCGGATGCGCTCCCAGAAGCTCCGCCGGCGACCAGACTCCTGCCACGCCTTC
CATCCAGAGGAGAATGCCCAGGACTGCGGCGGCGCCTCGGACACCTCAGCCTCGCCGCCC
CTACTCCTGCTGCCTGTGTGTGCCTGGGGGCTACTGCCCCAACTCCTGCGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF08473</identifier>
            <name>VGCC_alpha2</name>
          </pfam>
          <pfam>
            <identifier>PF08399</identifier>
            <name>VWA_N</name>
          </pfam>
          <pfam>
            <identifier>PF13768</identifier>
            <name>VWA_3</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of light stimulus involved in visual perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ion transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q13936" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit alpha-1C</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1C subunit play an important role in excitation-contraction coupling in the heart. The various isoforms display marked differences in the sensitivity to DHP compounds. Binding of calmodulin or CABP1 at the same regulatory sites results in an opposit effects on the channel function.</specific-function>
        <gene-name>CACNA1C</gene-name>
        <locus>12p13.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>125-143
161-181
194-212
233-251
271-290
381-405
525-543
559-578
587-605
616-634
654-673
729-753
901-919
936-955
988-1006
1014-1032
1052-1071
1162-1186
1240-1258
1274-1293
1302-1320
1373-1391
1411-1430
1500-1524</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.7</theoretical-pi>
        <molecular-weight>248974.1</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1390</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1C</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M92270</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>529</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>529</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13936</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CACH2</synonym>
          <synonym>CACN2</synonym>
          <synonym>CACNL1A1</synonym>
          <synonym>Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle</synonym>
          <synonym>CCHL1A1</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav1.2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037015|Voltage-dependent L-type calcium channel subunit alpha-1C
MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAAR
QAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISI
VEWKPFEIIILLTIFANCVALAIYIPFPEDDSNATNSNLERVEYLFLIIFTVEAFLKVIA
YGLLFHPNAYLRNGWNLLDFIIVVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFR
VLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFMGKMHKTCYN
QEGIADVPAEDDPSPCALETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCI
TMEGWTDVLYWVNDAVGRDWPWIYFVTLIIIGSFFVLNLVLGVLSGEFSKEREKAKARGD
FQKLREKQQLEEDLKGYLDWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVA
GGDIEGENCGARLAHRISKSKFSRYWRRWNRFCRRKCRAAVKSNVFYWLVIFLVFLNTLT
IASEHYNQPNWLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGI
LETILVETKIMSPLGISVLRCVRLLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFL
FIIIFSLLGMQLFGGKFNFDEMQTRRSTFDNFPQSLLTVFQILTGEDWNSVMYDGIMAYG
GPSFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLADAESLTSAQKEEEEEKERKKLAR
TASPEKKQELVEKPAVGESKEEKIELKSITADGESPPATKINMDDLQPNENEDKSPYPNP
ETTGEEDEEEPEMPVGPRPRPLSELHLKEKAVPMPEASAFFIFSSNNRFRLQCHRIVNDT
IFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEIALKILGNADYVF
TSIFTLEIILKMTAYGAFLHKGSFCRNYFNILDLLVVSVSLISFGIQSSAINVVKILRVL
RVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSD
SSKQTEAECKGNYITYKDGEVDHPIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPEL
LYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVTFQEQGEQEYKNC
ELDKNQRQCVEYALKARPLRRYIPKNQHQYKVWYVVNSTYFEYLMFVLILLNTICLAMQH
YGQSCLFKIAMNILNMLFTGLFTVEMILKLIAFKPKGYFSDPWNVFDFLIVIGSIIDVIL
SETNHYFCDAWNTFDALIVVGSIVDIAITEVNPAEHTQCSPSMNAEENSRISITFFRLFR
VMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTE
INRNNNFQTFPQAVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFA
VFYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRI
KHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFALVRTALRI
KTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYATFLIQEYFRKFK
KRKEQGLVGKPSQRNALSLQAGLRTLHDIGPEIRRAISGDLTAEEELDKAMKEAVSAASE
DDIFRRAGGLFGNHVSYYQSDGRSAFPQTFTTQRPLHINKAGSSQGDTESPSHEKLVDST
FTPSSYSSTGSNANINNANNTALGRLPRPAGYPSTVSTVEGHGPPLSPAIRVQEVAWKLS
SNRERHVPMCEDLELRRDSGSAGTQAHCLLLRKANPSRCHSRESQAAMAGQEETSQDETY
EVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLGRRA
SFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPA
TPGSRGWPPQPVPTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLM
VPSQAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESA
ADNILSGGAPQSPNGALLPFVNCRDAGQDRAGGEEDAGCVRARGRPSEEELQDSRVYVSS
L</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016091|Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)
ATGGTCAATGAGAATACGAGGATGTACATTCCAGAGGAAAACCACCAAGGTTCCAACTAT
GGGAGCCCACGCCCCGCCCATGCCAACATGAATGCCAATGCGGCAGCGGGGCTGGCCCCT
GAGCACATCCCCACCCCGGGGGCTGCCCTGTCGTGGCAGGCGGCCATCGACGCAGCCCGG
CAGGCTAAGCTGATGGGCAGCGCTGGCAATGCGACCATCTCCACAGTCAGCTCCACGCAG
CGGAAGCGGCAGCAATATGGGAAACCCAAGAAGCAGGGCAGCACCACGGCCACACGCCCG
CCCCGAGCCCTGCTCTGCCTGACCCTGAAGAACCCCATCCGGAGGGCCTGCATCAGCATT
GTCGAATGGAAACCATTTGAAATAATTATTTTACTGACTATTTTTGCCAATTGTGTGGCC
TTAGCGATCTATATTCCCTTTCCAGAAGATGATTCCAACGCCACCAATTCCAACCTGGAA
CGAGTGGAATATCTCTTTCTCATAATTTTTACGGTGGAAGCGTTTTTAAAAGTAATCGCC
TATGGACTCCTCTTTCACCCCAATGCCTACCTCCGCAACGGCTGGAACCTACTAGATTTT
ATAATTGTGGTTGTGGGGCTTTTTAGTGCAATTTTAGAACAAGCAACCAAAGCAGATGGG
GCAAACGCTCTCGGAGGGAAAGGGGCCGGATTTGATGTGAAGGCGCTGAGGGCCTTCCGC
GTGCTGCGCCCCCTGCGGCTGGTGTCCGGAGTCCCAAGTCTCCAGGTGGTCCTGAATTCC
ATCATCAAGGCCATGGTCCCCCTGCTGCACATCGCCCTGCTTGTGCTGTTTGTCATCATC
ATCTACGCCATCATCGGCTTGGAGCTCTTCATGGGGAAGATGCACAAGACCTGCTACAAC
CAGGAGGGCATAGCAGATGTTCCAGCAGAAGATGACCCTTCCCCTTGTGCGCTGGAAACG
GGCCACGGGCGGCAGTGCCAGAACGGCACGGTGTGCAAGCCCGGCTGGGATGGTCCCAAG
CACGGCATCACCAACTTTGACAACTTTGCCTTCGCCATGCTCACGGTGTTCCAGTGCATC
ACCATGGAGGGCTGGACGGACGTGCTGTACTGGGTCAATGATGCCGTAGGAAGGGACTGG
CCCTGGATCTATTTTGTTACACTAATCATCATAGGGTCATTTTTTGTACTTAACTTGGTT
CTCGGTGTGCTTAGCGGAGAGTTTTCCAAAGAGAGGGAGAAGGCCAAGGCCCGGGGAGAT
TTCCAGAAGCTGCGGGAGAAGCAGCAGCTAGAAGAGGATCTCAAAGGCTACCTGGATTGG
ATCACTCAGGCCGAAGACATCGATCCTGAGAATGAGGACGAAGGCATGGATGAGGAGAAG
CCCCGAAACATGAGCATGCCCACCAGTGAGACCGAGTCCGTCAACACCGAAAACGTGGCT
GGAGGTGACATCGAGGGAGAAAACTGCGGGGCCAGGCTGGCCCACCGGATCTCCAAGTCA
AAGTTCAGCCGCTACTGGCGCCGGTGGAATCGGTTCTGCAGAAGGAAGTGCCGCGCCGCA
GTCAAGTCTAATGTCTTCTACTGGCTGGTGATTTTCCTGGTGTTCCTCAACACGCTCACC
ATTGCCTCTGAGCACTACAACCAGCCCAACTGGCTCACAGAAGTCCAAGACACGGCAAAC
AAGGCCCTGCTGGCCCTGTTCACGGCAGAGATGCTCCTGAAGATGTACAGCCTGGGCCTG
CAGGCCTACTTCGTGTCCCTCTTCAACCGCTTTGACTGCTTCGTCGTGTGTGGCGGCATC
CTGGAGACCATCCTGGTGGAGACCAAGATCATGTCCCCACTGGGCATCTCCGTGCTCAGA
TGCGTCCGGCTGCTGAGGATTTTCAAGATCACGAGGTACTGGAACTCCTTGAGCAACCTG
GTGGCATCCTTGCTGAACTCTGTGCGCTCCATCGCCTCCCTGCTCCTTCTCCTCTTCCTC
TTCATCATCATCTTCTCCCTCCTGGGGATGCAGCTCTTTGGAGGAAAGTTCAACTTTGAT
GAGATGCAGACCCGGAGGAGCACATTCGATAACTTCCCCCAGTCCCTCCTCACTGTGTTT
CAGATCCTGACCGGGGAGGACTGGAATTCGGTGATGTATGATGGGATCATGGCTTATGGC
GGCCCCTCTTTTCCAGGGATGTTAGTCTGTATTTACTTCATCATCCTCTTCATCTGTGGA
AACTATATCCTACTGAATGTGTTCTTGGCCATTGCTGTGGACAACCTGGCTGATGCTGAG
AGCCTCACATCTGCCCAAAAGGAGGAGGAAGAGGAGAAGGAGAGAAAGAAGCTGGCCAGG
ACTGCCAGCCCAGAGAAGAAACAAGAGTTGGTGGAGAAGCCGGCAGTGGGGGAATCCAAG
GAGGAGAAGATTGAGCTGAAATCCATCACGGCTGACGGAGAGTCTCCACCCGCCACCAAG
ATCAACATGGATGACCTCCAGCCCAATGAAAATGAGGATAAGAGCCCCTACCCCAACCCA
GAAACTACAGGAGAAGAGGATGAGGAGGAGCCAGAGATGCCTGTCGGCCCTCGCCCACGA
CCACTCTCTGAGCTTCACCTTAAGGAAAAGGCAGTGCCCATGCCAGAAGCCAGCGCGTTT
TTCATCTTCAGCTCTAACAACAGGTTTCGCCTCCAGTGCCACCGCATTGTCAATGACACG
ATCTTCACCAACCTGATCCTCTTCTTCATTCTGCTCAGCAGCATTTCCCTGGCTGCTGAG
GACCCGGTCCAGCACACCTCCTTCAGGAACCATATTCTGTTTTATTTTGATATTGTTTTT
ACCACCATTTTCACCATTGAAATTGCTCTGAAGATGACTGCTTATGGGGCTTTCTTGCAC
AAGGGTTCTTTCTGCCGGAACTACTTCAACATCCTGGACCTGCTGGTGGTCAGCGTGTCC
CTCATCTCCTTTGGCATCCAGTCCAGTGCAATCAATGTCGTGAAGATCTTGCGAGTCCTG
CGAGTACTCAGGCCCCTGAGGGCCATCAACAGGGCCAAGGGGCTAAAGCATGTGGTTCAG
TGTGTGTTTGTCGCCATCCGGACCATCGGGAACATCGTGATTGTCACCACCCTGCTGCAG
TTCATGTTTGCCTGCATCGGGGTCCAGCTCTTCAAGGGAAAGCTGTACACCTGTTCAGAC
AGTTCCAAGCAGACAGAGGCGGAATGCAAGGGCAACTACATCACGTACAAAGACGGGGAG
GTTGACCACCCCATCATCCAACCCCGCAGCTGGGAGAACAGCAAGTTTGACTTTGACAAT
GTTCTGGCAGCCATGATGGCCCTCTTCACCGTCTCCACCTTCGAAGGGTGGCCAGAGCTG
CTGTACCGCTCCATCGACTCCCACACGGAAGACAAGGGCCCCATCTACAACTACCGTGTG
GAGATCTCCATCTTCTTCATCATCTACATCATCATCATCGCCTTCTTCATGATGAACATC
TTCGTGGGCTTCGTCATCGTCACCTTTCAGGAGCAGGGGGAGCAGGAGTACAAGAACTGT
GAGCTGGACAAGAACCAGCGACAGTGCGTGGAATACGCCCTCAAGGCCCGGCCCCTGCGG
AGGTACATCCCCAAGAACCAGCACCAGTACAAAGTGTGGTACGTGGTCAACTCCACCTAC
TTCGAGTACCTGATGTTCGTCCTCATCCTGCTCAACACCATCTGCCTGGCCATGCAGCAC
TACGGCCAGAGCTGCCTGTTCAAAATCGCCATGAACATCCTCAACATGCTCTTCACTGGC
CTCTTCACCGTGGAGATGATCCTGAAGCTCATTGCCTTCAAACCCAAGCACTATTTCTGT
GATGCATGGAATACATTTGACGCCTTGATTGTTGTGGGTAGCATTGTTGATATAGCAATC
ACCGAGGTAAACCCAGCTGAACATACCCAATGCTCTCCCTCTATGAACGCAGAGGAAAAC
TCCCGCATCTCCATCACCTTCTTCCGCCTGTTCCGGGTCATGCGTCTGGTGAAGCTGCTG
AGCCGTGGGGAGGGCATCCGGACGCTGCTGTGGACCTTCATCAAGTCCTTCCAGGCCCTG
CCCTATGTGGCCCTCCTGATCGTGATGCTGTTCTTCATCTACGCGGTGATCGGGATGCAG
GTGTTTGGGAAAATTGCCCTGAATGATACCACAGAGATCAACCGGAACAACAACTTTCAG
ACCTTCCCCCAGGCCGTGCTGCTCCTCTTCAGGTGTGCCACCGGGGAGGCCTGGCAGGAC
ATCATGCTGGCCTGCATGCCAGGCAAGAAGTGTGCCCCAGAGTCCGAGCCCAGCAACAGC
ACGGAGGGTGAAACACCCTGTGGTAGCAGCTTTGCTGTCTTCTACTTCATCAGCTTCTAC
ATGCTCTGTGCCTTCCTGATCATCAACCTCTTTGTAGCTGTCATCATGGACAACTTTGAC
TACCTGACAAGGGACTGGTCCATCCTTGGTCCCCACCACCTGGATGAGTTTAAAAGAATC
TGGGCAGAGTATGACCCTGAAGCCAAGGGTCGTATCAAACACCTGGATGTGGTGACCCTC
CTCCGGCGGATTCAGCCGCCACTAGGTTTTGGGAAGCTGTGCCCTCACCGCGTGGCTTGC
AAACGCCTGGTCTCCATGAACATGCCTCTGAACAGCGACGGGACAGTCATGTTCAATGCC
ACCCTGTTTGCCCTGGTCAGGACGGCCCTGAGGATCAAAACAGAAGGGAACCTAGAACAA
GCCAATGAGGAGCTGCGGGCGATCATCAAGAAGATCTGGAAGCGGACCAGCATGAAGCTG
CTGGACCAGGTGGTGCCCCCTGCAGGTGATGATGAGGTCACCGTTGGCAAGTTCTACGCC
ACGTTCCTGATCCAGGAGTACTTCCGGAAGTTCAAGAAGCGCAAAGAGCAGGGCCTTGTG
GGCAAGCCCTCCCAGAGGAACGCGCTGTCTCTGCAGGCTGGCTTGCGCACACTGCATGAC
ATCGGGCCTGAGATCCGACGGGCCATCTCTGGAGATCTCACCGCTGAGGAGGAGCTGGAC
AAGGCCATGAAGGAGGCTGTGTCCGCTGCTTCTGAAGATGACATCTTCAGGAGGGCCGGT
GGCCTGTTCGGCAACCACGTCAGCTACTACCAAAGCGACGGCCGGAGCGCCTTCCCCCAG
ACCTTCACCACTCAGCGCCCGCTGCACATCAACAAGGCGGGCAGCAGCCAGGGCGACACT
GAGTCGCCATCCCACGAGAAGCTGGTGGACTCCACCTTCACCCCGAGCAGCTACTCGTCC
ACCGGCTCCAACGCCAACATCAACAACGCCAACAACACCGCCCTGGGTCGCCTCCCTCGC
CCCGCCGGCTACCCCAGCACGGTCAGCACTGTGGAGGGCCACGGGCCCCCCTTGTCCCCT
GCCATCCGGGTGCAGGAGGTGGCGTGGAAGCTCAGCTCCAACAGGTGCCACTCCCGGGAG
AGCCAGGCAGCCATGGCGGGTCAGGAGGAGACGTCTCAGGATGAGACCTATGAAGTGAAG
ATGAACCATGACACGGAGGCCTGCAGTGAGCCCAGCCTGCTCTCCACAGAGATGCTCTCC
TACCAGGATGACGAAAATCGGCAACTGACGCTCCCAGAGGAGGACAAGAGGGACATCCGG
CAATCTCCGAAGAGGGGTTTCCTCCGCTCTGCCTCACTAGGTCGAAGGGCCTCCTTCCAC
CTGGAATGTCTGAAGCGACAGAAGGACCGAGGGGGAGACATCTCTCAGAAGACAGTCCTG
CCCTTGCATCTGGTTCATCATCAGGCATTGGCAGTGGCAGGCCTGAGCCCCCTCCTCCAG
AGAAGCCATTCCCCTGCCTCATTCCCTAGGCCTTTTGCCACCCCACCAGCCACACCTGGC
AGCCGAGGCTGGCCCCCACAGCCCGTCCCCACCCTGCGGCTTGAGGGGGTCGAGTCCAGT
GAGAAACTCAACAGCAGCTTCCCATCCATCCACTGCGGCTCCTGGGCTGAGACCACCCCC
GGTGGCGGGGGCAGCAGCGCCGCCCGGAGAGTCCGGCCCGTCTCCCTCATGGTGCCCAGC
CAGGCTGGGGCCCCAGGGAGGCAGTTCCACGGCAGTGCCAGCAGCCTGGTGGAAGCGGTC
TTGATTTCAGAAGGACTGGGGCAGTTTGCTCAAGATCCCAAGTTCATCGAGGTCACCACC
CAGGAGCTGGCCGACGCCTGCGACATGACCATAGAGGAGATGGAGAGCGCGGCCGACAAC
ATCCTCAGCGGGGGCGCCCCACAGAGCCCCAATGGCGCCCTCTTACCCTTTGTGAACTGC
AGGGACGCGGGGCAGGACCGAGCCGGGGGCGAAGAGGACGCGGGCTGTGTGCGCGCGCGG
GGTCGACCGAGTGAGGAGGAGCTCCAGGACAGCAGGGTCTACGTCAGCAGCCTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF08763</identifier>
            <name>Ca_chan_IQ</name>
          </pfam>
          <pfam>
            <identifier>PF16905</identifier>
            <name>GPHH</name>
          </pfam>
          <pfam>
            <identifier>PF16885</identifier>
            <name>CAC1F_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveolar macromolecular signaling complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic shaft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T-tubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Z disc</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-actinin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult walking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling using extracellular calcium source</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell communication by electrical coupling involved in cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>growth hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction involved in micturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q01668" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit alpha-1D</name>
        <general-function>Voltage-gated calcium channel activity involved sa node cell action potential</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).</specific-function>
        <gene-name>CACNA1D</gene-name>
        <locus>3p14.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>127-145
164-183
196-214
236-254
274-293
382-406
524-543
559-577
586-604
615-633
653-673
728-752
887-905
922-941
954-972
979-998
1018-1037
1128-1148
1206-1224
1240-1259
1267-1288
1314-1333
1353-1372
1440-1464</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.73</theoretical-pi>
        <molecular-weight>245138.75</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1391</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1D</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M76558</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>179764</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>530</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>530</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q01668</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1D_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CACH3</synonym>
          <synonym>CACN4</synonym>
          <synonym>CACNL1A2</synonym>
          <synonym>Calcium channel, L type, alpha-1 polypeptide, isoform 2</synonym>
          <synonym>CCHL1A2</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav1.3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004633|Voltage-dependent L-type calcium channel subunit alpha-1D
MMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTVLSWQAAIDAA
RQAKAAQTMSTSAPPPVGSLSQRKRQQYAKSKKQGNSSNSRPARALFCLSLNNPIRRACI
SIVEWKPFDIFILLAIFANCVALAIYIPFPEDDSNSTNHNLEKVEYAFLIIFTVETFLKI
IAYGLLLHPNAYVRNGWNLLDFVIVIVGLFSVILEQLTKETEGGNHSSGKSGGFDVKALR
AFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFIGKMHKT
CFFADSDIVAEEDPAPCAFSGNGRQCTANGTECRSGWVGPNGGITNFDNFAFAMLTVFQC
ITMEGWTDVLYWMNDAMGFELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARG
DFQKLREKQQLEEDLKGYLDWITQAEDIDPENEEEGGEEGKRNTSMPTSETESVNTENVS
GEGENRGCCGSLCQAISKSKLSRRWRRWNRFNRRRCRAAVKSVTFYWLVIVLVFLNTLTI
SSEHYNQPDWLTQIQDIANKVLLALFTCEMLVKMYSLGLQAYFVSLFNRFDCFVVCGGIT
ETILVELEIMSPLGISVFRCVRLLRIFKVTRHWTSLSNLVASLLNSMKSIASLLLLLFLF
IIIFSLLGMQLFGGKFNFDETQTKRSTFDNFPQALLTVFQILTGEDWNAVMYDGIMAYGG
PSSSGMIVCIYFIILFICGNYILLNVFLAIAVDNLADAESLNTAQKEEAEEKERKKIARK
ESLENKKNNKPEVNQIANSDNKVTIDDYREEDEDKDPYPPCDVPVGEEEEEEEEDEPEVP
AGPRPRRISELNMKEKIAPIPEGSAFFILSKTNPIRVGCHKLINHHIFTNLILVFIMLSS
AALAAEDPIRSHSFRNTILGYFDYAFTAIFTVEILLKMTTFGAFLHKGAFCRNYFNLLDM
LVVGVSLVSFGIQSSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMI
VTTLLQFMFACIGVQLFKGKFYRCTDEAKSNPEECRGLFILYKDGDVDSPVVRERIWQNS
DFNFDNVLSAMMALFTVSTFEGWPALLYKAIDSNGENIGPIYNHRVEISIFFIIYIIIVA
FFMMNIFVGFVIVTFQEQGEKEYKNCELDKNQRQCVEYALKARPLRRYIPKNPYQYKFWY
VVNSSPFEYMMFVLIMLNTLCLAMQHYEQSKMFNDAMDILNMVFTGVFTVEMVLKVIAFK
PKGYFSDAWNTFDSLIVIGSIIDVALSEADPTESENVPVPTATPGNSEESNRISITFFRL
FRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIAMLFFIYAVIGMQMFGKVAMRDN
NQINRNNNFQTFPQAVLLLFRCATGEAWQEIMLACLPGKLCDPESDYNPGEEYTCGSNFA
IVYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWSEYDPEAKGRI
KHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVAMNMPLNSDGTVMFNATLFALVRTALKI
KTEGNLEQANEELRAVIKKIWKKTSMKLLDQVVPPAGDDEVTVGKFYATFLIQDYFRKFK
KRKEQGLVGKYPAKNTTIALQAGLRTLHDIGPEIRRAISCDLQDDEPEETKREEEDDVFK
RNGALLGNHVNHVNSDRRDSLQQTNTTHRPLHVQRPSIPPASDTEKPLFPPAGNSVCHNH
HNHNSIGKQVPTSTNANLNNANMSKAAHGKRPSIGNLEHVSENGHHSSHKHDREPQRRSS
VKRTRYYETYIRSDSGDEQLPTICREDPEIHGYFRDPHCLGEQEYFSSEECYEDDSSPTW
SRQNYGYYSRYPGRNIDSERPRGYHHPQGFLEDDDSPVCYDSRRSPRRRLLPPTPASHRR
SSFNFECLRRQSSQEEVPSSPIFPHRTALPLHLMQQQIMAVAGLDSSKAQKYSPSHSTRS
WATPPATPPYRDWTPCYTPLIQVEQSEALDQVNGSLPSLHRSSWYTDEPDISYRTFTPAS
LTVPSSFRNKNSDKQRSADSLVEAVLISEGLGRYARDPKFVSATKHEIADACDLTIDEME
SAASTLLNGNVRPRANGDVGPLSHRQDYELQDFGPGYSDEEPDPGRDEEDLADEMICITT
L</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020608|Voltage-dependent L-type calcium channel subunit alpha-1D (CACNA1D)
ATGATGATGATGATGATGATGAAAAAAATGCAGCATCAACGGCAGCAGCAAGCGGACCAC
GCGAACGAGGCAAACTATGCAAGAGGCACCAGACTTCCTCTTTCTGGTGAAGGACCAACT
TCTCAGCCGAATAGCTCCAAGCAAACTGTCCTGTCTTGGCAAGCTGCAATCGATGCTGCT
AGACAGGCCAAGGCTGCCCAAACTATGAGCACCTCTGCACCCCCACCTGTAGGATCTCTC
TCCCAAAGAAAACGTCAGCAATACGCCAAGAGCAAAAAACAGGGTAACTCGTCCAACAGC
CGACCTGCCCGCGCCCTTTTCTGTTTATCACTCAATAACCCCATCCGAAGAGCCTGCATT
AGTATAGTGGAATGGAAACCATTTGACATATTTATATTATTGGCTATTTTTGCCAATTGT
GTGGCCTTAGCTATTTACATCCCATTCCCTGAAGATGATTCTAATTCAACAAATCATAAC
TTGGAAAAAGTAGAATATGCCTTCCTGATTATTTTTACAGTCGAGACATTTTTGAAGATT
ATAGCGTATGGATTATTGCTACATCCTAATGCTTATGTTAGGAATGGATGGAATTTACTG
GATTTTGTTATAGTAATAGTAGGATTGTTTAGTGTAATTTTGGAACAATTAACCAAAGAA
ACAGAAGGCGGGAACCACTCAAGCGGCAAATCTGGAGGCTTTGATGTCAAAGCCCTCCGT
GCCTTTCGAGTGTTGCGACCACTTCGACTAGTGTCAGGAGTGCCCAGTTTACAAGTTGTC
CTGAACTCCATTATAAAAGCCATGGTTCCCCTCCTTCACATAGCCCTTTTGGTATTATTT
GTAATCATAATCTATGCTATTATAGGATTGGAACTTTTTATTGGAAAAATGCACAAAACA
TGTTTTTTTGCTGACTCAGATATCGTAGCTGAAGAGGACCCAGCTCCATGTGCGTTCTCA
GGGAATGGACGCCAGTGTACTGCCAATGGCACGGAATGTAGGAGTGGCTGGGTTGGCCCG
AACGGAGGCATCACCAACTTTGATAACTTTGCCTTTGCCATGCTTACTGTGTTTCAGTGC
ATCACCATGGAGGGCTGGACAGATGTGCTCTACTGGGTAAATGATGCGATAGGATGGGAA
TGGCCATGGGTGTATTTTGTTAGTCTGATCATCCTTGGCTCATTTTTCGTCCTTAACCTG
GTTCTTGGTGTCCTTAGTGGAGAATTCTCAAAGGAAAGAGAGAAGGCAAAAGCACGGGGA
GATTTCCAGAAGCTCCGGGAGAAGCAGCAGCTGGAGGAGGATCTAAAGGGCTACTTGGAT
TGGATCACCCAAGCTGAGGACATCGATCCGGAGAATGAGGAAGAAGGAGGAGAGGAAGGC
AAACGAAATACTAGCATGCCCACCAGCGAGACTGAGTCTGTGAACACAGAGAACGTCAGC
GGTGAAGGCGAGAACCGAGGCTGCTGTGGAAGTCTCTGGTGCTGGTGGAGACGGAGAGGC
GCGGCCAAGGCGGGGCCCTCTGGGTGTCGGCGGTGGGGTCAAGCCATCTCAAAATCCAAA
CTCAGCCGACGCTGGCGTCGCTGGAACCGATTCAATCGCAGAAGATGTAGGGCCGCCGTG
AAGTCTGTCACGTTTTACTGGCTGGTTATCGTCCTGGTGTTTCTGAACACCTTAACCATT
TCCTCTGAGCACTACAATCAGCCAGATTGGTTGACACAGATTCAAGATATTGCCAACAAA
GTCCTCTTGGCTCTGTTCACCTGCGAGATGCTGGTAAAAATGTACAGCTTGGGCCTCCAA
GCATATTTCGTCTCTCTTTTCAACCGGTTTGATTGCTTCGTGGTGTGTGGTGGAATCACT
GAGACGATCTTGGTGGAACTGGAAATCATGTCTCCCCTGGGGATCTCTGTGTTTCGGTGT
GTGCGCCTCTTAAGAATCTTCAAAGTGACCAGGCACTGGACTTCCCTGAGCAACTTAGTG
GCATCCTTATTAAACTCCATGAAGTCCATCGCTTCGCTGTTGCTTCTGCTTTTTCTCTTC
ATTATCATCTTTTCCTTGCTTGGGATGCAGCTGTTTGGCGGCAAGTTTAATTTTGATGAA
ACGCAAACCAAGCGGAGCACCTTTGACAATTTCCCTCAAGCACTTCTCACAGTGTTCCAG
ATCCTGACAGGCGAAGACTGGAATGCTGTGATGTACGATGGCATCATGGCTTACGGGGGC
CCATCCTCTTCAGGAATGATCGTCTGCATCTACTTCATCATCCTCTTCATTTGTGGTAAC
TATATTCTACTGAATGTCTTCTTGGCCATCGCTGTAGACAATTTGGCTGATGCTGAAAGT
CTGAACACTGCTCAGAAAGAAGAAGCGGAAGAAAAGGAGAGGAAAAAGATTGCCAGAAAA
GAGAGCCTAGAAAATAAAAAGAACAACAAACCAGAAGTCAACCAGATAGCCAACAGTGAC
AACAAGGTTACAATTGATGACTATAGAGAAGAGGATGAAGACAAGGACCCCTATCCGCCT
TGCGATGTGCCAGTAGGGGAAGAGGAAGAGGAAGAGGAGGAGGATGAACCTGAGGTTCCT
GCCGGACCCCGTCCTCGAAGGATCTCGGAGTTGAACATGAAGGAAAAAATTGCCCCCATC
CCTGAAGGGAGCGCTTTCTTCATTCTTAGCAAGACCAACCCGATCCGCGTAGGCTGCCAC
AAGCTCATCAACCACCACATCTTCACCAACCTCATCCTTGTCTTCATCATGCTGAGCAGC
GCTGCCCTGGCCGCAGAGGACCCCATCCGCAGCCACTCCTTCCGGAACACGATACTGGGT
TACTTTGACTATGCCTTCACAGCCATCTTTACTGTTGAGATCCTGTTGAAGATGACAACT
TTTGGAGCTTTCCTCCACAAAGGGGCCTTCTGCAGGAACTACTTCAATTTGCTGGATATG
CTGGTGGTTGGGGTGTCTCTGGTGTCATTTGGGATTCAATCCAGTGCCATCTCCGTTGTG
AAGATTCTGAGGGTCTTAAGGGTCCTGCGTCCCCTCAGGGCCATCAACAGAGCAAAAGGA
CTTAAGCACGTGGTCCAGTGCGTCTTCGTGGCCATCCGGACCATCGGCAACATCATGATC
GTCACCACCCTCCTGCAGTTCATGTTTGCCTGTATCGGGGTCCAGTTGTTCAAGGGGAAG
TTCTATCGCTGTACGGATGAAGCCAAAAGTAACCCTGAAGAATGCAGGGGACTTTTCATC
CTCTACAAGGATGGGGATGTTGACAGTCCTGTGGTCCGTGAACGGATCTGGCAAAACAGT
GATTTCAACTTCGACAACGTCCTCTCTGCTATGATGGCGCTCTTCACAGTCTCCACGTTT
GAGGGCTGGCCTGCGTTGCTGTATAAAGCCATCGACTCGAATGGAGAGAACATCGGCCCA
ATCTACAACCACCGCGTGGAGATCTCCATCTTCTTCATCATCTACATCATCATTGTAGCT
TTCTTCATGATGAACATCTTTGTGGGCTTTGTCATCGTTACATTTCAGGAACAAGGAGAA
AAAGAGTATAAGAACTGTGAGCTGGACAAAAATCAGCGTCAGTGTGTTGAATACGCCTTG
AAAGCACGTCCCTTGCGGAGATACATCCCCAAAAACCCCTACCAGTACAAGTTCTGGTAC
GTGGTGAACTCTTCGCCTTTCGAATACATGATGTTTGTCCTCATCATGCTCAACACACTC
TGCTTGGCCATGCAGCACTACGAGCAGTCCAAGATGTTCAATGATGCCATGGACATTCTG
AACATGGTCTTCACCGGGGTGTTCACCGTCGAGATGGTTTTGAAAGTCATCGCATTTAAG
CCTAAGGGGTATTTTAGTGACGCCTGGAACACGTTTGACTCCCTCATCGTAATCGGCAGC
ATTATAGACGTGGCCCTCAGCGAAGCAGACCCAACTGAAAGTGAAAATGTCCCTGTCCCA
ACTGCTACACCTGGGAACTCTGAAGAGAGCAATAGAATCTCCATCACCTTTTTCCGTCTT
TTCCGAGTGATGCGATTGGTGAAGCTTCTCAGCAGGGGGGAAGGCATCCGGACATTGCTG
TGGACTTTTATTAAGTCCTTTCAGGCGCTCCCGTATGTGGCCCTCCTCATAGCCATGCTG
TTCTTCATCTATGCGGTCATTGGCATGCAGATGTTTGGGAAAGTTGCCATGAGAGATAAC
AACCAGATCAATAGGAACAATAACTTCCAGACGTTTCCCCAGGCGGTGCTGCTGCTCTTC
AGGTGTGCAACAGGTGAGGCCTGGCAGGAGATCATGCTGGCCTGTCTCCCAGGGAAGCTC
TGTGACCCTGAGTCAGATTACAACCCCGGGGAGGAGTATACATGTGGGAGCAACTTTGCC
ATTGTCTATTTCATCAGTTTTTACATGCTCTGTGCATTTCTGATCATCAATCTGTTTGTG
GCTGTCATCATGGATAATTTCGACTATCTGACCCGGGACTGGTCTATTTTGGGGCCTCAC
CATTTAGATGAATTCAAAAGAATATGGTCAGAATATGACCCTGAGGCAAAGGGAAGGATA
AAACACCTTGATGTGGTCACTCTGCTTCGACGCATCCAGCCTCCCCTGGGGTTTGGGAAG
TTATGTCCACACAGGGTAGCGTGCAAGAGATTAGTTGCCATGAACATGCCTCTCAACAGT
GACGGGACAGTCATGTTTAATGCAACCCTGTTTGCTTTGGTTCGAACGGCTCTTAAGATC
AAGACCGAAGGGAACCTGGAGCAAGCTAATGAAGAACTTCGGGCTGTGATAAAGAAAATT
TGGAAGAAAACCAGCATGAAATTACTTGACCAAGTTGTCCCTCCAGCTGGTGATGATGAG
GTAACCGTGGGGAAGTTCTATGCCACTTTCCTGATACAGGACTACTTTAGGAAATTCAAG
AAACGGAAAGAACAAGGACTGGTGGGAAAGTACCCTGCGAAGAACACCACAATTGCCCTA
CAGGCGGGATTAAGGACACTGCATGACATTGGGCCAGAAATCCGGCGTGCTATATCGTGT
GATTTGCAAGATGACGAGCCTGAGGAAACAAAACGAGAAGAAGAAGATGATGTGTTCAAA
AGAAATGGTGCCCTGCTTGGAAACCATGTCAATCATGTTAATAGTGATAGGAGAGATTCC
CTTCAGCAGACCAATACCACCCACCGTCCCCTGCATGTCCAAAGGCCTTCAATTCCACCT
GCAAGTGATACTGAGAAACCGCTGTTTCCTCCAGCAGGAAATTCGGTGTGTCATAACCAT
CATAACCATAATTCCATAGGAAAGCAAGTTCCCACCTCAACAAATGCCAATCTCAATAAT
GCCAATATGTCCAAAGCTGCCCATGGAAAGCGGCCCAGCATTGGGAACCTTGAGCATGTG
TCTGAAAATGGGCATCATTCTTCCCACAAGCATGACCGGGAGCCTCAGAGAAGGTCCAGT
GTGAAAAGAACCCGCTATTATGAAACTTACATTAGGTCCGACTCAGGAGATGAACAGCTC
CCAACTATTTGCCGGGAAGACCCAGAGATACATGGCTATTTCAGGGACCCCCACTGCTTG
GGGGAGCAGGAGTATTTCAGTAGTGAGGAATGCTACGAGGATGACAGCTCGCCCACCTGG
AGCAGGCAAAACTATGGCTACTACAGCAGATACCCAGGCAGAAACATCGACTCTGAGAGG
CCCCGAGGCTACCATCATCCCCAAGGATTCTTGGAGGACGATGACTCGCCCGTTTGCTAT
GATTCACGGAGATCTCCAAGGAGACGCCTACTACCTCCCACCCCAGCATCCCACCGGAGA
TCCTCCTTCAACTTTGAGTGCCTGCGCCGGCAGAGCAGCCAGGAAGAGGTCCCGTCGTCT
CCCATCTTCCCCCATCGCACGGCCCTGCCTCTGCATCTAATGCAGCAACAGATCATGGCA
GTTGCCGGCCTAGATTCAAGTAAAGCCCAGAAGTACTCACCGAGTCACTCGACCCGGTCG
TGGGCCACCCCTCCAGCAACCCCTCCCTACCGGGACTGGACACCGTGCTACACCCCCCTG
ATCCAAGTGGAGCAGTCAGAGGCCCTGGACCAGGTGAACGGCAGCCTGCCGTCCCTGCAC
CGCAGCTCCTGGTACACAGACGAGCCCGACATCTCCTACCGGACTTTCACACCAGCCAGC
CTGACTGTCCCCAGCAGCTTCCGGAACAAAAACAGCGACAAGCAGAGGAGTGCGGACAGC
TTGGTGGAGGCAGTCCTGATATCCGAAGGCTTGGGACGCTATGCAAGGGACCCAAAATTT
GTGTCAGCAACAAAACACGAAATCGCTGATGCCTGTGACCTCACCATCGACGAGATGGAG
AGTGCAGCCAGCACCCTGCTTAATGGGAACGTGCGTCCCCGAGCCAACGGGGATGTGGGC
CCCCTCTCACACCGGCAGGACTATGAGCTACAGGACTTTGGTCCTGGCTACAGCGACGAA
GAGCCAGACCCTGGGAGGGATGAGGAGGACCTGGCGGATGAAATGATATGCATCACCACC
TTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF08763</identifier>
            <name>Ca_chan_IQ</name>
          </pfam>
          <pfam>
            <identifier>PF16905</identifier>
            <name>GPHH</name>
          </pfam>
          <pfam>
            <identifier>PF16885</identifier>
            <name>CAC1F_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>L-type voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Z disc</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-actinin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ankyrin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity involved in cardiac muscle cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity involved SA node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during cardiac muscle cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during SA node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of atrial cardiac muscle cell membrane repolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate by cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of potassium ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O60840" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit alpha-1F</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).</specific-function>
        <gene-name>CACNA1F</gene-name>
        <locus>Xp11.23</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>93-111
130-149
162-180
202-220
240-259
348-372
530-549
565-583
592-610
621-639
659-679
734-758
872-890
907-926
939-957
964-983
1003-1022
1113-1133
1191-1209
1225-1244
1252-1273
1291-1310
1330-1349
1417-1441</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.96</theoretical-pi>
        <molecular-weight>220675.9</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1393</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1F</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ006216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3183953</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>531</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>531</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60840</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1F_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CACNAF1</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav1.4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037197|Voltage-dependent L-type calcium channel subunit alpha-1F
MSESEGGKDTTPEPSPANGAGPGPEWGLCPGPPAVEGESSGASGLGTPKRRNQHSKHKTV
AVASAQRSPRALFCLTLANPLRRSCISIVEWKPFDILILLTIFANCVALGVYIPFPEDDS
NTANHNLEQVEYVFLVIFTVETVLKIVAYGLVLHPSAYIRNGWNLLDFIIVVVGLFSVLL
EQGPGRPGDAPHTGGKPGGFDVKALRAFRVLRPLRLVSGVPSLHIVLNSIMKALVPLLHI
ALLVLFVIIIYAIIGLELFLGRMHKTCYFLGSDMEAEEDPSPCASSGSGRACTLNQTECR
GRWPGPNGGITNFDNFFFAMLTVFQCVTMEGWTDVLYWMQDAMGYELPWVYFVSLVIFGS
FFVLNLVLGVLSGEFSKEREKAKARGDFQKQREKQQMEEDLRGYLDWITQAEELDMEDPS
ADDNLGSMAEEGRAGHRPQLAELTNRRRGRLRWFSHSTRSTHSTSSHASLPASDTGSMTE
TQGDEDEEEGALASCTRCLNKIMKTRVCRRLRRANRVLRARCRRAVKSNACYWAVLLLVF
LNTLTIASEHHGQPVWLTQIQEYANKVLLCLFTVEMLLKLYGLGPSAYVSSFFNRFDCFV
VCGGILETTLVEVGAMQPLGISVLRCVRLLRIFKVTRHWASLSNLVASLLNSMKSIASLL
LLLFLFIIIFSLLGMQLFGGKFNFDQTHTKRSTFDTFPQALLTVFQILTGEDWNVVMYDG
IMAYGGPFFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLASGDAGTAKDKGGEKSNEK
DLPQENEGLVPGVEKEEEEGARREGADMEEEEEEEEEEEEEEEEEGAGGVELLQEVVPKE
KVVPIPEGSAFFCLSQTNPLRKGCHTLIHHHVFTNLILVFIILSSVSLAAEDPIRAHSFR
NHILGYFDYAFTSIFTVEILLKMTVFGAFLHRGSFCRSWFNMLDLLVVSVSLISFGIHSS
AISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMIVTTLLQFMFACIGVQ
LFKGKFYTCTDEAKHTPQECKGSFLVYPDGDVSRPLVRERLWVNSDFNFDNVLSAMMALF
TVSTFEGWPALLYKAIDAYAEDHGPIYNYRVEISVFFIVYIIIIAFFMMNIFVGFVIITF
RAQGEQEYQNCELDKNQRQCVEYALKAQPLRRYIPKNPHQYRVWATVNSAAFEYLMFLLI
LLNTVALAMQHYEQTAPFNYAMDILNMVFTGLFTIEMVLKIIAFKPKHYFTDAWNTFDAL
IVVGSIVDIAVTEVNNGGHLGESSEDSSRISITFFRLFRVMRLVKLLSKGEGIRTLLWTF
IKSFQALPYVALLIAMIFFIYAVIGMQMFGKVALQDGTQINRNNNFQTFPQAVLLLFRCA
TGEAWQEIMLASLPGNRCDPESDFGPGEEFTCGSNFAIAYFISFFMLCAFLIINLFVAVI
MDNFDYLTRDWSILGPHHLDEFKRIWSEYDPGAKGRIKHLDVVALLRRIQPPLGFGKLCP
HRVACKRLVAMNMPLNSDGTVTFNATLFALVRTSLKIKTEGNLEQANQELRIVIKKIWKR
MKQKLLDEVIPPPDEEEVTVGKFYATFLIQDYFRKFRRRKEKGLLGNDAAPSTSSALQAG
LRSLQDLGPEMRQALTCDTEEEEEEGQEGVEEEDEKDLETNKATMVSQPSARRGSGISVS
LPVGDRLPDSLSFGPSDDDRGTPTSSQPSVPQAGSNTHRRGSGALIFTIPEEGNSQPKGT
KGQNKQDEDEEVPDRLSYLDEQAGTPPCSVLLPPHRAQRYMDGHLVPRRRLLPPTPAGRK
PSFTIQCLQRQGSCEDLPIPGTYHRGRNSGPNRAQGSWATPPQRGRLLYAPLLLVEEGAA
GEGYLGRSSGPLRTFTCLHVPGTHSDPSHGKRGSADSLVEAVLISEGLGLFARDPRFVAL
AKQEIADACRLTLDEMDNAASDLLAQGTSSLYSDEESILSRFDEEDLGDEMACVHAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011693|Voltage-dependent L-type calcium channel subunit alpha-1F (CACNA1F)
ATGTCGGAATCTGAAGGCGGGAAAGACACCACCCCAGAGCCCAGTCCAGCCAATGGGGCA
GGCCCTGGTCCCGAATGGGGGCTGTGCCCCGGGCCCCCAGCTGTGGAAGGTGAAAGCAGT
GGGGCATCAGGCCTAGGGACCCCTAAGCGAAGAAACCAGCACAGCAAGCACAAGACAGTG
GCAGTGGCCAGTGCCCAGCGGTCACCTCGGGCACTCTTCTGCCTCACCCTGGCCAATCCT
CTGCGACGGTCCTGCATCAGCATCGTGGAGTGGAAGCCCTTCGACATCCTCATCCTGCTG
ACCATCTTTGCCAACTGCGTGGCCCTGGGAGTTTACATCCCCTTCCCTGAGGACGACTCC
AACACTGCCAACCACAACCTGGAGCAGGTGGAGTACGTATTCCTGGTGATTTTCACTGTG
GAGACGGTGCTCAAGATCGTGGCCTACGGGCTGGTGCTCCACCCCAGCGCCTACATCCGC
AATGGCTGGAACCTACTCGACTTCATCATCGTCGTGGTCGGGCTGTTCAGCGTTCTGCTG
GAGCAGGGCCCCGGACGGCCAGGCGACGCCCCGCACACCGGGGGAAAGCCAGGAGGCTTC
GATGTGAAGGCATTGAGGGCGTTTCGGGTGCTGCGGCCACTGAGGCTGGTGTCTGGGGTC
CCGAGCCTGCACATAGTGCTCAATTCCATCATGAAGGCTCTGGTGCCGCTGCTGCACATT
GCACTGCTCGTGCTCTTCGTCATCATCATTTATGCCATCATTGGGCTCGAGCTGTTCCTT
GGACGAATGCACAAGACGTGCTACTTCCTGGGATCCGACATGGAAGCGGAGGAGGACCCA
TCGCCCTGTGCGTCTTCGGGATCAGGGCGTGCGTGCACGCTGAACCAGACTGAGTGCCGC
GGGCGCTGGCCAGGGCCCAATGGAGGCATCACCAACTTTGACAACTTCTTCTTCGCCATG
CTGACAGTCTTCCAGTGTGTCACCATGGAAGGCTGGACCGATGTGCTCTACTGGATGCAA
GATGCCATGGGGTATGAACTGCCCTGGGTGTACTTTGTGAGCCTTGTCATCTTTGGGTCC
TTCTTCGTCCTCAACCTTGTGCTTGGCGTCCTGAGTGGGGAGTTCTCCAAGGAGAGAGAG
AAAGCGAAAGCTCGCGGGGACTTCCAGAAGCAGCGGGAGAAGCAGCAGATGGAGGAAGAC
CTGCGGGGCTACCTGGACTGGATCACTCAAGCCGAAGAGCTGGACATGGAGGACCCCTCC
GCCGATGACAACCTTGGGCCACAGCTGGCCGAGCTGACCAATAGGAGGCGTGGACGTCTG
CGCTGGTTCAGTCATTCTACTCGCTCCACACACTCCACCAGCAGCCATGCCAGCCTCCCA
GCCAGTGACACCGGTTCCATGACAGAGACCCAAGGCGATGAGGATGAGGAGGAGGGGGCT
CTGGCCAGCTGTACACGCTGCCTAAACAAGATCATGAAAACCAGAGTCTGCCGCCGCCTC
CGCCGAGCCAACCGGGTCCTTCGGGCACGCTGCCGTCGGGCAGTGAAGTCCAATGCCTGC
TACTGGGCTGTGCTGTTGCTCGTCTTCCTCAACACGTTGACCATCGCCTCTGAGCACCAC
GGGCAGCCTGTGTGGCTCACCCAGATCCAGGAGTATGCCAACAAAGTGTTGCTCTGTCTG
TTCACGGTGGAGATGCTTCTCAAATTGTACGGTCTGGGCCCCTCTGCCTATGTGTCTTCC
TTCTTCAACCGCTTTGACTGCTTTGTGGTCTGTGGGGGCATCCTAGAGACCACCTTGGTG
GAGGTGGGTGCCATGCAGCCCTTGGGCATCTCAGTGCTCCGATGTGTGCGCCTCCTCAGG
ATCTTTAAGGTCACCAGACACTGGGCTTCTCTGAGCAATCTGGTGGCATCCCTGCTCAAT
TCAATGAAATCCATCGCATCCTTGCTGCTTCTCCTCTTCCTCTTCATCATTATCTTCTCC
CTGCTTGGCATGCAGCTGTTTGGGGGCAAGTTCAACTTTGACCAGACCCACACCAAGCGA
AGCACCTTTGACACGTTCCCCCAGGCCCTCCTCACTGTCTTTCAGATCCTGACAGGTGAG
GACTGGAACGTGGTCATGTATGATGGTATCATGGCATATGGTGGCCCCTTCTTCCCAGGA
ATGTTGGTGTGCATCTATTTCATCATTCTCTTCATCTGTGGCAACTACATCCTGTTGAAC
GTGTTTCTTGCCATTGCTGTGGACAACCTGGCCAGTGGAGATGCAGGCACTGCCAAGGAC
AAGGGCGGGGAGAAGAGCAATGAGAAGGATCTCCCACAGGAGAATGAAGGCCTGGTGCCT
GGTGTGGAGAAAGAGGAAGAGGAGGGTGCAAGGAGGGAAGGAGCAGACATGGAGGAGGAG
GAGGAGGAGGAAGAAGAGGAAGAAGAGGAAGAAGAGGAAGAGGGTGCAGGGGGTGTGGAA
CTCCTGCAGGAAGTTGTACCCAAGGAGAAGGTGGTACCCATCCCTGAGGGCAGCGCCTTC
TTCTGCCTCAGCCAAACCAACCCGCTGAGGAAGGGCTGCCACACCCTCATCCACCATCAT
GTCTTCACCAATCTTATCCTGGTGTTCATCATCCTCAGCAGTGTGTCCCTGGCCGCTGAG
GACCCCATCCGAGCCCACTCCTTCCGCAACCATATTCTGGGTTACTTCGATTATGCCTTC
ACCTCCATTTTCACTGTGGAGATTCTACTAAAGATGACAGTGTTTGGGGCCTTCCTGCAC
CGCGGCTCCTTCTGCCGTAGCTGGTTTAATATGTTGGATCTGCTGGTGGTCAGTGTGTCC
CTCATCTCCTTTGGCATCCACTCCAGCGCCATCTCGGTGGTGAAGATTCTGCGAGTACTC
CGAGTACTGCGGCCCCTCCGAGCCATCAACAGGGCCAAGGGACTCAAGCATGTGGTGCAG
TGTGTATTTGTGGCCATCCGGACCATCGGAAACATCATGATTGTCACCACACTTCTGCAA
TTTATGTTCGCCTGCATCGGGGTGCAGCTCTTCAAGGGGAAATTCTACACCTGCACGGAC
GAGGCCAAACACACCCCTCAAGAATGCAAGGGCTCCTTCCTGGTATACCCAGATGGAGAC
GTGTCACGGCCCCTGGTCCGGGAGCGGCTCTGGGTCAACAGTGATTTCAACTTTGACAAT
GTCCTTTCAGCCATGATGGCCCTGTTCACTGTCTCCACCTTTGAAGGCTGGCCTGCACTG
CTATACAAGGCCATCGATGCATATGCAGAGGACCACGGCCCCATCTATAATTACCGTGTG
GAGATCTCAGTGTTCTTCATTGTCTACATCATCATCATTGCGTTCTTCATGATGAACATC
TTCGTGGGCTTCGTCATCATCACTTTCCGTGCCCAGGGCGAGCAGGAGTACCAAAACTGT
GAGCTGGACAAGAACCAGCGTCAATGTGTGGAATATGCCCTCAAGGCCCAGCCACTCCGC
CGTTACATCCCCAAGAACCCGCATCAGTATCGTGTGTGGGCCACTGTGAACTCTGCTGCC
TTTGAGTACCTGATGTTCCTGCTCATCCTGCTCAACACAGTTGCCCTAGCCATGCAGCAC
TATGAGCAGACTGCTCCCTTCAACTATGCCATGGACATCCTCAACATGGTCTTCACTGGC
CTCTTCACTATTGAGATGGTGCTCAAAATCATCGCCTTCAAGCCCAAGCATTACTTCACT
GATGCCTGGAACACGTTTGACGCTCTTATTGTGGTGGGCAGCATAGTGGATATTGCCGTC
ACTGAAGTCAATAATGGTGGCCACCTTGGCGAGAGCTCTGAGGACAGCTCCCGCATTTCC
ATTACCTTCTTTCGCCTCTTCCGAGTTATGCGGCTGGTCAAGCTTCTCAGTAAGGGTGAA
GGGATCCGCACATTGCTCTGGACATTCATCAAGTCCTTCCAGGCCTTGCCCTATGTGGCT
CTTCTCATCGCAATGATATTCTTCATCTATGCCGTCATTGGCATGCAGATGTTCGGCAAG
GTGGCTCTTCAGGATGGCACACAGATAAACCGAAACAACAACTTCCAGACCTTTCCACAG
GCTGTGCTGCTTCTGTTCAGGTGTGCCACTGGTGAGGCATGGCAGGAGATAATGCTTGCC
AGCCTTCCCGGAAATCGGTGTGATCCTGAGTCTGACTTCGGCCCTGGTGAAGAGTTTACC
TGTGGTAGCAATTTTGCCATCGCCTATTTCATCAGCTTCTTCATGCTCTGTGCCTTCCTG
ATCATAAATCTCTTTGTGGCTGTGATCATGGACAACTTTGATTATCTCACCAGAGATTGG
TCCATCCTGGGCCCCCATCACCTTGATGAATTCAAGAGGATCTGGTCTGAATATGACCCT
GGGGCCAAGGGCCGCATCAAACACTTGGATGTGGTTGCCCTGCTGAGACGTATCCAGCCC
CCTCTGGGATTTGGGAAGCTGTGCCCACACCGAGTGGCCTGCAAGAGACTTGTGGCAATG
AACATGCCCCTCAACTCAGATGGGACGGTGACATTCAACGCCACACTCTTTGCCCTGGTC
CGGACATCCCTGAAGATCAAAACAGAAGGGAACCTGGAGCAAGCCAACCAGGAGCTGCGG
ATTGTCATCAAAAAGATCTGGAAGCGGATGAAACAGAAGCTGCTAGATGAGGTCATCCCC
CCACCAGACGAGGAGGAGGTCACCGTGGGCAAATTCTACGCCACATTTCTGATCCAGGAC
TATTTCCGCAAATTCCGGCGGAGGAAAGAAAAAGGGCTACTAGGCAACGACGCCGCCCCT
AGCACCTCTTCCGCCCTTCAGGCTGGTCTGCGGAGCCTGCAGGACTTGGGTCCTGAGATG
CGGCAGGCCCTCACCTGTGACACAGAGGAGGAGGAAGAAGAGGGGCAGGAGGGAGTGGAG
GAGGAAGATGAAAAGGACTTGGAAACTAACAAAGCCACGATGGTCTCCCAGCCCTCAGCT
CGCCGGGGCTCCGGGATTTCTGTGTCTCTGCCTGTCGGGGACAGACTTCCAGATTCACTC
TCCTTTGGGCCCAGTGATGATGACAGGGGGACTCCCACCTCCAGTCAGCCCAGTGTGCCC
CAGGCTGGATCCAACACCCACAGGAGAGGCTCTGGGGCTCTCATTTTCACCATCCCAGAA
GAAGGAAATTCTCAGCCCAAGGGAACCAAAGGGCAAAACAAGCAAGATGAGGATGAGGAA
GTCCCTGATCGGCTTTCCTACCTAGATGAGCAGGCAGGGACTCCCCCGTGCTCAGTCCTT
TTGCCACCTCACAGAGCTCAGAGATACATGGATGGGCACCTGGTACCACGCCGCCGTCTG
CTGCCCCCCACACCTGCAGGTCGGAAGCCCTCCTTCACCATCCAGTGTCTGCAGCGCCAG
GGCAGTTGTGAGGATTTACCCATCCCAGGCACCTATCATCGTGGGCGAAATTCAGGGCCC
AATAGGGCTCAGGGTTCCTGGGCAACACCACCTCAGCGGGGTCGGCTCCTGTATGCCCCG
CTGTTGTTGGTGGAAGAGGGCGCAGCGGGGGAGGGGTACCTCGGCAGATCCAGTGGCCCA
CTGCGCACCTTCACCTGTCTGCACGTGCCTGGAACCCACTCGGACCCCAGCCATGGGAAG
AGGGGCAGTGCCGACAGCTTGGTGGAGGCTGTGCTTATCTCAGAGGGTCTGGGCCTCTTT
GCTCGAGACCCACGTTTCGTGGCCCTGGCCAAGCAGGAGATTGCAGATGCGTGTCGCCTG
ACGCTGGATGAGATGGACAATGCTGCCAGTGACCTGCTGGCACAGGGAACCAGCTCTCTC
TATAGCGACGAGGAGTCCATCCTCTCCCGCTTCGATGAGGAGGACTTGGGAGACGAGATG
GCCTGCGTCCACGCCCTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF08763</identifier>
            <name>Ca_chan_IQ</name>
          </pfam>
          <pfam>
            <identifier>PF16905</identifier>
            <name>GPHH</name>
          </pfam>
          <pfam>
            <identifier>PF16885</identifier>
            <name>CAC1F_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dendrite morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of light stimulus involved in visual perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q13698" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit alpha-1S</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle.</specific-function>
        <gene-name>CACNA1S</gene-name>
        <locus>1q32</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>52-70
89-108
121-139
161-179
199-218
310-334
433-451
467-486
495-513
524-542
562-581
637-661
800-818
835-854
867-885
893-911
931-950
1041-1065
1119-1137
1153-1172
1181-1199
1232-1250
1270-1289
1357-1381</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.36</theoretical-pi>
        <molecular-weight>212348.1</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1S</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U30707</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1698403</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>528</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>528</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13698</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1S_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CACH1</synonym>
          <synonym>CACN1</synonym>
          <synonym>CACNL1A3</synonym>
          <synonym>Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav1.1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016764|Voltage-dependent L-type calcium channel subunit alpha-1S
MEPSSPQDEGLRKKQPKKPVPEILPRPPRALFCLTLENPLRKACISIVEWKPFETIILLT
IFANCVALAVYLPMPEDDNNSLNLGLEKLEYFFLIVFSIEAAMKIIAYGFLFHQDAYLRS
GWNVLDFTIVFLGVFTVILEQVNVIQSHTAPMSSKGAGLDVKALRAFRVLRPLRLVSGVP
SLQVVLNSIFKAMLPLFHIALLVLFMVIIYAIIGLELFKGKMHKTCYFIGTDIVATVENE
EPSPCARTGSGRRCTINGSECRGGWPGPNHGITHFDNFGFSMLTVYQCITMEGWTDVLYW
VNDAIGNEWPWIYFVTLILLGSFFILNLVLGVLSGEFTKEREKAKSRGTFQKLREKQQLD
EDLRGYMSWITQGEVMDVEDFREGKLSLDEGGSDTESLYEIAGLNKIIQFIRHWRQWNRI
FRWKCHDIVKSKVFYWLVILIVALNTLSIASEHHNQPLWLTRLQDIANRVLLSLFTTEML
MKMYGLGLRQYFMSIFNRFDCFVVCSGILEILLVESGAMTPLGISVLRCIRLLRIFKITK
YWTSLSNLVASLLNSIRSIASLLLLLFLFIVIFALLGMQLFGGRYDFEDTEVRRSNFDNF
PQALISVFQVLTGEDWTSMMYNGIMAYGGPSYPGMLVCIYFIILFVCGNYILLNVFLAIA
VDNLAEAESLTSAQKAKAEEKKRRKMSKGLPDKSEEEKSTMAKKLEQKPKGEGIPTTAKL
KIDEFESNVNEVKDPYPSADFPGDDEEDEPEIPLSPRPRPLAELQLKEKAVPIPEASSFF
IFSPTNKIRVLCHRIVNATWFTNFILLFILLSSAALAAEDPIRADSMRNQILKHFDIGFT
SVFTVEIVLKMTTYGAFLHKGSFCRNYFNMLDLLVVAVSLISMGLESSAISVVKILRVLR
VLRPLRAINRAKGLKHVVQCMFVAISTIGNIVLVTTLLQFMFACIGVQLFKGKFFRCTDL
SKMTEEECRGYYYVYKDGDPMQIELRHREWVHSDFHFDNVLSAMMSLFTVSTFEGWPQLL
YKAIDSNAEDVGPIYNNRVEMAIFFIIYIILIAFFMMNIFVGFVIVTFQEQGETEYKNCE
LDKNQRQCVQYALKARPLRCYIPKNPYQYQVWYIVTSSYFEYLMFALIMLNTICLGMQHY
NQSEQMNHISDILNVAFTIIFTLEMILKLMAFKARGYFGDPWNVFDFLIVIGSIIDVILS
EIDTFLASSGGLYCLGGGCGNVDPDESARISSAFFRLFRVMRLIKLLSRAEGVRTLLWTF
IKSFQALPYVALLIVMLFFIYAVIGMQMFGKIALVDGTQINRNNNFQTFPQAVLLLFRCA
TGEAWQEILLACSYGKLCDPESDYAPGEEYTCGTNFAYYYFISFYMLCAFLVINLFVAVI
MDNFDYLTRDWSILGPHHLDEFKAIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKFCP
HRVACKRLVGMNMPLNSDGTVTFNATLFALVRTALKIKTEGNFEQANEELRAIIKKIWKR
TSMKLLDQVIPPIGDDEVTVGKFYATFLIQEHFRKFMKRQEEYYGYRPKKDIVQIQAGLR
TIEEEAAPEICRTVSGDLAAEEELERAMVEAAMEEGIFRRTGGLFGQVDNFLERTNSLPP
VMANQRPLQFAEIEMEEMESPVFLEDFPQDPRTNPLARANTNNANANVAYGNSNHSNSHV
FSSVHYEREFPEETETPATRGRALGQPCRVLGPHSKPCVEMLKGLLTQRAMPRGQAPPAP
CQCPRVESSMPEDRKSSTPGSLHEETPHSRSTRENTSRCSAPATALLIQKALVRGGLGTL
AADANFIMATGQALADACQMEPEEVEIMATELLKGREAPEGMASSLGCLNLGSSLGSLDQ
HQGSQETLIPPRL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016765|Voltage-dependent L-type calcium channel subunit alpha-1S (CACNA1S)
ATGGAGCCATCCTCACCCCAGGATGAAGGCCTGAGGAAGAAACAGCCCAAGAAGCCAGTT
CCTGAGATTCTGCCAAGGCCACCCCGGGCCTTGTTCTGCCTGACCCTGGAGAACCCCCTG
AGGAAGGCCTGCATCAGCATTGTAGAATGGAAGCCCTTCGAGACGATCATCTTGCTCACC
ATCTTTGCCAATTGTGTGGCCCTGGCCGTGTACCTGCCCATGCCGGAAGATGACAACAAC
TCTCTGAACCTCGGCCTGGAGAAGCTGGAGTATTTCTTCCTCATTGTCTTCTCGATTGAA
GCCGCCATGAAGATCATTGCCTACGGCTTCTTATTCCACCAGGACGCTTACCTGCGCAGT
GGCTGGAATGTGCTGGACTTCACCATTGTCTTCCTGGGGGTCTTCACCGTGATTCTGGAA
CAGGTTAACGTCATCCAAAGCCACACAGCCCCAATGAGCAGCAAAGGAGCCGGCTTGGAT
GTCAAGGCCCTCAGAGCCTTCCGAGTGCTCAGACCCCTCCGGCTGGTGTCGGGGGTGCCT
AGCCTGCAGGTGGTCCTGAACTCCATCTTCAAGGCCATGCTCCCCCTCTTTCACATCGCC
CTGCTGGTCCTCTTTATGGTCATCATCTATGCCATCATCGGGCTGGAGCTCTTCAAGGGC
AAGATGCACAAGACCTGCTACTTCATTGGTACAGATATCGTGGCCACGGTGGAGAATGAA
GAGCCATCGCCCTGCGCCAGGACGGGCTCAGGGCGCCGGTGCACCATCAATGGCAGTGAG
TGCCGGGGCGGCTGGCCAGGGCCCAACCATGGCATCACCCACTTCGACAACTTCGGCTTC
TCCATGCTCACCGTGTACCAGTGCATTACCATGGAGGGATGGACTGACGTCCTTTACTGG
GTCAATGATGCCATCGGGAATGAGTGGCCCTGGATCTATTTTGTCACCCTCATTTTGCTG
GGATCCTTCTTCATCCTCAACCTGGTGCTGGGTGTCCTGAGTGGGGAATTCACCAAGGAG
CGGGAGAAGGCCAAGTCCAGGGGAACCTTCCAGAAGCTCCGGGAGAAGCAGCAACTAGAT
GAGGACCTTCGGGGCTACATGAGCTGGATCACGCAGGGCGAGGTCATGGATGTTGAGGAC
TTCAGAGAAGGAAAACTGTCTTTGGATGAAGGTGGCTCTGACACAGAGAGCCTGTATGAA
ATTGCAGGCTTGAACAAAATCATCCAGTTCATCCGACATTGGAGGCAGTGGAACCGCATC
TTTCGCTGGAAGTGCCATGACATCGTGAAGTCCAAGGTCTTCTATTGGCTGGTGATTCTC
ATCGTTGCCCTCAACACCCTGTCTATCGCCTCAGAGCACCACAACCAGCCTCTCTGGCTG
ACCCGTTTGCAAGACATTGCCAACCGGGTGCTGCTGTCCCTCTTCACCACTGAGATGCTG
ATGAAGATGTACGGGCTGGGCCTGCGCCAGTACTTCATGTCTATCTTCAACCGCTTCGAC
TGCTTCGTGGTGTGTAGCGGTATCCTGGAGATCCTGCTGGTGGAGTCGGGTGCCATGACA
CCCCTGGGCATCTCCGTGCTCCGCTGCATCCGCCTCCTGAGGATCTTCAAGATCACCAAA
TATTGGACGTCGCTGAGCAACCTGGTGGCATCCCTGCTCAACTCCATCCGCTCCATCGCC
TCCCTGCTGCTGCTGCTCTTCCTCTTCATCGTCATCTTCGCCCTCCTGGGCATGCAGCTC
TTTGGGGGGAGGTATGACTTTGAAGACACAGAAGTACGGCGCAGCAACTTTGACAACTTT
CCCCAAGCCCTCATCAGCGTCTTCCAGGTACTGACAGGGGAAGACTGGACCTCAATGATG
TACAATGGGATCATGGCCTACGGCGGGCCGTCCTACCCTGGCATGCTTGTGTGCATTTAC
TTCATCATCCTTTTCGTCTGTGGCAACTACATCCTGCTCAATGTCTTCCTGGCCATTGCC
GTGGACAACCTGGCCGAGGCGGAGAGCCTGACTTCTGCCCAGAAGGCCAAGGCTGAGGAG
AAAAAACGCAGGAAGATGTCCAAGGGTCTCCCAGACAAGTCAGAAGAGGAGAAGTCAACG
ATGGCCAAGAAGCTGGAGCAGAAACCCAAGGGTGAGGGCATCCCCACCACTGCCAAGCTG
AAAATCGATGAGTTTGAATCTAATGTCAATGAGGTGAAGGATCCCTACCCCTCAGCCGAC
TTCCCAGGGGATGACGAGGAAGATGAGCCTGAGATCCCGCTGAGCCCCCGACCACGTCCC
CTGGCTGAGCTGCAGCTGAAAGAGAAGGCCGTGCCCATTCCAGAAGCCAGCTCCTTCTTC
ATCTTCAGCCCCACCAATAAGATCCGTGTCCTGTGTCACCGCATCGTCAATGCCACCTGG
TTTACCAACTTCATCCTGCTCTTCATCCTGCTCAGCAGCGCTGCACTGGCTGCGGAAGAC
CCCATCCGGGCTGATTCCATGAGAAATCAGATCCTTAAACACTTTGACATCGGGTTCACC
TCTGTCTTCACTGTGGAGATTGTCCTCAAGATGACGACCTACGGAGCCTTCCTGCACAAG
GGTTCCTTCTGCCGCAATTACTTCAACATGCTGGACCTGCTGGTGGTGGCCGTGTCCCTC
ATCTCCATGGGACTTGAGTCCAGTGCCATCTCCGTGGTGAAGATCCTGAGGGTGCTGAGG
GTGCTCCGACCACTCAGAGCCATCAACAGAGCCAAGGGGTTGAAGCACGTGGTGCAGTGC
ATGTTCGTGGCCATCAGCACCATCGGGAACATCGTGCTGGTCACTACCCTCCTACAGTTC
ATGTTTGCCTGCATCGGCGTCCAGCTCTTCAAGGGGAAGTTCTTCAGGTGCACCGACTTG
TCCAAGATGACAGAGGAGGAGTGCAGGGGCTACTACTACGTGTACAAGGACGGGGACCCC
ATGCAGATAGAGCTGCGTCACCGCGAGTGGGTACACAGCGACTTCCACTTCGACAATGTG
CTCTCAGCCATGATGTCCCTCTTCACGGTCTCCACCTTCGAGGGATGGCCTCAGCTGCTG
TACAAGGCCATAGACTCCAATGCGGAGGACGTGGGTCCCATCTACAACAACCGTGTGGAG
ATGGCCATCTTCTTCATCATCTACATCATCCTCATTGCCTTCTTCATGATGAACATCTTT
GTGGGCTTCGTCATTGTCACCTTCCAGGAGCAGGGAGAGACTGAGTACAAGAACTGTGAG
CTGGACAAGAACCAGCGCCAATGTGTACAGTATGCCCTGAAGGCCCGCCCACTGAGGTGC
TACATTCCCAAAAACCCATACCAGTACCAGGTGTGGTACATTGTCACCTCCTCCTACTTT
GAATACCTGATGTTTGCCCTCATCATGCTCAACACCATCTGCCTCGGCATGCAGCACTAC
AACCAGTCGGAGCAGATGAACCACATCTCAGACATCCTCAATGTGGCCTTCACTATCATC
TTCACCCTGGAGATGATCCTCAAGCTCATGGCCTTCAAGGCCAGGGGCTACTTTGGAGAC
CCCTGGAATGTGTTTGACTTCCTGATTGTCATTGGCAGCATCATTGATGTCATCCTCAGT
GAGATCGACACTTTCCTGGCCTCCAGCGGGGGACTGTATTGCCTGGGTGGAGGCTGCGGG
AACGTTGACCCAGATGAGAGTGCCCGCATCTCCAGCGCCTTCTTCCGCCTGTTCCGTGTC
ATGAGGCTGATCAAGCTGCTGAGCCGGGCAGAAGGAGTGCGAACCCTCCTGTGGACGTTC
ATCAAGTCCTTCCAGGCCCTACCCTACGTGGCTCTGCTCATCGTCATGCTCTTCTTCATC
TACGCTGTCATCGGCATGCAGATGTTTGGGAAGATCGCCTTGGTGGATGGGACCCAAATA
AACCGGAACAACAACTTCCAGACCTTCCCACAAGCTGTGCTACTGCTCTTCAGGTGTGCA
ACAGGTGAGGCCTGGCAGGAGATCCTACTGGCCTGCAGCTATGGGAAGCTGTGTGACCCA
GAGTCGGACTATGCCCCAGGGGAGGAGTACACATGTGGCACCAACTTTGCATACTACTAC
TTCATCAGCTTCTACATGCTCTGTGCCTTCCTGGTCATCAACCTCTTTGTGGCTGTCATC
ATGGACAATTTTGACTACCTCACCCGGGACTGGTCCATCCTGGGCCCTCATCACCTGGAT
GAGTTCAAGGCCATCTGGGCAGAGTATGACCCAGAGGCTAAGGGGAGAATCAAACACCTG
GACGTGGTGACCCTGCTGAGAAGGATTCAGCCCCCTCTGGGCTTTGGGAAGTTCTGCCCA
CATCGGGTAGCTTGTAAGCGGCTGGTGGGCATGAACATGCCCCTGAACAGCGACGGCACA
GTCACCTTCAATGCCACACTCTTTGCCCTGGTCCGCACGGCACTCAAGATCAAGACGGAA
GGTAACTTTGAGCAGGCCAACGAGGAGCTGAGGGCCATCATCAAGAAGATCTGGAAGAGA
ACCAGCATGAAGCTCTTGGACCAGGTCATCCCTCCAATAGGAGATGATGAGGTGACAGTG
GGGAAGTTCTACGCCACATTCCTCATCCAGGAGCACTTCCGGAAGTTCATGAAACGCCAA
GAGGAGTATTATGGCTATCGGCCCAAGAAGGACATTGTACAGATCCAGGCAGGGCTGCGG
ACCATTGAGGAAGAGGCAGCCCCCGAGATCTGTCGCACGGTCTCAGGAGACCTGGCTGCT
GAGGAGGAGCTGGAGAGAGCCATGGTGGAGGCTGCGATGGAGGAGGGAATATTCCGGAGG
ACTGGAGGCCTGTTTGGCCAGGTGGACAACTTCCTGGAAAGGACCAACTCCCTGCCCCCC
GTCATGGCCAATCAGAGACCCCTCCAGTTTGCTGAGATAGAGATGGAAGAGATGGAGTCA
CCTGTCTTCTTGGAGGACTTCCCACAAGATCCACGCACCAACCCCCTGGCTCGTGCCAAT
ACCAACAATGCCAACGCCAATGTCGCCTATGGCAACAGCAACCATAGCAACAGCCATGTG
TTTTCCAGTGTCCACTATGAAAGGGAGTTCCCAGAAGAGACAGAGACGCCTGCTACCAGA
GGACGAGCCCTTGGCCAACCCTGCAGGGTCCTGGGACCCCACAGCAAACCCTGTGTGGAG
ATGCTGAAGGGACTGCTGACCCAGAGGGCAATGCCCAGAGGCCAGGCACCTCCTGCCCCC
TGCCAGTGCCCCAGGGTGGAGTCCTCCATGCCTGAGGACAGAAAGAGCTCCACACCAGGG
TCTCTTCATGAGGAGACACCCCACAGCAGGAGCACCAGGGAGAATACTTCCAGGTGCTCA
GCACCAGCTACAGCCCTGCTGATCCAAAAGGCTCTGGTTCGAGGGGGCCTGGGCACCTTG
GCAGCTGATGCAAACTTCATCATGGCAACAGGCCAGGCCCTGGCAGATGCCTGCCAAATG
GAACCAGAGGAAGTGGAGATCATGGCAACAGAGCTACTGAAAGGACGAGAGGCCCCAGAG
GGCATGGCCAGCTCCCTGGGATGCCTGAACCTCGGGTCCTCCCTGGGCAGCCTCGACCAA
CACCAGGGCTCCCAGGAGACCCTTATTCCTCCAAGGCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF08763</identifier>
            <name>Ca_chan_IQ</name>
          </pfam>
          <pfam>
            <identifier>PF16905</identifier>
            <name>GPHH</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>I band</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T-tubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endoplasmic reticulum organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extraocular skeletal muscle development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myoblast fusion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle adaptation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle fiber development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>striated muscle contraction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q02641" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit beta-1</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.</specific-function>
        <gene-name>CACNB1</gene-name>
        <locus>17q21-q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.75</theoretical-pi>
        <molecular-weight>65712.995</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1401</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M92303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>179806</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q02641</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CACB1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CAB1</synonym>
          <synonym>CACNLB1</synonym>
          <synonym>Calcium channel voltage-dependent subunit beta 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000603|Voltage-dependent L-type calcium channel subunit beta-1
MVQKTSMSRGPYPPSQEIPMEVFDPSPQGKYSKRKGRFKRSDGSTSSDTTSNSFVRQGSA
ESYTSRPSDSDVSLEEDREALRKEAERQALAQLEKAKTKPVAFAVRTNVGYNPSPGDEVP
VQGVAITFEPKDFLHIKEKYNNDWWIGRLVKEGCEVGFIPSPVKLDSLRLLQEQKLRQNR
LGSSKSGDNSSSSLGDVVTGTRRPTPPASAKQKQKSTEHVPPYDVVPSMRPIILVGPSLK
GYEVTDMMQKALFDFLKHRFDGRISITRVTADISLAKRSVLNNPSKHIIIERSNTRSSLA
EVQSEIERIFELARTLQLVALDADTINHPAQLSKTSLAPIIVYIKITSPKVLQRLIKSRG
KSQSKHLNVQIAASEKLAQCPPEMFDIILDENQLEDACEHLAEYLEAYWKATHPPSSTPP
NPLLNRTMATAALAASPAPVSNLQGPYLASGDQPLERATGEHASMHEYPGELGQPPGLYP
SSHPPGRAGTLRALSRQDTFDADTPGSRNSAYTELGDSCVDMETDPSEGPGLGDPAGGGT
PPARQGSWEDEEEDYEEELTDNRNRGRNKARYCAEGGGPVLGRNKNELEGWGRGVYIR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010071|Voltage-dependent L-type calcium channel subunit beta-1 (CACNB1)
ATGGTCCAGAAGACCAGCATGTCCCGGGGCCCTTACCCACCCTCCCAGGAGATCCCCATG
GAGGTCTTCGACCCCAGCCCGCAGGGCAAATACAGCAAGAGGAAAGGGCGATTCAAACGG
TCAGATGGGAGCACGTCCTCGGATACCACATCCAACAGCTTTGTCCGCCAGGGCTCAGCG
GAGTCCTACACCAGCCGTCCATCAGACTCTGATGTATCTCTGGAGGAGGACCGGGAAGCC
TTAAGGAAGGAAGCAGAGCGCCAGGCATTAGCGCAGCTCGAGAAGGCCAAGACCAAGCCA
GTGGCATTTGCTGTGCGGACAAATGTTGGCTACAATCCGTCTCCAGGGGATGAGGTGCCT
GTGCAGGGAGTGGCCATCACCTTCGAGCCCAAAGACTTCCTGCACATCAAGGAGAAATAC
AATAATGACTGGTGGATCGGGCGGCTGGTGAAGGAGGGCTGTGAGGTTGGCTTCATTCCC
AGCCCCGTCAAACTGGACAGCCTTCGCCTGCTGCAGGAACAGAAGCTGCGCCAGAACCGC
CTCGGCTCCAGCAAATCAGGCGATAACTCCAGTTCCAGTCTGGGAGATGTGGTGACTGGC
ACCCGCCGCCCCACACCCCCTGCCAGTGCCAAACAGAAGCAGAAGTCGACAGAGCATGTG
CCCCCCTATGACGTGGTGCCTTCCATGAGGCCCATCATCCTGGTGGGACCGTCGCTCAAG
GGCTACGAGGTTACAGACATGATGCAGAAAGCTTTATTTGACTTCTTGAAGCATCGGTTT
GATGGCAGGATCTCCATCACTCGTGTGACGGCAGATATTTCCCTGGCTAAGCGCTCAGTT
CTCAACAACCCCAGCAAACACATCATCATTGAGCGCTCCAACACACGCTCCAGCCTGGCT
GAGGTGCAGAGTGAAATCGAGCGAATCTTCGAGCTGGCCCGGACCCTTCAGTTGGTCGCT
CTGGATGCTGACACCATCAATCACCCAGCCCAGCTGTCCAAGACCTCGCTGGCCCCCATC
ATTGTTTACATCAAGATCACCTCTCCCAAGGTACTTCAAAGGCTCATCAAGTCCCGAGGA
AAGTCTCAGTCCAAACACCTCAATGTCCAAATAGCGGCCTCGGAAAAGCTGGCACAGTGC
CCCCCTGAAATGTTTGACATCATCCTGGATGAGAACCAATTGGAGGATGCCTGCGAGCAT
CTGGCGGAGTACTTGGAAGCCTATTGGAAGGCCACACACCCGCCCAGCAGCACGCCACCC
AATCCGCTGCTGAACCGCACCATGGCTACCGCAGCCCTGGCTGCCAGCCCTGCCCCTGTC
TCCAACCTCCAGGGACCCTACCTTGCTTCCGGGGACCAGCCACTGGAACGGGCCACCGGG
GAGCACGCCAGCATGCACGAGTACCCAGGGGAGCTGGGCCAGCCCCCAGGCCTTTACCCC
AGCAGCCACCCACCAGGCCGGGCAGGCACGCTACGGGCACTGTCCCGCCAAGACACTTTT
GATGCCGACACCCCCGGCAGCCGAAACTCTGCCTACACGGAGCTGGGAGACTCATGTGTG
GACATGGAGACTGACCCCTCAGAGGGGCCAGGGCTTGGAGACCCTGCAGGGGGCGGCACG
CCCCCAGCCCGACAGGGATCCTGGGAGGACGAGGAAGAAGACTATGAGGAAGAGCTGACC
GACAACCGGAACCGGGGCCGGAATAAGGCCCGCTACTGCGCTGAGGGTGGGGGTCCAGTT
TTGGGGCGCAACAAGAATGAGCTGGAGGGCTGGGGACGAGGCGTCTACATTCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00625</identifier>
            <name>Guanylate_kin</name>
          </pfam>
          <pfam>
            <identifier>PF12052</identifier>
            <name>VGCC_beta4Aa_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T-tubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein targeting to membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q08289" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit beta-2</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.</specific-function>
        <gene-name>CACNB2</gene-name>
        <locus>10p12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.26</theoretical-pi>
        <molecular-weight>73579.925</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1402</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNB2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S60415</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>300417</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q08289</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CACB2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CAB2</synonym>
          <synonym>CACNLB2</synonym>
          <synonym>Calcium channel voltage-dependent subunit beta 2</synonym>
          <synonym>Lambert-Eaton myasthenic syndrome antigen B</synonym>
          <synonym>MYSB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004623|Voltage-dependent L-type calcium channel subunit beta-2
MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKNRFKGSDGSTS
SDTTSNSFVRQGSADSYTSRPSDSDVSLEEDREAVRREAERQAQAQLEKAKTKPVAFAVR
TNVSYSAAHEDDVPVPGMAISFEAKDFLHVKEKFNNDWWIGRLVKEGCEIGFIPSPVKLE
NMRLQHEQRAKQGKFYSSKSGGNSSSSLGDIVPSSRKSTPPSSAIDIDATGLDAEENDIP
ANHRSPKPSANSVTSPHSKEKRMPFFKKTEHTPPYDVVPSMRPVVLVGPSLKGYEVTDMM
QKALFDFLKHRFEGRISITRVTADISLAKRSVLNNPSKHAIIERSNTRSSLAEVQSEIER
IFELARTLQLVVLDADTINHPAQLSKTSLAPIIVYVKISSPKVLQRLIKSRGKSQAKHLN
VQMVAADKLAQCPPELFDVILDENQLEDACEHLADYLEAYWKATHPPSSSLPNPLLSRTL
ATSSLPLSPTLASNSQGSQGDQRTDRSAPIRSASQAEEEPSVEPVKKSQHRSSSSAPHHN
HRSGTSRGLSRQETFDSETQESRDSAYVEPKEDYSHDHVDHYASHRDHNHRDETHGSSDH
RHRESRHRSRDVDREQDHNECNKQRSRHKSKDRYCEKDGEVISKKRNEAGEWNRDVYIRQ
</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021669|Voltage-dependent L-type calcium channel subunit beta-2 (CACNB2)
ATGCAGTGCTGCGGGCTGGTGCATCGCCGGCGAGTACGGGTGTCCTATGGTTCGGCAGAC
TCCTACACTAGCCGTCCATCCGATTCCGATGTATCTCTGGAGGAGGACCGGGAGGCAGTG
CGCAGAGAAGCGGAGCGGCAGGCCCAGGCACAGTTGGAAAAAGCAAAGACAAAGCCCGTT
GCATTTGCGGTTCGGACAAATGTCAGCTACAGTGCGGCCCATGAAGATGATGTTCCAGTG
CCTGGCATGGCCATCTCATTCGAAGCAAAAGATTTTCTGCATGTTAAGGAAAAATTTAAC
AATGACTGGTGGATAGGGCGATTGGTAAAAGAAGGCTGTGAAATCGGATTCATTCCAAGC
CCAGTCAAACTAGAAAACATGAGGCTGCAGCATGAACAGAGAGCCAAGCAAGGGAAATTC
TACTCCAGTAAATCAGGAGGAAATTCATCATCCAGTTTGGGTGACATAGTACCTAGTTCC
AGAAAATCAACACCTCCATCATCTGCTATAGACATAGATGCTACTGGCTTAGATGCAGAA
GAAAATGATATTCCAGCAAACCACCGCTCCCCTAAACCCAGTGCAAACAGTGTAACGTCA
CCCCACTCCAAAGAGAAAAGAATGCCCTTCTTTAAGAAGACAGAGCACACTCCTCCGTAT
GATGTGGTACCTTCCATGCGACCAGTGGTCCTAGTGGGCCCTTCTCTGAAGGGCTACGAG
GTCACAGATATGATGCAAAAAGCGCTGTTTGATTTTTTAAAACACAGATTTGAAGGGCGG
ATATCCATCACAAGGGTCACCGCTGACATCTCGCTTGCCAAACGCTCGGTATTAAACAAT
CCCAGTAAGCACGCAATAATAGAAAGATCCAACACAAGGTCAAGCTTAGCGGAAGTTCAG
AGTGAAATCGAAAGGATTTTTGAACTTGCAAGAACATTGCAGTTGGTGGTCCTTGACGCG
GATACAATTAATCATCCAGCTCAACTCAGTAAAACCTCCTTGGCCCCTATTATAGTATAT
GTAAAGATTTCTTCTCCTAAGGTTTTACAAAGGTTAATAAAATCTCGAGGGAAATCTCAA
GCTAAACACCTCAACGTCCAGATGGTAGCAGCTGATAAACTGGCTCAGTGTCCTCCAGAG
CTGTTCGATGTGATCTTGGATGAGAACCAGCTTGAGGATGCCTGTGAGCACCTTGCCGAC
TATCTGGAGGCCTACTGGAAGGCCACCCATCCTCCCAGCAGTAGCCTCCCCAACCCTCTC
CTTAGCCGTACATTAGCCACTTCAAGTCTGCCTCTTAGCCCCACCCTAGCCTCTAATTCA
CAGGGTTCTCAAGGTGATCAGAGGACTGATCGCTCCGCTCCTATCCGTTCTGCTTCCCAA
GCTGAAGAAGAACCTAGTGTGGAACCAGTCAAGAAATCCCAGCACCGCTCTTCCTCCTCA
GCCCCACACCACAACCATCGCAGTGGGACAAGTCGCGGCCTCTCCAGGCAAGAGACATTT
GACTCGGAAACCCAGGAGAGTCGAGACTCTGCCTACGTAGAGCCAAAGGAAGATTATTCC
CATGACCACGTGGACCACTATGCCTCACACCGTGACCACAACCACAGAGACGAGACCCAC
GGGAGCAGTGACCACAGACACAGGGAGTCCCGGCACCGTTCCCGGGACGTGGATCGAGAG
CAGGACCACAACGAGTGCAACAAGCAGCGCAGCCGTCATAAATCCAAGGATCGCTACTGT
GAAAAGGATGGAGAAGTGATATCAAAAAAACGGAATGAGGCTGGGGAGTGGAACAGGGAT
GTTTACATCCGCCAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00625</identifier>
            <name>Guanylate_kin</name>
          </pfam>
          <pfam>
            <identifier>PF12052</identifier>
            <name>VGCC_beta4Aa_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>L-type voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P54284" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit beta-3</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.</specific-function>
        <gene-name>CACNB3</gene-name>
        <locus>12q13</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.31</theoretical-pi>
        <molecular-weight>54531.425</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1403</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNB3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X76555</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>435135</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P54284</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CACB3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CAB3</synonym>
          <synonym>CACNLB3</synonym>
          <synonym>Calcium channel voltage-dependent subunit beta 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004631|Voltage-dependent L-type calcium channel subunit beta-3
MYDDSYVPGFEDSEAGSADSYTSRPSLDSDVSLEEDRESARREVESQAQQQLERAKHKPV
AFAVRTNVSYCGVLDEECPVQGSGVNFEAKDFLHIKEKYSNDWWIGRLVKEGGDIAFIPS
PQRLESIRLKQEQKARRSGNPSSLSDIGNRRSPPPSLAKQKQKQAEHVPPYDVVPSMRPV
VLVGPSLKGYEVTDMMQKALFDFLKHRFDGRISITRVTADLSLAKRSVLNNPGKRTIIER
SSARSSIAEVQSEIERIFELAKSLQLVVLDADTINHPAQLAKTSLAPIIVFVKVSSPKVL
QRLIRSRGKSQMKHLTVQMMAYDKLVQCPPESFDVILDENQLEDACEHLAEYLEVYWRAT
HHPAPGPGLLGPPSAIPGLQNQQLLGERGEEHSPLERDSLMPSDEASESSRQAWTGSSQR
SSRHLEEDYADAYQDLYQPHRQHTSGLPSANGHDPQDRLLAQDSEHNHSDRNWQRNRPWP
KDSY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019274|Voltage-dependent L-type calcium channel subunit beta-3 (CACNB3)
ATGTATGACGACTCCTACGTGCCCGGGTTTGAGGACTCGGAGGCGGGTTCAGCCGACTCC
TACACCAGCCGCCCATCTCTGGACTCAGACGTCTCCCTGGAGGAGGACCGGGAGAGTGCC
CGGCGTGAAGTAGAGAGCCAGGCTCAGCAGCAGCTCGAAAGGGCCAAGCACAAACCTGTG
GCATTTGCGGTGAGGACCAATGTCAGCTACTGTGGCGTACTGGATGAGGAGTGCCCAGTC
CAGGGCTCTGGAGTCAACTTTGAGGCCAAAGATTTTCTGCACATTAAAGAGAAGTACAGC
AATGACTGGTGGATCGGGCGGCTAGTGAAAGAGGGCGGGGACATCGCCTTCATCCCCAGC
CCCCAGCGCCTGGAGAGCATCCGGCTCAAACAGGAGCAGAAGGCCAGGAGATCTGGGAAC
CCTTCCAGCCTGAGTGACATTGGCAACCGACGCTCCCCTCCGCCATCTCTAGCCAAGCAG
AAGCAAAAGCAGGCGGAACATGTTCCCCCATATGACGTGGTGCCCTCCATGCGGCCTGTG
GTGCTGGTGGGACCCTCTCTGAAAGGTTATGAGGTCACAGACATGATGCAGAAGGCTCTC
TTCGACTTCCTCAAACACAGATTTGATGGCAGGATCTCCATCACCCGAGTCACAGCCGAC
CTCTCCCTGGCAAAGCGATCTGTGCTCAACAATCCGGGCAAGAGGACCATCATTGAGCGC
TCCTCTGCCCGCTCCAGCATTGCGGAAGTGCAGAGTGAGATCGAGCGCATATTTGAGCTG
GCCAAATCCCTGCAGCTAGTAGTGTTGGACGCTGACACCATCAACCACCCAGCACAGCTG
GCCAAGACCTCGCTGGCCCCCATCATCGTCTTTGTCAAAGTGTCCTCACCAAAGGTACTC
CAGCGTCTCATTCGCTCCCGGGGGAAGTCACAGATGAAGCACCTGACCGTACAGATGATG
GCATATGATAAGCTGGTTCAGTGCCCACCGGAGTCATTTGATGTGATTCTGGATGAGAAC
CAGCTGGAGGATGCCTGTGAGCACCTGGCTGAGTACCTGGAGGTTTACTGGCGGGCCACG
CACCACCCAGCCCCTGGCCCCGGACTTCTGGGTCCTCCCAGTGCCATCCCCGGACTTCAG
AACCAGCAGCTGCTGGGGGAGCGTGGCGAGGAGCACTCCCCCCTTGAGCGGGACAGCTTG
ATGCCCTCTGATGAGGCCAGCGAGAGCTCCCGCCAAGCCTGGACAGGATCTTCACAGCGT
AGCTCCCGCCACCTGGAGGAGGACTATGCAGATGCCTACCAGGACCTGTACCAGCCTCAC
CGCCAACACACCTCGGGGCTGCCTAGTGCTAACGGGCATGACCCCCAAGACCGGCTTCTA
GCCCAGGACTCAGAGCACAACCACAGTGACCGGAACTGGCAGCGCAACCGGCCTTGGCCC
AAGGATAGCTACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00625</identifier>
            <name>Guanylate_kin</name>
          </pfam>
          <pfam>
            <identifier>PF12052</identifier>
            <name>VGCC_beta4Aa_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O00305" source="Swiss-Prot">
        <name>Voltage-dependent L-type calcium channel subunit beta-4</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.</specific-function>
        <gene-name>CACNB4</gene-name>
        <locus>2q22-q23</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.77</theoretical-pi>
        <molecular-weight>58168.625</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1404</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNB4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U95020</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2058727</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00305</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CACB4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CAB4</synonym>
          <synonym>CACNLB4</synonym>
          <synonym>Calcium channel voltage-dependent subunit beta 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004627|Voltage-dependent L-type calcium channel subunit beta-4
MSSSSYAKNGTADGPHSPTSQVARGTTTRRSRLKRSDGSTTSTSFILRQGSADSYTSRPS
DSDVSLEEDREAIRQEREQQAAIQLERAKSKPVAFAVKTNVSYCGALDEDVPVPSTAISF
DAKDFLHIKEKYNNDWWIGRLVKEGCEIGFIPSPLRLENIRIQQEQKRGRFHGGKSSGNS
SSSLGEMVSGTFRATPTSTAKQKQKVTEHIPPYDVVPSMRPVVLVGPSLKGYEVTDMMQK
ALFDFLKHRFDGRISITRVTADISLAKRSVLNNPSKRAIIERSNTRSSLAEVQSEIERIF
ELARSLQLVVLDADTINHPAQLIKTSLAPIIVHVKVSSPKVLQRLIKSRGKSQSKHLNVQ
LVAADKLAQCPPEMFDVILDENQLEDACEHLGEYLEAYWRATHTTSSTPMTPLLGRNLGS
TALSPYPTAISGLQSQRMRHSNHSTENSPIERRSLMTSDENYHNERARKSRNRLSSSSQH
SRDHYPLVEEDYPDSYQDTYKPHRNRGSPGGYSHDSRHRL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011692|Voltage-dependent L-type calcium channel subunit beta-4 (CACNB4)
ATGTCCTCCTCCTCCTACGCCAAGAACGGGACCGCGGACGGGCCGCACTCCCCCACCTCG
CAGGTGGCCCGAGGCACCACAACCCGGAGGAGCAGGTTGAAAAGATCCGATGGCAGCACC
ACTTCGACCAGCTTCATCCTCAGACAGGGTTCAGCGGATTCCTACACAAGCAGGCCGTCT
GACTCCGATGTCTCTTTGGAAGAGGACCGGGAAGCAATTCGACAGGAGAGAGAACAGCAA
GCAGCTATCCAGCTTGAGAGAGCAAAGTCCAAACCTGTAGCATTTGCCGTGAAGACAAAT
GTGAGCTACTGCGGCGCCCTGGACGAGGATGTGCCTGTTCCAAGCACAGCTATCTCCTTT
GATGCTAAAGACTTTCTACATATTAAAGAGAAATATAACAATGATTGGTGGATAGGAAGG
CTGGTGAAAGAGGGCTGTGAAATTGGCTTCATTCCAAGTCCACTCAGATTGGAGAACATA
CGGATCCAGCAAGAACAAAAAAGAGGACGTTTTCACGGAGGGAAATCAAGTGGAAATTCT
TCTTCAAGTCTTGGAGAAATGGTATCTGGGACATTCCGAGCAACTCCCACATCAACAGCA
AAACAGAAGCAAAAAGTGACGGAGCACATTCCTCCTTACGATGTTGTACCGTCAATGCGT
CCGGTGGTGTTAGTGGGGCCGTCACTGAAAGGTTACGAGGTAACAGACATGATGCAGAAA
GCCCTCTTTGATTTCCTGAAGCACAGGTTTGATGGGAGGATTTCAATAACGAGAGTGACA
GCTGACATTTCTCTTGCTAAGAGGTCTGTCCTAAATAATCCCAGCAAGAGAGCAATAATT
GAACGTTCGAACACCCGGTCCAGCTTAGCGGAAGTACAAAGTGAAATTGAAAGAATCTTT
GAGTTGGCAAGATCTTTGCAACTGGTTGTTCTTGATGCAGACACCATCAATCACCCAGCA
CAACTTATAAAGACTTCCTTAGCACCAATTATTGTTCATGTAAAAGTCTCATCTCCAAAG
GTTTTACAGCGGTTGATTAAATCTAGAGGAAAGTCACAAAGTAAACACTTGAATGTTCAA
CTGGTGGCAGCTGATAAACTTGCACAATGCCCCCCAGAAATGTTTGATGTTATATTGGAT
GAAAATCAGCTTGAGGATGCATGTGAACATCTAGGGGAGTACCTGGAGGCGTACTGGCGT
GCCACCCACACAACCAGTAGCACACCCATGACCCCGCTGCTGGGAAGGAATTTGGGCTCC
ACGGCACTCTCACCATATCCCACAGCAATTTCTGGGTTACAGAGTCAGCGAATGAGGCAC
AGCAACCACTCCACAGAGAACTCTCCAATTGAAAGACGAAGTCTAATGACCTCTGATGAA
AATTATCACAATGAAAGGGCTCGGAAGAGTAGGAACCGCTTGTCTTCCAGTTCTCAGCAT
AGCCGAGATCATTACCCTCTTGTGGAAGAAGATTACCCTGACTCATACCAGGACACTTAC
AAACCCCATAGGAACCGAGGATCACCTGGGGGATATAGCCATGACTCCCGACATAGGCTT
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00625</identifier>
            <name>Guanylate_kin</name>
          </pfam>
          <pfam>
            <identifier>PF12052</identifier>
            <name>VGCC_beta4Aa_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult walking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of light stimulus involved in visual perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle fiber development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuronal action potential propagation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Peyer's patch development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spleen development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thymus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q00975" source="Swiss-Prot">
        <name>Voltage-dependent N-type calcium channel subunit alpha-1B</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons.</specific-function>
        <gene-name>CACNA1B</gene-name>
        <locus>9q34</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>96-114
133-152
164-183
188-206
226-245
332-356
483-501
517-536
545-562
574-592
612-631
685-709
1152-1169
1186-1205
1218-1236
1247-1265
1285-1304
1392-1416
1472-1490
1506-1525
1534-1552
1564-1582
1602-1621
1684-1708</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>262493.84</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1389</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M94172</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>179758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>533</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>533</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q00975</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>BIII</synonym>
          <synonym>Brain calcium channel III</synonym>
          <synonym>CACH5</synonym>
          <synonym>CACNL1A5</synonym>
          <synonym>Calcium channel, L type, alpha-1 polypeptide isoform 5</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav2.2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004369|Voltage-dependent N-type calcium channel subunit alpha-1B
MVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIAQRARTMALYN
PIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWPPFEYMILATIIANCIVLALEQHLPD
GDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFVFHKGSYLRNGWNVMDFVVVLTGILA
TAGTDFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMVPLLQIGLLLFFAILMFAII
GLEFYMGKFHKACFPNSTDAEPVGDFPCGKEAPARLCEGDTECREYWPGPNFGITNFDNI
LFAILTVFQCITMEGWTDILYNTNDAAGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFA
KERERVENRRAFLKLRRQQQIERELNGYLEWIFKAEEVMLAEEDRNAEEKSPLDVLKRAA
TKKSRNDLIHAEEGEDRFADLCAVGSPFARASLKSGKTESSSYFRRKEKMFRFFIRRMVK
AQSFYWVVLCVVALNTLCVAMVHYNQPRRLTTTLYFAEFVFLGLFLTEMSLKMYGLGPRS
YFRSSFNCFDFGVIVGSVFEVVWAAIKPGSSFGISVLRALRLLRIFKVTKYWSSLRNLVV
SLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFQDETPTTNFDTFPAAILTVFQIL
TGEDWNAVMYHGIESQGGVSKGMFSSFYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTK
DEEEMEEAANQKLALQKAKEVAEVSPMSAANISIAARQQNSAKARSVWEQRASQLRLQNL
RASCEALYSEMDPEERLRFATTRHLRPDMKTHLDRPLVVELGRDGARGPVGGKARPEAAE
APEGVDPPRRHHRHRDKDKTPAAGDQDRAEAPKAESGEPGAREERPRPHRSHSKEAAGPP
EARSERGRGPGPEGGRRHHRRGSPEEAAEREPRRHRAHRHQDPSKECAGAKGERRARHRG
GPRAGPREAESGEEPARRHRARHKAQPAHEAVEKETTEKEATEKEAEIVEADKEKELRNH
QPREPHCDLETSGTVTVGPMHTLPSTCLQKVEEQPEDADNQRNVTRMGSQPPDPNTIVHI
PVMLTGPLGEATVVPSGNVDLESQAEGKKEVEADDVMRSGPRPIVPYSSMFCLSPTNLLR
RFCHYIVTMRYFEVVILVVIALSSIALAAEDPVRTDSPRNNALKYLDYIFTGVFTFEMVI
KMIDLGLLLHPGAYFRDLWNILDFIVVSGALVAFAFSGSKGKDINTIKSLRVLRVLRPLK
TIKRLPKLKAVFDCVVNSLKNVLNILIVYMLFMFIFAVIAVQLFKGKFFYCTDESKELER
DCRGQYLDYEKEEVEAQPRQWKKYDFHYDNVLWALLTLFTVSTGEGWPMVLKHSVDATYE
EQGPSPGYRMELSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKVMSECSLEKNERACI
DFAISAKPLTRYMPQNRQSFQYKTWTFVVSPPFEYFIMAMIALNTVVLMMKFYDAPYEYE
LMLKCLNIVFTSMFSMECVLKIIAFGVLNYFRDAWNVFDFVTVLGSITDILVTEIAETNN
FINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQV
FGNIALDDDTSINRHNNFRTFLQALMLLFRSATGEAWHEIMLSCLSNQACDEQANATECG
SDFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEFIRVWAEYDPAA
CGRISYNDMFEMLKHMSPPLGLGKKCPARVAYKRLVRMNMPISNEDMTVHFTSTLMALIR
TALEIKLAPAGTKQHQCDAELRKEISVVWANLPQKTLDLLVPPHKPDEMTVGKVYAALMI
FDFYKQNKTTRDQMQQAPGGLSQMGPVSLFHPLKATLEQTQPAVLRGARVFLRQKSSTSL
SNGGAIQNQESGIKESVSWGTQRTQDAPHEARPPLERGHSTEIPVGRSGALAVDVQMQSI
TRRGPDGEPQPGLESQGRAASMPRLAAETQPVTDASPMKRSISTLAQRPRGTHLCSTTPD
RPPPSQASSHHHHHRCHRRRDRKQRSLEKGPSLSADMDGAPSSAVGPGLPPGEGPTGCRR
ERERRQERGRSQERRQPSSSSSEKQRFYSCDRFGGREPPKPKPSLSSHPTSPTAGQEPGP
HPQGSGSVNGSPLLSTSGASTPGRGGRRQLPQTPLTPRPSITYKTANSSPIHFAGAQTSL
PAFSPGRLSRGLSEHNALLQRDPLSQPLAPGSRIGSDPYLGQRLDSEASVHALPEDTLTF
EEAVATNSGRSSRTSYVSSLTSQSHPLRRVPNGYHCTLGLSSGGRARHSYHHPDQDHWC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011606|Voltage-dependent N-type calcium channel subunit alpha-1B (CACNA1B)
ATGGTCCGCTTCGGGGACGAGCTGGGCGGCCGCTATGGGGGCCCCGGCGGCGGAGAGCGG
GCCCGGGGCGGCGGGGCCGGCGGGGCGGGGGGCCCGGGTCCCGGGGGGCTGCAGCCCGGC
CAGCGGGTCCTCTACAAGCAATCGATCGCGCAGCGCGCGCGGACCATGGCGCTGTACAAC
CCCATCCCGGTCAAGCAGAACTGCTTCACCGTCAACCGCTCGCTCTTCGTCTTCAGCGAG
GACAACGTCGTCCGCAAATACGCGAAGCGCATCACCGAGTGGCCTCCATTCGAGTATATG
ATCCTGGCCACCATCATCGCCAACTGCATCGTGCTGGCCCTGGAGCAGCACCTCCCTGAT
GGGGACAAAACGCCCATGTCCGAGCGGCTGGACGACACGGAGCCCTATTTCATCGGGATC
TTTTGCTTCGAGGCAGGGATCAAAATCATCGCTCTGGGCTTTGTCTTCCACAAGGGCTCT
TACCTGCGGAACGGCTGGAACGTCATGGACTTCGTGGTCGTCCTCACAGGGATCCTTGCC
ACGGCTGGAACTGACTTCGACCTGCGAACACTGAGGGCTGTGCGTGTGCTGAGGCCCCTG
AAGCTGGTGTCTGGGATTCCAAGTTTGCAGGTGGTGCTCAAGTCCATCATGAAGGCCATG
GTTCCACTCCTGCAGATTGGGCTGCTTCTCTTCTTTGCCATCCTCATGTTTGCCATCATT
GGCCTGGAGTTCTACATGGGCAAGTTCCACAAGGCCTGTTTCCCCAACAGCACAGATGCG
GAGCCCGTGGGTGACTTCCCCTGTGGCAAGGAGGCCCCAGCCCGGCTGTGCGAGGGCGAC
ACTGAGTGCCGGGAGTACTGGCCAGGACCCAACTTTGGCATCACCAACTTTGACAATATC
CTGTTTGCCATCTTGACGGTGTTCCAGTGCATCACCATGGAGGGCTGGACTGACATCCTC
TATAATACAAACGATGCGGCCGGCAACACCTGGAACTGGCTCTACTTCATCCCTCTCATC
ATCATCGGCTCCTTCTTCATGCTCAACCTGGTGCTGGGCGTGCTCTCGGGGGAGTTTGCC
AAGGAGCGAGAGAGGGTGGAGAACCGCCGCGCCTTCCTGAAGCTGCGCCGGCAGCAGCAG
ATCGAGCGAGAGCTCAACGGGTACCTGGAGTGGATCTTCAAGGCGGAGGAAGTCATGCTG
GCCGAGGAGGACAGGAATGCAGAGGAGAAGTCCCCTTTGGACGTGCTGAAGAGAGCGGCC
ACCAAGAAGAGCAGAAATGACCTGATCCACGCAGAGGAGGGAGAGGACCGGTTTGCAGAT
CTCTGTGCTGTTGGATCCCCCTTCGCCCGCGCCAGCCTCAAGAGCGGGAAGACAGAGAGC
TCGTCATACTTCCGGAGGAAGGAGAAGATGTTCCGGTTTTTTATCCGGCGCATGGTGAAG
GCTCAGAGCTTCTACTGGGTGGTGCTGTGCGTGGTGGCCCTGAACACACTGTGTGTGGCC
ATGGTGCATTACAACCAGCCGCGGCGGCTTACCACGACCCTGTATTTTGCAGAGTTTGTT
TTCCTGGGTCTCTTCCTCACAGAGATGTCCCTGAAGATGTATGGCCTGGGGCCCAGAAGC
TACTTCCGGTCCTCCTTCAACTGCTTCGACTTTGGGGTCATCGTGGGGAGCGTCTTTGAA
GTGGTCTGGGCGGCCATCAAGCCGGGAAGCTCCTTTGGGATCAGTGTGCTGCGGGCCCTC
CGCCTGCTGAGGATCTTCAAAGTCACGAAGTACTGGAGCTCCCTGCGGAACCTGGTGGTG
TCCCTGCTGAACTCCATGAAGTCCATCATCAGCCTGCTCTTCTTGCTCTTCCTGTTCATT
GTGGTCTTCGCCCTGCTGGGGATGCAGCTGTTTGGGGGACAGTTCAACTTCCAGGATGAG
ACTCCCACAACCAACTTCGACACCTTCCCTGCCGCCATCCTCACTGTCTTCCAGATCCTG
ACGGGAGAGGACTGGAATGCAGTGATGTATCACGGGATCGAATCGCAAGGCGGCGTCAGC
AAAGGCATGTTCTCGTCCTTTTACTTCATTGTCCTGACACTGTTCGGAAACTACACTCTG
CTGAATGTCTTTCTGGCCATCGCTGTGGACAACCTGGCCAACGCCCAAGAGCTGACCAAG
GATGAAGAGGAGATGGAAGAAGCAGCCAATCAGAAGCTTGCTCTGCAAAAGGCCAAAGAA
GTGGCTGAAGTCAGCCCCATGTCTGCCGCGAACATCTCCATCGCCGCCAGGCAGCAGAAC
TCGGCCAAGGCGCGCTCGGTGTGGGAGCAGCGGGCCAGCCAGCTACGGCTGCAGAACCTG
CGGGCCAGCTGCGAGGCGCTGTACAGCGAGATGGACCCCGAGGAGCGGCTGCGCTTCGCC
ACTACGCGCCACCTGCGGCCCGACATGAAGACGCACCTGGACCGGCCGCTGGTGGTGGAG
CTGGGCCGCGACGGCGCGCGGGGGCCCGTGGGAGGCAAAGCCCGACCTGAGGCTGCGGAG
GCCCCCGAGGGCGTCGACCCTCCGCGCAGGCACCACCGGCACCGCGACAAGGACAAGACC
CCCGCGGCGGGGGACCAGGACCGAGCAGAGGCCCCGAAGGCGGAGAGCGGGGAGCCCGGT
GCCCGGGAGGAGCGGCCGCGGCCGCACCGCAGCCACAGCAAGGAGGCCGCGGGGCCCCCG
GAGGCGCGGAGCGAGCGCGGCCGAGGCCCAGGCCCCGAGGGCGGCCGGCGGCACCACCGG
CGCGGCTCCCCGGAGGAGGCGGCCGAGCGGGAGCCCCGACGCCACCGCGCGCACCGGCAC
CAGGATCCGAGCAAGGAGTGCGCCGGCGCCAAGGGCGAGCGGCGCGCGCGGCACCGCGGC
GGCCCCCGAGCGGGGCCCCGGGAGGCGGAGAGCGGGGAGGAGCCGGCGCGGCGGCACCGG
GCCCGGCACAAGGCGCAGCCTGCTCACGAGGCTGTGGAGAAGGAGACCACGGAGAAGGAG
GCCACGGAGAAGGAGGCTGAGATAGTGGAAGCCGACAAGGAAAAGGAGCTCCGGAACCAC
CAGCCCCGGGAGCCACACTGTGACCTGGAGACCAGTGGGACTGTGACTGTGGGTCCCATG
CACACACTGCCCAGCACCTGTCTCCAGAAGGTGGAGGAACAGCCAGAGGATGCAGACAAT
CAGCGGAACGTCACTCGCATGGGCAGTCAGCCCCCAGACCCGAACACTATTGTACATATC
CCAGTGATGCTGACGGGCCCTCTTGGGGAAGCCACGGTCGTTCCCAGTGGTAACGTGGAC
CTGGAAAGCCAAGCAGAGGGGAAGAAGGAGGTGGAAGCGGATGACGTGATGAGGAGCGGC
CCCCGGCCTATCGTCCCATACAGCTCCATGTTCTGTTTAAGCCCCACCAACCTGCTCCGC
CGCTTCTGCCACTACATCGTGACCATGAGGTACTTCGAGGTGGTCATTCTCGTGGTCATC
GCCTTGAGCAGCATCGCCCTGGCTGCTGAGGACCCAGTGCGCACAGACTCGCCCAGGAAC
AACGCTCTGAAATACCTGGATTACATTTTCACTGGTGTCTTTACCTTTGAGATGGTGATA
AAGATGATCGACTTGGGACTGCTGCTTCACCCTGGAGCCTATTTCCGGGACTTGTGGAAC
ATTCTGGACTTCATTGTGGTCAGTGGCGCCCTGGTGGCGTTTGCTTTCTCAGGATCCAAA
GGGAAAGACATCAATACCATCAAGTCTCTGAGAGTCCTTCGTGTCCTGCGGCCCCTCAAG
ACCATCAAACGGCTGCCCAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACTCCCTGAAG
AATGTCCTCAACATCTTGATTGTCTACATGCTCTTCATGTTCATATTTGCCGTCATTGCG
GTGCAGCTCTTCAAAGGGAAGTTTTTCTACTGCACAGATGAATCCAAGGAGCTGGAGAGG
GACTGCAGGGGTCAGTATTTGGATTATGAGAAGGAGGAAGTGGAAGCTCAGCCCAGGCAG
TGGAAGAAATACGACTTTCACTACGACAATGTGCTCTGGGCTCTGCTGACGCTGTTCACA
GTGTCCACGGGAGAAGGCTGGCCCATGGTGCTGAAACACTCCGTGGATGCCACCTATGAG
GAGCAGGGTCCAAGCCCTGGGTACCGCATGGAGCTGTCCATCTTCTACGTGGTCTACTTT
GTGGTCTTTCCCTTCTTCTTCGTCAACATCTTTGTGGCTTTGATCATCATCACCTTCCAG
GAGCAGGGGGACAAGGTGATGTCTGAATGCAGCCTGGAGAAGAACGAGAGGGCTTGCATT
GACTTCGCCATCAGCGCCAAACCCCTGACACGGTACATGCCCCAAAACCGGCAGTCGTTC
CAGTATAAGACGTGGACATTTGTGGTCTCCCCGCCCTTTGAATACTTCATCATGGCCATG
ATAGCCCTCAACACTGTGGTGCTGATGATGAAGTTCTATGATGCACCCTATGAGTACGAG
CTGATGCTGAAATGCCTGAACATCGTGTTCACATCCATGTTCTCCATGGAATGCGTGCTG
AAGATCATCGCCTTTGGGGTGCTGAACTATTTCAGAGATGCCTGGAATGTCTTTGACTTT
GTCACTGTGTTGGGAAGTATTACTGATATTTTAGTAACAGAGATTGCGGAAACGAACAAT
TTCATCAACCTCAGCTTCCTCCGCCTCTTTCGAGCTGCGCGGCTGATCAAGCTGCTCCGC
CAGGGCTACACCATCCGCATCCTGCTGTGGACCTTTGTCCAGTCCTTCAAGGCCCTGCCC
TACGTGTGTCTGCTCATTGCCATGCTGTTCTTCATCTACGCCATCATCGGCATGCAGGTG
TTTGGGAATATTGCCCTGGATGATGACACCAGCATCAACCGCCACAACAACTTCCGGACG
TTTTTGCAAGCCCTGATGCTGCTGTTCAGGAGCGCCACGGGGGAGGCCTGGCACGAGATC
ATGCTGTCCTGCCTGAGCAACCAGGCCTGTGATGAGCAGGCCAATGCCACCGAGTGTGGA
AGTGACTTTGCCTACTTCTACTTCGTCTCCTTCATCTTCCTGTGCTCCTTTCTGATGTTG
AACCTCTTTGTGGCTGTGATCATGGACAATTTTGAGTACCTCACGCGGGACTCTTCCATC
CTAGGTCCTCACCACTTGGATGAGTTCATCCGGGTCTGGGCTGAATACGACCCGGCTGCG
TGTGGGCGCATCAGTTACAATGACATGTTTGAGATGCTGAAACACATGTCCCCGCCTCTG
GGGCTGGGGAAGAAATGCCCTGCTCGAGTTGCTTACAAGCGCCTGGTTCGCATGAACATG
CCCATCTCCAACGAGGACATGACTGTTCACTTCACGTCCACGCTGATGGCCCTCATCCGG
ACGGCACTGGAGATCAAGCTGGCCCCAGCTGGGACAAAGCAGCATCAGTGTGACGCGGAG
TTGAGGAAGGAGATTTCCGTTGTGTGGGCCAATCTGCCCCAGAAGACTTTGGACTTGCTG
GTACCACCCCATAAGCCTGATGAGATGACAGTGGGGAAGGTTTATGCAGCTCTGATGATA
TTCGACTTCTACAAGCAGAACAAAACCACCAGAGACCAGATGCAGCAGGCTCCTGGAGGC
CTCTCCCAGATGGGTCCTGTGTCCCTGTTCCACCCTCTGAAGGCCACCCTGGAGCAGACA
CAGCCGGCTGTGCTCCGAGGAGCCCGGGTTTTCCTTCGACAGAAGAGTTCCACCTCCCTC
AGCAATGGCGGGGCCATACAAAACCAAGAGAGTGGCATCAAAGAGTCTGTCTCCTGGGGC
ACTCAAAGGACCCAGGATGCACCCCATGAGGCCAGGCCACCCCTGGAGCGTGGCCACTCC
ACAGAGATCCCTGTGGGGCGGTCAGGAGCACTGGCTGTGGACGTTCAGATGCAGAGCATA
ACCCGGAGGGGCCCTGATGGGGAGCCCCAGCCTGGGCTGGAGAGCCAGGGTCGAGCGGCC
TCCATGCCCCGCCTTGCGGCCGAGACTCAGCCCGTCACAGATGCCAGCCCCATGAAGCGC
TCCATCTCCACGCTGGCCCAGCGGCCCCGTGGGACTCATCTTTGCAGCACCACCCCGGAC
CGCCCACCCCCTAGCCAGGCGTCGTCGCACCACCACCACCACCGCTGCCACCGCCGCAGG
GACAGGAAGCAGAGGTCCCTGGAGAAGGGGCCCAGCCTGTCTGCCGATATGGATGGCGCA
CCAAGCAGTGCTGTGGGGCCGGGGCTGCCCCCGGGAGAGGGGCCTACAGGCTGCCGGCGG
GAACGAGAGCGCCGGCAGGAGCGGGGCCGGTCCCAGGAGCGGAGGCAGCCCTCATCCTCC
TCCTCGGAGAAGCAGCGCTTCTACTCCTGCGACCGCTTTGGGGGCCGTGAGCCCCCGAAG
CCCAAGCCCTCCCTCAGCAGCCACCCAACGTCGCCAACAGCTGGCCAGGAGCCGGGACCC
CACCCACAGGGCAGTGGTTCCGTGAATGGGAGCCCCTTGCTGTCAACATCTGGTGCTAGC
ACCCCCGGCCGCGGTGGGCGGAGGCAGCTCCCCCAGACGCCCCTGACTCCCCGCCCCAGC
ATCACCTACAAGACGGCCAACTCCTCACCCATCCACTTCGCCGGGGCTCAGACCAGCCTC
CCTGCCTTCTCCCCAGGCCGGCTCAGCCGTGGGCTTTCCGAACACAACGCCCTGCTGCAG
AGAGACCCCCTCAGCCAGCCCCTGGCCCCTGGCTCTCGAATTGGCTCTGACCCTTACCTG
GGGCAGCGTCTGGACAGTGAGGCCTCTGTCCACGCCCTGCCTGAGGACACTCTCACTTTC
GAGGAGGCTGTGGCCACCAACTCGGGCCGCTCCTCCAGGACTTCCTACGTGTCCTCCCTG
ACCTCCCAGTCTCACCCTCTCCGCCGCGTGCCCAACGGTTACCACTGCACCCTGGGACTC
AGCTCGGGTGGCCGAGCACGGCACAGCTACCACCACCCTGACCAAGACCACTGGTGCTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF08763</identifier>
            <name>Ca_chan_IQ</name>
          </pfam>
          <pfam>
            <identifier>PF16905</identifier>
            <name>GPHH</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein C-terminus binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O00555" source="Swiss-Prot">
        <name>Voltage-dependent P/Q-type calcium channel subunit alpha-1A</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by the funnel toxin (Ftx) and by the omega-agatoxin-IVA (omega-Aga-IVA). They are however insensitive to dihydropyridines (DHP), and omega-conotoxin-GVIA (omega-CTx-GVIA).</specific-function>
        <gene-name>CACNA1A</gene-name>
        <locus>19p13.2-p13.1</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>99-117
136-155
168-185
191-209
229-248
336-360
488-506
522-541
550-568
579-597
617-636
690-714
1243-1261
1278-1297
1310-1328
1340-1358
1378-1397
1485-1509
1565-1593
1599-1618
1627-1645
1653-1671
1691-1710
1783-1807</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.1</theoretical-pi>
        <molecular-weight>282362.39</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1388</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF004884</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2213913</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>532</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00555</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>BI</synonym>
          <synonym>Brain calcium channel I</synonym>
          <synonym>CACH4</synonym>
          <synonym>CACN3</synonym>
          <synonym>CACNL1A4</synonym>
          <synonym>Calcium channel, L type, alpha-1 polypeptide isoform 4</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav2.1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000709|Voltage-dependent P/Q-type calcium channel subunit alpha-1A
MARFGDEMPARYGGGGSGAAAGVVVGSGGGRGAGGSRQGGQPGAQRMYKQSMAQRARTMA
LYNPIPVRQNCLTVNRSLFLFSEDNVVRKYAKKITEWPPFEYMILATIIANCIVLALEQH
LPDDDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFAFHKGSYLRNGWNVMDFVVVLTG
ILATVGTEFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMIPLLQIGLLLFFAILIF
AIIGLEFYMGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQ
FDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTWNWLYFIPLIIIGSFFMLNLVLGVLS
GEFAKERERVENRRAFLKLRRQQQIERELNGYMEWISKAEEVILAEDETDGEQRHPFDGA
LRRTTIKKSKTDLLNPEEAEDQLADIASVGSPFARASIKSAKLENSTFFHKKERRMRFYI
RRMVKTQAFYWTVLSLVALNTLCVAIVHYNQPEWLSDFLYYAEFIFLGLFMSEMFIKMYG
LGTRPYFHSSFNCFDCGVIIGSIFEVIWAVIKPGTSFGISVLRALRLLRIFKVTKYWASL
RNLVVSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFDEGTPPTNFDTFPAAIMT
VFQILTGEDWNEVMYDGIKSQGGVQGGMVFSIYFIVLTLFGNYTLLNVFLAIAVDNLANA
QELTKDEQEEEEAANQKLALQKAKEVAEVSPLSAANMSIAVKEQQKNQKPAKSVWEQRTS
EMRKQNLLASREALYNEMDPDERWKAAYTRHLRPDMKTHLDRPLVVDPQENRNNNTNKSR
AAEPTVDQRLGQQRAEDFLRKQARYHDRARDPSGSAGLDARRPWAGSQEAELSREGPYGR
ESDHHAREGSLEQPGFWEGEAERGKAGDPHRRHVHRQGGSRESRSGSPRTGADGEHRRHR
AHRRPGEEGPEDKAERRARHREGSRPARGGEGEGEGPDGGERRRRHRHGAPATYEGDARR
EDKERRHRRRKENQGSGVPVSGPNLSTTRPIQQDLGRQDPPLAEDIDNMKNNKLATAESA
APHGSLGHAGLPQSPAKMGNSTDPGPMLAIPAMATNPQNAASRRTPNNPGNPSNPGPPKT
PENSLIVTNPSGTQTNSAKTARKPDHTTVDIPPACPPPLNHTVVQVNKNANPDPLPKKEE
EKKEEEEDDRGEDGPKPMPPYSSMFILSTTNPLRRLCHYILNLRYFEMCILMVIAMSSIA
LAAEDPVQPNAPRNNVLRYFDYVFTGVFTFEMVIKMIDLGLVLHQGAYFRDLWNILDFIV
VSGALVAFAFTGNSKGKDINTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVNSLKNVFNI
LIVYMLFMFIFAVVAVQLFKGKFFHCTDESKEFEKDCRGKYLLYEKNEVKARDREWKKYE
FHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRMEMSIFYVVYFVVFPF
FFVNIFVALIIITFQEQGDKMMEEYSLEKNERACIDFAISAKPLTRHMPQNKQSFQYRMW
QFVVSPPFEYTIMAMIALNTIVLMMKFYGASVAYENALRVFNIVFTSLFSLECVLKVMAF
GILNYFRDAWNIFDFVTVLGSITDILVTEFGNNFINLSFLRLFRAARLIKLLRQGYTIRI
LLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIGIDVEDEDSDEDEFQITEHNNFR
TFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGILTRECGNEFAYFYFVSFIFLCSF
LMLNLFVAVIMDNFEYLTRDSSILGPHHLDEYVRVWAEYDPAAWGRMPYLDMYQMLRHMS
PPLGLGKKCPARVAYKRLLRMDLPVADDNTVHFNSTLMALIRTALDIKIAKGGADKQQMD
AELRKEMMAIWPNLSQKTLDLLVTPHKSTDLTVGKIYAAMMIMEYYRQSKAKKLQAMREE
QDRTPLMFQRMEPPSPTQEGGPGQNALPSTQLDPGGALMAHESGLKESPSWVTQRAQEMF
QKTGTWSPEQGPPTDMPNSQPNSQSVEMREMGRDGYSDSEHYLPMEGQGRAASMPRLPAE
NQRRRGRPRGNNLSTISDTSPMKRSASVLGPKARRLDDYSLERVPPEENQRHHQRRRDRS
HRASERSLGRYTDVDTGLGTDLSMTTQSGDLPSKERDQERGRPKDRKHRQHHHHHHHHHH
PPPPDKDRYAQERPDHGRARARDQRWSRSPSEGREHMAHRQGSSSVSGSPAPSTSGTSTP
RRGRRQLPQTPSTPRPHVSYSPVIRKAGGSGPPQQQQQQQQQQQAVARPGRAATSGPRRY
PGPTAEPLAGDRPPTGGHSSGRSPRMERRVPGPARSESPRACRHGGARWPASGPHVSEGP
PGPRHHGYYRGSDYDEADGPGSGGGEEAMAGAYDAPPPVRHASSGATGRSPRTPRASGPA
CASPSRHGRRLPNGYYPAHGLARPRGPGSRKGLHEPYSESDDDWC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010260|Voltage-dependent P/Q-type calcium channel subunit alpha-1A (CACNA1A)
ATGGCCCGCTTCGGAGACGAGATGCCGGCCCGCTACGGGGGAGGAGGCTCCGGGGCAGCC
GCCGGGGTGGTCGTGGGCAGCGGAGGCGGGCGAGGAGCCGGGGGCAGCCGGCAGGGCGGG
CAGCCCGGGGCGCAAAGGATGTACAAGCAGTCAATGGCGCAGAGAGCGCGGACCATGGCA
CTCTACAACCCCATCCCCGTCCGACAGAACTGCCTCACGGTTAACCGGTCTCTCTTCCTC
TTCAGCGAAGACAACGTGGTGAGAAAATACGCCAAAAAGATCACCGAATGGCCTCCCTTT
GAATATATGATTTTAGCCACCATCATAGCGAATTGCATCGTCCTCGCACTGGAGCAGCAT
CTGCCTGATGATGACAAGACCCCGATGTCTGAACGGCTGGATGACACAGAACCATACTTC
ATTGGAATTTTTTGTTTCGAGGCTGGAATTAAAATCATTGCCCTTGGGTTTGCCTTCCAC
AAAGGCTCCTACTTGAGGAATGGCTGGAATGTCATGGACTTTGTGGTGGTGCTAACGGGC
ATCTTGGCGACAGTTGGGACGGAGTTTGACCTACGGACGCTGAGGGCAGTTCGAGTGCTG
CGGCCGCTCAAGCTGGTGTCTGGAATCCCAAGTTTACAAGTCGTCCTGAAGTCGATCATG
AAGGCGATGATCCCTTTGCTGCAGATCGGCCTCCTCCTATTTTTTGCAATCCTTATTTTT
GCAATCATAGGGTTAGAATTTTATATGGGAAAATTTCATACCACCTGCTTTGAAGAGGGG
ACAGATGACATTCAGGGTGAGTCTCCGGCTCCATGTGGGACAGAAGAGCCCGCCCGCACC
TGCCCCAATGGGACCAAATGTCAGCCCTACTGGGAAGGGCCCAACAACGGGATCACTCAG
TTCGACAACATCCTGTTTGCAGTGCTGACTGTTTTCCAGTGCATAACCATGGAAGGGTGG
ACTGATCTCCTCTACAATAGCAACGATGCCTCAGGGAACACTTGGAACTGGTTGTACTTC
ATCCCCCTCATCATCATCGGCTCCTTTTTTATGCTGAACCTTGTGCTGGGTGTGCTGTCA
GGGGAGTTTGCCAAAGAAAGGGAACGGGTGGAGAACCGGCGGGCTTTTCTGAAGCTGAGG
CGGCAACAACAGATTGAACGTGAGCTCAATGGGTACATGGAGTGGATCTCAAAAGCAGAA
GAGGTGATCCTCGCCGAGGATGAAACTGACGGGGAGCAGAGGCATCCCTTTGATGGAGCT
CTGCGGAGAACCACCATAAAGAAAAGCAAGACAGATTTGCTCAACCCCGAAGAGGCTGAG
GATCAGCTGGCTGATATAGCCTCTGTGGGTTCTCCCTTCGCCCGAGCCAGCATTAAAAGT
GCCAAGCTGGAGAACTCGACCTTTTTTCACAAAAAGGAGAGGAGGATGCGTTTCTACATC
CGCCGCATGGTCAAAACTCAGGCCTTCTACTGGACTGTACTCAGTTTGGTAGCTCTCAAC
ACGCTGTGTGTTGCTATTGTTCACTACAACCAGCCCGAGTGGCTCTCCGACTTCCTTTAC
TATGCAGAATTCATTTTCTTAGGACTCTTTATGTCCGAAATGTTTATAAAAATGTACGGG
CTTGGGACGCGGCCTTACTTCCACTCTTCCTTCAACTGCTTTGACTGTGGGGTTATCATT
GGGAGCATCTTCGAGGTCATCTGGGCTGTCATAAAACCTGGCACATCCTTTGGAATCAGC
GTGTTACGAGCCCTCAGGTTATTGCGTATTTTCAAAGTCACAAAGTACTGGGCATCTCTC
AGAAACCTGGTCGTCTCTCTCCTCAACTCCATGAAGTCCATCATCAGCCTGTTGTTTCTC
CTTTTCCTGTTCATTGTCGTCTTCGCCCTTTTGGGAATGCAACTCTTCGGCGGCCAGTTT
AATTTCGATGAAGGGACTCCTCCCACCAACTTCGATACTTTTCCAGCAGCAATAATGACG
GTGTTTCAGATCCTGACGGGCGAAGACTGGAACGAGGTCATGTACGACGGGATCAAGTCT
CAGGGGGGCGTGCAGGGCGGCATGGTGTTCTCCATCTATTTCATTGTACTGACGCTCTTT
GGGAACTACACCCTCCTGAATGTGTTCTTGGCCATCGCTGTGGACAATCTGGCCAACGCC
CAGGAGCTCACCAAGGTGGAGGCGGACGAGCAAGAGGAAGAAGAAGCAGCGAACCAGAAA
CTTGCCCTACAGAAAGCCAAGGAGGTGGCAGAAGTGAGTCCTCTGTCCGCGGCCAACATG
TCTATAGCTGTGAAAGAGCAACAGAAGAATCAAAAGCCAGCCAAGTCCGTGTGGGAGCAG
CGGACCAGTGAGATGCGAAAGCAGAACTTGCTGGCCAGCCGGGAGGCCCTGTATAACGAA
ATGGACCCGGACGAGCGCTGGAAGGCTGCCTACACGCGGCACCTGCGGCCAGACATGAAG
ACGCACTTGGACCGGCCGCTGGTGGTGGACCCGCAGGAGAACCGCAACAACAACACCAAC
AAGAGCCGGGCGGCCGAGCCCACCGTGGACCAGCGCCTCGGCCAGCAGCGCGCCGAGGAC
TTCCTCAGGAAACAGGCCCGCTACCACGATCGGGCCCGGGACCCCAGCGGCTCGGCGGGC
CTGGACGCACGGAGGCCCTGGGCGGGAAGCCAGGAGGCCGAGCTGAGCCGGGAGGGACCC
TACGGCCGCGAGTCGGACCACCACGCCCGGGAGGGCAGCCTGGAGCAACCCGGGTTCTGG
GAGGGCGAGGCCGAGCGAGGCAAGGCCGGGGACCCCCACCGGAGGCACGTGCACCGGCAG
GGGGGCAGCAGGGAGAGCCGCAGCGGGTCCCCGCGCACGGGCGCGGACGGGGAGCATCGA
CGTCATCGCGCGCACCGCAGGCCCGGGGAGGAGGGTCCGGAGGACAAGGCGGAGCGGAGG
GCGCGGCACCGCGAGGGCAGCCGGCCGGCCCGGGGCGGCGAGGGCGAGGGCGAGGGCCCC
GACGGGGGCGAGCGCAGGAGAAGGCACCGGCATGGCGCTCCAGCCACGTACGAGGGGGAC
GCGCGGAGGGAGGACAAGGAGCGGAGGCATCGGAGGAGGAAAGAGAACCAGGGCTCCGGG
GTCCCTGTGTCGGGCCCCAACCTGTCAACCACCCGGCCAATCCAGCAGGACCTGGGCCGC
CAAGACCCACCCCTGGCAGAGGATATTGACAACATGAAGAACAACAAGCTGGCCACCGCG
GAGTCGGCCGCTCCCCACGGCAGCCTTGGCCACGCCGGCCTGCCCCAGAGCCCAGCCAAG
ATGGGAAACAGCACCGACCCCGGCCCCATGCTGGCCATCCCTGCCATGGCCACCAACCCC
CAGAACGCCGCCAGCCGCCGGACGCCCAACAACCCGGGGAACCCATCCAATCCCGGCCCC
CCCAAGACCCCCGAGAATAGCCTTATCGTCACCAACCCCAGCGGCACCCAGACCAATTCA
GCTAAGACTGCCAGGAAACCCGACCACACCACAGTGGACATCCCCCCAGCCTGCCCACCC
CCCCTCAACCACACCGTCGTACAAGTGAACAAAAACGCCAACCCAGACCCACTGCCAAAA
AAAGAGGAAGAGAAGAAGGAGGAGGAGGAAGACGACCGTGGGGAAGACGGCCCTAAGCCA
ATGCCTCCCTATAGCTCCATGTTCATCCTGTCCACGACCAACCCCCTTCGCCGCCTGTGC
CATTACATCCTGAACCTGCGCTACTTTGAGATGTGCATCCTCATGGTCATTGCCATGAGC
AGCATCGCCCTGGCCGCCGAGGACCCTGTGCAGCCCAACGCACCTCGGAACAACGTGCTG
CGATACTTTGACTACGTTTTTACAGGCGTCTTTACCTTTGAGATGGTGATCAAGATGATT
GACCTGGGGCTCGTCCTGCATCAGGGTGCCTACTTCCGTGACCTCTGGAATATTCTCGAC
TTCATAGTGGTCAGTGGGGCCCTGGTAGCCTTTGCCTTCACTGGCAATAGCAAAGGAAAA
GACATCAACACGATTAAATCCCTCCGAGTCCTCCGGGTGCTACGACCTCTTAAAACCATC
AAGCGGCTGCCAAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACTCACTTAAAAACGTC
TTCAACATCCTCATCGTCTACATGCTATTCATGTTCATCTTCGCCGTGGTGGCTGTGCAG
CTCTTCAAGGGGAAATTCTTCCACTGCACTGACGAGTCCAAAGAGTTTGAGAAAGATTGT
CGAGGCAAATACCTCCTCTACGAGAAGAATGAGGTGAAGGCGCGAGACCGGGAGTGGAAG
AAGTATGAATTCCATTACGACAATGTGCTGTGGGCTCTGCTGACCCTCTTCACCGTGTCC
ACGGGAGAAGGCTGGCCACAGGTCCTCAAGCATTCGGTGGACGCCACCTTTGAGAACCAG
GGCCCCAGCCCCGGGTACCGCATGGAGATGTCCATTTTCTACGTCGTCTACTTTGTGGTG
TTCCCCTTCTTCTTTGTCAATATCTTTGTGGCCTTGATCATCATCACCTTCCAGGAGCAA
GGGGACAAGATGATGGAGGAATACAGCCTGGAGAAAAATGAGAGGGCCTGCATTGATTTC
GCCATCAGCGCCAAGCCGCTGACCCGACACATGCCGCAGAACAAGCAGAGCTTCCAGTAC
CGCATGTGGCAGTTCGTGGTGTCTCCGCCTTTCGAGTACACGATCATGGCCATGATCGCC
CTCAACACCATCGTGCTTATGATGAAGTTCTATGGGGCTTCTGTTGCTTATGAAAATGCC
CTGCGGGTGTTCAACATCGTCTTCACCTCCCTCTTCTCTCTGGAATGTGTGCTGAAAGTC
ATGGCTTTTGGGATTCTGAATTATTTCCGCGATGCCTGGAACATCTTCGACTTTGTGACT
GTTCTGGGCAGCATCACCGATATCCTCGTGACTGAGTTTGGGAATCCGAATAACTTCATC
AACCTGAGCTTTCTCCGCCTCTTCCGAGCTGCCCGGCTCATCAAACTTCTCCGTCAGGGT
TACACCATCCGCATTCTTCTCTGGACCTTTGTGCAGTCCTTCAAGGCCCTGCCTTATGTC
TGTCTGCTGATCGCCATGCTCTTCTTCATCTATGCCATCATTGGGATGCAGGTGTTTGGT
AACATTGGCATCGACGTGGAGGACGAGGACAGTGATGAAGATGAGTTCCAAATCACTGAG
CACAATAACTTCCGGACCTTCTTCCAGGCCCTCATGCTTCTCTTCCGGAGTGCCACCGGG
GAAGCTTGGCACAACATCATGCTTTCCTGCCTCAGCGGGAAACCGTGTGATAAGAACTCT
GGCATCCTGACTCGAGAGTGTGGCAATGAATTTGCTTATTTTTACTTTGTTTCCTTCATC
TTCCTCTGCTCGTTTCTGATGCTGAATCTCTTTGTCGCCGTCATCATGGACAACTTTGAG
TACCTCACCCGAGACTCCTCCATCCTGGGCCCCCACCACCTGGATGAGTACGTGCGTGTC
TGGGCCGAGTATGACCCCGCAGCTTGGGGCCGCATGCCTTACCTGGACATGTATCAGATG
CTGAGACACATGTCTCCGCCCCTGGGTCTGGGGAAGAAGTGTCCGGCCAGAGTGGCTTAC
AAGCGGCTTCTGCGGATGGACCTGCCCGTCGCAGATGACAACACCGTCCACTTCAATTCC
ACCCTCATGGCTCTGATCCGCACAGCCCTGGACATCAAGATTGCCAAGGGAGGAGCCGAC
AAACAGCAGATGGACGCTGAGCTGCGGAAGGAGATGATGGCGATTTGGCCCAATCTGTCC
CAGAAGACGCTAGACCTGCTGGTCACACCTCACAAGTCCACGGACCTCACCGTGGGGAAG
ATCTACGCAGCCATGATGATCATGGAGTACTACCGGCAGAGCAAGGCCAAGAAGCTGCAG
GCCATGCGCGAGGAGCAGGACCGGACACCCCTCATGTTCCAGCGCATGGAGCCCCCGTCC
CCAACGCAGGAAGGGGGACCTGGCCAGAACGCCCTCCCCTCCACCCAGCTGGACCCAGGA
GGAGCCCTGATGGCTCACGAAAGCGGCCTCAAGGAGAGCCCGTCCTGGGTGACCCAGCGT
GCCCAGGAGATGTTCCAGAAGACGGGCACATGGAGTCCGGAACAAGGCCCCCCTACCGAC
ATGCCCAACAGCCAGCCTAACTCTCAGTCCGTGGAGATGCGAGAGATGGGCAGAGATGGC
TACTCCGACAGCGAGCACTACCTCCCCATGGAAGGCCAGGGCCGGGCTGCCTCCATGCCC
CGCCTCCCTGCAGAGAACCAGAGGAGAAGGGGCCGGCCACGTGGGAATAACCTCAGTACC
ATCTCAGACACCAGCCCCATGAAGCGTTCAGCCTCCGTGCTGGGCCCCAAGGCCCGACGC
CTGGACGATTACTCGCTGGAGCGGGTCCCGCCCGAGGAGAACCAGCGGCACCACCAGCGG
CGCCGCGACCGCAGCCACCGCGCCTCTGAGCGCTCCCTGGGCCGCTACACCGATGTGGAC
ACAGGCTTGGGGACAGACCTGAGCATGACCACCCAATCCGGGGACCTGCCGTCGAAGGAG
CGGGACCAGGAGCGGGGCCGGCCCAAGGATCGGAAGCATCGACAGCACCACCACCACCAC
CACCACCACCACCATCCCCCGCCCCCCGACAAGGACCGCTATGCCCAGGAACGGCCGGAC
CACGGCCGGGCACGGGCTCGGGACCAGCGCTGGTCCCGCTCGCCCAGCGAGGGCCGAGAG
CACATGGCGCACCGGCAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF08763</identifier>
            <name>Ca_chan_IQ</name>
          </pfam>
          <pfam>
            <identifier>PF16905</identifier>
            <name>GPHH</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>syntaxin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult walking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion-dependent exocytosis of neurotransmitter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular chloride ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebellar molecular layer development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebellar Purkinje cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebellum maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dendrite morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>musculoskeletal movement, spinal reflex action</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular process controlling balance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor clustering</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of acetylcholine secretion, neurotransmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhythmic synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spinal cord motor neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sulfur amino acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vestibular nucleus development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q15878" source="Swiss-Prot">
        <name>Voltage-dependent R-type calcium channel subunit alpha-1E</name>
        <general-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1E gives rise to R-type calcium currents. R-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by nickel, and partially by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), omega-conotoxin-GVIA (omega-CTx-GVIA), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1E subunit could be involved in the modulation of firing patterns of neurons which is important for information processing.</general-function>
        <specific-function>Calcium channel activity</specific-function>
        <gene-name>CACNA1E</gene-name>
        <locus>1q25.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>90-108
128-146
159-173
186-205
224-244
327-350
477-496
510-529
539-557
568-586
606-625
679-703
1149-1165
1190-1209
1218-1240
1255-1272
1292-1311
1399-1422
1480-1498
1514-1533
1542-1560
1572-1590
1610-1629
1699-1724</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>261729.05</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1392</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>534</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q15878</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1E_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>BII</synonym>
          <synonym>Brain calcium channel II</synonym>
          <synonym>CACH6</synonym>
          <synonym>CACNL1A6</synonym>
          <synonym>Calcium channel, L type, alpha-1 polypeptide, isoform 6</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav2.3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008863|Voltage-dependent R-type calcium channel subunit alpha-1E
MARFGEAVVARPGSGDGDSDQSRNRQGTPVPASGQAAAYKQTKAQRARTMALYNPIPVRQ
NCFTVNRSLFIFGEDNIVRKYAKKLIDWPPFEYMILATIIANCIVLALEQHLPEDDKTPM
SRRLEKTEPYFIGIFCFEAGIKIVALGFIFHKGSYLRNGWNVMDFIVVLSGILATAGTHF
NTHVDLRTLRAVRVLRPLKLVSGIPSLQIVLKSIMKAMVPLLQIGLLLFFAILMFAIIGL
EFYSGKLHRACFMNNSGILEGFDPPHPCGVQGCPAGYECKDWIGPNDGITQFDNILFAVL
TVFQCITMEGWTTVLYNTNDALGATWNWLYFIPLIIIGSFFVLNLVLGVLSGEFAKERER
VENRRAFMKLRRQQQIERELNGYRAWIDKAEEVMLAEENKNAGTSALEVLRRATIKRSRT
EAMTRDSSDEHCVDISSVGTPLARASIKSAKVDGVSYFRHKERLLRISIRHMVKSQVFYW
IVLSLVALNTACVAIVHHNQPQWLTHLLYYAEFLFLGLFLLEMSLKMYGMGPRLYFHSSF
NCFDFGVTVGSIFEVVWAIFRPGTSFGISVLRALRLLRIFKITKYWASLRNLVVSLMSSM
KSIISLLFLLFLFIVVFALLGMQLFGGRFNFNDGTPSANFDTFPAAIMTVFQILTGEDWN
EVMYNGIRSQGGVSSGMWSAIYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEQEEE
EAFNQKHALQKAKEVSPMSAPNMPSIERDRRRRHHMSMWEPRSSHLRERRRRHHMSVWEQ
RTSQLRKHMQMSSQEALNREEAPTMNPLNPLNPLSSLNPLNAHPSLYRRPRAIEGLALGL
ALEKFEEERISRGGSLKGDGGDRSSALDNQRTPLSLGQREPPWLARPCHGNCDPTQQEAG
GGEAVVTFEDRARHRQSQRRSRHRRVRTEGKESSSASRSRSASQERSLDEAMPTEGEKDH
ELRGNHGAKEPTIQEERAQDLRRTNSLMVSRGSGLAGGLDEADTPLVLPHPELEVGKHVV
LTEQEPEGSSEQALLGNVQLDMGRVISQSEPDLSCITANTDKATTESTSVTVAIPDVDPL
VDSTVVHISNKTDGEASPLKEAEIREDEEEVEKKKQKKEKRETGKAMVPHSSMFIFSTTN
PIRRACHYIVNLRYFEMCILLVIAASSIALAAEDPVLTNSERNKVLRYFDYVFTGVFTFE
MVIKMIDQGLILQDGSYFRDLWNILDFVVVVGALVAFALANALGTNKGRDIKTIKSLRVL
RVLRPLKTIKRLPKLKAVFDCVVTSLKNVFNILIVYKLFMFIFAVIAVQLFKGKFFYCTD
SSKDTEKECIGNYVDHEKNKMEVKGREWKRHEFHYDNIIWALLTLFTVSTGEGWPQVLQH
SVDVTEEDRGPSRSNRMEMSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKMMEECSLE
KNERACIDFAISAKPLTRYMPQNRHTFQYRVWHFVVSPSFEYTIMAMIALNTVVLMMKYY
SAPCTYELALKYLNIAFTMVFSLECVLKVIAFGFLNYFRDTWNIFDFITVIGSITEIILT
DSKLVNTSGFNMSFLKLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFI
YAIIGMQVFGNIKLDEESHINRHNNFRSFFGSLMLLFRSATGEAWQEIMLSCLGEKGCEP
DTTAPSGQNENERCGTDLAYVYFVSFIFFCSFLMLNLFVAVIMDNFEYLTRDSSILGPHH
LDEFVRVWAEYDRAACGRIHYTEMYEMLTLMSPPLGLGKRCPSKVAYKRLVLMNMPVAED
MTVHFTSTLMALIRTALDIKIAKGGADRQQLDSELQKETLAIWPHLSQKMLDLLVPMPKA
SDLTVGKIYAAMMIMDYYKQSKVKKQRQQLEEQKNAPMFQRMEPSSLPQEIIANAKALPY
LQQDPVSGLSGRSGYPSMSPLSPQDIFQLACMDPADDGQFQERQSLEPEVSELKSVQPSN
HGIYLPSDTQEHAGSGRASSMPRLTVDPQVVTDPSSMRRSFSTIRDKRSNSSWLEEFSME
RSSENTYKSRRRSYHSSLRLSAHRLNSDSGHKSDTHRSGGRERGRSKERKHLLSPDVSRC
NSEERGTQADWESPERRQSRSPSEGRSQTPNRQGTGSLSESSIPSVSDTSTPRRSRRQLP
PVPPKPRPLLSYSSLIRHAGSISPPADGSEEGSPLTSQALESNNACLTESSNSPHPQQSQ
HASPQRYISEPYLALHEDSHASDCGEEETLTFEAAVATSLGRSNTIGSAPPLRHSWQMPN
GHYRRRRRGGPGPGMMCGAVNNLLSDTEEDDKC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051557|Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E)
ATGGCTCGCTTCGGGGAGGCGGTGGTCGCCAGGCCAGGGTCCGGCGATGGAGACTCGGAC
CAGAGCAGGAACCGGCAAGGAACCCCCGTGCCGGCCTCGGGGCAGGCGGCCGCCTACAAG
CAGACGAAAGCACAGAGGGCGCGGACTATGGCTTTGTACAACCCCATTCCCGTCCGGCAG
AACTGTTTCACCGTCAACAGATCCCTGTTCATCTTCGGAGAAGATAACATTGTCAGGAAA
TATGCCAAGAAGCTCATCGATTGGCCGCCATTTGAGTACATGATCCTGGCCACCATCATT
GCCAACTGCATCGTCCTGGCCCTGGAGCAGCATCTTCCTGAGGATGACAAGACCCCCATG
TCCCGAAGACTGGAGAAGACAGAACCTTATTTCATTGGGATCTTTTGCTTTGAAGCTGGG
ATCAAAATTGTGGCCCTGGGGTTCATCTTCCATAAGGGCTCTTACCTCCGCAATGGCTGG
AATGTCATGGACTTCATCGTGGTCCTCAGTGGCATCCTGGCCACTGCAGGAACCCACTTC
AATACTCACGTGGACCTGAGGACCCTCCGGGCTGTGCGTGTCCTGCGGCCTTTGAAGCTC
GTGTCAGGGATACCTAGCCTGCAGATTGTGTTGAAGTCCATCATGAAGGCCATGGTACCT
CTTCTGCAGATTGGCCTTCTGCTCTTCTTTGCCATCCTGATGTTTGCTATCATTGGTTTG
GAGTTCTACAGTGGCAAGTTACATCGAGCATGCTTCATGAACAATTCAGGTATTCTAGAA
GGATTTGACCCCCCTCACCCATGTGGTGTGCAGGGCTGCCCAGCTGGTTATGAATGCAAG
GACTGGATCGGCCCCAATGATGGGATCACCCAGTTTGATAACATCCTTTTTGCTGTGCTG
ACTGTCTTCCAGTGCATCACCATGGAAGGGTGGACCACTGTGCTGTACAATACCAATGAT
GCCTTAGGAGCCACCTGGAATTGGCTGTACTTCATCCCCCTCATCATCATTGGATCCTTC
TTTGTTCTCAACCTAGTCCTGGGAGTGCTTTCCGGGGAATTTGCCAAAGAGAGAGAGAGA
GTGGAGAACCGAAGGGCTTTCATGAAGCTGCGGCGCCAGCAGCAGATTGAGCGTGAGCTG
AATGGCTACCGTGCCTGGATAGACAAAGCAGAGGAAGTCATGCTCGCTGAAGAAAATAAA
AATGCTGGAACATCCGCCTTAGAAGTGCTTCGAAGGGCAACCATCAAGAGGAGCCGGACA
GAGGCCATGACTCGAGACTCCAGTGATGAGCACTGTGTTGATATCTCCTCTGTGGGCACA
CCTCTGGCCCGAGCCAGTATCAAAAGTGCAAAGGTAGACGGGGTCTCTTATTTCCGGCAC
AAGGAAAGGCTTCTGCGCATCTCCATTCGCCACATGGTTAAATCCCAGGTGTTTTACTGG
ATTGTGCTGAGCCTTGTGGCACTCAACACTGCCTGTGTGGCCATTGTCCATCACAACCAG
CCCCAGTGGCTCACCCACCTCCTCTACTATGCAGAATTTCTGTTTCTGGGACTCTTCCTC
TTGGAGATGTCCCTGAAGATGTATGGCATGGGGCCTCGCCTTTATTTTCACTCTTCATTC
AACTGCTTTGATTTTGGGGTCACAGTGGGCAGTATCTTTGAAGTGGTCTGGGCAATCTTC
AGACCTGGTACGTCTTTTGGAATCAGTGTCTTGCGAGCCCTCCGGCTTCTAAGAATATTT
AAAATAACCAAGTATTGGGCTTCCCTACGGAATTTGGTGGTCTCCTTGATGAGCTCAATG
AAGTCTATCATCAGTTTGCTTTTCCTCCTCTTCCTCTTCATCGTTGTCTTTGCTCTCCTA
GGAATGCAGTTATTTGGAGGCAGGTTTAACTTTAATGATGGGACTCCTTCGGCAAATTTT
GATACCTTCCCTGCAGCCATCATGACTGTGTTCCAGATCCTGACGGGTGAGGACTGGAAT
GAGGTGATGTACAATGGGATCCGCTCCCAGGGTGGGGTCAGCTCAGGCATGTGGTCTGCC
ATCTACTTCATTGTGCTCACCTTGTTTGGCAACTACACGCTACTGAATGTGTTCTTGGCT
ATCGCTGTGGATAATCTCGCCAACGCCCAGGAACTGACCAAGGATGAACAGGAGGAAGAA
GAGGCCTTCAACCAGAAACATGCACTGCAGAAGGCCAAGGAGGTCAGCCCGATGTCTGCA
CCCAACATGCCTTCGATCGAAAGAGACAGAAGGAGAAGACACCACATGTCGATGTGGGAG
CCACGCAGCAGCCACCTGAGGGAGCGGAGGCGCCGGCACCACATGTCCGTGTGGGAGCAG
CGTACCAGCCAGCTGAGGAAGCACATGCAGATGTCCAGCCAGGAGGCCCTCAACAGAGAG
GAGGCGCCGACCATGAACCCGCTCAACCCCCTCAACCCGCTCAGCTCCCTCAACCCGCTC
AATGCCCACCCCAGCCTTTATCGGCGACCCAGGGCCATTGAGGGCCTGGCCCTGGGCCTG
GCCCTGGAGAAGTTCGAGGAGGAGCGCATCAGCCGTGGGGGGTCCCTCAAGGGGGATGGA
GGGGACCGATCCAGTGCCCTGGACAACCAGAGGACCCCTTTGTCCCTGGGCCAGCGGGAG
CCACCATGGCTGGCCAGGCCCTGTCATGGAAACTGTGACCCGACTCAGCAGGAGGCAGGG
GGAGGAGAGGCTGTGGTGACCTTTGAGGACCGGGCCAGGCACAGGCAGAGCCAACGGCGC
AGCCGGCATCGCCGCGTCAGGACAGAAGGCAAGGAGTCCTCTTCAGCCTCCCGGAGCAGG
TCTGCCAGCCAGGAACGCAGTCTGGATGAAGCCATGCCCACTGAAGGGGAGAAGGACCAT
GAGCTCAGGGGCAACCATGGTGCCAAGGAGCCAACGATCCAAGAAGAGAGAGCCCAGGAT
TTAAGGAGGACCAACAGTCTGATGGTGTCCAGAGGCTCCGGGCTGGCAGGAGGCCTTGAT
GAGGCTGACACCCCCCTAGTCCTGCCCCATCCTGAGCTGGAAGTGGGGAAGCACGTGGTG
CTGACGGAGCAGGAGCCAGAAGGCAGCAGTGAGCAGGCCCTGCTGGGGAATGTGCAGCTA
GACATGGGCCGGGTCATCAGCCAGAGCGAGCCTGACCTCTCCTGCATCACGGCCAACACG
GACAAGGCCACCACCGAGAGCACCAGCGTCACCGTCGCCATCCCCGACGTGGACCCCTTG
GTGGACTCAACCGTGGTGCACATTAGCAACAAGACGGATGGGGAAGCCAGTCCCTTGAAG
GAGGCAGAGATCAGAGAGGATGAGGAGGAGGTGGAGAAGAAGAAGCAGAAGAAGGAGAAG
CGTGAGACAGGCAAAGCCATGGTGCCCCACAGCTCAATGTTCATCTTCAGCACCACCAAC
CCGATCCGGAGGGCCTGCCACTACATCGTGAACCTGCGCTACTTTGAGATGTGCATCCTC
CTGGTGATTGCAGCCAGCAGCATCGCCCTGGCGGCAGAGGACCCCGTCCTGACCAACTCG
GAGCGCAACAAAGTCCTGAGGTATTTTGACTATGTGTTCACGGGCGTGTTCACCTTTGAG
ATGGTTATAAAGATGATAGACCAAGGCTTGATCCTGCAGGATGGGTCCTACTTCCGAGAC
TTGTGGAACATCCTGGACTTTGTGGTGGTCGTTGGCGCATTGGTGGCCTTTGCTCTGGCG
AACGCTTTGGGAACCAACAAAGGACGGGACATCAAGACCATCAAGTCTCTGCGGGTGCTC
CGAGTTCTAAGGCCACTGAAAACCATCAAGCGCTTGCCCAAGCTCAAGGCCGTCTTCGAC
TGCGTAGTGACCTCCTTGAAGAATGTCTTCAACATACTCATTGTGTACAAGCTCTTCATG
TTCATCTTTGCTGTCATCGCAGTTCAGCTCTTCAAGGGAAAGTTCTTTTATTGCACGGAC
AGTTCCAAGGACACAGAGAAGGAGTGCATAGGCAACTATGTAGATCATGAGAAAAACAAG
ATGGAGGTGAAGGGCCGGGAATGGAAGCGCCATGAATTCCACTACGACAACATTATCTGG
GCCCTGCTGACCCTCTTCACCGTCTCCACAGGGGAAGGATGGCCTCAAGTTCTGCAGCAC
TCTGTAGATGTGACAGAGGAAGACCGAGGCCCAAGCCGCAGCAACCGCATGGAGATGTCT
ATCTTTTATGTAGTCTACTTTGTGGTCTTCCCCTTCTTCTTTGTCAATATCTTTGTGGCT
CTCATCATCATCACCTTCCAGGAGCAAGGGGATAAGATGATGGAGGAGTGCAGCCTGGAG
AAGAATGAGAGGGCGTGCATCGACTTCGCCATCAGCGCCAAACCTCTCACCCGCTACATG
CCGCAGAACAGACACACCTTCCAGTACCGCGTGTGGCACTTTGTGGTGTCTCCGTCCTTT
GAGTACACCATTATGGCCATGATCGCCTTGAATACTGTTGTGCTGATGATGAAGTATTAT
TCTGCTCCCTGTACCTATGAGCTGGCCCTGAAGTACCTGAATATCGCCTTCACCATGGTG
TTTTCCCTGGAATGTGTCCTGAAGGTCATCGCTTTTGGCTTTTTGAACTATTTCCGAGAC
ACCTGGAATATCTTTGACTTCATCACCGTGATTGGCAGTATCACAGAAATTATCCTGACA
GACAGCAAGCTGGTGAACACCAGTGGCTTCAATATGAGCTTTCTGAAGCTCTTCCGAGCT
GCCCGCCTCATAAAGCTCCTGCGTCAGGGCTATACCATACGCATTTTGCTGTGGACCTTT
GTGCAGTCCTTTAAGGCCCTCCCTTATGTCTGCCTTTTAATTGCCATGCTTTTCTTCATT
TATGCCATCATTGGGATGCAGGTATTTGGAAACATAAAATTAGACGAGGAGAGTCACATC
AACCGGCACAACAACTTCCGGAGTTTCTTTGGGTCCCTAATGCTACTCTTCAGGAGTGCC
ACAGGTGAGGCCTGGCAGGAGATTATGCTGTCATGCCTTGGGGAGAAGGGCTGTGAGCCT
GACACCACCGCACCATCAGGGCAGAACGAGAACGAACGCTGCGGCACCGATCTGGCCTAC
GTGTACTTTGTCTCCTTCATCTTCTTCTGCTCCTTCTTGATGCTCAACCTGTTTGTGGCC
GTCATCATGGACAACTTTGAGTACCTGACTCGGGACTCCTCCATCCTGGGGCCTCACCAC
TTGGACGAGTTTGTCCGCGTCTGGGCAGAATATGACCGAGCAGCATGTGGCCGCATCCAT
TACACTGAGATGTATGAAATGCTGACTCTCATGTCACCTCCGCTAGGCCTCGGCAAGAGA
TGTCCCTCCAAAGTGGCATATAAGAGGTTGGTCCTGATGAACATGCCAGTAGCTGAGGAC
ATGACGGTCCACTTCACCTCCACACTTATGGCTCTGATCCGGACAGCTCTGGACATTAAA
ATTGCCAAAGGTGGTGCAGACAGGCAGCAGCTAGACTCAGAGCTACAAAAGGAGACCCTA
GCCATCTGGCCTCACCTATCCCAGAAGATGCTGGATCTGCTTGTGCCCATGCCCAAAGCC
TCTGACCTGACTGTGGGCAAAATCTATGCAGCAATGATGATCATGGACTACTATAAGCAG
AGTAAGGTGAAGAAGCAGAGGCAGCAGCTGGAGGAACAGAAAAATGCCCCCATGTTCCAG
CGCATGGAGCCTTCATCTCTGCCTCAGGAGATCATTGCTAATGCCAAAGCCCTGCCTTAC
CTCCAGCAGGACCCCGTTTCAGGCCTGAGTGGCCGGAGTGGATACCCTTCGATGAGTCCA
CTCTCTCCCCAGGATATATTCCAGTTGGCTTGTATGGACCCCGCCGATGACGGACAGTTC
CAAGAACGGCAGTCTCTGGAGCCAGAGGTTAGTGAATTAAAAAGCGTGCAGCCCTCTAAC
CATGGCATCTACCTTCCTTCGGACACCCAGGAGCATGCGGGATCTGGGAGGGCATCTTCT
ATGCCACGTCTGACTGTGGATCCCCAGGTGGTGACAGACCCTAGCTCCATGAGACGTTCA
TTTTCCACTATTCGGGATAAGCGTTCAAATTCCTCGTGGTTGGAGGAATTCTCCATGGAG
CGAAGCAGTGAAAATACCTACAAGTCCCGTCGCCGGAGTTACCACTCCTCCTTGCGGCTG
TCAGCCCACCGCCTGAACTCTGATTCAGGCCACAAGTCTGACACTCACCGCTCAGGGGGC
AGGGAGCGGGGACGATCAAAAGAGCGAAAGCATCTTCTCTCTCCTGATGTCTCCCGCTGC
AATTCAGAAGAGCGAGGGACCCAGGCTGACTGGGAGTCCCCAGAGCGCCGTCAATCCAGG
TCACCCAGTGAGGGCAGGTCACAGACGCCCAACAGACAGGGCACAGGTTCCCTAAGTGAG
AGCTCCATCCCCTCTGTCTCTGACACCAGCACCCCAAGAAGAAGTCGTCGGCAGCTCCCA
CCCGTCCCGCCAAAGCCCCGGCCCCTCCTTTCCTACAGCTCCCTGATTCGACACGCGGGC
AGCATCTCTCCACCTGCTGATGGAAGCGAGGAGGGCTCCCCGCTGACCTCCCAAGCTCTG
GAGAGCAACAATGCTTGCCTGACCGAGTCTTCCAACTCTCCGCACCCCCAGCAGAGCCAA
CATGCCTCCCCACAGCGCTACATCTCCGAGCCCTACTTGGCCCTGCACGAAGACTCCCAC
GCCTCAGACTGTGGTGAGGAGGAGACGCTCACTTTCGAAGCAGCCGTGGCTACTAGCCTG
GGCCGTTCCAACACCATCGGCTCAGCCCCACCCCTGCGGCATAGCTGGCAGATGCCCAAC
GGGCACTATCGGCGGCGGAGGCGCGGGGGGCCTGGGCCAGGCATGATGTGTGGGGCTGTC
AACAACCTGCTAAGTGACACGGAAGAAGATGACAAATGCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF08763</identifier>
            <name>Ca_chan_IQ</name>
          </pfam>
          <pfam>
            <identifier>PF16905</identifier>
            <name>GPHH</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chemical synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O43497" source="Swiss-Prot">
        <name>Voltage-dependent T-type calcium channel subunit alpha-1G</name>
        <general-function>Scaffold protein binding</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channel is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.</specific-function>
        <gene-name>CACNA1G</gene-name>
        <locus>17q22</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>81-101
120-141
151-170
176-193
214-234
371-395
744-764
778-799
806-824
833-856
868-888
940-964
1273-1295
1314-1334
1345-1364
1379-1400
1411-1434
1512-1537
1611-1631
1646-1667
1675-1693
1708-1731
1746-1766
1827-1854</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.57</theoretical-pi>
        <molecular-weight>262468.62</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1394</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1G</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF134986</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>6625659</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>535</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>535</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O43497</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1G_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Cav3.1c</synonym>
          <synonym>KIAA1123</synonym>
          <synonym>NBR13</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav3.1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000964|Voltage-dependent T-type calcium channel subunit alpha-1G
MDEEEDGAGAEESGQPRSFMRLNDLSGAGGRPGPGSAEKDPGSADSEAEGLPYPALAPVV
FFYLSQDSRPRSWCLRTVCNPWFERISMLVILLNCVTLGMFRPCEDIACDSQRCRILQAF
DDFIFAFFAVEMVVKMVALGIFGKKCYLGDTWNRLDFFIVIAGMLEYSLDLQNVSFSAVR
TVRVLRPLRAINRVPSMRILVTLLLDTLPMLGNVLLLCFFVFFIFGIVGVQLWAGLLRNR
CFLPENFSLPLSVDLERYYQTENEDESPFICSQPRENGMRSCRSVPTLRGDGGGGPPCGL
DYEAYNSSSNTTCVNWNQYYTNCSAGEHNPFKGAINFDNIGYAWIAIFQVITLEGWVDIM
YFVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQRESQLMREQRVRFLSNA
STLASFSEPGSCYEELLKYLVYILRKAARRLAQVSRAAGVRVGLLSSPAPLGGQETQPSS
SCSRSHRRLSVHHLVHHHHHHHHHYHLGNGTLRAPRASPEIQDRDANGSRRLMLPPPSTP
ALSGAPPGGAESVHSFYHADCHLEPVRCQAPPPRSPSEASGRTVGSGKVYPTVHTSPPPE
TLKEKALVEVAASSGPPTLTSLNIPPGPYSSMHKLLETQSTGACQSSCKISSPCLKADSG
ACGPDSCPYCARAGAGEVELADREMPDSDSEAVYEFTQDAQHSDLRDPHSRRQRSLGPDA
EPSSVLAFWRLICDTFRKIVDSKYFGRGIMIAILVNTLSMGIEYHEQPEELTNALEISNI
VFTSLFALEMLLKLLVYGPFGYIKNPYNIFDGVIVVISVWEIVGQQGGGLSVLRTFRLMR
VLKLVRFLPALQRQLVVLMKTMDNVATFCMLLMLFIFIFSILGMHLFGCKFASERDGDTL
PDRKNFDSLLWAIVTVFQILTQEDWNKVLYNGMASTSSWAALYFIALMTFGNYVLFNLLV
AILVEGFQAEEISKREDASGQLSCIQLPVDSQGGDANKSESEPDFFSPSLDGDGDRKKCL
ALVSLGEHPELRKSLLPPLIIHTAATPMSLPKSTSTGLGEALGPASRRTSSSGSAEPGAA
HEMKSPPSARSSPHSPWSAASSWTSRRSSRNSLGRAPSLKRRSPSGERRSLLSGEGQESQ
DEEESSEEERASPAGSDHRHRGSLEREAKSSFDLPDTLQVPGLHRTASGRGSASEHQDCN
GKSASGRLARALRPDDPPLDGDDADDEGNLSKGERVRAWIRARLPACCLERDSWSAYIFP
PQSRFRLLCHRIITHKMFDHVVLVIIFLNCITIAMERPKIDPHSAERIFLTLSNYIFTAV
FLAEMTVKVVALGWCFGEQAYLRSSWNVLDGLLVLISVIDILVSMVSDSGTKILGMLRVL
RLLRTLRPLRVISRAQGLKLVVETLMSSLKPIGNIVVICCAFFIIFGILGVQLFKGKFFV
CQGEDTRNITNKSDCAEASYRWVRHKYNFDNLGQALMSLFVLASKDGWVDIMYDGLDAVG
VDQQPIMNHNPWMLLYFISFLLIVAFFVLNMFVGVVVENFHKCRQHQEEEEARRREEKRL
RRLEKKRRNLMLDDVIASGSSASAASEAQCKPYYSDYSRFRLLVHHLCTSHYLDLFITGV
IGLNVVTMAMEHYQQPQILDEALKICNYIFTVIFVLESVFKLVAFGFRRFFQDRWNQLDL
AIVLLSIMGITLEEIEVNASLPINPTIIRIMRVLRIARVLKLLKMAVGMRALLDTVMQAL
PQVGNLGLLFMLLFFIFAALGVELFGDLECDETHPCEGLGRHATFRNFGMAFLTLFRVST
GDNWNGIMKDTLRDCDQESTCYNTVISPIYFVSFVLTAQFVLVNVVIAVLMKHLEESNKE
AKEEAELEAELELEMKTLSPQPHSPLGSPFLWPGVEGPDSPDSPKPGALHPAAHARSASH
FSLEHPTDRQLFDTISLLIQGSLEWELKLMDELAGPGGQPSAFPSAPSLGGSDPQIPLAE
MEALSLTSEIVSEPSCSLALTDDSLPDDMHTLLLSALESNMQPHPTELPGPDLLTVRKSG
VSRTHSLPNDSYMCRHGSTAEGPLGHRGWGLPKAQSGSVLSVHSQPADTSYILQLPKDAP
HLLQPHSAPTWGTIPKLPPPGRSPLAQRPLRRQAAIRTDSLDVQGLGSREDLLAEVSGPS
PPLARAYSFWGQSSTQAQQHSRSHSKISKHMTPPAPCPGPEPNWGKGPPETRSSLELDTE
LSWISGDLLPPGGQEEPPSPRDLKKCYSVEAQSCQRRPTSWLDEQRRHSIAVSCLDSGSQ
PHLGTDPSNLGGQPLGGPGSRPKKKLSPPSITIDPPESQGPRTPPSPGICLRRRAPSSDS
KDPLASGPPDSMAASPSPKKDVLSLSGLSSDPADLDP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021643|Voltage-dependent T-type calcium channel subunit alpha-1G (CACNA1G)
ATGGACGAGGAGGAGGATGGAGCGGGCGCCGAGGAGTCGGGACAGCCCCGGAGCTTCATG
CGGCTCAACGACCTGTCGGGGGCCGGGGGCCGGCCGGGGCCGGGGTCAGCAGAAAAGGAC
CCGGGCAGCGCGGACTCCGAGGCGGAGGGGCTGCCGTACCCGGCGCTGGCCCCGGTGGTT
TTCTTCTACTTGAGCCAGGACAGCCGCCCGCGGAGCTGGTGTCTCCGCACGGTCTGTAAC
CCCTGGTTTGAGCGCATCAGCATGTTGGTCATCCTTCTCAACTGCGTGACCCTGGGCATG
TTCCGGCCATGCGAGGACATCGCCTGTGACTCCCAGCGCTGCCGGATCCTGCAGGCCTTT
GATGACTTCATCTTTGCCTTCTTTGCCGTGGAGATGGTGGTGAAGATGGTGGCCTTGGGC
ATCTTTGGGAAAAAGTGTTACCTGGGAGACACTTGGAACCGGCTTGACTTTTTCATCGTC
ATCGCAGGGATGCTGGAGTACTCGCTGGACCTGCAGAACGTCAGCTTCTCAGCTGTCAGG
ACAGTCCGTGTGCTGCGACCGCTCAGGGCCATTAACCGGGTGCCCAGCATGCGCATCCTT
GTCACGTTGCTGCTGGATACGCTGCCCATGCTGGGCAACGTCCTGCTGCTCTGCTTCTTC
GTCTTCTTCATCTTCGGCATCGTCGGCGTCCAGCTGTGGGCAGGGCTGCTTCGGAACCGA
TGCTTCCTACCTGAGAATTTCAGCCTCCCCCTGAGCGTGGACCTGGAGCGCTATTACCAG
ACAGAGAACGAGGATGAGAGCCCCTTCATCTGCTCCCAGCCACGCGAGAACGGCATGCGG
TCCTGCAGAAGCGTGCCCACGCTGCGCGGGGACGGGGGCGGTGGCCCACCTTGCGGTCTG
GACTATGAGGCCTACAACAGCTCCAGCAACACCACCTGTGTCAACTGGAACCAGTACTAC
ACCAACTGCTCAGCGGGGGAGCACAACCCCTTCAAGGGCGCCATCAACTTTGACAACATT
GGCTATGCCTGGATCGCCATCTTCCAGGTCATCACGCTGGAGGGCTGGGTCGACATCATG
TACTTTGTGATGGATGCTCATTCCTTCTACAATTTCATCTACTTCATCCTCCTCATCATC
GTGGGCTCCTTCTTCATGATCAACCTGTGCCTGGTGGTGATTGCCACGCAGTTCTCAGAG
ACCAAGCAGCGGGAAAGCCAGCTGATGCGGGAGCAGCGTGTGCGGTTCCTGTCCAACGCC
AGCACCCTGGCTAGCTTCTCTGAGCCCGGCAGCTGCTATGAGGAGCTGCTCAAGTACCTG
GTGTACATCCTTCGTAAGGCAGCCCGCAGGCTGGCTCAGGTCTCTCGGGCAGCAGGTGTG
CGGGTTGGGCTGCTCAGCAGCCCAGCACCCCTCGGGGGCCAGGAGACCCAGCCCAGCAGC
AGCTGCTCTCGCTCCCACCGCCGCCTATCCGTCCACCACCTGGTGCACCACCACCACCAC
CATCACCACCACTACCACCTGGGCAATGGGACGCTCAGGGCCCCCCGGGCCAGCCCGGAG
ATCCAGGACAGGGATGCCAATGGGTCCCGCCGGCTCATGCTGCCACCACCCTCGACGCCT
GCCCTCTCCGGGGCCCCCCCTGGTGGCGCAGAGTCTGTGCACAGCTTCTACCATGCCGAC
TGCCACTTAGAGCCAGTCCGCTGCCAGGCGCCCCCTCCCAGGTCCCCATCTGAGGCATCC
GGCAGGACTGTGGGCAGCGGGAAGGTGTATCCCACCGTGCACACCAGCCCTCCACCGGAG
ACGCTGAAGGAGAAGGCACTAGTAGAGGTGGCTGCCAGCTCTGGGCCCCCAACCCTCACC
AGCCTCAACATCCCACCCGGGCCCTACAGCTCCATGCACAAGCTGCTGGAGACACAGAGT
ACAGGTGCCTGCCAAAGCTCTTGCAAGATCTCCAGCCCTTGCTTGAAAGCAGACAGTGGA
GCCTGTGGTCCAGACAGCTGCCCCTACTGTGCCCGGGCCGGGGCAGGGGAGGTGGAGCTC
GCCGACCGTGAAATGCCTGACTCAGACAGCGAGGCAGTTTATGAGTTCACACAGGATGCC
CAGCACAGCGACCTCCGGGACCCCCACAGCCGGCGGCAACGGAGCCTGGGCCCAGATGCA
GAGCCCAGCTCTGTGCTGGCCTTCTGGAGGCTAATCTGTGACACCTTCCGAAAGATTGTG
GACAGCAAGTACTTTGGCCGGGGAATCATGATCGCCATCCTGGTCAACACACTCAGCATG
GGCATCGAATACCACGAGCAGCCCGAGGAGCTTACCAACGCCCTAGAAATCAGCAACATC
GTCTTCACCAGCCTCTTTGCCCTGGAGATGCTGCTGAAGCTGCTTGTGTATGGTCCCTTT
GGCTACATCAAGAATCCCTACAACATCTTCGATGGTGTCATTGTGGTCATCAGCGTGTGG
GAGATCGTGGGCCAGCAGGGGGGCGGCCTGTCGGTGCTGCGGACCTTCCGCCTGATGCGT
GTGCTGAAGCTGGTGCGCTTCCTGCCGGCGCTGCAGCGGCAGCTGGTGGTGCTCATGAAG
ACCATGGACAACGTGGCCACCTTCTGCATGCTGCTTATGCTCTTCATCTTCATCTTCAGC
ATCCTGGGCATGCATCTCTTCGGCTGCAAGTTTGCCTCTGAGCGGGATGGGGACACCCTG
CCAGACCGGAAGAATTTTGACTCCTTGCTCTGGGCCATCGTCACTGTCTTTCAGATCCTG
ACCCAGGAGGACTGGAACAAAGTCCTCTACAATGGTATGGCCTCCACGTCGTCCTGGGCG
GCCCTTTATTTCATTGCCCTCATGACCTTCGGCAACTACGTGCTCTTCAATTTGCTGGTC
GCCATTCTGGTGGAGGGCTTCCAGGCGGAGGAAATCAGCAAACGGGAAGATGCGAGTGGA
CAGTTAAGCTGTATTCAGCTGCCTGTCGACTCCCAGGGGGGAGATGCCAACAAGTCCGAA
TCAGAGCCCGATTTCTTCTCACCCAGCCTGGATGGTGATGGGGACAGGAAGAAGTGCTTG
GCCTTGGTGTCCCTGGGAGAGCACCCGGAGCTGCGGAAGAGCCTGCTGCCGCCTCTCATC
ATCCACACGGCCGCCACACCCATGTCGCTGCCCAAGAGCACCAGCACGGGCCTGGGCGAG
GCGCTGGGCCCTGCGTCGCGCCGCACCAGCAGCAGCGGGTCGGCAGAGCCTGGGGCGGCC
CACGAGATGAAGTCACCGCCCAGCGCCCGCAGCTCTCCGCACAGCCCCTGGAGCGCTGCA
AGCAGCTGGACCAGCAGGCGCTCCAGCCGGAACAGCCTCGGCCGTGCACCCAGCCTGAAG
CGGAGAAGCCCAAGTGGAGAGCGGCGGTCCCTGTTGTCGGGAGAAGGCCAGGAGAGCCAG
GATGAAGAGGAGAGCTCAGAAGAGGAGCGGGCCAGCCCTGCGGGCAGTGACCATCGCCAC
AGGGGGTCCCTGGAGCGGGAGGCCAAGAGTTCCTTTGACCTGCCAGACACACTGCAGGTG
CCAGGGCTGCATCGCACTGCCAGTGGCCGAGGGTCTGCTTCTGAGCACCAGGACTGCAAT
GGCAAGTCGGCTTCAGGGCGCCTGGCCCGGGCCCTGCGGCCTGATGACCCCCCACTGGAT
GGGGATGACGCCGATGACGAGGGCAACCTGAGCAAAGGGGAACGGGTCCGCGCGTGGATC
CGAGCCCGACTCCCTGCCTGCTGCCTCGAGCGAGACTCCTGGTCAGCCTACATCTTCCCT
CCTCAGTCCAGGTTCCGCCTCCTGTGTCACCGGATCATCACCCACAAGATGTTCGACCAC
GTGGTCCTTGTCATCATCTTCCTTAACTGCATCACCATCGCCATGGAGCGCCCCAAAATT
GACCCCCACAGCGCTGAACGCATCTTCCTGACCCTCTCCAATTACATCTTCACCGCAGTC
TTTCTGGCTGAAATGACAGTGAAGGTGGTGGCACTGGGCTGGTGCTTCGGGGAGCAGGCG
TACCTGCGGAGCAGTTGGAACGTGCTGGACGGGCTGTTGGTGCTCATCTCCGTCATCGAC
ATTCTGGTGTCCATGGTCTCTGACAGCGGCACCAAGATCCTGGGCATGCTGAGGGTGCTG
CGGCTGCTGCGGACCCTGCGCCCGCTCAGGGTGATCAGCCGGGCGCAGGGGCTGAAGCTG
GTGGTGGAGACGCTGATGTCCTCACTGAAACCCATCGGCAACATTGTAGTCATCTGCTGT
GCCTTCTTCATCATTTTCGGCATCTTGGGGGTGCAGCTCTTCAAAGGGAAGTTTTTCGTG
TGCCAGGGCGAGGATACCAGGAACATCACCAATAAATCGGACTGTGCCGAGGCCAGTTAC
CGGTGGGTCCGGCACAAGTACAACTTTGACAACCTTGGCCAGGCCCTGATGTCCCTGTTC
GTTTTGGCCTCCAAGGATGGTTGGGTGGACATCATGTACGATGGGCTGGATGCTGTGGGC
GTGGACCAGCAGCCCATCATGAACCACAACCCCTGGATGCTGCTGTACTTCATCTCGTTC
CTGCTCATTGTGGCCTTCTTTGTCCTGAACATGTTTGTGGGTGTGGTGGTGGAGAACTTC
CACAAGTGTCGGCAGCACCAGGAGGAAGAGGAGGCCCGGCGGCGGGAGGAGAAGCGCCTA
CGAAGACTGGAGAAAAAGAGAAGGAAAGCCCAGTGCAAACCTTACTACTCCGACTACTCC
CGCTTCCGGCTCCTCGTCCACCACTTGTGCACCAGCCACTACCTGGACCTCTTCATCACA
GGTGTCATCGGGCTGAACGTGGTCACCATGGCCATGGAGCACTACCAGCAGCCCCAGATT
CTGGATGAGGCTCTGAAGATCTGCAACTACATCTTCACTGTCATCTTTGTCTTGGAGTCA
GTTTTCAAACTTGTGGCCTTTGGTTTCCGTCGGTTCTTCCAGGACAGGTGGAACCAGCTG
GACCTGGCCATTGTGCTGCTGTCCATCATGGGCATCACGCTGGAGGAAATCGAGGTCAAC
GCCTCGCTGCCCATCAACCCCACCATCATCCGCATCATGAGGGTGCTGCGCATTGCCCGA
GTGCTGAAGCTGCTGAAGATGGCTGTGGGCATGCGGGCGCTGCTGGACACGGTGATGCAG
GCCCTGCCCCAGGTGGGGAACCTGGGACTTCTCTTCATGTTGTTGTTTTTCATCTTTGCA
GCTCTGGGCGTGGAGCTCTTTGGAGACCTGGAGTGTGACGAGACACACCCCTGTGAGGGC
CTGGGCCGTCATGCCACCTTTCGGAACTTTGGCATGGCCTTCCTAACCCTCTTCCGAGTC
TCCACAGGTGACAATTGGAATGGCATTATGAAGGACACCCTCCGGGACTGTGACCAGGAG
TCCACCTGCTACAACACGGTCATCTCGCCTATCTACTTTGTGTCCTTCGTGCTGACGGCC
CAGTTCGTGCTAGTCAACGTGGTGATCGCCGTGCTGATGAAGCACCTGGAGGAGAGCAAC
AAGGAGGCCAAGGAGGAGGCCGAGCTAGAGGCTGAGCTGGAGCTGGAGATGAAGACCCTC
AGCCCCCAGCCCCACTCGCCACTGGGCAGCCCCTTCCTCTGGCCTGGGGTCGAGGGCCCC
GACAGCCCCGACAGCCCCAAGCCTGGGGCTCTGCACCCAGCGGCCCACGCGAGATCAGCC
TCCCACTTTTCCCTGGAGCACCCCACGGACAGGCAGCTGTTTGACACCATATCCCTGCTG
ATCCAGGGCTCCCTGGAGTGGGAGCTGAAGCTGATGGACGAGCTGGCAGGCCCAGGGGGC
CAGCCCTCTGCCTTCCCTTCTGCCCCCAGCCTGGGAGGCTCCGACCCACAGATGCAGCCC
CACCCCACGGAGCTGCCAGGACCAGACTTACTGACTGTGCGGAAGTCTGGGGTCAGCCGA
ACGCACTCTCTGCCCAATGACAGCTACATGTGTCGGCATGGGAGCACTGCCGAGGGGCCC
CTGGGACACAGGGGCTGGGGGCTCCCCAAAGCTCAGTCAGGCTCCGTCTTGTCCGTTCAC
TCCCAGCCAGCAGATACCAGCTACATCCTGCAGCTTCCCAAAGATGCACCTCATCTGCTC
CAGCCCCACAGCGCCCCAACCTGGGGCACCATCCCCAAACTGCCCCCACCAGGACGCTCC
CCTTTGGCTCAGAGGCCACTCAGGCGCCAGGCAGCAATAAGGACTGACTCCTTGGACGTT
CAGGGTCTGGGCAGCCGGGAAGACCTGCTGGCAGAGGTGAGTGGGCCCTCCCCGCCCCTG
GCCCGGGCCTACTCTTTCTGGGGCCAGTCAAGTACCCAGGCACAGCAGCACTCCCGCAGC
CACAGCAAGATCTCCAAGCACATGACCCCGCCAGCCCCTTGCCCAGGCCCAGAACCCAAC
TGGGGCAAGGGCCCTCCAGAGACCAGAAGCAGCTTAGAGTTGGACACGGAGCTGAGCTGG
ATTTCAGGAGACCTCCTGCCCCCTGGCGGCCAGGAGGAGCCCCCATCCCCACGGGACCTG
AAGAAGTGCTACAGCGTGGAGGCCCAGAGCTGCCAGCGCCGGCCTACGTCCTGGCTGGAT
GAGCAGAGGAGACACTCTATCGCCGTCAGCTGCCTGGACAGCGGCTCCCAACCCCACCTG
GGCACAGACCCCTCTAACCTTGGGGGCCAGCCTCTTGGGGGGCCTGGGAGCCGGCCCAAG
AAAAAACTCAGCCCGCCTAGTATCACCATAGACCCCCCCGAGAGCCAAGGTCCTCGGACC
CCGCCCAGCCCTGGTATCTGCCTCCGGAGGAGGGCTCCGTCCAGCGACTCCAAGGATCCC
TTGGCCTCTGGCCCCCCTGACAGCATGGCTGCCTCGCCCTCCCCAAAGAAAGATGTGCTG
AGTCTCTCCGGTTTATCCTCTGACCCAGCAGACCTGGACCCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>low voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of atrial cardiac muscle cell membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nickel cation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O95180" source="Swiss-Prot">
        <name>Voltage-dependent T-type calcium channel subunit alpha-1H</name>
        <general-function>Scaffold protein binding</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.</specific-function>
        <gene-name>CACNA1H</gene-name>
        <locus>16p13.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>101-119
142-160
170-184
194-212
233-253
395-419
794-814
828-849
856-874
883-906
918-938
991-1015
1291-1313
1332-1352
1363-1382
1397-1418
1429-1452
1530-1555
1617-1637
1652-1673
1681-1699
1714-1737
1752-1772
1836-1863</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.38</theoretical-pi>
        <molecular-weight>259160.2</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1395</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1H</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF051946</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>14670397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>536</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>536</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1H_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Low-voltage-activated calcium channel alpha1 3.2 subunit</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav3.2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001722|Voltage-dependent T-type calcium channel subunit alpha-1H
MTEGARAADEVRVPLGAPPPGPAALVGASPESPGAPGREAERGSELGVSPSESPAAERGA
ELGADEEQRVPYPALAATVFFCLGQTTRPRSWCLRLVCNPWFEHVSMLVIMLNCVTLGMF
RPCEDVECGSERCNILEAFDAFIFAFFAVEMVIKMVALGLFGQKCYLGDTWNRLDFFIVV
AGMMEYSLDGHNVSLSAIRTVRVLRPLRAINRVPSMRILVTLLLDTLPMLGNVLLLCFFV
FFIFGIVGVQLWAGLLRNRCFLDSAFVRNNNLTFLRPYYQTEEGEENPFICSSRRDNGMQ
KCSHIPGRRELRMPCTLGWEAYTQPQAEGVGAARNACINWNQYYNVCRSGDSNPHNGAIN
FDNIGYAWIAIFQVITLEGWVDIMYYVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIAT
QFSETKQRESQLMREQRARHLSNDSTLASFSEPGSCYEELLKYVGHIFRKVKRRSLRLYA
RWQSRWRKKVDPSAVQGQGPGHRQRRAGRHTASVHHLVYHHHHHHHHHYHFSHGSPRRPG
PEPGACDTRLVRAGAPPSPPSPGRGPPDAESVHSIYHADCHIEGPQERARVAHAAATAAA
SLRLATGLGTMNYPTILPSGVGSGKGSTSPGPKGKWAGGPPGTGGHGPLSLNSPDPYEKI
PHVVGEHGLGQAPGHLSGLSVPCPLPSPPAGTLTCELKSCPYCTRALEDPEGELSGSESG
DSDGRGVYEFTQDVRHGDRWDPTRPPRATDTPGPGPGSPQRRAQQRAAPGEPGWMGRLWV
TFSGKLRRIVDSKYFSRGIMMAILVNTLSMGVEYHEQPEELTNALEISNIVFTSMFALEM
LLKLLACGPLGYIRNPYNIFDGIIVVISVWEIVGQADGGLSVLRTFRLLRVLKLVRFLPA
LRRQLVVLVKTMDNVATFCTLLMLFIFIFSILGMHLFGCKFSLKTDTGDTVPDRKNFDSL
LWAIVTVFQILTQEDWNVVLYNGMASTSSWAALYFVALMTFGNYVLFNLLVAILVEGFQA
EGDANRSDTDEDKTSVHFEEDFHKLRELQTTELKMCSLAVTPNGHLEGRGSLSPPLIMCT
AATPMPTPKSSPFLDAAPSLPDSRRGSSSSGDPPLGDQKPPASLRSSPCAPWGPSGAWSS
RRSSWSSLGRAPSLKRRGQCGERESLLSGEGKGSTDDEAEDGRAAPGPRATPLRRAESLD
PRPLRPAALPPTKCRDRDGQVVALPSDFFLRIDSHREDAAELDDDSEDSCCLRLHKVLEP
YKPQWCRSREAWALYLFSPQNRFRVSCQKVITHKMFDHVVLVFIFLNCVTIALERPDIDP
GSTERVFLSVSNYIFTAIFVAEMMVKVVALGLLSGEHAYLQSSWNLLDGLLVLVSLVDIV
VAMASAGGAKILGVLRVLRLLRTLRPLRVISRAPGLKLVVETLISSLRPIGNIVLICCAF
FIIFGILGVQLFKGKFYYCEGPDTRNISTKAQCRAAHYRWVRRKYNFDNLGQALMSLFVL
SSKDGWVNIMYDGLDAVGVDQQPVQNHNPWMLLYFISFLLIVSFFVLNMFVGVVVENFHK
CRQHQEAEEARRREEKRLRRLERRRRSTFPSPEAQRRPYYADYSPTRRSIHSLCTSHYLD
LFITFIICVNVITMSMEHYNQPKSLDEALKYCNYVFTIVFVFEAALKLVAFGFRRFFKDR
WNQLDLAIVLLSLMGITLEEIEMSAALPINPTIIRIMRVLRIARVLKLLKMATGMRALLD
TVVQALPQVGNLGLLFMLLFFIYAALGVELFGRLECSEDNPCEGLSRHATFSNFGMAFLT
LFRVSTGDNWNGIMKDTLRECSREDKHCLSYLPALSPVYFVTFVLVAQFVLVNVVVAVLM
KHLEESNKEAREDAELDAEIELEMAQGPGSARRVDADRPPLPQESPGARDAPNLVARKVS
VSRMLSLPNDSYMFRPVVPASAPHPRPLQEVEMETYGAGTPLGSVASVHSPPAESCASLQ
IPLAVSSPARSGEPLHALSPRGTARSPSLSRLLCRQEAVHTDSLEGKIDSPRDTLDPAEP
GEKTPVRPVTQGGSLQSPPRSPRPASVRTRKHTFGQRCVSSRPAAPGGEEAEASDPADEE
VSHITSSACPWQPTAEPHGPEASPVAGGERDLRRLYSVDAQGFLDKPGRADEQWRPSAEL
GSGEPGEAKAWGPEAEPALGARRKKKMSPPCISVEPPAEDEGSARPSAAEGGSTTLRRRT
PSCEATPHRDSLEPTEGSGAGGDPAAKGERWGQASCRAEHLTVPSFAFEPLDLGVPSGDP
FLDGSHSVTPESRASSSGAIVPLEPPESEPPMPVGDPPEKRRGLYLTVPQCPLEKPGSPS
ATPAPGGGADDPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010610|Voltage-dependent T-type calcium channel subunit alpha-1H (CACNA1H)
ATGACCGAGGGCGCACGGGCCGCCGACGAGGTCCGGGTGCCCCTGGGCGCGCCGCCCCCT
GGCCCTGCGGCGTTGGTGGGGGCGTCCCCGGAGAGCCCCGGGGCGCCGGGACGCGAGGCG
GAGCGGGGGTCCGAGCTCGGCGTGTCACCCTCCGAGAGCCCGGCGGCCGAGCGCGGCGCG
GAGCTGGGTGCCGACGAGGAGCAGCGCGTCCCGTACCCGGCCTTGGCGGCCACGGTCTTC
TTCTGCCTCGGTCAGACCACGCGGCCGCGCAGCTGGTGCCTCCGGCTGGTCTGCAACCCA
TGGTTCGAGCACGTGAGCATGCTGGTAATCATGCTCAACTGCGTGACCCTGGGCATGTTC
CGGCCCTGTGAGGACGTTGAGTGCGGCTCCGAGCGCTGCAACATCCTGGAGGCCTTTGAC
GCCTTCATTTTCGCCTTTTTTGCGGTGGAGATGGTCATCAAGATGGTGGCCTTGGGGCTG
TTCGGGCAGAAGTGTTACCTGGGTGACACGTGGAACAGGCTGGATTTCTTCATCGTCGTG
GCGGGCATGATGGAGTACTCGTTGGACGGACACAACGTGAGCCTCTCGGCTATCAGGACC
GTGCGGGTGCTGCGGCCCCTCCGCGCCATCAACCGCGTGCCTAGCATGCGGATCCTGGTC
ACTCTGCTGCTGGATACGCTGCCCATGCTCGGGAACGTCCTTCTGCTGTGCTTCTTCGTC
TTCTTCATTTTCGGCATCGTTGGCGTCCAGCTCTGGGCTGGCCTCCTGCGGAACCGCTGC
TTCCTGGACAGTGCCTTTGTCAGGAACAACAACCTGACCTTCCTGCGGCCGTACTACCAG
ACGGAGGAGGGCGAGGAGAACCCGTTCATCTGCTCCTCACGCCGAGACAACGGCATGCAG
AAGTGCTCGCACATCCCCGGCCGCCGCGAGCTGCGCATGCCCTGCACCCTGGGCTGGGAG
GCCTACACGCAGCCGCAGGCCGAGGGGGTGGGCGCTGCACGCAACGCCTGCATCAACTGG
AACCAGTACTACAACGTGTGCCGCTCGGGTGACTCCAACCCCCACAACGGTGCCATCAAC
TTCGACAACATCGGCTACGCCTGGATTGCCATCTTCCAGGTGATCACGCTGGAAGGCTGG
GTGGACATCATGTACTACGTCATGGACGCCCACTCATTCTACAACTTCATCTATTTCATC
CTGCTCATCATCGTGGGCTCCTTCTTCATGATCAACCTGTGCCTGGTGGTGATTGCCACG
CAGTTCTCGGAGACGAAGCAGCGGGAGAGTCAGCTGATGCGGGAGCAGCGGGCACGCCAC
CTGTCCAACGACAGCACGCTGGCCAGCTTCTCCGAGCCTGGCAGCTGCTACGAAGAGCTG
CTGAAGTACGTGGGCCACATATTCCGCAAGGTCAAGCGGCGCAGCTTGCGCCTCTACGCC
CGCTGGCAGAGCCGCTGGCGCAAGAAGGTGGACCCCAGTGCTGTGCAAGGCCAGGGTCCC
GGGCACCGCCAGCGCCGGGCAGGCAGGCACACAGCCTCGGTGCACCACCTGGTCTACCAC
CACCATCACCACCACCACCACCACTACCATTTCAGCCATGGCAGCCCCCGCAGGCCCGGC
CCCGAGCCAGGCGCCTGCGACACCAGGCTGGTCCGAGCTGGCGCGCCCCCCTCGCCACCT
TCCCCAGGCCGCGGACCCCCCGACGCAGAGTCTGTGCACAGCATCTACCATGCCGACTGC
CACATAGAGGGGCCGCAGGAGAGGGCCCGGGTGGCACATGCCGCAGCCACTGCCGCTGCC
AGCCTCAGACTGGCCACAGGGCTGGGCACCATGAACTACCCCACGATCCTGCCCTCAGGG
GTGGGCAGCGGCAAAGGCAGCACCAGCCCCGGACCCAAGGGGAAGTGGGCCGGTGGACCG
CCAGGCACCGGGGGGCACGGCCCGTTGAGCTTGAACAGCCCTGATCCCTACGAGAAGATC
CCGCATGTGGTCGGGGAGCATGGACTGGGCCAGGCCCCTGGCCATCTGTCGGGCCTCAGT
GTGCCCTGCCCCCTGCCCAGCCCCCCAGCGGGCACACTGACCTGTGAGCTGAAGAGCTGC
CCGTACTGCACCCGTGCCCTGGAGGACCCGGAGGGTGAGCTCAGCGGCTCGGAAAGTGGA
GACTCAGATGGCCGTGGCGTCTATGAATTCACGCAGGACGTCCGGCACGGTGACCGCTGG
GACCCCACGCGACCACCCCGTGCGACGGACACACCAGGCCCAGGCCCAGGCAGCCCCCAG
CGGCGGGCACAGCAGAGGGCAGCCCCGGGCGAGCCAGGCTGGATGGGCCGCCTCTGGGTT
ACCTTCAGCGGCAAGCTGCGCCGCATCGTGGACAGCAAGTACTTCAGCCGTGGCATCATG
ATGGCCATCCTTGTCAACACGCTGAGCATGGGCGTGGAGTACCATGAGCAGCCCGAGGAG
CTGACTAATGCTCTGGAGATCAGCAACATCGTGTTCACCAGCATGTTTGCCCTGGAGATG
CTGCTGAAGCTGCTGGCCTGCGGCCCTCTGGGCTACATCCGGAACCCGTACAACATCTTC
GACGGCATCATCGTGGTCATCAGCGTCTGGGAGATCGTGGGGCAGGCGGACGGTGGCTTG
TCTGTGCTGCGCACCTTCCGGCTGCTGCGTGTGCTGAAGCTGGTGCGCTTTCTGCCAGCC
CTGCGGCGCCAGCTCGTGGTGCTGGTGAAGACCATGGACAACGTGGCTACCTTCTGCACG
CTGCTCATGCTCTTCATTTTCATCTTCAGCATCCTGGGCATGCACCTTTTCGGCTGCAAG
TTCAGCCTGAAGACAGACACCGGAGACACCGTGCCTGACAGGAAGAACTTCGACTCCCTG
CTGTGGGCCATCGTCACCGTGTTCCAGATCCTGACCCAGGAGGACTGGAACGTGGTCCTG
TACAACGGCATGGCCTCCACCTCCTCCTGGGCCGCCCTCTACTTCGTGGCCCTCATGACC
TTCGGCAACTATGTGCTCTTCAACCTGCTGGTGGCCATCCTCGTGGAGGGCTTCCAGGCG
GAGGGCGATGCCAACAGATCCGACACGGACGAGGACAAGACGTCGGTCCACTTCGAGGAG
GACTTCCACAAGCTCAGAGAACTCCAGACCACAGAGCTGAAGATGTGTTCCCTGGCCGTG
ACCCCCAACGGGCACCTGGAGGGACGAGGCAGCCTGTCCCCTCCCCTCATCATGTGCACA
GCTGCCACGCCCATGCCTACCCCCAAGAGCTCACCATTCCTGGATGCAGCCCCCAGCCTC
CCAGACTCTCGGCGTGGCAGCAGCAGCTCCGGGGACCCGCCACTGGGAGACCAGAAGCCT
CCGGCCAGCCTCCGAAGTTCTCCCTGTGCCCCCTGGGGCCCCAGTGGCGCCTGGAGCAGC
CGGCGCTCCAGCTGGAGCAGCCTGGGCCGTGCCCCCAGCCTCAAGCGCCGCGGCCAGTGT
GGGGAACGTGAGTCCCTGCTGTCTGGCGAGGGCAAGGGCAGCACCGACGACGAAGCTGAG
GACGGCAGGGCCGCGCCCGGGCCCCGTGCCACCCCACTGCGGCGGGCCGAGTCCCTGGAC
CCACGGCCCCTGCGGCCGGCCGCCCTCCCGCCTACCAAGTGCCGCGATCGCGACGGGCAG
GTGGTGGCCCTGCCCAGCGACTTCTTCCTGCGCATCGACAGCCACCGTGAGGATGCAGCC
GAGCTTGACGACGACTCGGAGGACAGCTGCTGCCTCCGCCTGCATAAAGTGCTGGAGCCC
TACAAGCCCCAGTGGTGCCGGAGCCGCGAGGCCTGGGCCCTCTACCTCTTCTCCCCACAG
AACCGGTTCCGCGTCTCCTGCCAGAAGGTCATCACACACAAGATGTTTGATCACGTGGTC
CTCGTCTTCATCTTCCTCAACTGCGTCACCATCGCCCTGGAGAGGCCTGACATTGATCCC
GGCAGCACCGAGCGGGTCTTCCTCAGCGTCTCCAATTACATCTTCACGGCCATCTTCGTG
GCGGAGATGATGGTGAAGGTGGTGGCCCTGGGGCTGCTGTCCGGCGAGCACGCCTACCTG
CAGAGCAGCTGGAACCTGCTGGATGGGCTGCTGGTGCTGGTGTCCCTGGTGGACATTGTC
GTGGCCATGGCCTCGGCTGGTGGCGCCAAGATCCTGGGTGTTCTGCGCGTGCTGCGTCTG
CTGCGGACCCTGCGGCCTCTGAGGGTCATCAGCCGGGCCCCGGGCCTCAAGCTGGTGGTG
GAGACGCTGATATCATCACTCAGGCCCATTGGGAACATCGTCCTCATCTGCTGCGCCTTC
TTCATCATTTTTGGCATTTTGGGTGTGCAGCTCTTCAAAGGGAAGTTCTACTACTGCGAG
GGCCCCGACACCAGGAACATCTCCACCAAGGCACAGTGCCGGGCCGCCCACTACCGCTGG
GTGCGACGCAAGTACAACTTCGACAACCTGGGCCAGGCCCTGATGTCGCTGTTCGTGCTG
TCATCCAAGGATGGATGGGTGAACATCATGTACGACGGGCTGGATGCCGTGGGTGTCGAC
CAGCAGCCTGTGCAGAACCACAACCCCTGGATGCTGCTGTACTTCATCTCCTTCCTGCTC
ATCGTCAGCTTCTTCGTGCTCAACATGTTCGTGGGCGTCGTGGTCGAGAACTTCCACAAG
TGCCGGCAGCACCAGGAGGCGGAGGAGGCGCGGCGGCGAGAGGAGAAGCGGCTGCGGCGC
CTAGAGAGGAGGCGCAGGAAGGCCCAGCGCCGGCCCTACTATGCCGACTACTCGCCCACG
CGCCGCTCCATTCACTCGCTGTGCACCAGCCACTATCTCGACCTCTTCATCACCTTCATC
ATCTGTGTCAACGTCATCACCATGTCCATGGAGCACTATAACCAACCCAAGTCGCTGGAC
GAGGCCCTCAAGTACTGCAACTACGTCTTCACCATCGTGTTTGTCTTCGAGGCTGCACTG
AAGCTGGTAGCATTTGGGTTCCGTCGGTTCTTCAAGGACAGGTGGAACCAGCTGGACCTG
GCCATCGTGCTGCTGTCACTCATGGGCATCACGCTGGAGGAGATAGAGATGAGCGCCGCG
CTGCCCATCAACCCCACCATCATCCGCATCATGCGCGTGCTTCGCATTGCCCGTGTGCTG
AAGCTGCTGAAGATGGCTACGGGCATGCGCGCCCTGCTGGACACTGTGGTGCAAGCTCTC
CCCCAGGTGGGGAACCTGGGCCTTCTTTTCATGCTCCTGTTTTTTATCTATGCTGCGCTG
GGAGTGGAGCTGTTCGGGAGGCTGGAGTGCAGTGAAGACAACCCCTGCGAGGGCCTGAGC
AGGCACGCCACCTTCAGCAACTTCGGCATGGCCTTCCTCACGCTGTTCCGCGTGTCCACG
GGGGACAACTGGAACGGGATCATGAAGGACACGCTGCGCGAGTGCTCCCGTGAGGACAAG
CACTGCCTGAGCTACCTGCCGGCCCTGTCGCCCGTCTACTTCGTGACCTTCGTGCTGGTG
GCCCAGTTCGTGCTGGTGAACGTGGTGGTGGCCGTGCTCATGAAGCACCTGGAGGAGAGC
AACAAGGAGGCACGGGAGGATGCGGAGCTGGACGCCGAGATCGAGCTGGAGATGGCGCAG
GGCCCCGGGAGTGCACGCCGGGTGGACGCGGACAGGCCTCCCTTGCCCCAGGAGAGTCCG
GGCGCCAGGGACGCCCCAAACCTGGTTGCACGCAAGGTGTCCGTGTCCAGGATGCTCTCG
CTGCCCAACGACAGCTACATGTTCAGGCCCGTGGTGCCTGCCTCGGCGCCCCACCCCCGC
CCGCTGCAGGAGGTGGAGATGGAGACCTATGGGGCCGGCACCCCCTTGGGCTCCGTTGCC
TCTGTGCACTCTCCGCCCGCAGAGTCCTGTGCCTCCCTCCAGATCCCATTGGCTGTGTCG
TCCCCAGCCAGGAGCGGCGAGCCCCTCCACGCCCTGTCCCCTCGGGGCACAGCCCGCTCC
CCCAGTCTCAGCCGGCTGCTCTGCAGACAGGAGGCTGTGCACACCGATTCCTTGGAAGGG
AAGATTGACAGCCCTAGGGACACCCTGGATCCTGCAGAGCCTGGTGAGAAAACCCCGGTG
AGGCCGGTGACCCAGGGGGGCTCCCTGCAGTCCCCACCACGCTCCCCACGGCCCGCCAGC
GTCCGCACTCGTAAGCATACCTTCGGACAGCGCTGCGTCTCCAGCCGGCCGGCGGCCCCA
GGCGGAGAGGAGGCCGAGGCCTCGGACCCAGCCGACGAGGAGGTCAGCCACATCACCAGC
TCCGCCTGCCCCTGGCAGCCCACAGCCGAGCCCCATGGCCCCGAAGCCTCTCCGGTGGCC
GGCGGCGAGCGGGACCTGCGCAGGCTCTACAGCGTGGATGCTCAGGGCTTCCTGGACAAG
CCGGGCCGGGCAGACGAGCAGTGGCGGCCCTCGGCGGAGCTGGGCAGCGGGGAGCCTGGG
GAGGCGAAGGCCTGGGGCCCTGAGGCCGAGCCCGCTCTGGGTGCGCGCAGAAAGAAGAAG
ATGAGCCCCCCCTGCATCTCGGTGGAACCCCCTGCGGAGGACGAGGGCTCTGCGCGGCCC
TCCGCGGCAGAGGGCGGCAGCACCACACTGAGGCGCAGGACCCCGTCCTGTGAGGCCACG
CCTCACAGGGACTCCCTGGAGCCCACAGAGGGCTCAGGCGCCGGGGGGGACCCTGCAGCC
AAGGGGGAGCGCTGGGGCCAGGCCTCCTGCCGGGCTGAGCACCTGACCGTCCCCAGCTTT
GCCTTTGAGCCGCTGGACCTCGGGGTCCCCAGTGGAGACCCTTTCTTGGACGGTAGCCAC
AGTGTGACCCCAGAATCCAGAGCTTCCTCTTCAGGGGCCATAGTGCCCCTGGAACCCCCA
GAATCAGAGCCTCCCATGCCCGTCGGTGACCCCCCAGAGAAGAGGCGGGGGCTGTACCTC
ACAGTCCCCCAGTGTCCTCTGGAGAAACCAGGGTCCCCCTCAGCCACCCCTGCCCCAGGG
GGTGGTGCAGATGACCCCGTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>low voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aldosterone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to potassium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cortisol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle organ development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myoblast fusion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of acrosome reaction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9P0X4" source="Swiss-Prot">
        <name>Voltage-dependent T-type calcium channel subunit alpha-1I</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Gates in voltage ranges similar to, but higher than alpha 1G or alpha 1H (By similarity).</specific-function>
        <gene-name>CACNA1I</gene-name>
        <locus>22q13.1</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>79-99
121-141
149-168
174-191
212-232
378-398
641-661
677-697
703-721
730-753
765-785
842-862
1167-1187
1210-1230
1245-1265
1273-1294
1305-1325
1411-1431
1486-1506
1523-1543
1557-1577
1584-1607
1622-1642
1710-1730</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.52</theoretical-pi>
        <molecular-weight>245100.8</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1396</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CACNA1I</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF129133</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5565888</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>537</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>537</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9P0X4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAC1I_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Ca(v)3.3</synonym>
          <synonym>KIAA1120</synonym>
          <synonym>Voltage-gated calcium channel subunit alpha Cav3.3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000024|Voltage-dependent T-type calcium channel subunit alpha-1I
MAESASPPSSSAAAPAAEPGVTTEQPGPRSPPSSPPGLEEPLDGADPHVPHPDLAPIAFF
CLRQTTSPRNWCIKMVCNPWFECVSMLVILLNCVTLGMYQPCDDMDCLSDRCKILQVFDD
FIFIFFAMEMVLKMVALGIFGKKCYLGDTWNRLDFFIVMAGMVEYSLDLQNINLSAIRTV
RVLRPLKAINRVPSMRILVNLLLDTLPMLGNVLLLCFFVFFIFGIIGVQLWAGLLRNRCF
LEENFTIQGDVALPPYYQPEEDDEMPFICSLSGDNGIMGCHEIPPLKEQGRECCLSKDDV
YDFGAGRQDLNASGLCVNWNRYYNVCRTGSANPHKGAINFDNIGYAWIVIFQVITLEGWV
EIMYYVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQREHRLMLEQRQRYL
SSSTVASYAEPGDCYEEIFQYVCHILRKAKRRALGLYQALQSRRQALGPEAPAPAKPGPH
AKEPRHYHGKTKGQGDEGRHLGSRHCQTLHGPASPGNDHSGRELCPQHSPLDATPHTLVQ
PIPATLASDPASCPCCQHEDGRRPSGLGSTDSGQEGSGSGSSAGGEDEADGDGARSSEDG
ASSELGKEEEEEEQADGAVWLCGDVWRETRAKLRGIVDSKYFNRGIMMAILVNTVSMGIE
HHEQPEELTNILEICNVVFTSMFALEMILKLAAFGLFDYLRNPYNIFDSIIVIISIWEIV
GQADGGLSVLRTFRLLRVLKLVRFMPALRRQLVVLMKTMDNVATFCMLLMLFIFIFSILG
MHIFGCKFSLRTDTGDTVPDRKNFDSLLWAIVTVFQILTQEDWNVVLYNGMASTSPWASL
YFVALMTFGNYVLFNLLVAILVEGFQAEGDANRSYSDEDQSSSNIEEFDKLQEGLDSSGD
PKLCPIPMTPNGHLDPSLPLGGHLGPAGAAGPAPRLSLQPDPMLVALGSRKSSVMSLGRM
SYDQRSLSSSRSSYYGPWGRSAAWASRRSSWNSLKHKPPSAEHESLLSAERGGGARVCEV
AADEGPPRAAPLHTPHAHHIHHGPHLAHRHRHHRRTLSLDNRDSVDLAELVPAVGAHPRA
AWRAAGPAPGHEDCNGRMPSIAKDVFTKMGDRGDRGEDEEEIDYTLCFRVRKMIDVYKPD
WCEVREDWSVYLFSPENRFRVLCQTIIAHKLFDYVVLAFIFLNCITIALERPQIEAGSTE
RIFLTVSNYIFTAIFVGEMTLKVVSLGLYFGEQAYLRSSWNVLDGFLVFVSIIDIVVSLA
SAGGAKILGVLRVLRLLRTLRPLRVISRAPGLKLVVETLISSLKPIGNIVLICCAFFIIF
GILGVQLFKGKFYHCLGVDTRNITNRSDCMAANYRWVHHKYNFDNLGQALMSLFVLASKD
GWVNIMYNGLDAVAVDQQPVTNHNPWMLLYFISFLLIVSFFVLNMFVGVVVENFHKCRQH
QEAEEARRREEKRLRRLEKKRRKAQRLPYYATYCHTRLLIHSMCTSHYLDIFITFIICLN
VVTMSLEHYNQPTSLETALKYCNYMFTTVFVLEAVLKLVAFGLRRFFKDRWNQLDLAIVL
LSVMGITLEEIEINAALPINPTIIRIMRVLRIARVLKLLKMATGMRALLDTVVQALPQVG
NLGLLFMLLFFIYAALGVELFGKLVCNDENPCEGMSRHATFENFGMAFLTLFQVSTGDNW
NGIMKDTLRDCTHDERSCLSSLQFVSPLYFVSFVLTAQFVLINVVVAVLMKHLDDSNKEA
QEDAEMDAELELEMAHGLGPGPRLPTGSPGAPGRGPGGAGGGGDTEGGLCRRCYSPAQEN
LWLDSVSLIIKDSLEGELTIIDNLSGSIFHHYSSPAGCKKCHHDKQEVQLAETEAFSLNS
DRSSSILLGDDLSLEDPTACPPGRKDSKGELDPPEPMRVGDLGECFFPLSSTAVSPDPEN
FLCEMEEIPFNPVRSWLKHDSSQAPPSPFSPDASSPLLPMPAEFFHPAVSASQKGPEKGT
GTGTLPKIALQGSWASLRSPRVNCTLLRQATGSDTSLDASPSSSAGSLQTTLEDSLTLSD
SPRRALGPPAPAPGPRAGLSPAARRRLSLRGRGLFSLRGLRAHQRSHSSGGSTSPGCTHH
DSMDPSDEEGRGGAGGGGAGSEHSETLSSLSLTSLFCPPPPPPAPGLTPARKFSSTSSLA
APGRPHAAALAHGLARSPSWAADRSKDPPGRAPLPMGLGPLAPPPQPLPGELEPGDAASK
RKR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0015995|Voltage-dependent T-type calcium channel subunit alpha-1I (CACNA1I)
ATGGCTGAGAGCGCCTCCCCGCCCTCCTCATCTGCAGCAGCCCCAGCCGCTGAGCCAGGA
GTCACCACGGAGCAGCCCGGACCCCGGAGCCCCCCATCCTCCCCGCCAGGCCTGGAGGAG
CCTCTGGATGGAGCTGATCCTCATGTCCCACACCCAGACCTGGCGCCTATTGCCTTCTTC
TGCCTGCGACAGACCACCAGCCCCCGGAACTGGTGCATCAAGATGGTGTGCAACCCGTGG
TTTGAATGTGTCAGCATGCTGGTGATCCTGCTGAACTGCGTGACACTTGGCATGTACCAG
CCGTGCGACGACATGGACTGCCTGTCCGACCGCTGCAAGATCCTGCAGGTCTTTGATGAC
TTCATCTTTATCTTCTTTGCCATGGAGATGGTGCTCAAGATGGTGGCCCTGGGGATTTTT
GGCAAGAAGTGCTACCTCGGGGACACATGGAACCGCCTGGATTTCTTCATCGTCATGGCA
GGGATGGTCGAGTACTCCCTGGACCTTCAGAACATCAACCTGTCAGCCATCCGCACCGTG
CGCGTCCTGAGGCCCCTCAAAGCCATCAACCGCGTGCCCAGTATGCGGATCCTGGTGAAC
CTGCTCCTGGACACACTGCCCATGCTGGGGAATGTCCTGCTGCTCTGCTTCTTTGTCTTC
TTCATCTTTGGCATCATAGGTGTGCAGCTCTGGGCGGGCCTGCTGCGTAACCGCTGCTTC
CTGGAGGAGAACTTCACCATACAAGGGGATGTGGCCTTGCCCCCATACTACCAGCCGGAG
GAGGATGATGAGATGCCCTTCATCTGCTCCCTGTCGGGCGACAATGGGATAATGGGCTGC
CATGAGATCCCCCCGCTCAAGGAGCAGGGCCGTGAGTGCTGCCTGTCCAAGGACGACGTC
TACGACTTTGGGGCGGGGCGCCAGGACCTCAATGCCAGCGGCCTCTGTGTCAACTGGAAC
CGTTACTACAATGTGTGCCGCACGGGCAGCGCCAACCCCCACAAGGGTGCCATCAACTTT
GACAACATCGGTTATGCTTGGATTGTCATCTTCCAGGTGATCACTCTGGAAGGCTGGGTG
GAGATCATGTACTACGTGATGGATGCTCACTCCTTCTACAACTTCATCTACTTCATCCTG
CTTATCATAGTGGGCTCCTTCTTCATGATCAACCTGTGCCTCGTTGTCATAGCGACCCAG
TTCTCGGAGACCAAGCAACGGGAGCACCGGCTGATGCTGGAGCAGCGGCAGCGCTACCTG
TCCTCCAGCACGGTGGCCAGCTACGCCGAGCCTGGCGACTGCTACGAGGAGATCTTCCAG
TATGTCTGCCACATCCTGCGCAAGGCCAAGCGCCGCGCCCTGGGCCTCTACCAGGCCCTG
CAGAGCCGGCGCCAGGCCCTGGGCCCGGAGGCCCCGGCCCCCGCCAAACCTGGGCCCCAC
GCCAAGGAGCCCCGGCACTACCAGCTGTGCCCGCAACATAGCCCCCTGGATGCGACGCCC
CACACCCTGGTGCAGCCCATCCCCGCCACGCTGGCTTCCGATCCCGCCAGCTGCCCTTGC
TGCCAGCATGAGGACGGCCGGCGGCCCTCGGGCCTGGGCAGCACCGACTCGGGCCAGGAG
GGCTCGGGCTCCGGGAGCTCCGCTGGTGGCGAGGACGAGGCGGATGGGGACGGGGCCCGG
AGCAGCGAGGACGGAGCCTCCTCAGAACTGGGGAAGGAGGAGGAGGAGGAGGAGCAGGCG
GATGGGGCGGTCTGGCTGTGCGGGGATGTGTGGCGGGAGACGCGAGCCAAGCTGCGCGGC
ATCGTGGACAGCAAGTACTTCAACCGGGGCATCATGATGGCCATCCTGGTCAACACCGTC
AGCATGGGCATCGAGCACCACGAGCAGCCGGAGGAGCTGACCAACATCCTGGAGATCTGC
AATGTGGTCTTCACCAGCATGTTTGCCCTGGAGATGATCCTGAAGCTGGCTGCATTTGGG
CTCTTCGACTACCTGCGTAACCCCTACAACATCTTCGACAGCATCATTGTCATCATCAGC
ATCTGGGAGATTGTGGGGCAGGCGGACGGTGGGCTGTCGGTGCTGCGGACCTTCCGGCTG
CTGCGCGTGCTGAAACTGGTGCGCTTCATGCCTGCCCTGCGGCGCCAGCTCGTGGTGCTC
ATGAAGACCATGGACAACGTGGCCACCTTCTGCATGCTGCTCATGCTCTTCATCTTCATC
TTCAGCATCCTTGGGATGCATATTTTTGGCTGCAAGTTCAGCCTCCGCACGGACACTGGA
GACACGGTGCCCGACAGGAAGAACTTCGACTCCCTGCTGTGGGCCATCGTCACTGTGTTC
CAGATCCTCACCCAGGAGGACTGGAACGTCGTTCTCTACAATGGCATGGCCTCCACTTCT
CCCTGGGCCTCCCTCTACTTTGTCGCCCTCATGACCTTCGGCAACTATGTGCTCTTCAAC
CTGCTGGTGGCCATCCTGGTGGAGGGCTTCCAGGCGGAGGGTGACGCCAATCGCTCCTAC
TCGGACGAGGACCAGAGCTCATCCAACATAGAAGAGTTTGATAAGCTCCAGGAAGGCCTG
GACAGCAGCGGAGATCCCAAGCTCTGCCCAATCCCCATGACCCCCAATGGGCACCTGGAC
CCCAGTCTCCCACTGGGTGGGCACCTAGGTCCTGCTGGGGCTGCGGGACCTGCCCCCCGA
CTCTCACTGCAGCCGGACCCCATGCTGGTGGCCCTGGGCTCCCGAAAGAGCAGTGTCATG
TCTCTAGGGAGGATGAGCTATGACCAGCGCTCCCTGTCCAGCTCCCGGAGCTCCTACTAC
GGGCCATGGGGCCGCAGCGCGGCCTGGGCCAGCCGTCGCTCCAGCTGGAACAGCCTCAAG
CACAAGCCGCCGTCGGCGGAGCATGAGTCCCTGCTCTCTGCGGAGCGCGGCGGCGGCGCC
CGGGTCTGCGAGGTTGCCGCGGACGAGGGGCCGCCGCGGGCCGCACCCCTGCACACCCCA
CACGCCCACCACATTCATCACGGGCCCCATCTGGCGCACCGCCACCGCCACCACCGCCGG
ACGCTGTCCCTCGACAACAGGGACTCGGTGGACCTGGCCGAGCTGGTGCCCGCGGTGGGC
GCCCACCCCCGGGCCGCCTGGAGGGCGGCAGGCCCGGCCCCCGGGCATGAGGACTGCAAT
GGCAGGATGCCCAGCATCGCCAAAGACGTCTTCACCAAGATGGGCGACCGCGGGGATCGC
GGGGAGGATGAGGAGGAAATCGACTACACCCTGTGCTTCCGCGTCCGCAAGATGATCGAC
GTCTATAAGCCCGACTGGTGCGAGGTCCGCGAAGACTGGTCTGTCTACCTCTTCTCTCCC
GAGAACAGGTTCCGGGTCCTGTGTCAGACCATTATTGCCCACAAACTCTTCGACTACGTC
GTCCTGGCCTTCATCTTTCTCAACTGCATCACCATCGCCCTGGAGCGGCCTCAGATCGAG
GCCGGCAGCACCGAACGCATCTTTCTCACCGTGTCCAACTACATCTTCACGGCCATCTTC
GTGGGCGAGATGACATTGAAGGTAGTCTCGCTGGGCCTGTACTTCGGCGAGCAGGCGTAC
CTACGCAGCAGCTGGAACGTGCTGGATGGCTTTCTTGTCTTCGTGTCCATCATCGACATC
GTGGTGTCCCTGGCCTCAGCCGGGGGAGCCAAGATCTTGGGGGTCCTCCGAGTCTTGCGG
CTCCTGCGCACCCTACGCCCCCTGCGTGTCATCAGCCGGGCGCCGGGCCTGAAGCTGGTG
GTGGAGACACTCATCTCCTCCCTCAAGCCCATCGGCAACATCGTGCTCATCTGCTGTGCC
TTCTTCATCATCTTTGGCATCCTGGGAGTGCAGCTCTTCAAGGGCAAGTTCTACCACTGT
CTGGGCGTGGACACCCGCAACATCACCAACCGCTCGGACTGCATGGCCGCCAACTACCGC
TGGGTCCATCACAAATACAACTTCGACAACCTGGGCCAGGCTCTGATGTCCCTCTTTGTC
CTGGCATCCAAGGATGGTTGGGTGAACATCATGTACAATGGACTGGATGCTGTTGCTGTG
GACCAGCAGCCTGTGACCAACCACAACCCCTGGATGCTGCTGTACTTCATCTCCTTCCTG
CTCATCGTCAGCTTCTTTGTGCTCAACATGTTTGTGGGTGTCGTGGTGGAGAACTTCCAC
AAGTGCCGGCAGCACCAGGAGGCTGAAGAGGCACGGCGGCGTGAGGAGAAGCGGCTGCGG
CGCCTGGAGAAGAAGCGCCGGAAGGCCCAGCGGCTGCCCTACTATGCCACCTATTGTCAC
ACCCGGCTGCTCATCCACTCCATGTGCACCAGCCACTACCTGGACATCTTCATCACCTTC
ATCATCTGCCTCAACGTGGTCACCATGTCCCTGGAGCACTACAATCAGCCCACGTCCCTG
GAGACAGCCCTCAAGTACTGCAACTATATGTTCACCACTGTCTTTGTGCTGGAGGCTGTG
CTGAAGCTGGTGGCATTTGGTCTGAGGCGCTTCTTCAAGGACCGATGGAACCAGCTGGAC
CTGGCCATTGTGCTACTGTCAGTCATGGGCATCACCCTGGAGGAGATCGAGATCAATGCG
GCCCTGCCCATCAATCCCACCATCATCCGCATCATGAGGGTTCTGCGCATTGCCCGAGTG
CTGAAGCTGTTGAAGATGGCCACAGGAATGCGGGCCCTGCTGGACACGGTGGTGCAAGCT
TTGCCCCAGGTGGGCAACCTGGGCCTCCTCTTCATGCTGCTCTTCTTCATCTATGCTGCT
CTCGGGGTGGAGCTCTTTGGGAAGCTGGTCTGCAACGACGAGAACCCGTGCGAGGGCATG
AGCCGGCATGCCACCTTCGAGAACTTCGGCATGGCCTTCCTCACACTCTTCCAGGTCTCC
ACGGGTGACAACTGGAACGGGATCATGAAGGACACGCTGCGGGACTGCACCCACGACGAG
CGCAGCTGCCTGAGCAGCCTGCAGTTTGTGTCGCCGCTGTACTTCGTGAGCTTCGTGCTC
ACCGCGCAGTTCGTGCTCATCAACGTGGTGGTGGCTGTGCTCATGAAGCACCTGGACGAC
AGCAACAAGGAGGCGCAGGAGGACGCCGAGATGGATGCCGAGCTCGAGCTGGAGATGGCC
CATGGCCTGGGCCCTGGCCCGAGGCTGCCTACCGGCTCCCCGGGCGCCCCTGGCCGAGGG
CCGGGAGGGGCGGGCGGCGGGGGCGACACCGAGGGCGGCTTGTGCCGGCGCTGCTACTCG
CCTGCCCAGGAGAACCTGTGGCTGGACAGCGTCTCTTTAATCATCAAGGACTCCTTGGAG
GGGGAGCTGACCATCATCGACAACCTGTCGGGCTCCATCTTCCACCACTACTCCTCGCCT
GCCGGCTGCAAGAAGTGTCACCACGACAAGCAAGAGGTGCAGCTGGCTGAGACGGAGGCC
TTCTCCCTGAACTCAGACAGGTCCTCGTCCATCCTGCTGGGTGACGACCTGAGTCTCGAG
GACCCCACAGCCTGCCCACCTGGCCGCAAAGACAGCAAGGGTGAGCTGGACCCACCTGAG
CCCATGCGTGTGGGAGACCTGGGCGAATGCTTCTTCCCCTTGTCCTCTACGGCCGTCTCG
CCGGATCCAGAGAACTTCCTGTGTGAGATGGAGGAGATCCCATTCAACCCTGTCCGGTCC
TGGCTGAAACATGACAGCAGTCAAGCACCCCCAAGTCCCTTCTCCCCGGATGCCTCCAGC
CCTCTCCTGCCCATGCCAGCCGAGTTCTTCCACCCTGCAGTGTCTGCCAGCCAGAAAGGC
CCAGAAAAGGGCACTGGCACTGGAACCCTCCCCAAGATTGCGCTGCAGGGCTCCTGGGCA
TCTCTGCGGTCACCAAGGGTCAACTGTACCCTCCTCCGGCAGGCCACCGGGAGCGACACG
TCGCTGGACGCCAGCCCCAGCAGCTCCGCGGGCAGCCTGCAGACCACGCTCGAGGACAGC
CTGACCCTGAGCGACAGCCCCCGGCGTGCCCTGGGGCCGCCCGCGCCTGCTCCAGGACCC
CGGGCCGGCCTGTCCCCCGCCGCTCGCCGCCGCCTGAGCCTGCGCGGCCGGGGCCTCTTC
AGCCTGCGGGGGCTGCGGGCGCATCAGCGCAGCCACAGCAGCGGGGGCTCCACCAGCCCG
GGCTGCACCCACCACGACTCCATGGACCCCTCGGACGAGGAGGGCCGCGGTGGCGCGGGC
GGCGGGGGCGCGGGCAGCGAGCACTCGGAGACCCTCAGCAGCCTCTCGCTCACCTCCCTC
TTCTGCCCGCCGCCCCCGCCGCCAGCCCCCGGCCTCACGCCCGCCAGGAAGTTCAGCAGC
ACCAGCAGCCTGGCCGCCCCCGGCCGCCCCCACGCCGCCGCCCTGGCCCACGGCCTGGCC
CGGAGCCCCTCGTGGGCCGCGGACCGCAGCAAGGACCCCCCCGGCCGGGCACCGCTGCCC
ATGGGCCTGGGCCCCTTGGCGCCCCCGCCGCAACCGCTCCCCGGAGAGCTGGAGCCGGGA
GACGCCGCCAGCAAGAGGAAGAGATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>low voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuronal action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="13">
      <id>BE0000956</id>
      <name>Nuclear receptor subfamily 1 group I member 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19965</ref-id>
            <pubmed-id>16054614</pubmed-id>
            <citation>Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75469" source="Swiss-Prot">
        <name>Nuclear receptor subfamily 1 group I member 2</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes.</specific-function>
        <gene-name>NR1I2</gene-name>
        <locus>3q12-q13.3</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.44</theoretical-pi>
        <molecular-weight>49761.245</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7968</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR1I2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF061056</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3511138</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O75469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NR1I2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Orphan nuclear receptor PAR1</synonym>
          <synonym>Orphan nuclear receptor PXR</synonym>
          <synonym>Pregnane X receptor</synonym>
          <synonym>PXR</synonym>
          <synonym>Steroid and xenobiotic receptor</synonym>
          <synonym>SXR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001903|Nuclear receptor subfamily 1 group I member 2
MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATGYHFNVMTCEG
CKGFFRRAMKRNARLRCPFRKGACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEE
RRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDAQMKTFDTTFSHFKNFRLPGVLSS
GCELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLL
PHMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWE
CGRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYVLMQAISLFSPDRPGVLQHR
VVDQLQEQFAITLKSYIECNRPQPAHRFLFLKIMAMLTELRSINAQHTQRLLRIQDIHPF
ATPLMQELFGITGS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010672|Nuclear receptor subfamily 1 group I member 2 (NR1I2)
CTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACA
GAGTCTGTTCCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGTCGGAGGTCCCCAAATC
TGCCGTGTATGTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGA
TGCAAGGGCTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCCCTTCCGG
AAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCTGCCGCCTGCGC
AAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACGAGGCCGTGGAGGAG
AGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACAGGGACTCAGCCACTGGGAGTG
CAGGGGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGATGGACGCTCAGATGAAA
ACCTTTGACACTACCTTCTCCCATTTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGT
GGCTGCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGC
CAGGTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGC
AGTGTCTGGAACTACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTG
CCCCACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTC
ATCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCT
TTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAG
TGTGGCCGGCTGTCCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTG
GAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTAT
GTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCCAGGTGTGCTGCAGCACCGC
GTGGTGGACCAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAAT
CGGCCCCAGCCTGCTCATAGGTTCTTGTTCCTGAAGATCATGGCTATGCTCACCGAGCTC
CGCAGCATCAATGCTCAGCACACCCAGCGGCTGCTGCGCATCCAGGACATACACCCCTTT
GCTACGCCCCTCATGCAGGAGTTGTTCGGCATCACAGGTAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug export</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme>
      <id>BE0002887</id>
      <name>Cytochrome P450 2C8</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15162</ref-id>
            <pubmed-id>15601807</pubmed-id>
            <citation>Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.</citation>
          </article>
          <article>
            <ref-id>A38112</ref-id>
            <pubmed-id>26721703</pubmed-id>
            <citation>Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10632" source="Swiss-Prot">
        <name>Cytochrome P450 2C8</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).</specific-function>
        <gene-name>CYP2C8</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>55824.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1325</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIC8</synonym>
          <synonym>Cytochrome P450 form 1</synonym>
          <synonym>Cytochrome P450 IIC2</synonym>
          <synonym>Cytochrome P450 MP-12</synonym>
          <synonym>Cytochrome P450 MP-20</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>moderate</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0000731</id>
      <name>Cytochrome P450 11B1, mitochondrial</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16886</ref-id>
            <pubmed-id>976190</pubmed-id>
            <citation>Cheng SC, Suzuki K, Sadee W, Harding BW: Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrinology. 1976 Oct;99(4):1097-106.</citation>
          </article>
          <article>
            <ref-id>A14813</ref-id>
            <pubmed-id>11996015</pubmed-id>
            <citation>Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P15538" source="Swiss-Prot">
        <name>Cytochrome P450 11B1, mitochondrial</name>
        <general-function>Steroid 11-beta-monooxygenase activity</general-function>
        <specific-function>Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.</specific-function>
        <gene-name>CYP11B1</gene-name>
        <locus>8q21</locus>
        <cellular-location>Mitochondrion membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.42</theoretical-pi>
        <molecular-weight>57572.44</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2591</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP11B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M32879</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181333</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1359</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P15538</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>C11B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CYPXIB1</synonym>
          <synonym>Cytochrome P-450c11</synonym>
          <synonym>Cytochrome P450C11</synonym>
          <synonym>S11BH</synonym>
          <synonym>Steroid 11-beta-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037064|Cytochrome P450 11B1, mitochondrial
MALRAKAEVCMAVPWLSLQRAQALGTRAARVPRTVLPFEAMPRRPGNRWLRLLQIWREQG
YEDLHLEVHQTFQELGPIFRYDLGGAGMVCVMLPEDVEKLQQVDSLHPHRMSLEPWVAYR
QHRGHKCGVFLLNGPEWRFNRLRLNPEVLSPNAVQRFLPMVDAVARDFSQALKKKVLQNA
RGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFM
PRSLSRWTSPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFSRPQQYTSIVAELLLNAELS
PDAIKANSMELTAGSVDTTVFPLLMTLFELARNPNVQQALRQESLAAAASISEHPQKATT
ELPLLRAALKETLRLYPVGLFLERVASSDLVLQNYHIPAGTLVRVFLYSLGRNPALFPRP
ERYNPQRWLDIRGSGRNFYHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHLQVETLTQED
IKMVYSFILRPSMFPLLTFRAIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016190|Cytochrome P450 11B1, mitochondrial (CYP11B1)
ATGGCACTCAGGGCAAAGGCAGAGGTGTGCATGGCAGTGCCCTGGCTGTCCCTGCAAAGG
GCACAGGCACTGGGCACGAGAGCCGCCCGGGTCCCCAGGACAGTGCTGCCCTTTGAAGCC
ATGCCCCGGCGTCCAGGCAACAGGTGGCTGAGGCTGCTGCAGATCTGGAGGGAGCAGGGT
TATGAGGACCTGCACCTGGAAGTACACCAGACCTTCCAGGAACTAGGGCCCATTTTCAGG
TACGACTTGGGAGGAGCAGGCATGGTGTGTGTGATGCTGCCGGAGGACGTGGAGAAGCTG
CAACAGGTGGACAGCCTGCATCCCCACAGGATGAGCCTGGAGCCCTGGGTGGCCTACAGA
CAACATCGTGGGCACAAATGTGGCGTGTTCTTGCTGAATGGGCCTGAATGGCGCTTCAAC
CGATTGCGGCTGAATCCAGAAGTGCTGTCGCCCAACGCTGTGCAGAGGTTCCTCCCGATG
GTGGATGCAGTGGCCAGGGACTTCTCCCAGGCCCTGAAGAAGAAGGTGCTGCAGAACGCC
CGGGGGAGCCTGACCCTGGACGTCCAGCCCAGCATCTTCCACTACACCATAGAAGCCAGC
AACTTGGCTCTTTTTGGAGAGCGGCTGGGCCTGGTTGGCCACAGCCCCAGTTCTGCCAGC
CTGAACTTCCTCCATGCCCTGGAGGTCATGTTCAAATCCACCGTCCAGCTCATGTTCATG
CCCAGGAGCCTGTCTCGCTGGACCAGCCCCAAGGTGTGGAAGGAGCACTTTGAGGCCTGG
GACTGCATCTTCCAGTACGGCGACAACTGTATCCAGAAAATCTATCAGGAACTGGCCTTC
AGCCGCCCTCAACAGTACACCAGCATCGTGGCGGAGCTCCTGTTGAATGCGGAACTGTCG
CCAGATGCCATCAAGGCCAACTCTATGGAACTCACTGCAGGGAGCGTGGACACGACGGTG
TTTCCCTTGCTGATGACGCTCTTTGAGCTGGCTCGGAACCCCAACGTGCAGCAGGCCCTG
CGCCAGGAGAGCCTGGCCGCCGCAGCCAGCATCAGTGAACATCCCCAGAAGGCAACCACC
GAGCTGCCCTTGCTGCGTGCGGCCCTCAAGGAGACCTTGCGGCTCTACCCTGTGGGTCTG
TTTCTGGAGCGAGTGGCGAGCTCAGACTTGGTGCTTCAGAACTACCACATCCCAGCTGGG
ACATTGGTGCGCGTGTTCCTCTACTCTCTGGGTCGCAACCCCGCCTTGTTCCCGAGGCCT
GAGCGCTATAACCCCCAGCGCTGGCTAGACATCAGGGGCTCCGGCAGGAACTTCTACCAC
GTGCCCTTTGGCTTTGGCATGCGCCAGTGCCTTGGGCGGCGCCTGGCAGAGGCAGAGATG
CTGCTGCTGCTGCACCATGTGCTGAAACACCTCCAGGTGGAGACACTAACCCAAGAGGAC
ATAAAGATGGTCTACAGCTTCATATTGAGGCCCAGCATGTTCCCCCTCCTCACCTTCAGA
GCCATCAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>corticosterone 18-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid 11-beta-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aldosterone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>C21-steroid hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to peptide hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to potassium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cortisol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>secondary metabolite biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers>
    <carrier position="15">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A178126</ref-id>
            <pubmed-id>9144743</pubmed-id>
            <citation>Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M: Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm Res. 1997 Apr;14(4):522-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
    <carrier position="16">
      <id>BE0004879</id>
      <name>alpha1-acid glycoprotein</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A178126</ref-id>
            <pubmed-id>9144743</pubmed-id>
            <citation>Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M: Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm Res. 1997 Apr;14(4):522-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02763" source="Swiss-Prot">
        <name>Alpha-1-acid glycoprotein 1</name>
        <general-function/>
        <specific-function>Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.</specific-function>
        <gene-name>ORM1</gene-name>
        <locus>9q31-q32</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>4.66</theoretical-pi>
        <molecular-weight>23511.38</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8498</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ORM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02544</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>757907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02763</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A1AG1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AGP 1</synonym>
          <synonym>AGP1</synonym>
          <synonym>OMD 1</synonym>
          <synonym>Orosomucoid-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001842|Alpha-1-acid glycoprotein 1
MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAFRNEEYNKSVQ
EIQATFFYFTPNKTEDTIFLREYQTRQDQCIYNTTYLNVQRENGTISRYVGGQEHFAHLL
ILRDTKTYMLAFDVNDEKNWGLSVYADKPETTKEQLGEFYEALDCLRIPKSDVVYTDWKK
DKCEPLEKQHEKERKQEEGES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010649|Alpha-1-acid glycoprotein 1 (ORM1)
ATGGCGCTGTCCTGGGTTCTTACAGTCCTGAGCCTCCTACCTCTGCTGGAAGCCCAGATC
CCATTGTGTGCCAACCTAGTACCGGTGCCCATCACCAACGCCACCCTGGACCGGATCACT
GGCAAGTGGTTTTATATCGCATCGGCCTTTCGAAACGAGGAGTACAATAAGTCGGTTCAG
GAGATCCAAGCAACCTTCTTTTACTTCACCCCCAACAAGACAGAGGACACGATCTTTCTC
AGAGAGTACCAGACCCGACAGGACCAGTGCATCTATAACACCACCTACCTGAATGTCCAG
CGGGAAAATGGGACCATCTCCAGATACGTGGGAGGCCAAGAGCATTTCGCTCACTTGCTG
ATCCTCAGGGACACCAAGACCTACATGCTTGCTTTTGACGTGAACGATGAGAAGAACTGG
GGGCTGTCTGTCTATGCTGACAAGCCAGAGACGACCAAGGAGCAACTGGGAGAGTTCTAC
GAAGCTCTCGACTGCTTGCGCATTCCCAAGTCAGATGTCGTGTACACCGATTGGAAAAAG
GATAAGTGTGAGCCACTGGAGAAGCAGCACGAGAAGGAGAGGAAACAGGAGGAGGGGGAA
TCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00061</identifier>
            <name>Lipocalin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute-phase response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of immune system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P19652" source="Swiss-Prot">
        <name>Alpha-1-acid glycoprotein 2</name>
        <general-function/>
        <specific-function>Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability. Appears to function in modulating the activity of the immune system during the acute-phase reaction.</specific-function>
        <gene-name>ORM2</gene-name>
        <locus>9q32</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>4.76</theoretical-pi>
        <molecular-weight>23602.43</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>BC015964</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>16359000</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P19652</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A1AG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AGP 2</synonym>
          <synonym>AGP2</synonym>
          <synonym>OMD 2</synonym>
          <synonym>Orosomucoid-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007040|Alpha-1-acid glycoprotein 2
MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDRITGKWFYIASAFRNEEYNKSVQ
EIQATFFYFTPNKTEDTIFLREYQTRQNQCFYNSSYLNVQRENGTVSRYEGGREHVAHLL
FLRDTKTLMFGSYLDDEKNWGLSFYADKPETTKEQLGEFYEALDCLCIPRSDVMYTDWKK
DKCEPLEKQHEKERKQEEGES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012546|Alpha-1-acid glycoprotein 2 (ORM2)
ATGGCGCTGTCCTGGGTTCTTACAGTCCTGAGCCTCCTACCTCTGCTGGAAGCCCAGATC
CCATTGTGTGCCAACCTAGTACCGGTGCCCATCACCAACGCCACCCTGGACCGGATCACT
GGCAAGTGGTTTTATATCGCATCGGCCTTTCGAAACGAGGAGTACAATAAGTCGGTTCAG
GAGATCCAAGCAACCTTCTTTTACTTTACCCCCAACAAGACAGAGGACACGATCTTTCTC
AGAGAGTACCAGACCCGCCAGAACCAGTGCTTCTATAACTCCAGTTACCTGAATGTCCAG
CGGGAGAATGGGACCGTCTCCAGATACGAGGGAGGCCGAGAACATGTTGCTCACCTGCTG
TTCCTTAGGGACACCAAGACCTTGATGTTTGGTTCCTACCTGGACGATGAGAAGAACTGG
GGGCTGTCTTTCTATGCTGACAAGCCAGAGACGACCAAGGAGCAACTGGGAGAGTTCTAC
GAAGCTCTCGACTGCTTGTGCATTCCCAGGTCAGATGTCATGTACACCGACTGGAAAAAG
GATAAGTGTGAGCCACTGGAGAAGCAGCACGAGAAGGAGAGGAAACAGGAGGAGGGGGAA
TCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00061</identifier>
            <name>Lipocalin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute-phase response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of immune system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters>
    <transporter position="1">
      <id>BE0001069</id>
      <name>Canalicular multispecific organic anion transporter 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16012</ref-id>
            <pubmed-id>12011477</pubmed-id>
            <citation>Johnson DR, Klaassen CD: Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. Toxicol Sci. 2002 Jun;67(2):182-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q92887" source="Swiss-Prot">
        <name>Canalicular multispecific organic anion transporter 1</name>
        <general-function>Organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.</specific-function>
        <gene-name>ABCC2</gene-name>
        <locus>10q24</locus>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions>28-48
69-89
94-114
127-147
166-186
314-334
361-381
438-458
462-482
545-565
588-608
972-992
1034-1054
1098-1118
1120-1140
1212-1232
1235-1255</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.46</theoretical-pi>
        <molecular-weight>174205.64</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:53</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCC2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U63970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1764162</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>780</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92887</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 2</synonym>
          <synonym>Canalicular multidrug resistance protein</synonym>
          <synonym>CMOAT</synonym>
          <synonym>CMOAT1</synonym>
          <synonym>CMRP</synonym>
          <synonym>MRP2</synonym>
          <synonym>Multidrug resistance-associated protein 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010748|Canalicular multispecific organic anion transporter 1
MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSS
TTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYS
RQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILI
FSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS
KFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSG
TKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIG
YLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGET
VNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAIL
STKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFS
QLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMI
SSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLD
IMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNIL
FGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLD
IYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIV
EKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAAS
ITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETG
KVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQR
DMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRI
VNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMF
YVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSW
ITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTS
EIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGI
TCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTII
PQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIG
QRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMD
SDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010749|Canalicular multispecific organic anion transporter 1 (ABCC2)
ATGCTGGAGAAGTTCTGCAACTCTACTTTTTGGAATTCCTCATTCCTGGACAGTCCGGAG
GCAGACCTGCCACTTTGTTTTGAGCAAACTGTTCTGGTGTGGATTCCCTTGGGCTTCCTA
TGGCTCCTGGCCCCCTGGCAGCTTCTCCACGTGTATAAATCCAGGACCAAGAGATCCTCT
ACCACCAAACTCTATCTTGCTAAGCAGGTATTCGTTGGTTTTCTTCTTATTCTAGCAGCC
ATAGAGCTGGCCCTTGTACTCACAGAAGACTCTGGACAAGCCACAGTCCCTGCTGTTCGA
TATACCAATCCAAGCCTCTACCTAGGCACATGGCTCCTGGTTTTGCTGATCCAATACAGC
AGACAATGGTGTGTACAGAAAAACTCCTGGTTCCTGTCCCTATTCTGGATTCTCTCGATA
CTCTGTGGCACTTTCCAATTTCAGACTCTGATCCGGACACTCTTACAGGGTGACAATTCT
AATCTAGCCTACTCCTGCCTGTTCTTCATCTCCTACGGATTCCAGATCCTGATCCTGATC
TTTTCAGCATTTTCAGAAAATAATGAGTCATCAAATAATCCATCATCCATAGCTTCATTC
CTGAGTAGCATTACCTACAGCTGGTATGACAGCATCATTCTGAAAGGCTACAAGCGTCCT
CTGACACTCGAGGATGTCTGGGAAGTTGATGAAGAGATGAAAACCAAGACATTAGTGAGC
AAGTTTGAAACGCACATGAAGAGAGAGCTGCAGAAAGCCAGGCGGGCACTCCAGAGACGG
CAGGAGAAGAGCTCCCAGCAGAACTCTGGAGCCAGGCTGCCTGGCTTGAACAAGAATCAG
AGTCAAAGCCAAGATGCCCTTGTCCTGGAAGATGTTGAAAAGAAAAAAAAGAAGTCTGGG
ACCAAAAAAGATGTTCCAAAATCCTGGTTGATGAAGGCTCTGTTCAAAACTTTCTACATG
GTGCTCCTGAAATCATTCCTACTGAAGCTAGTGAATGACATCTTCACGTTTGTGAGTCCT
CAGCTGCTGAAATTGCTGATCTCCTTTGCAAGTGACCGTGACACATATTTGTGGATTGGA
TATCTCTGTGCAATCCTCTTATTCACTGCGGCTCTCATTCAGTCTTTCTGCCTTCAGTGT
TATTTCCAACTGTGCTTCAAGCTGGGTGTAAAAGTACGGACAGCTATCATGGCTTCTGTA
TATAAGAAGGCATTGACCCTATCCAACTTGGCCAGGAAGGAGTACACCGTTGGAGAAACA
GTGAACCTGATGTCTGTGGATGCCCAGAAGCTCATGGATGTGACCAACTTCATGCACATG
CTGTGGTCAAGTGTTCTACAGATTGTCTTATCTATCTTCTTCCTATGGAGAGAGTTGGGA
CCCTCAGTCTTAGCAGGTGTTGGGGTGATGGTGCTTGTAATCCCAATTAATGCGATACTG
TCCACCAAGAGTAAGACCATTCAGGTCAAAAATATGAAGAATAAAGACAAACGTTTAAAG
ATCATGAATGAGATTCTTAGTGGAATCAAGATCCTGAAATATTTTGCCTGGGAACCTTCA
TTCAGAGACCAAGTACAAAACCTCCGGAAGAAAGAGCTCAAGAACCTGCTGGCCTTTAGT
CAACTACAGTGTGTAGTAATATTCGTCTTCCAGTTAACTCCAGTCCTGGTATCTGTGGTC
ACATTTTCTGTTTATGTCCTGGTGGATAGCAACAATATTTTGGATGCACAAAAGGCCTTC
ACCTCCATTACCCTCTTCAATATCCTGCGCTTTCCCCTGAGCATGCTTCCCATGATGATC
TCCTCCATGCTCCAGGCCAGTGTTTCCACAGAGCGGCTAGAGAAGTACTTGGGAGGGGAT
GACTTGGACACATCTGCCATTCGACATGACTGCAATTTTGACAAAGCCATGCAGTTTTCT
GAGGCCTCCTTTACCTGGGAACATGATTCGGAAGCCACAGTCCGAGATGTGAACCTGGAC
ATTATGGCAGGCCAACTTGTGGCTGTGATAGGCCCTGTCGGCTCTGGGAAATCCTCCTTG
ATATCAGCCATGCTGGGAGAAATGGAAAATGTCCACGGGCACATCACCATCAAGGGCACC
ACTGCCTATGTCCCACAGCAGTCCTGGATTCAGAATGGCACCATAAAGGACAACATCCTT
TTTGGAACAGAGTTTAATGAAAAGAGGTACCAGCAAGTACTGGAGGCCTGTGCTCTCCTC
CCAGACTTGGAAATGCTGCCTGGAGGAGATTTGGCTGAGATTGGAGAGAAGGGTATAAAT
CTTAGTGGGGGTCAGAAGCAGCGGATCAGCCTGGCCAGAGCTACCTACCAAAATTTAGAC
ATCTATCTTCTAGATGACCCCCTGTCTGCAGTGGATGCTCATGTAGGAAAACATATTTTT
AATAAGGTCTTGGGCCCCAATGGCCTGTTGAAAGGCAAGACTCGACTCTTGGTTACACAT
AGCATGCACTTTCTTCCTCAAGTGGATGAGATTGTAGTTCTGGGGAATGGAACAATTGTA
GAGAAAGGATCCTACAGTGCTCTCCTGGCCAAAAAAGGAGAGTTTGCTAAGAATCTGAAG
ACATTTCTAAGACATACAGGCCCTGAAGAGGAAGCCACAGTCCATGATGGCAGTGAAGAA
GAAGACGATGACTATGGGCTGATATCCAGTGTGGAAGAGATCCCCGAAGATGCAGCCTCC
ATAACCATGAGAAGAGAGAACAGCTTTCGTCGAACACTTAGCCGCAGTTCTAGGTCCAAT
GGCAGGCATCTGAAGTCCCTGAGAAACTCCTTGAAAACTCGGAATGTGAATAGCCTGAAG
GAAGACGAAGAACTAGTGAAAGGACAAAAACTAATTAAGAAGGAATTCATAGAAACTGGA
AAGGTGAAGTTCTCCATCTACCTGGAGTACCTACAAGCAATAGGATTGTTTTCGATATTC
TTCATCATCCTTGCGTTTGTGATGAATTCTGTGGCTTTTATTGGATCCAACCTCTGGCTC
AGTGCTTGGACCAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGG
GACATGAGAGTTGGAGTCTACGGAGCTCTGGGATTAGCCCAAGGTATATTTGTGTTCATA
GCACATTTCTGGAGTGCCTTTGGTTTCGTCCATGCATCAAATATCTTGCACAAGCAACTG
CTGAACAATATCCTTCGAGCACCTATGAGATTTTTTGACACAACACCCACAGGCCGGATT
GTGAACAGGTTTGCCGGCGATATTTCCACAGTGGATGACACCCTGCCTCAGTCCTTGCGC
AGCTGGATTACATGCTTCCTGGGGATAATCAGCACCCTTGTCATGATCTGCATGGCCACT
CCTGTCTTCACCATCATCGTCATTCCTCTTGGCATTATTTATGTATCTGTTCAGATGTTT
TATGTGTCTACCTCCCGCCAGCTGAGGCGTCTGGACTCTGTCACCAGGTCCCCAATCTAC
TCTCACTTCAGCGAGACCGTATCAGGTTTGCCAGTTATCCGTGCCTTTGAGCACCAGCAG
CGATTTCTGAAACACAATGAGGTGAGGATTGACACCAACCAGAAATGTGTCTTTTCCTGG
ATCACCTCCAACAGGTGGCTTGCAATTCGCCTGGAGCTGGTTGGGAACCTGACTGTCTTC
TTTTCAGCCTTGATGATGGTTATTTATAGAGATACCCTAAGTGGGGACACTGTTGGCTTT
GTTCTGTCCAATGCACTCAATATCACACAAACCCTGAACTGGCTGGTGAGGATGACATCA
GAAATAGAGACCAACATTGTGGCTGTTGAGCGAATAACTGAGTACACAAAAGTGGAAAAT
GAGGCACCCTGGGTGACTGATAAGAGGCCTCCGCCAGATTGGCCCAGCAAAGGCAAGATC
CAGTTTAACAACTACCAAGTGCGGTACCGACCTGAGCTGGATCTGGTCCTCAGAGGGATC
ACTTGTGACATCGGTAGCATGGAGAAGATTGGTGTGGTGGGCAGGACAGGAGCTGGAAAG
TCATCCCTCACAAACTGCCTCTTCAGAATCTTAGAGGCTGCCGGTGGTCAGATTATCATT
GATGGAGTAGATATTGCTTCCATTGGGCTCCACGACCTCCGAGAGAAGCTGACCATCATC
CCCCAGGACCCCATCCTGTTCTCTGGAAGCCTGAGGATGAATCTCGACCCTTTCAACAAC
TACTCAGATGAGGAGATTTGGAAGGCCTTGGAGCTGGCTCACCTCAAGTCTTTTGTGGCC
AGCCTGCAACTTGGGTTATCCCACGAAGTGACAGAGGCTGGTGGCAACCTGAGCATAGGC
CAGAGGCAGCTGCTGTGCCTGGGCAGGGCTCTGCTTCGGAAATCCAAGATCCTGGTCCTG
GATGAGGCCACTGCTGCGGTGGATCTAGAGACAGACAACCTCATTCAGACGACCATCCAA
AACGAGTTCGCCCACTGCACAGTGATCACCATCGCCCACAGGCTGCACACCATCATGGAC
AGTGACAAGGTAATGGTCCTAGACAACGGGAAGATTATAGAGTGCGGCAGCCCTGAAGAA
CTGCTACAAATCCCTGGACCCTTTTACTTTATGGCTAAGGAAGCTGGCATTGAGAATGTG
AACAGCACAAAATTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular chloride ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to arsenic-containing substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0001032</id>
      <name>P-glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A24333</ref-id>
            <pubmed-id>21459122</pubmed-id>
            <citation>Rigalli JP, Ruiz ML, Perdomo VG, Villanueva SS, Mottino AD, Catania VA: Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology. 2011 Jul 11;285(1-2):18-24. doi: 10.1016/j.tox.2011.03.015. Epub 2011 Apr 1.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
        <name>Multidrug resistance protein 1</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
        <gene-name>ABCB1</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>141477.255</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:40</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MDR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.44</synonym>
          <synonym>ATP-binding cassette sub-family B member 1</synonym>
          <synonym>MDR1</synonym>
          <synonym>P-glycoprotein 1</synonym>
          <synonym>PGY1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G2/M transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stem cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0003642</id>
      <name>Solute carrier organic anion transporter family member 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15970</ref-id>
            <pubmed-id>8779893</pubmed-id>
            <citation>Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P46721" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 1A2</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.</specific-function>
        <gene-name>SLCO1A2</gene-name>
        <locus>12p12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>21-40
60-80
87-111
156-184
204-224
243-267
312-333
354-377
382-405
514-536
546-571
606-623</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.75</theoretical-pi>
        <molecular-weight>74144.105</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10956</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U21943</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>885978</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P46721</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OATP</synonym>
          <synonym>OATP-1</synonym>
          <synonym>OATP-A</synonym>
          <synonym>OATP1</synonym>
          <synonym>OATP1A2</synonym>
          <synonym>Organic anion-transporting polypeptide 1</synonym>
          <synonym>SLC21A3</synonym>
          <synonym>Sodium-independent organic anion transporter</synonym>
          <synonym>Solute carrier family 21 member 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007000|Solute carrier organic anion transporter family member 1A2
MGETEKRIETHRIRCLSKLKMFLLAITCAFVSKTLSGSYMNSMLTQIERQFNIPTSLVGF
INGSFEIGNLLLIIFVSYFGTKLHRPIMIGIGCVVMGLGCFLKSLPHFLMNQYEYESTVS
VSGNLSSNSFLCMENGTQILRPTQDPSECTKEVKSLMWVYVLVGNIVRGMGETPILPLGI
SYIEDFAKFENSPLYIGLVETGAIIGPLIGLLLASFCANVYVDTGFVNTDDLIITPTDTR
WVGAWWFGFLICAGVNVLTAIPFFFLPNTLPKEGLETNADIIKNENEDKQKEEVKKEKYG
ITKDFLPFMKSLSCNPIYMLFILVSVIQFNAFVNMISFMPKYLEQQYGISSSDAIFLMGI
YNLPPICIGYIIGGLIMKKFKITVKQAAHIGCWLSLLEYLLYFLSFLMTCENSSVVGINT
SYEGIPQDLYVENDIFADCNVDCNCPSKIWDPVCGNNGLSYLSACLAGCETSIGTGINMV
FQNCSCIQTSGNSSAVLGLCDKGPDCSLMLQYFLILSAMSSFIYSLAAIPGYMVLLRCMK
SEEKSLGVGLHTFCTRVFAGIPAPIYFGALMDSTCLHWGTLKCGESGACRIYDSTTFRYI
YLGLPAALRGSSFVPALIILILLRKCHLPGENASSGTELIETKVKGKENECKDIYQKSTV
LKDDELKTKL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012532|Solute carrier organic anion transporter family member 1A2 (SLCO1A2)
ATGGGAGAAACTGAGAAAAGAATTGAAACCCATAGAATAAGATGTCTTTCCAAGTTGAAG
ATGTTTCTGTTGGCAATAACATGTGCATTTGTATCCAAAACACTGTCTGGATCTTATATG
AATTCCATGCTCACACAAATAGAGAGACAATTCAACATCCCAACATCTCTAGTTGGATTC
ATTAATGGAAGCTTTGAGATTGGAAATCTTTTGTTGATTATATTTGTGAGTTATTTTGGA
ACCAAACTGCATAGACCTATAATGATTGGCATTGGATGTGTGGTTATGGGCTTAGGCTGT
TTCTTAAAATCACTACCTCATTTCCTCATGAACCAATATGAATATGAATCTACAGTTTCA
GTTTCAGGCAACTTGTCCTCAAACAGTTTCTTGTGTATGGAAAATGGAACCCAGATTTTA
AGACCAACGCAGGATCCATCAGAGTGTACAAAGGAAGTTAAATCATTAATGTGGGTGTAC
GTCCTAGTAGGCAATATTGTACGTGGAATGGGTGAAACTCCCATCCTGCCTTTGGGTATT
TCCTATATAGAAGATTTTGCCAAATTTGAAAATTCTCCTTTATATATTGGGCTTGTAGAA
ACAGGAGCTATTATTGGTCCTTTGATTGGACTTTTGTTGGCATCATTCTGTGCAAATGTT
TATGTTGACACTGGATTTGTGAACACAGATGATCTGATCATAACTCCCACTGACACTCGT
TGGGTCGGTGCATGGTGGTTTGGCTTTCTGATTTGTGCAGGAGTTAACGTGCTCACTGCC
ATTCCTTTTTTCTTTTTGCCCAACACACTTCCAAAGGAAGGACTAGAGACTAATGCTGAC
ATCATTAAAAATGAAAATGAAGACAAACAAAAAGAAGAGGTCAAGAAGGAAAAATATGGA
ATCACTAAAGATTTTCTACCTTTCATGAAAAGTCTTTCCTGCAATCCAATTTATATGCTT
TTCATACTTGTAAGTGTGATACAGTTCAATGCATTCGTTAACATGATCTCCTTCATGCCT
AAATACCTAGAACAGCAATATGGAATATCATCTTCAGATGCAATCTTTCTAATGGGTATT
TATAACTTACCTCCAATATGTATTGGATATATAATTGGTGGTTTAATTATGAAGAAGTTC
AAGATTACTGTCAAACAAGCTGCCCACATAGGATGTTGGTTATCCTTACTTGAGTATCTT
CTCTATTTTTTATCTTTTCTCATGACTTGTGAAAATTCTTCAGTTGTTGGAATAAATACC
TCTTATGAAGGAATTCCACAAGATTTATATGTGGAAAATGACATCTTTGCTGATTGCAAT
GTGGATTGCAACTGTCCATCTAAAATATGGGATCCTGTGTGTGGAAACAATGGCTTGTCA
TATCTGTCAGCTTGTCTTGCTGGTTGTGAGACATCCATTGGAACGGGAATAAACATGGTG
TTCCAAAATTGCAGCTGTATTCAAACATCAGGAAATTCATCTGCAGTTCTTGGGCTGTGC
GACAAAGGACCTGACTGTTCCTTGATGCTCCAGTACTTCCTAATCTTGTCAGCGATGAGC
AGTTTCATTTATTCTTTGGCTGCCATACCTGGATATATGGTTCTCTTGAGGTGTATGAAA
TCTGAAGAGAAGTCCCTTGGTGTGGGATTACATACATTTTGCACAAGAGTATTTGCTGGC
ATTCCTGCACCTATATATTTTGGCGCTTTAATGGATTCCACATGTTTACACTGGGGAACT
TTGAAATGTGGTGAGTCAGGGGCATGCAGGATATATGATTCCACCACCTTCAGATACATC
TACCTCGGATTGCCGGCAGCACTAAGAGGATCAAGCTTTGTTCCAGCCTTAATCATCTTA
ATTCTTTTGAGGAAGTGTCATCTACCTGGTGAAAATGCCTCTTCAGGAACAGAGCTTATA
GAGACAAAAGTCAAAGGGAAGGAAAATGAGTGCAAAGATATATACCAAAAGTCCACGGTT
TTGAAAGATGATGAATTGAAAACTAAATTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="14">
      <id>BE0000703</id>
      <name>Bile salt export pump</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33345</ref-id>
            <pubmed-id>24014644</pubmed-id>
            <citation>Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="O95342" source="Swiss-Prot">
        <name>Bile salt export pump</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.</specific-function>
        <gene-name>ABCB11</gene-name>
        <locus>2q24</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>63-83
148-168
216-236
241-261
320-340
354-374
756-776
795-815
870-890
891-911
980-1000
1012-1032</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.52</theoretical-pi>
        <molecular-weight>146405.83</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:42</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF091582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3873243</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCBB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family B member 11</synonym>
          <synonym>BSEP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010492|Bile salt export pump
MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW
LMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN
QNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR
RIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK
LTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE
VERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLV
QIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI
EFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT
VDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF
IMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV
LSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG
NQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST
YEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL
GTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML
GQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL
SLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI
EALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV
ISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF
VDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID
GHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF
VMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA
LDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI
S</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010493|Bile salt export pump (ABCB11)
ATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT
GAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT
GATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG
CTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA
CTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC
CAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC
CAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA
TTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA
TGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG
AGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA
AGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC
ATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA
CTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT
CTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG
GCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG
GTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA
GTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCACTGGCC
TTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC
CAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG
GAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA
CCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT
GAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC
CTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA
AAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC
GTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA
GTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA
GAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC
ATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT
GGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG
CTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG
CTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC
AGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT
GAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA
AATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG
ACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG
TCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC
TATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA
GTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG
GGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT
GGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA
CTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT
GCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG
GGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA
CTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC
AATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG
AGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG
ATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA
AATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT
GAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT
TACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC
AGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG
ATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT
TATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA
ATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT
GTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA
GTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC
ACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT
GGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC
CAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC
AAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT
GTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT
AGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG
CTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT
CTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC
CAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT
GAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC
AGTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercellular canaliculus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid-exporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>canalicular bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-exporting ATPase activity, phosphorylative mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>canalicular bile acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>